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Malaria and schistosomiasis represent the two most prevalent parasitic infections with 
grievous repercussions on the socio-economic development of affected countries, mainly in 
sub-Saharan Africa and South-East Asia. Despite their ravaging effects, the treatments of 
these two diseases have been committed to a limited arsenal of drugs that are threatened by 
resistance. This scenario, therefore, calls for decisive steps being taken towards the discovery 
and development of novel drugs with the ability to target multiple parasite stages and be 
efficacious against resistant parasite strains to achieve effective control and treatment of 
malaria and schistosomiasis.  
Originating from a World Health Organisation-Tropical Disease Research initiative, a 
phenotypic whole cell screening was conducted on a commercial library against       
Plasmodium falciparum whereupon novel hits exemplified by compound 1, embodying a 
pyridobenzimidazole (PBI) scaffold, were found to portray in vitro potency against both 
chloroquine sensitive and resistant parasites. Initial medicinal chemistry iterations generated 
analogues including 2 from which improved in vitro potency and demonstrable in vivo efficacy 




Figure 1: Phenotypic whole cell screening hit 1, initial lead 2 and medicinal chemistry plan 







In this thesis, further structural diversity around the PBI motif 3 (Figure 1) was pursued with 
the aim of generating analogues for structure-activity and structure-property relationship 
studies.  Beyond the asexual blood stage activity, the library of compounds generated was 
also evaluated for activity against the liver and gametocyte stages of Plasmodium.  
In exploring the probable mechanism of antimalarial action based on their planar morphology 
and existence of basic centres, the compounds were evaluated for their capacity to disrupt 
the heme detoxification process, a recognised druggable target in antimalarial drug discovery. 
Prioritised compounds, based on in vitro potency, were progressed for in vitro drug 
metabolism and pharmacokinetics assessment, including metabolic stability and cytotoxicity 
against Chinese hamster ovarian cell lines. Representative compounds were evaluated for 
their interaction potential with the human ether-a-go-go-related gene (hERG), a potassium 
ion channel whose inhibition can cause potentially fatal irregular heartbeats due to perturbed 
repolarisation of the myocardial action potential. In vivo proof-of-concept efficacy and 
pharmacokinetics studies were carried out on the most promising leads according to a 
predetermined screening cascade.    
Arising from this work, structure-activity relationship (SAR) trends were discernible with 
electron withdrawing substituents on the aromatic side appendage providing active 
analogues compared to compounds comprising hydrophilic electron-releasing or donating 
substituents. Following in vitro microsomal metabolic stability analysis, the series displayed 
moderate to good metabolic stability with compounds incorporating heteroaromatic side 
groups showing increased susceptibility to biotransformation usually arising from the 
aromatic ring.   In a P. berghei mouse model at an oral dose of 50mg/kg over four consecutive 
days, two compounds 1j/GMP-19 and 4i/GMP-75 achieved 98% and 99.9% reduction in 
parasitaemia and led to mean survival days of 12 and 14, respectively, compared to the 
untreated infected mice which survived for only 6 days.  
A drug repositioning approach was pursued, exploiting the cellular and biological similarities 
in the haemoglobin degradation pathways existent in both Plasmodium parasites and 
schistosomes.  Out of the 57 analogues tested, 12 were found to be potent inhibitors of the 
adult worms (IC50 ≤ 2 µM), with several compounds also displaying potency against the newly 




Structural features consistent with good antischistosomal potency, interestingly, overlapped 
with those present in some compounds that also showed good antiplasmodial activity. 
Prioritised compounds subjected to in vivo efficacy studies in mice infected with schistosomes 
identified 1b/GMP-09, 1j/GMP-19 and 4i/GMP-75 with modest antischistosomal activity (55-
70% total worm reduction).  
Metabolic stability and physicochemical properties correlated with observed in vivo efficacy 
and solubility- limited absorption was implicated to contribute to low in vivo exposure of the 
compounds. Further profiling of physicochemical parameters revealed the interdependence 
of the properties and that crystallinity, as measured by the melting point, influenced 
compound solubility.  
In summary, the work pursued in this thesis has unravelled the structural features compatible 
with potent antimalarial and antischistosomal activities of N-aryl substituted 3-
trifluoromethyl PBI derivatives. Additionally, structure-property trends of generated 
analogues have been delineated. The evolvable nature of the structure-activity and structure-
property relationship trends make these compounds appealing as candidates for further 
optimisation campaigns to impart improvements in physicochemical properties and drug 
metabolism and pharmacokinetics attributes without abrogating activity. Moreover, having 
identified the overlap as well as divergence in chemical spaces relating to antimalarial and 
antischistosomal potencies of these series inspire further investigations into the mechanisms 
of observed antiparasitic actions. Finally, that this work has identified targets which are pan-
active across multiple stages of both Plasmodium and schistosomes, and possessing 
favourable safety profiles, provide an exciting opportunity for pursuing these analogues as 
antimalarial and antischistosomal leads with the potential for malaria chemoprevention and 
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1.1 Chapter overview 
 
This chapter will provide a background to malaria and schistosomiasis. The epidemiology, life 
cycles and an account of the control and treatment of these parasitic diseases will be covered 
together with the challenges and opportunities for drug discovery and development of newer 
therapies. To follow is a discussion on some of the methods used in drug discovery to identify 
leads for further development. The physicochemical parameters crucial to drug-likeness will 
be described, as will their interrelationships and impact on drug efficacy. Some of the 
strategies to modify physicochemical characteristics towards improving their suitability for 
development will also be presented. The chapter will conclude with a description of 
pharmacokinetic parameters and their influence on in vivo studies and how they are used to 





Malaria is caused by parasites of the plasmodia genus of which four major species are 
implicated: P. falciparum, P. malaria, P. ovale and P. vivax.1–3 A plasmodium species of simian 
origin P. knowlesi, has also been reported to be infectious to humans albeit with milder 
virulence.4,5 Plasmodium species differ in their geographical distribution and hence the global 
variations in the type of malaria. However, it is P. falciparum and P. vivax that are mostly 
responsible for infections in Africa and South-East Asia, respectively, with falciparum 
infections being the leading cause of malaria fatalities world-wide.1,6,7 
Recent statistics by the World Health Organisation (WHO) concede that there were 216 
million cases and close to half a million fatalities due to malaria.8 Consistently, most cases of 
morbidity and mortality occur not only in Africa but also among the most vulnerable 
populations comprising children below five years and pregnant women.9,10 
The negative impact that malaria exerts on productivity, human resource capital and 
expenditure on treatment further strains the already fragile economies of the poor countries, 
leading to an endless cycle of poverty.11–13 
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1.2.2 Life cycle and pathophysiology 
 
Malaria transmission relies on both the non-vertebrate mosquito vector and the definite 
vertebrate human host.14 A bite, during a blood meal, from a female Anopheles mosquito 
deposits the plasmodium sporozoites in a human host (Figure 1.1).7 The sporozoites are 
subsequently translocated from the site of injection to the liver, via the blood stream, where 
they mature into schizonts. After several multiplication cycles in the liver, the schizonts 
produce merozoites which are released into systemic circulation where they infect the red 
blood cells and hence initiate the erythrocytic phase of plasmodium infection. Asexual 
division continues within the erythrocytes, where the merozoites transform into trophozoites 
and blood schizonts, which proliferate and rupture, releasing more merozoites to infect even 
more red blood cells.15,16 If untreated, this cycle of bursting of red blood cells and re-infection 
continues unabated. Some of the merozoites differentiate into male and female gametes, the 
sexual forms of the parasite.3,17 The gametocytes are taken up by a mosquito during a blood-
meal and mature within the gut. In a subsequent encounter with a human host, the infected 
mosquito injects the mature sporozoites thus completing the life cycle of the parasite.18 
While some of the sporozoites move to the blood stream resulting in the erythrocytic stage 
of infection, some dormant forms, referred to as hypnozoites, may lodge in the liver, as occurs 
with infections mediated by P. ovale and P. vivax.  Once activated by various stimuli such as 
infections, these otherwise dormant forms can initiate a new infection. 19,20 
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Rupture of red blood cells is a typical sequela of malaria infections often accompanied by a 
cassette of symptoms such as fever, headaches, chills, vomiting, anaemia, joint pains and 
coloured urine.5,21,22 If not treated promptly, the disease can affect other organs beyond the 
circulatory system. Cerebral malaria is a severe form of the disease wherein the parasites 
lodge in the brain leading to impairments in neural and cognitive functions and is frequently 
fatal in the absence of speedy treatment.23,24 Other organs and tissues that may be 
compromised in untreated malaria include kidneys, liver and spleen whose diminished 
functions can deteriorate to life-threatening conditions including hypoglycaemia, metabolic 





Figure 1.1: Plasmodium life cycle.7 
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1.2.3 Treatment and prevention 
 
Malaria control aims to provide relief of the clinical symptoms inflicted by the asexual 
erythrocytic stage of the disease14 and to prevent vector-to-host transmission propagated 
through the bite by an infected female Anopheles mosquito.  A further goal is to clear the 
dormant liver forms that are candidates for future activation and harbour the potential to 
initiate new infections.27,28  
Non-therapeutic approaches, targeting vector control, complement chemotherapy in the 
management of malaria. Insecticide treated mosquito nets (ITNs), Indoor Residual Spraying 
(IRS) with insecticides and mosquito repellents have been employed to prevent vector-host 
interactions thereby reducing malaria transmission. Commonly used insecticides for ITNs and 
IRS are those based on pyrethroids due to their environmental and human safety profiles. 
Other approaches have encompassed the clearing of or disinfecting stagnant water to destroy 
the breeding grounds for the mosquitoes to disrupt the parasite life cycle.29–31 
Finding a vaccine against malaria has been elusive and efforts are yet to bear fruit owing to 
challenges associated with the heterogeneity of surface proteins expressed by the parasite.  
The Plasmodium parasite has a complicated life cycle and a similarly complex genetic make-
up.  For this reason it has been difficult to come up with a product that can induce antibody 
production to curtail the reproduction and proliferation of the parasite in vivo.28–30  Even for 
the most promising malaria vaccine under clinical investigation, affordability and accessibility 
by the target population are a concern due to the likelihood that it will, of necessity, require 
additional caution regarding storage facilities to maintain the cold chain besides the more 
costly intravenous mode of administration.32 These are unfavourable profiles for an 
intervention intended to alleviate the suffering of a poor population for which costs of 
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Chemotherapy remains, largely, the mainstay of malaria control and has witnessed 
interesting evolution since the first antimalarial drug, quinine, an alkaloid from the bark of 
the cinchona tree Cinchona officinalis, Rubiciae that grows wildly in South America.15,35 
Quinine was used to treat fevers from as far back as the 16th century even before proper 
understanding of the pathogenesis of malaria. It was, however, not until the 19th century that 
chemical isolation of quinine was attained.35,36  
Events surrounding the two major World Wars necessitated greater supplies of quinine which 
natural sources could not satiate. Pressed by the need to protect the military against the 
ravages of malaria, investments were made towards the discovery of antimalarial drugs.35,37 
The initial approach was to explore chemical synthesis as an alternative to the botanical 
source of quinine. Despite being unsuccessful, the scaffold present in quinine provided an 
important starting point for the synthesis of active antimalarial analogues.36,38,39 
Chloroquine (CQ), a 4-aminoquinoline, is the most well-known and, arguably, the most 
successful quinine-like antimalarial drug of the 20th century. Used clinically since the 1930s, 
CQ was the backbone of malaria treatment till.  resistant parasites emerged and spread, 
prompting the relegation in use of what was a promising drug in the fight against malaria. By 
the 1970s, CQ had been discontinued in many countries40–43. Nonetheless, CQ still finds use, 
in combination with other standard antimalarial drugs, in areas where there is no widespread 
resistance to CQ.  
Prior to the discovery of chloroquine, other quinoline agents employed as antimalarials, 
although to a limited extent, included pamaquine and mepacrine (quinacrine)35,44. 
Subsequent research identified primaquine, an 8-amino quinoline, which displayed 
remarkable activity against malaria caused by P. vivax and P. ovale species and had superior 
safety profiles compared to pamaquine. Primaquine quickly found use as a prophylactic and 
radical cure drug20. The quinoline methanol mefloquine was discovered by the American-
based Walter Reed Army Institute of Research in the late 1960s and it demonstrates superior 
activity to chloroquine including potency against CQR strains of the parasite.45–47  
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Besides the quinoline antimalarials, other drugs were discovered that target previously 
unexplored biosynthetic pathways in the plasmodium parasite such as folic acid biosynthesis. 
For instance, proguanil is an inhibitor of the dihydrofolate reductase (DHFR) enzyme which is 
essential in the conversion of dihydrofolate to tetrahydrofolate, a key step in the synthesis of 
parasite DNA (Figure 1.2).48,49 Chlorproguanil, a chlorinated analogue of proguanil was 
discovered in subsequent studies and has been used in combination with dapsone, a  
sulphonamide, for the treatment of uncomplicated malaria but haemolysis in glucose-6-
phosphate dehydrogenase (G6PD)- deficient patients led to its withdrawal from clinical use.50 
Pyrimethamine, a 2,4-diaminopyrimidine, with structural congruence to proguanil also 
inhibits the dihydrofolate reductase enzyme and is an important antimalarial drug when used 
in combination with others.49,51–53 
In the 1970s, the sulphonamides were characterised to have antimalarial activity in addition 
to the previously documented antibacterial effects. This class of drugs was found to interfere 
with synthesis of DNA albeit at a different target from DHFR inhibiting drugs: they inhibit the 
enzyme dihydropteroate synthase (DHPTS) that catalyses the first step in the pathway 
involving synthesis of dihydrofolate from para-amino benzoic acid (Figure 1.2). Due to 
structural similarities, sulphonamides act as competitive inhibitors, blocking the uptake of 
para-amino benzoic acid, which is the substrate for this process. Exploiting synergy, 
antimalarial therapies were employed using the antifolate drugs such as pyrimethamine and 
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Figure 1.2: Diagrammatic depiction of the steps in folic acid synthesis in plasmodium and targets of 
action of antifolate drugs. 
 
Unfortunately, resistance to sulphonamides quickly developed causing a decline in the use of 
this class of agents.41,56,57 There is renewed interest in the use of antifolates in the context of 
combinational therapy with other standard antimalarial drugs. Typically, sulfadoxine-
pyrimethamine combination is the preferred option for prevention of malaria among 
pregnant women and is widely used in intermittent preventive therapy due to its safety 
profile while trimethoprim-sulfamethoxazole (co-trimoxazole®) has been widely used in 
treatment of childhood fevers, bacterial infections and traveller’s diarrhoea. 54,58–61 
In the decades between 1960 and 1980, the other new chemical entities discovered and 
employed in the treatment of malaria include atovaquone, piperaquine, pyronaridine, 
lumefantrine and naphthoquine (Figure 1.3), which portray a prolonged duration of action. 
Notably, lumefantrine, piperaquine and pyronaridine have since found utility as partner drugs 
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Other agents discovered to have antimalarial activity are the tetracycline antibiotics such as 
tetracycline, doxycycline and minocycline (Figure 1.3), which remain recommended in the 
management of some cases of malaria in combination with suitable standard drugs.62,66,67  
It is perhaps the introduction of the artemisinin-derived drugs in the 21st century that has 
resuscitated hopes of conquering malaria. Artemisinin is obtained from the Chinese herb 
Qinhao (Sweet wormwood) Artemisia annua L., Compositae whose traditional use in 
treatment of fevers in China for over 2000 years sparked interest in the research into its 
antimalarial properties.37,68 Although evidence existed as far back as the 1970s of their 
antimalarial potential, the artemisinins were not widely used until in the early 2000 when 
they received WHO approval as the drugs of choice for uncomplicated malaria.56,69 In their 
work, Chinese researchers unravelled the structure of the active antimalarial component 
where they demonstrated a unique endoperoxide functionality, which is critical to their 
antimalarial action.34,61,68  
Clinically, artemisinin is not administered but rather its derivatives, chiefly: artesunate, 
artemether and the active metabolite dihydroartemisinin, which have superior efficacy and 
physicochemical qualities compared to the precursor artemisinin.70 A significant advantage of 
the artemisinins is their ability to quickly clear blood parasites to below detectable levels.20 
These drugs also have a short elimination half-life and therefore do not encourage selection 
pressure for development of resistance. A set-back, however, with the artemisinins when 
used alone is recrudescence, the re-appearing of plasmodium parasites after initial apparent 
cure due to their short in vivo half-life.21  
To curb resistance and to achieve high efficacy, the artemisinin drugs are therefore used in 
combination with other standard anti-malarial drugs like lumefantrine, mefloquine, 
amodiaquine, sulfadoxine plus pyrimethamine (SP) and piperaquine. It is recommended that 
the drugs used in combination with the artemisinins act via a different mechanism and have 
a slower in vivo elimination to achieve synergy and reduce the chances of development of 
resistance in addition to minimizing side effects.43,71–73 
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The current artemisinin combination therapy (ACT) regimen include: artemether plus 
lumefantrine; artesunate plus chloroquine, amodiaquine or mefloquine; artesunate plus 
sulfadoxine-pyrimethamine and dihydroartemisinin plus piperaquine and are the 
recommended first-line treatment in falciparum malaria endemic regions.1,34,74,75 Formulation 
of these drugs as fixed dose combinations (FDCs) has improved drug dosing regimen and 
encouraged patient adherence.21,23 Second-line antimalarial drugs are used in the event of 
treatment failure or resistance to the first line regimen. Usually, the recommendation is to 
use an alternative ACT expected to be effective based on resistance data in the respective 
region. Artesunate or quinine may also be used in combination with a tetracycline antibiotic 
such as tetracycline, doxycycline or clindamycin.21,36,67,76 In the case of severe complicated 
malaria, limited options exist involving the use of either quinine, artesunate or artemether 
administered intravenously or intramusculary25,74  On the other hand, primaquine is currently 
the only available drug for radical cure while investigations with tafenoquine are at advanced 
stages.29,77,78 
Malaria prophylaxis is a particularly important malaria control strategy especially in people 
traveling to endemic areas from otherwise malaria-free regions.26 In this case, the individuals 
receive prescribed doses of drugs before, during and after the visit. Ideal features of drugs 
used in prophylaxis include a long half-life to ensure adequate drug levels are maintained for 
sufficient periods to prevent infections and to maintain low parasite count in the blood. Drugs 
used presently for prophylaxis against malaria include an ACT or quinine together with SP, 
proguanil plus atovaquone and mefloquine.15 Primaquine has also been used for malaria 
prophylaxis with the necessary precaution47 as have been antibiotics like azithromycin in 
combination with a standard antimalarial drug such as CQ.79,80  
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Figure 1.3: Past and current antimalarial drugs. 
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1.2.4 Challenges in malaria chemotherapy 
 
Despite impressive strides taken towards malaria eradication, challenges still abound with the 
most formidable being the emergence and spread of drug-resistant parasites that threaten 
the longevity of current therapies.83–86  This situation is further spurred, in part, by irrational 
drug use of the limited treatment options.85,86 Travelling and interactions among people from 
malaria endemic and non-endemic regions also contribute to the obstacles in malaria 
eradication as transmission remains an undeniable reality.57,87,88 Unfortunately, not all 
malaria-infected people have access to treatment, a scenario that perpetuates the pool of 
infected hosts who then serve as reservoirs for future infections. On the other hand, reports 
abound of mosquitoes developing resistance to some of the insecticides used in IRS, thereby 
reducing the effectiveness of this critical complementary approach to malaria control.31,89,90  
The unsatisfactory safety profiles of some of the present antimalarial drugs warrants the 
search for better alternatives. Primaquine, the sole agent in clinical use with activity against 
the hepatic forms of P. vivax, causes fatal haemolysis among patients lacking glucose-6-
phosphate dehydrogenase (G6PD), an enzyme involved in regulating cellular oxidative 
stress.20,91 Amodiaquine, on the other hand, is associated with hepatotoxicity and blood 
toxicities, including agranulocytosis and aplastic anaemia, thought to result from its 
metabolism to the quinone imine and aldehyde reactive metabolites, respectively.92–95 Skin 
reactions have been reported with quinine ascribed to its ability to induce 
photosensitivity.96,97 Some partner drugs like the sulphonamides may cause severe 
hypersensitivity reactions like the Stevens-John’s syndrome98,99 while neurological 
repercussions have been described in the use mefloquine amongst some patients.100–102   
Most of the current drugs are active at only one of the Plasmodium life cycle stages, chiefly 
the erythrocytic phase associated with clinical symptoms of malaria. Drugs capable of 
targeting all the life cycle stages of the plasmodia parasite are required if malaria transmission 
is to be blocked and radical cure achieved, in addition to the relief of clinical symptoms.1,18 
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Newer drugs acting by novel mechanisms and with the capacity to interrupt the parasite life 
cycle at multiple stages are therefore a dire need. Furthermore, for a long time, there have 
been no formulations convenient for the paediatric populations who are disproportionately 
affected by the malaria scourge. Only recently have dispersible ACT formulations103,104 as well 
as rectal artesunate105,106 been made available for use in this crucial population segment.  
 
1.2.5 Antimalarial drug development pipeline 
 
The vibrant antimalarial drug discovery and development efforts witnessed in the past 
century gradually waned off and, by the last quarter of the century, there was virtually a 
paucity in research in this therapeutic area with no new antimalarial chemotypes discovered. 
Since malaria, as with other numerous tropical diseases, afflicts mainly the world’s poorest, 
there is projected meagre returns on investments in this disease despite the significant public 
health impact it poses.36,75  
Despite the prolonged dearth, there has been a laudable renaissance towards antimalarial 
drug discovery arising from a greater sense of responsibility amongst the scientific community 
that has prompted joint efforts in tackling diseases like malaria that have received limited 
focus yet. This positive development has been spearheaded by the budding of product 
development partnerships like Medicines for Malaria Venture (MMV) and Drugs for 
Neglected Diseases initiative (DNDi) and fanned by the benevolence of funding agencies such 
as the Bill and Melinda Gates Foundation. Consequently, the recent decade has seen a 
flourishing of partnerships and collaborations featuring academic institutions, 
pharmaceutical companies, sponsors and non-governmental organisations geared towards 
drug discovery for diseases of the poor.3,14,61 
In this private-public partnership, the aim is to inspire and encourage greater commitment to 
finding new drugs for diseases which would otherwise remain neglected due to the prospects 
of low financial returns on investment.107 As a result, there has been impressive progress in 
the translation of basic research and the advancement of hit molecules to pre-clinical studies. 
Several molecules are in preclinical stages of development because of these efforts and others 
have been investigated in the clinic (Figure 1.4).   
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Moreover, owing to the support in basic research into understanding parasite biochemistry, 
physiology and disease pathophysiology, additional diverse targets upon which potential 
antimalarial drug discovery programmes can be based, have been unravelled.  
The current antimalarial drug pipeline is robust in terms of the number, and diversity of 
chemical structure as well as putative mechanisms of action of the investigational agents.  The 
potential drugs range from modifications of previously documented antimalarial scaffolds as 
in AQ-13, a chloroquine analogue61, the pre-clinical candidate dihydrofolate reductase 
inhibitor P218,108 drug hybrids exemplified by trioxaquines that combine features of the 
artemisinins and quinoline antimalarial drugs,17 artemisinin-mimics containing a peroxide 
moiety such as 1,2,4-trioxolanes typified by OZ439 (artefenomel) in advanced clinical 
trials.7,17,109 Others are novel chemical scaffolds with hitherto unexplored biochemical 
pathways in malaria chemotherapy such as the Phase II candidate MMV390048  which targets 
the parasite’s phosphatidylinositol 4-kinase (PfPI4K),110,111the triazolopyrimidine 
dihydroorotate dehydrogenase (DHODH) inhibitor DSM265,112,113 the spiroindolone 
cipargamin (NITD609)1,114 and the imidazolopiperazine KAF156113,115 which are all in Phase II 
clinical trials.29 The prevailing commitment towards enriching the drug development pipeline 
should be sustained especially since we are confronted perennially with the challenge of drug 
resistance.   
                         Chapter 1                                                                                  Introduction and Literature Review 
 




Figure 1.4: Antimalarial agents in pre-clinical and clinical development. 
  
                         Chapter 1                                                                                  Introduction and Literature Review 
 





1.3.1 Epidemiology, transmission and life cycle 
 
 
The public health importance of schistosomiasis is attested to by statistics revealing that there 
are over 200 million people infected, 700 million at risk of infection and that the disease is 
endemic in 78 countries.116–118 This profile makes schistosomiasis rank only second to malaria 
in terms of prevalence among parasitic infections.116,119 Close to 250,000 deaths were 
reported in 2016 due to schistosome-related infections, a figure that is disputed by others, 
citing underestimation.120 As with malaria, schistosomiasis is rife in regions experiencing 
tropical and sub-tropical climates, chiefly sub-Saharan Africa, Middle East, Caribbean and 
South America, where over 90% of the global incidences and mortalities are recorded.121–124  
Schistosomiasis, also known as bilharzia or bilharziosis, is caused by trematodes of the 
Schistosoma genus with the most prevalent species being mansoni, japonicum and 
haematobium.125 Other implicated species, albeit to a rather local extent, include S. 
intercalatum, S. guineensis (West and Central Africa) and S. mekongii (Laos and 
Cambodia).17,126 There is geographical variation in the global distribution of the major 
schistosoma species and hence prevalence in the different forms of schistosomiasis: S. 
mansoni is predominant in Africa, the Middle East, Caribbean and South America, whereas S. 
haematobium is reported mainly in Africa with S. japonicum being prevalent in Asia, 
particularly in China and the Philippines.125,127 The differences in the geographical distribution 
of the schistosome species emanates from the optimum habitats for the types of the snails, 
which are intermediate hosts, critical in the completion of their respective life cycles. Thus, S. 
mansoni replicate in certain species of Biomphalaria snails, S. haematobium utilises Bulinus 
spp while S. japonicum depend on the Oncomelania spp.127  
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Figure 1.5: Global distribution of schistosomiasis.126 
 
The life cycle of schistosomes depends on the human definitive host and an intermediate snail 
vector situated in fresh water environments.128 Infection to humans occurs when they 
interact with fresh water infested with the appropriate snail vector whereupon the larval 
form, cercaria, penetrates the skin. The cercaria sheds off its tail during this invasion, 
transforming into a schistosomula, and migrates to the lungs via the venous arm of the 
circulatory system.17 Subsequently, the juvenile worms move to the hepatic portal system 
after entering the arterial circulation through the pulmonary capillaries, where they mature 
into adult worms. Mature male and female worms pair up inseparably, with the female 
embedded in the gynaecophoric groove of the male, and, depending on the species, migrate 
to either the mesenteric vessels-in the case of S. mansoni and S. japonicum-or to the urinary 
bladder vessels, in infections caused by S. haematobium.129 At these sites, the adult worms 
reproduce sexually, with the female laying eggs, some of which are shed in faeces or urine. 
The eggs, in fresh water, hatch into ciliated forms called miracidia which encounter and infect 
aquatic snails of the appropriate species. While in the intermediate snail vector, the 
miracidium transforms by asexual reproduction to a cercaria, before infecting the next human 
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Figure 1.6: Transmission of schistosomiasis.129 
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1.3.2 Pathophysiology and complications of schistosomiasis 
 
The presentation of schistosomiasis is inextricably connected to the events characterising the 
invasion and migration phases, response of the host immune system to the eggs and the 
presence of the adult worms in the sites of lodging.126,129 Cercarial dermatitis, also referred 
to as “swimmer’s itch”, is an allergic reaction of the skin in response to the penetration of 
cercaria of schistosomes for which the human host is unsuitable for their further 
development.130 Katayama fever, a syndrome of acute schistosomiasis, presents with a host 
of generalised non-specific symptoms comprising, headache, cough, diarrhoea, malaise, 
myalgia and poor appetite.126,129,130 
Immune-induced hypersensitivity reactions against the eggs are largely responsible for the 
manifestations of schistosomiasis.116 When the paired adult worms lodge in the mesenteric 
venules of the gastrointestinal tract, they may cause an array of symptoms ranging from 
abdominal discomfort, bleeding, to intestinal obstruction in case of heavy worm burden. 
Malnutrition due to impaired food absorption is commonly reported in countries with high 
endemicity.125 Chronic inflammation, propagated in part by the evasion of immune response 
by the eggs, result in formation of granulomatous lesions and fibrosis in affected organs with 
consequent compromise of organ function in advanced disease. Some of the complications 
of chronic schistosomiasis include portal hypertension,132–134 liver scarring and fibrosis and 
gastro-intestinal ulceration and anaemia. Other complications secondary to hepatic 
involvement include ascites and oesophageal varices which can be potentially fatal.128,130  
In schistosomiasis induced by haematobium species, immune reactions to the eggs laid by the 
adult worms residing in the renal venules may cause ulceration of the epithelia of the urinary 
lining causing blood to appear in the urine, a condition termed haematuria.125,135 Sustained 
inflammation of the renal apparatus predisposes patients to cancer of the urinary bladder, 
and increased risk of acquiring urinary tract infections caused by urinary retention.128,130 
Female genital schistosomiasis attracts special attention due to its implication as an 
exacerbating factor for the transmission of HIV/AIDs infection due to the compromised 
mucosal barrier secondary to urogenital schistosomiasis136.  
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Besides, the female reproductive system can be severely damaged leading to miscarriages, 
barrenness and ectopic pregnancies which have poor prognosis in advanced 
schistosomiasis.137  
 Embolism of adult worms and concomitant laying of eggs in ectopic sites such as in the brain 
and spinal cord, can present with debilitating pathologies relating to impaired cognitive, 
neural and motor functions.138,117 Due to the insidious nature of the disease, many of the 
symptoms and complications of schistosomiasis are usually only detected in advanced stages. 
This is further confounded by the fact that most of the symptoms are non-specific and present 
in myriad other diseases, leading to frequent misdiagnosis of schistosomiasis.125,127 
 
1.3.3 Treatment, control and prevention 
 
The control and elimination of schistosomiasis depends on treatment of infected persons and 
blocking transmission of the parasites from the intermediate snail host to humans.134,139 
Consequently, multipronged approaches comprising chemotherapy, snail vector control and 
public health campaigns relating to improvements in hygiene and sanitation have been 
employed.127  Snail control has entailed use of natural and chemical molluscides with 
significant contribution to the schistosomiasis control agenda although, is some instances, at 
the expense of interference with other aquatic life forms.137 Despite enduring efforts, public 
health education on hygiene and sanitation especially with regards to proper disposal of 
human waste and human-snail habitat contact remain underachieved due to the poor living 
conditions and economic activities of most of the communities where the disease is 
endemic.127  
In the absence of a vaccine against infections by schistosomes, chemotherapy, therefore, 
remains the backbone of schistosomiasis control.140 Praziquantel (Figure 1.7), a 
pyrazinoisoquinoline analogue, is the drug of choice for the treatment of all types of human 
schistosomiasis.141,142 The drug, introduced in the 1980s, changed the landscape of 
schistosomiasis treatment which was until then, managed by a limited range of drugs with 
unfavourable toxicological profiles besides being costly.143  
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Praziquantel is active against the adult worms with little activity towards the juvenile worms, 
a factor that necessitates repeated administration to ensure effective control.116,121,144 The 
safety, affordability (largely due to generous donations and sponsorship) and ease of 
administration (single oral dose) of praziquantel has endeared it as a tool for mass drug 
administration especially among school-going children who are vastly affected by 
schistosomiasis.145,146 Other important drugs deployed in treatment to schistosomiasis, albeit 
to a lesser extent, are metrifonate and oxamniquine (Figure 1.7) which are singly active 
against infections caused by haematobium and mansoni species.126,130  Oxamniquine has 
particularly been extensively used in Brazil but has since been replaced by praziquantel 




Figure 1.7: Drugs used in the treatment of schistosomiasis. 
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1.3.4 Challenges and opportunities in antischistosomal chemotherapy and drug discovery 
 
The treatment of schistosomiasis remains inadequate especially with the dependence upon 
only one drug which, although induces activity in all the adult worms causing human 
schistosomiasis, has no activity against the immature stages.17,140,147 As such, transmission of 
the disease and re-infection are bound to persist. Besides, the complete reliance on a single 
therapeutic agent for a disease with such high morbidity and mortality is deeply unsafe and 
is potentially catastrophic should resistance emerge in the absence of an effective 
alternative.142,148  
Praziquantel, the sole drug employed in the treatment of schistosomiasis, is associated with 
a bitter taste making it unappealing to children who are the most infected individuals. 
Additionally, the drug is sold as a racemic mixture although it is established that only one 
isomer is responsible for its schistosomicidal activity.127,145 In view of these challenges, there 
is a compelling need to find alternative active agents as antischistosomal drugs that can 
backup praziquantel in the possible setting of resistance and importantly, that will display 
potency against the newly transformed schistosomula in addition to being active against adult 
worms.149  
Schistosomiasis has remained, largely, a neglected tropical disease with little investments in 
drug discovery and development. Among others, two factors seem to be contributing to this 
fate: the disease course subsequent to infection with schistosomiasis is insidious with 
generalised non-specific symptoms mirrored by other ailments with only serious effects 
observable in overly progressed cases.125,140,150 The second, and perhaps more important, 
reason is that there is no motivation for investments in a disease that affects mostly the 
impoverished populations who may not afford the cost of treatment to return the heavy 
investments in research and development.151,152 Consequently, there are few agents in the 
discovery phase for antischistosomal efficacy and the drug development pipeline has been, 
virtually, empty. The landscape is, however, gently changing with improved commitment to 
drug discovery for schistosomiasis, fuelled by concerted efforts and collaborations between 
academic research institutions and the pharmaceutical industry.148 
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There is some progress towards populating the drug discovery pipeline which is currently 
replete mostly with drugs that have been extensively studied for other disease conditions. 
Some of these drugs are detailed in the context of drug repurposing and repositioning, 
discussed later.120  
 
1.4 Approaches to drug discovery and development 
 
1.4.1 Whole cell screening and target-based strategies 
 
Advances in technology and the advent of combinatorial chemistry has accelerated the pace 
at which compounds are tested for biological activity and thus, the progress of medicinal 
chemistry programs.153 The large compound libraries and the improved infrastructure that 
allows for automation has made it possible to screen large volumes of compounds within a 
relatively short time.17 This high throughput screening has increasingly been utilised and 
continues to provide new starting points for several medicinal chemistry optimisation 
campaigns16,78,140 and the thriving private-public partnership ventures have created platforms 
for sharing chemical and biological resources thus enhancing tropical and neglected tropical 
diseases drug discovery efforts.7,140,148,154  
Compounds can either be tested against whole parasitic cells or, if characterised, the isolated, 
purified target to which ligands bind to induce pharmacological outcomes.155 Each of the two 
approaches have attendant benefits and pitfalls; whole cell screening, however, has proven 
to be more successful in providing new clinical candidates than other approaches.17 Some 
molecules in preclinical and clinical development whose frontrunner leads were identified via 
this approach include the antimalarial candidates: triazolopyrimidine (DSM265), 
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Chemical matter identified to be potent in a whole cell screening assay have inherent 
physicochemical properties that allow for traversing biological membranes of the parasite 
and subsequent interaction with the target that result in the observed activity.17 Inversely, in 
target-based screening, the drug molecule is tested for its ability to bind to the target in 
isolation, without the milieu characterising the whole cell or parasite. This inadequate 
recapitulation of biological systems is deemed to be among the chief reasons for the failure 
of many target-based hits to induce in vivo efficacy.148,157 The fact that activity is observed in 
whole cell screens regardless of the knowledge of the target protein is of benefit in the search 
for novel sites and modes of action; thus, making whole cell screening an appealing technique 
in exploring hitherto unidentified drug targets.17 
Moreover, it is not uncommon for a drug to produce a pharmacological effect by interacting 
or interfering with multiple physiological or biochemical pathways which would be 
unrecognised in the classical target-based screening approach.17,140 Besides, a target may be 
discovered not to be critical in the survival of the parasite or that its inhibition is insufficient 
to bring about the desired outcome. A prevailing downside of whole cell screening, however, 
is the need for subsequent target deconvolution, which can be laborious and lengthy, delaying 
lead development, a fact that has made others to prefer target-based screening.17  
Proponents of the target-based screening strategy argue that knowledge of the target protein 
to which investigational agents bind to produce the desired effect would facilitate quicker 
medicinal chemistry iterations leading to the identification of more potent analogues.17,155 
This has been greatly augmented by the application of in silico tools and availability of X-ray 
crystallographic structures of numerous protein targets leading to the burgeoning field of 
computer-aided drug discovery. Testament to the utility of the target-based approach is the 





                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
25 
 
1.4.2 In silico and computer-aided drug discovery 
 
As intimated previously, drug efficacy is driven by various factors including those relating to 
the drug, biological and physiological environment of the parasite and host. The 
understanding and adequate documentation of these variables can allow for rationale 
execution of medicinal chemistry plans and inform decisions at the various stages of early 
drug discovery, preclinical assessments and even in vivo experimentation. In silico and 
computational tools have progressively become integrated in drug discovery platforms where 
they have contributed to the expedited progress and cost reduction towards development of 
clinical candidates.156,158,159 
Simple yet powerful tools and guidelines such as the Lipinski rule of 5 (Figure 1.8) continue to 
direct medicinal chemistry programmes in the selection, design and synthesis of molecules 
with appropriate characteristics to enhance their in vivo efficacy. The properties described by 
Lipinski such as molecular weight, number of hydrogen bond donor and acceptor groups and 
lipophilicity influence physicochemical traits and therefore drug metabolism and 
pharmacokinetics (DMPK).160 Careful control of these parameters within acceptable limits is 
crucial. There are however notable exceptions to this rule for which rationale reference is to 
be observed depending on the series and projects.161,162  
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• Molecular weight ≤ 500 Da 
• No. of hydrogen bond acceptors ≤10 





Figure 1.8: Lipinski rule of five (a), Craig plot (b) and the Topliss decision tree (c). 
a. Lipinski criteria for good oral absorption 
b. Craig plot 
c. Topliss tree 
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The Craig plot (Figure 1.8)163 forms another pertinent reference resource for medicinal 
chemistry teams. In elucidating structure-activity and structure-property relationships, 
various groups differing in electronic and lipophilic characters are explored. A scaffold with 
an evolvable structure-activity relationship (SAR) profile will then point to the favoured 
quadrant within the Craig plot from which several analogues may be pursued to drive the 
medicinal chemistry plan. Physicochemical data generated in silico can be used for prioritising 
synthesis of analogues predicted to bear more drug-like attributes. The rational synthesis of 
such selected target compounds redeems time and resources.164   
A complementary medicinal chemistry tool is the Topliss decision tree165,166 (Figure 1.8) that 
gives guidance on how initial assay results with forerunner analogues can direct choice of 
subsequent alterations. For example, a lipophilic group associated with improved potency 
may trigger synthesis of second generation analogues with an additional lipophilic group or 
with greater lipophilicity. If, however, the lipophilic group results in abrogation of activity, a 
more hydrophilic group may be selected, and should this analogue be more active than its 
precursor, an additional hydrophilic or a more hydrophilic moiety may be considered.  
The chemical structures of compounds can be used to generate their physicochemical and in 
in silico absorption, distribution, metabolism and excretion (ADME) attributes readily by use 
of several software such as Chemdraw®167 and Stardrop®,168–171 respectively. Together with 
the medicinal chemistry tools discussed above, a limited number of analogues can be 
rationally synthesized to gain understanding of the SAR of a given series and evaluate its 
developability, based on predicted physicochemical properties, without excessive indulgence 
of the expensive organic synthesis resources and time.172,173  
Technological advancements and improved understanding of biochemical and physiological 
mechanisms and pathways has also paved way for the development of physiological-based 
pharmacokinetic (PBPK) and pharmacokinetic-pharmacodynamic (PKPD) simulation software 
such as SIMCYP®174–177 and Gastroplus®178–180 that can assist with predicting drug exposure in 
different scenarios. Such platforms can estimate DMPK profiles and provide useful insights to 
drug discovery project teams.181,182 
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Molecular docking and modelling studies have become synchronised in many Pharma set-ups 
and play a vital role from the inception of medicinal chemistry projects.167,183–185This field has 
been buoyed by the greater understanding and maturation of the areas of molecular biology, 
genomics, proteomics and X-ray crystallography.186 With more protein targets being 
identified and isolated in purified form, and their X-ray structures being unravelled, target-
based drug discovery, discussed earlier, has become popular. The X-ray structures reveal the 
architecture of the putative binding sites with regards to nature and arrangement of amino 
acid residues involved in interactions with the ligand. This information facilitates the design 
and synthesis of analogues predicted to possess greater and better binding affinity and, 
hence, potency.155,187–189 
 
1.4.3 Drug repurposing and repositioning 
 
The escalating costs of de novo drug discovery has inspired other alternatives with the 
prospects of shortening the time and reduce financial investments in this already expensive 
venture. This is particularly appropriate for diseases of the poor such as malaria and 
schistosomiasis for which returns on investments are expected to be dismal.151,190 One way 
of finding new drugs is by exploring new therapeutic indications for already existing drugs 
utilised in different disease conditions; a concept referred to as drug repurposing.17 
Otherwise, if the reference drugs are used as templates to guide further medicinal chemistry 
optimisation to generate analogues for new therapeutic uses, the approach is termed drug 
repositioning. Drug rescue is another closely related term which applies when a lead 
compound, previously terminated from development, or a drug withdrawn from clinical use, 
due to a liability like toxicity, undergoes structural alterations to circumvent the shortcomings 
prior to being investigated in a disease of interest.17,191  
A common starting point for drug repositioning is biochemical or pharmacological similarities 
between the targets in the diseases of interest. Additionally, retrospective analysis of the 
clinical effect of a drug may reveal an unexpected or unintended outcome that may form the 
basis for future investigations into the new use of the drug.17,125,190 For instance, during co-
infections, the treatment of one of the diseases may result in the remission of the other 
disease thereby arousing interest in the potential use of the drug in the other disease.  
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These similarities in molecular and cell biology or unexpected clinical observations may then 
be exploited to furnish new analogues for evaluation as potential drugs.192 These methods 
have been used in drug discovery and development in several therapeutic areas including 
malaria and schistosomiasis.67,78,193  
Methotrexate, an antifolate anticancer agent attracted interest for testing as an antimalarial 
agent based on the premise that both cancer cells and malaria parasites require folic acid for 
their survival and are rapidly multiplying cells in comparison to normal cells. In the use of 
methotrexate as an anticancer drug, high doses are used which induce toxicity in patients. 
However, at low doses, methotrexate can clear the malaria parasites without adverse 
toxicity.74  
The antihistaminic drug astemizole, was identified in a high throughput screen against                
P. falciparum and shown to be active against multiple plasmodia strains.194,195 Astemizole was 
previously withdrawn from clinical use due to severe cardiotoxicity believed to arise from 
disruptions in the functions of potassium ion channels that control myocardial 
contractions.196–198 Chemical evolution based on astemizole structure have been pursued to 
generate active analogues with potentially safer profiles.199  
Tinidazole is a nitroimidazole drug and an analogue of metronidazole which is used in the 
treatment of amoebic dysentery. In the treatment of a patient established to be co-infected 
with malaria, tinidazole was found to cause remission of malaria symptoms and 
parasitological cure with activity against the hepatic forms of the parasite. This has led to the 
investigation into the potential therapeutic application of tinidazole in P. vivax malaria.107,199  
 
 
Figure 1.9: Examples of repurposed and repositioned drugs for malaria. 
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Evaluation of the antischistosomal effects of the anticancer drugs miltefosine200 and 
chlorambucil201 in animal models revealed interesting in vivo efficacy, with the latter leading 
to over 85% total worm reduction, with greater activity being against the juvenile worms.120 
In another study on an oncology drug library at the National Cancer Institute, the kinase 
inhibitors trametinib and vandetanib were identified with good efficacy in a murine model of 
schistosomiasis (Figure 1.10).202  
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This work prompts further investigation of kinases as druggable targets in antischistosomal 
drug discovery.  Other approved drugs such as perhexiline (angina),203 clofazimine (antibiotic) 
and doramectin (antihelminthic)204 have also demonstrated promising in vivo 
antischistosomal activity and can serve as important leads (Figure 1.10).  
Regarding drug repositioning and repurposing in the discovery of new antischistosomal 
agents from antimalarial drugs and leads, similarities in the haemoglobin catabolism between 
plasmodia and schistosomes have been cited (Figure 1.11). Haemoglobin is the oxygen-
carrying protein in the blood of mammals. Blood-feeding parasites such as Plasmodium and 
the schistosomes depend on haemoglobin for their nutritional requirements.149,205 These 
parasites degrade haemoglobin, the process in which amino acids are liberated and utilised 
for nourishment while the non-globin part, heme, is released as waste product (Figure 1.11). 
However, free heme is toxic to the parasite which has developed a mechanism to convert it 
to the inert hemozoin.206 This heme detoxification pathway is a druggable target and is 
certainly one of the contributing mechanisms of action of notable antimalarial agents such as 










                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
32 
 
Several drugs used in the treatment of malaria have exhibited antischistosomal 
properties.120,190 This observation has sparked interest in the testing of antimalarial lead 
compounds in antischistosomal assays as a way of identifying potential starting points for 
drug discovery towards schistosomiasis. To this end, an open resource referred to as the 
“Malaria Box” has been availed by the Medicines for Malaria Venture (MMV) for screening 
against neglected tropical diseases (NTDs) including schistosomiasis.209–211  
Derivatives featuring the N,N’-diarylurea (MMV665852) and 2,3-dianilinoquinoxaline 
(MMV007224) scaffolds (Figure 1.12) are two examples of active antischistosomal hits arising 
from the utilisation of this resource in a repositioning approach and are promising lead 
candidates for further development.120,212  
 
 
Figure 1.12: Antischistosomal drug leads from MMV Malaria Box. 
 
 
There is a general overlap in the global epidemiological profiles of malaria and schistosomiasis 
making co-infections with the two diseases a frequent occurrence.154 Some researchers have 
exploited this co-incidence to assess the antischistosomal impact of clinically approved 
antimalarial drugs.206 In West Africa, Keiser and co-workers observed the antischistosomal 
efficacy of mefloquine when used in intermittent preventive therapy against malaria among 
expectant mothers. A similar observation was registered in the use of ACTs containing 
artesunate and artemether among school going children with greater efficacy noted when 
administered together with the standard antischistosomal drug, praziquantel.154,206,213  
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Artemisinins have been shown to be particularly active against the immature worms, a profile 
lacking with praziquantel. There is therefore pleasant synergy when the two drugs are used 
together. Having an antimalarial agent that contains antischistosomal activity is an advantage 
on many fronts: It will be cheaper to treat two diseases with one drug, reducing both the costs 
and pill burden hence improving patient compliance. There is also the advantage of reducing 
potential for drug-drug interactions since fewer medications would be required. There is, 
however, concern over the potential for selection of drug-resistant plasmodia parasites if 
antimalarial drugs are to be used as antischistosomal agents, indiscriminately in malaria 
endemic regions.125  
These examples provide credit to the deployment of drug repurposing and repositioning 
approaches as cheaper and quicker alternatives to drug discovery and development. Indeed, 
a previous analysis showed that, in 2004, close to 40% of the registered drugs by the US FDA 
were investigated for other indications other than those for which they were originally 
discovered and registered.74   
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1.5 Physicochemical properties in drug discovery and development 
 
Physical and chemical characteristics like molecular weight, lipophilicity, number of hydrogen 
bond donors and acceptors, the total polar surface area, number of rotatable bonds and 
dihedral angles influence the overall properties of a compound and have a bearing on such 
important properties as solubility and permeability. These molecular properties have been 
used to prioritise compounds for their drug-likeness due to their influence on DMPK 
properties upon which in vivo efficacy depends. 159,162,186,214 
 
1.5.1    Solubility 
 
Solubility, the maximum concentration of a dissolved substance under specific solvent 
conditions, is among the essential physicochemical properties (PCPs) that impact greatly on 
the probability of a drug lead to be developed further.215 For orally administered solid drugs, 
disintegration into smaller particles precedes dissolution and absorption processes. 
Therefore, bioavailability, the fraction of administered dose that reaches systemic circulation, 
is directly linked to the solubility of the drug. Poorly soluble drugs risk precipitating in 
biological fluids and thereby compromising drug absorption. Besides causing inadequate drug 
exposure, precipitation may lead to organ damage such as formation of renal crystals in the 
kidneys or gastrointestinal (GIT) discormfort.216 For injectable medications, low solubility 
would necessitate the use of large infusion volumes or frequent dosing that may increase the 
costs of the medication.   
In the early drug discovery and development phases, knowledge of the solubility profiles of 
compounds is vital for several reasons. The bioassays performed to guide project decisions 
can only produce reliable results if the compounds analysed have acceptable solubility. Poor 
solubility may lead to skewed judgements and decisions owing to inaccurate biological activity 
results.217  For instance, a highly insoluble compound may register artificially low potency 
since insufficient concentrations of the compound are attained in the assay conditions. 
Moreover, the poorly soluble compound is also likely to show exaggeratedly high metabolic 
stability since, due to precipitation, not all the compound is exposed to the drug metabolising 
enzymes during the assay.164,217  
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During lead optimization and pre-clinical evaluation, reproducible results are more likely with 
compounds having good solubility. This also allows for in vitro to in vivo correlations and dose 
projections. The solubility profiles of candidate compounds would guide formulation 
strategies for animal dosing experiments and, if advanced further, clinical trials.160 
Compounds with a combination of good potency, adequate permeability and solubility are 
predicted to require lower doses to achieve the desired therapeutic outcomes.  
During clinical trials, poorly soluble drugs are associated with erratic absorption and 
inconsistent exposures in test subjects. The inter-individual variability in the 
pharmacokinetics of a drug candidate can derail its development and may necessitate further 
investigations to meet recommendations and restrictions set by drug regulatory authorities. 
This can significantly increase the overall costs and time taken in drug development.215  
 
1.5.2    Lipophilicity and permeability 
 
Frequently, drugs must traverse biological membranes such as those of the gastrointestinal 
system and blood vessels to reach their sites of action. Thus, lead compounds require not only 
good solubility but also the right lipophilicity. Lipophilicity (LogP) is defined as the ratio of the 
concentration of a drug when partitioned between a lipid layer (usually n-octanol) and an 
aqueous layer (water). Substances with high logP values have the propensity to distribute into 
the octanol layer more than the aqueous layer whereas low logP signifies the ease of 
association of a compound with the aqueous layer over the organic phase. Whereas solubility 
is requisite for a compound to dissolve, lipophilicity allows it to traverse the phospholipid 
membranes. Solubility and lipophilicity are thus contrasting yet inseparable parameters that 
collectively drive bioavailability.218–221  
Besides influencing drug absorption, lipophilicity affects other PK parameters and its 
optimisation can improve the drug-likeness of early drug discovery leads.220 For instance, 
highly lipophilic molecules are associated with increased capacity for interaction with 
biomolecules such as proteins leading to high plasma protein binding which reduces the free 
fraction of drug available to interact with receptors. It is the unbound drug concentration that 
determines in vivo activity.  
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This tissue-binding propensity causes high volumes of distribution, decreased clearance and 
prolongation of elimination half-life.222 Whereas this might be desirable in certain cases, it 
can potentially be a source of toxicity especially through drug-drug interactions when another 
high protein-binding drug is co-administered and compete for binding to the same proteins 
or in disease conditions where binding profiles may be altered due to decreased levels of 
proteins. In both these instances, the concentration of free drug may be elevated above the 
therapeutic range leading to toxicity.223  
Toxicity, due to off-target interactions, seems to increase with an increase in lipophilicity as 
does the susceptibility to drug metabolism.224 The cytochrome P450 drug metabolizing 
enzymes, which are responsible for the biotransformation of most marketed drugs contain a 
hydrophobic pocket which makes highly lipophilic drugs good substrates, a property that 
renders them metabolically labile and can compromise their suitability as leads. Interestingly, 
hydrophobic interactions, and hence high lipophilicity, are often key mediators of drug-target 
binding that precede a pharmacological outcome. It is therefore of paramount importance to 
ensure a proper balance between the solubility and lipophilicity of a lead compound to boost 
its chances of eliciting the intended clinical outcome with good potency, efficacy and safety 
profiles. 
The speed at which molecules cross the semipermeable membranes is a measure of their 
permeability. As with other physicochemical attributes, the permeability of a compound 
depends on multiple factors including size, polarity and lipophilicity.225 Smaller molecules can 
travel faster across the membrane while the correct balance of polarity is required for 
association with the phospholipid bi-layers that are made up of inner hydrophobic and outer 
hydrophilic centres. Lipophilicity will mediate the interactions of the compound with the 
hydrophobic interiors while polar groups ensure that the drug can associate with the 
hydrophilic surfaces on the epithelial cells of the gastrointestinal membranes, crucial for 
absorption of orally administered drugs. Jointly, solubility, permeability and metabolic 
stability are key in determining the eventual drug concentration in the systemic circulation, 
hence, the bioavailability.226  
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1.5.3    Biopharmaceutical Classification System 
 
The relevance of determining physicochemical profiles of leads upstream in the drug 
development continuum is exemplified by the Biopharmaceutical Classification System (BCS); 
a system developed to predict oral bioavailability based on in vitro parameters chiefly 
solubility and permeability.160,216 A closely related Biopharmaceutical Drug Disposition and 
Classification System (BDDS) factors in the disposition of a drug and the potentials for drug-
drug interactions based on its physicochemical attributes.227 Based on the BCS, drugs are 
classified into any of the four quadrants according to their solubility and permeability profiles 
(Figure 1.13).  
Compounds that are both highly soluble and permeable I, are predicted to be easily absorbed 
and have high bioavailability. Some compounds may be highly soluble but poorly permeable 
(II) for example highly polar molecules (antibiotics, peptides). These drugs would require 
modifying their polarity by introducing lipophilic groups as in pro-drugs. The increased 
lipophilicity is expected to enhance permeability.  In some cases, the drug leads may be 
sufficiently lipophilic with good permeation ability but with low soluble (III). In such cases, 
formulation strategies would be required to influence the dissolution profile.  
The least favourable category comprises leads or drugs that have both low solubility and poor 
permeability (IV) and for which in vitro-to- in vivo correlation is impossible. This category is 
associated with high drug development costs as investments in formulation strategies to 
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Figure 1.13: The Biopharmaceutics Classification System. 
 
Many drug discovery projects use information on the solubility, permeability and metabolic 
stability of series to prioritise compounds for further development as these have better 
potentials of translating into clinical candidates. Moreover, based on the logical prediction 
that compounds with good solubility and permeability profiles are more likely to achieve high 
exposures in vivo, pharmaceutical companies have used the BCS in conjunction with other 
tests such as in vitro and in vivo animal ADME studies, to seek and obtain biowaivers from 
drug regulatory authorities such as the FDA. This approach has been instrumental in 
expediting the progress to registration of new drugs that would have otherwise required 
extended and costly bioequivalence studies.216,230–232  
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1.5.4 Strategies to improve physicochemical characteristics 
 
The hits and initial leads of drug discovery projects are often characterised by inadequate 
PCPs that require optimisation and one of the key properties targeted is solubility.217,233 
Approaches to improve solubility include physical methods, chemical modification and 
supramolecular-derivation. Formulation strategies may also be employed in the later stages, 
usually as a last resort, when structure-based modification is unsuccessful.216 Physical 
methods of improving solubility entail approaches such as reducing particle size to increase 
the surface area of particles that are in contact with the solvent system to maximise solute-
solvent interactions. As a result, the dissolution and absorption of the active pharmaceutical 
ingredient is enhanced. Other physical approaches include use of dispersion systems and co-
formulations.234–236 
Chemical structure modification, a commonly used technique in medicinal chemistry, has 
been successful in elucidating the structure-solubility relationship profiles of many compound 
series.216 In this method, changes to the lead compound are executed by, for example, 
introducing groups that improve polar interactions (OH, NH, SH). The ensuing hydrogen-bond 
polar interactions between the compound and the solvent increase the solubility of the 
analogues. Introducing polar groups in the pro-drug strategy has been critical in improving 
solubility of several drugs.237  
Aromaticity is a feature associated with high lipophilicity which as mentioned earlier, has 
reciprocal relationship to solubility.238 The dense electron character and flat architecture in 
various aromatic compounds encourage pi-pi stacking resulting in low energy forms with high 
melting points and increased solvation energy. Improvements in solubility can, therefore, be 
achieved by de-aromatisation of molecules.239 As such, cyclic saturated systems have been 
used in SAR optimisation programs aimed at improving solubility. Planarity and molecular 
symmetry are features that favour crystal packing and low energy conformations associated 
with decreased solubility; when disrupted, molecules with higher energy states and better 
solubility can be realised.239 This can be achieved via substitutions at appropriate sites on a 
given scaffold such as at benzylic positions or in di-aryl systems. 
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Reduction in molecular size is another avenue for the generation of more soluble analogues. 
For compounds containing cyclic aliphatic or aromatic rings, a SAR campaign using smaller 
rings or lipophilic groups can be explored and if these alternatives result in similarly active 
compounds, these are preferred as they will possess better solubility. 
Medicinal chemistry changes to improve permeability are those that will increase lipophilicity 
and are often opposite to those that favour solubility. The changes include reducing polarity 
by transforming polar functional groups to non-polar ones for example, converting carboxylic 
acid group to an ester and hydroxyl group to an ether. These added moieties are usually 
cleaved after absorption to unmask the previously covered functional group to accomplish 
the pharmacological action; this is the pro-drug concept.162,186 Moreover, reducing molecular 
size has the potential to improve permeability as it does for solubility.218 
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1.6 Pharmacokinetic principles in drug discovery and development 
 
The changes that occur on a drug following its administration into a living system define its 
pharmacokinetic profile. In the case of an orally administered drug, the events occurring 
include the ADME processes. As safety is paramount in drug discovery projects, the study of 
the toxicological profile is increasingly being front-loaded in which case the acronym ADMET 
is used.240–243  
Absorption of a drug describes the phase where the drug crosses the biological membranes 
of the gastrointestinal tract before entering the systemic circulation. Since dissolution of the 
solid drug into aqueous biological media must take place followed by penetration of the drug 
molecules across the GIT membranes, both solubility and permeability are pre-requisites for 
absorption. Once absorbed into the mesenteric vessels of the GIT, the drug is transported to 
the liver via the hepatic portal circulation which conveys nutrient-rich blood from the GIT to 
the liver. During this first passage through the liver, significant drug metabolism may occur, 
hence first pass metabolism, before the drug finally enters the general systemic circulation.242 
This phenomenon can influence the amount of drug that eventually reaches target sites of 
action. Bioavailability is the fraction of the administered oral dose that eventually reaches the 
systemic circulation and is thus a function of both the solubility, permeability and metabolic 
stability of a drug. 
The body recognises drugs as being foreign substances and endeavours to eliminate them, 
usually after bio-transformations. Drug metabolism occurs principally in the liver as it has high 
concentrations of drug-metabolising enzymes and is highly perfused.244 Other sites such as 
the kidney, gastro-intestinal tract, blood plasma and lungs may also participate in drug 
metabolism albeit, to a lesser extent. Metabolism may be classified largely as either phase I 
or Phase II. In phase I, the drug is modified mainly to increase its polarity to enhance its 
removal from the body. Phase I reactions include oxidation, reduction and hydrolysis and take 
place mainly in the microsomes of the smooth endoplasmic reticulum where Cytochrome 
P450 (CYP450) superfamily of enzymes are located. Phase II reactions occur mainly in the 
cytosol and involve the attachment of a polar group, such as glucuronide or sulphate via 
conjugation reactions mediated by the soluble transferase enzymes.242,245–247 
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Over 90% of marketed drugs undergo metabolism mediated by the CYP450 enzymes making 
in vitro drug metabolism profiling therefore using these enzymes a compelling practice in 
many drug discovery programs.248,249  The ability of a new chemical entity to withstand 
metabolism to an acceptable degree is an important parameter as it impacts on the 
bioavailability and hence pharmacological outcome, in combination with the 
potency.241,242,250,251 Thus, metabolic stability assays are important components of early drug 
discovery screening cascades for their role not only is choosing analogues with suitable 
metabolic stability but also providing insights critical in identifying metabolic hotspots in a 
molecule. The information can assist medicinal chemistry teams in executing chemical 
modifications to address this liability.155,252 
In many cases, metabolism produces inactive metabolites. However, active metabolites can 
be formed following biotransformation with the potential to prolong the pharmacological 
action of the parent compound. Such an observation may prompt research teams to 
synthesize the active metabolite and study its biological activity, in vitro drug metabolism and 
pharmacokinetics. In the case of pro-drugs, metabolism usually serves to cleave off the 
protecting group to reveal the active pharmacological entity. On the other hand, toxic 
metabolites have been characterised for some compounds and have resulted in 
discontinuation from development or withdrawal from the market of previously approved 
drugs. Metabolite identification studies, especially for compounds with structural alerts are, 
therefore, recommended in drug discovery.240,252,253 Medicinal chemistry optimization of 
metabolic stability is usually viable with the replacement of the labile functionalities with 
alternative groups that are more resistant to metabolism but that preserve the ability of the 
molecule to interact with its biological target hence maintaining biological activity.254,255   
Since drugs are xenobiotics, they should be removed from the body after achieving their 
pharmacological activities. The process of excretion occurs mainly in the kidney although 
other organs such as the liver, skin, lungs, tears and even breast milk, may play a role.256  
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A rapidly cleared drug may have a short-lived pharmacological effect whereas overly 
prolonged drug concentrations may be a cause for the toxicity of some drugs. In the case of 
rapidly cleared drugs, combination with other agents that reduce their clearance to improve 
their half-life can be explored as seen in the co-administration of the antibiotic penicillin with 
the renal re-uptake inhibitor probenecid in the treatment of certain bacterial infections.257,258 
Prolonged drug exposure long after completing desired pharmacological actions raises 
propensity for toxicity and drug-drug interactions during co-treatment with other drugs. 
Chemical modifications may also be applied to optimise the excretion profile of a compound.  
Drug safety is fundamental and delineating this property via toxicity assessments as early as 
possible is crucial in identifying compounds with greater chances of advancing to the 
clinic.155,242 The ideal compound should be potent with minimal toxicity observed as a higher 
selectivity index during in vitro assays and wider therapeutic window in clinical evaluations.  
The selectivity is determined by establishing the concentration of compound required to 
produce a desired effect in the target in comparison to the concentration at which inhibition 
of normal cells is achieved: the higher the ratio, the better the selectivity and, hence, safety 
of the drug.242,245 
In addition to the tests in mammalian cell lines, interactions with other specific targets such 
as the human ether-a-go-go-related (hERG) gene have become crucial. This gene controls the 
expression of potassium ion channels that regulate ion flux during myocardial activity.259–261 
Disruptions in the function of these ion channels have been reported with drugs like 
astemizole leading to fatal heart attacks and is the reason for the withdrawal of the drug from 
the market.262 Additionally, during pre-clinical animal studies, acute and chronic effects of the 
selected leads are investigated on major systems including the heart, kidneys, liver, lungs and 
nervous system. Other studies include effects on the reproductive system, mutagenicity and 
carcinogenicity.263   
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1.7 Chapter Summary 
 
This chapter has provided a background to malaria and schistosomiasis that are the focus of 
the research work upon which this thesis is based. Insights into the prevalence, current 
treatment options and challenges as well as the current state of discovery and development 
of new interventions, were discussed. The chapter further described the opportunities and 
compelling need for discovering newer therapeutic agents against these diseases and the 
various approaches to drug discovery and development including the application of whole cell 
screening and drug repositioning which are of special interest in this thesis. Finally, the 
physical and chemical characteristics of drugs as well as in vitro ADME properties have been 
discussed in relation to how they influence in vivo studies and pharmacological outcomes.   
  
                         Chapter 1                                                                                  Introduction and Literature Review 
 





(1)  Burrows, J. N.; Hooft van Huijsduijnen, R.; Möhrle, J. J.; Oeuvray, C.; Wells, T. N. 
Designing the next Generation of Medicines for Malaria Control and Eradication. Malar. J. 
2013, 12 (1), 187. 
(2)  Tangpukdee, N.; Duangdee, C.; Wilairatana, P.; Krudsood, S. Malaria Diagnosis: A Brief 
Review. Korean J. Parasitol. 2009, 47 (2), 93–102. 
(3)  Flannery, E. L.; Chatterjee, A. K.; Winzeler, E. A. Antimalarial Drug Discovery — 
Approaches and Progress towards New Medicines. Nat. Rev. Microbiol. 2013, 11 (12), 849–
862. 
(4)  Carter, R.; Mendis, K. N. Evolutionary and Historical Aspects of the Burden of Malaria. 
Clin. Microbiol. Rev. 2002, 15 (4), 564–594. 
(5)  Murphy, S. C.; Shott, J. P.; Parikh, S.; Etter, P.; Prescott, W. R.; Stewart, V. A. Review 
Article: Malaria Diagnostics in Clinical Trials. Am. J. Trop. Med. Hyg. 2013, 89 (5), 824–839. 
(6)  Keurulainen, L.; Vahermo, M.; Puente-Felipe, M.; Sandoval-Izquierdo, E.; Crespo- 
Fernández, B.; Guijarro-López, L.; Huertas-Valentín, L.; de las Heras-Dueña, L.; Leino, T. O.; 
Siiskonen, A.; Ballell-Pages, L.; Sanz, L. M.; Castañeda-Casado, P.; Jiménez-Díaz, M. B.; 
Martínez-Martínez, M. S.; Viera, S.; Kiuru, P.; Calderón, F.; Yli-Kauhaluoma, J. A Developability-
Focused Optimization Approach Allows Identification of in vivo Fast-Acting Antimalarials: N -
[3-[(Benzimidazol-2-Yl)amino]propyl]amides. J. Med. Chem. 2015, 58 (11), 4573–4580. 
(7)  Biamonte, M. A.; Wanner, J.; Le Roch, K. G. Recent Advances in Malaria Drug 
Discovery. Bioorg. Med. Chem. Lett. 2013, 23 (10), 2829–2843. 
(8)  World Health Organisation (WHO). World Malaria Report; Geneva, 2017. 
(9)  Radloff, P.; Philips, J.; Nkeyi, M.; Kremsner, P.; Radloff, P.; Hutchinson, D.; Kremsner, 
P. Atovaquone and Proguanil for Plasmodium falciparum Malaria. Lancet 1996, 347 (9014), 
1511–1514. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
46 
 
(10)  Desai, M.; ter Kuile, F. O.; Nosten, F.; McGready, R.; Asamoa, K.; Brabin, B.; Newman, 
R. D. Epidemiology and Burden of Malaria in Pregnancy. Lancet Infect. Dis. 2007, 7 (2), 93–
104. 
(11)  Shepard, D. S.; Ettling, M. B.; Brinkmann, U.; Sauerborn, R. The Economic Cost of 
Malaria in Africa. Trop. Med. Parasitol. 1991, 42 (3), 199–203. 
(12)  Sachs, J.; Malaney, P. The Economic and Social Burden of Malaria. Nature 2002, 415 
(6872), 680–685. 
(13)  Chima, R. I.; Goodman, C. A.; Mills, A. The Economic Impact of Malaria in Africa: A 
Critical Review of the Evidence. Health Policy (New. York). 2003, 63 (1), 17–36. 
(14)  Barnett, D. S.; Guy, R. K. Antimalarials in Development in 2014. Chem. Rev. 2014, 114, 
11221–11241. 
(15)  Cox, F. E. History of the Discovery of the Malaria Parasites and Their Vectors. Parasit. 
Vectors 2010, 3 (Figure 1), 5. 
(16)  Bhagavathula, A. S.; Elnour, A. A.; Shehab, A. Alternatives to Currently Used 
Antimalarial Drugs: In Search of a Magic Bullet. Infect. Dis. Poverty 2016, 5 (1), 103. 
(17)  Njoroge, M.; Njuguna, N. M.; Mutai, P.; Ongarora, D. S. B.; Smith, P. W.; Chibale, K. 
Recent Approaches to Chemical Discovery and Development Against Malaria and the 
Neglected Tropical Diseases Human African Trypanosomiasis and Schistosomiasis. Chem. Rev. 
2014, 114 (22), 11138–11163. 
(18)  Wells, T. N. C.; Alonso, P. L.; Gutteridge, W. E. New Medicines to Improve Control and 
Contribute to the Eradication of Malaria. Nat. Rev. Drug Discov. 2009, 8 (11), 879–891. 
(19)  Mendis, K.; Sina, B. J.; Marchesini, P.; Carter, R. The Neglected Burden of Plasmodium 
Vivax Malaria. Am. J. Trop. Med. Hyg. 2001, 64 (1–2 Suppl), 97–106. 
(20)  Burgoine, K. L.; Bancone, G.; Nosten, F. The Reality of Using Primaquine. Malar. J. 
2010, 9 (1), 376. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
47 
 
(21)  Banek, K.; Lalani, M.; Staedke, S. G.; Chandramohan, D. Adherence to Artemisinin-
Based Combination Therapy for the Treatment of Malaria: A Systematic Review of the 
Evidence. Malar. J. 2014, 13, 7. 
(22)  Freedman, D. O. Malaria Prevention in Short-Term Travelers. N. Engl. J. Med. 2008, 
359 (6), 603–612. 
(23)  Lödige, M.; Hiersch, L. Design and Synthesis of Novel Hybrid Molecules against 
Malaria. Int. J. Med. Chem. 2015, 2015, 1–23. 
(24)  Garcia, C. R.; Markus, R. P.; Madeira, L. Tertian and Quartan Fevers: Temporal 
Regulation in Malarial Infection. J. Biol. Rhythms 2001, 16 (321), 436–443. 
(25)  Olliaro, P. L.; Taylor, W. R. J. Antimalarial Compounds: From Bench to Bedside. J. Exp. 
Biol. 2003, 206, 3753–3759. 
(26)  Sheehy, T. W.; Reba, R. C. Complications of Falciparum Malaria and Their Treatment. 
Ann. Intern. Med. 1967, 66 (4), 807–809. 
(27)  Hulden, L.; Hulden, L. Activation of the Hypnozoite: A Part of Plasmodium Vivax Life 
Cycle and Survival. Malar. J. 2011, 10 (1), 90. 
(28)  Fernando, D.; Rodrigo, C.; Rajapakse, S. Primaquine in Vivax Malaria: An Update and 
Review on Management Issues. Malar. J. 2011, 10 (1), 351. 
(29)  White, N. J. Can New Treatment Developments Combat Resistance in Malaria? Expert 
Opin. Pharmacother. 2016, 17 (10), 1303–1307. 
(30)  World Health Organization. The Use of DDT in Malaria Vector Control. WHO position 
statement 2007. 
(31)  Ranson, H.; N’Guessan, R.; Lines, J.; Moiroux, N.; Nkuni, Z.; Corbel, V. Pyrethroid 
Resistance in African Anopheline Mosquitoes: What Are the Implications for Malaria Control? 
Trends Parasitol. 2011, 27 (2), 91–98. 
(32)  Targett, G. A. T.; Moorthy, V. S.; Brown, G. V. Malaria Vaccine Research and 
Development: The Role of the WHO MALVAC Committee. Malar. J. 2013, 12 (1), 362. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
48 
 
(33)  Winzeler, E. A. Malaria Research in the Post-Geno Era. Nat. Rev. 2008, 455 (October), 
751–756. 
(34)  Na-Bangchang, K.; Karbwang, J. Current Status of Malaria Chemotherapy and the Role 
of Pharmacology in Antimalarial Drug Research and Development. Fundam. Clin. Pharmacol. 
2009, 23, 387–409. 
(35)  Meshnick, S. R.; Dobson, M. J. The History of Anti-Malarial Drugs. Antimalar. 
Chemother. Mech. Action, Resist. New Dir. Drug Discov. 1948, 14, 14–16. 
(36)  Achan, J.; Talisuna, A. O.; Erhart, A.; Yeka, A.; Tibenderana, J. K.; Baliraine, F. N.; 
Rosenthal, P. J.; D’Alessandro, U. Quinine, an Old Anti-Malarial Drug in a Modern World: Role 
in the Treatment of Malaria. Malar. J. 2011, 10 (1), 144. 
(37)  Chen, C. Development of Antimalarial Drugs and Their Application in China: A 
Historical Review. Infect. Dis. poverty 2014, 3 (1), 9. 
(38)  Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. Quinolines and Structurally Related 
Heterocycles as Antimalarials. Eur. J. Med. Chem. 2010, 45, 3245–3264. 
(39)  Foley, M.; Tilley, L. Quinoline Antimalarials: Mechanisms of Action and Resistance. Int. 
J. Parasitol. 1997, 27 (2), 231–240. 
(40)  Farooq, U.; Mahajan, R. C. Drug Resistance in Malaria. J. Vector Borne Dis. 2004, 41 
(3–4), 45–53. 
(41)  Klein, E. Y. Antimalarial Drug Resistance: A Review of the Biology and Strategies to 
Delay Emergence and Spread. Int. J. Antimicrob. Agents 2013, 41 (4), 311–317. 
(42)  Packard, R. M. The Origins of Antimalarial-Drug Resistance. N. Engl. J. Med. 2014, 371 
(5), 397–399. 
(43)  Antony, H. A.; Parija, S. C. Antimalarial Drug Resistance: An Overview. Trop. Parasitol. 
2016, 6 (1), 30–41. 
(44)  Vennerstrom, J. L.; Makler, M. T.; Angerhofer, C. K.; Williams, J. A. Antimalarial Dyes 
Revisited: Xanthenes, Azines, Oxazines, and Thiazines. Antimicrob. Agents Chemother. 1995, 
39 (12), 2671–2677. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
49 
 
(45)  Maguire, J. D.; Krisin; Marwoto, H.; Richie, T. L.; Fryauff, D. J.; Baird, J. K. Mefloquine 
Is Highly Efficacious against Chloroquine-Resistant Plasmodium Vivax Malaria and 
Plasmodium falciparum Malaria in Papua, Indonesia. Clin. Infect. Dis. 2006, 42 (8), 1067–1072. 
(46)  Sowunmi, A.; Oduola, A. M. J. Open Comparison of Mefloquine, 
Mefloquine/sulfadoxine/pyrimethamine and Chloroquine in Acute Uncomplicated 
Falciparum Malaria in Children. Trans. R. Soc. Trop. Med. Hyg. 1995, 89 (3), 303–305. 
(47)  Weiss, W. R.; Oloo, A. J.; Johnson, A.; Koech, D.; Hoffman, S. L. Daily Primaquine Is 
Effective for Prophylaxis against Falciparum Malaria in Kenya: Comparison with Mefloquine, 
Doxycycline, and Chloroquine plus Proguanil. J. Infect. Dis. 1995, 171 (6), 1569–1575. 
(48)  Fidock, D. A.; Wellems, T. E. Transformation with Human Dihydrofolate Reductase 
Renders Malaria Parasites Insensitive to WR99210 but Does Not Affect the Intrinsic Activity 
of Proguanil. Proc. Natl. Acad. Sci. 1997, 94 (20), 10931–10936. 
(49)  Plowe, C. V.; Djimde, A.; Bouare, M.; Doumbo, O.; Wellems, T. E. Pyrimethamine and 
Proguanil Resistance-Conferring Mutations in Plasmodium falciparum Dihydrofolate 
Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa. Am. J. Trop. Med. 
Hyg. 1995, 52 (6), 565–568. 
(50)  Van Malderen, C.; Van Geertruyden, J.-P.; Machevo, S.; González, R.; Bassat, Q.; 
Talisuna, A.; Yeka, A.; Nabasumba, C.; Piola, P.; Daniel, A.; Turyakira, E.; Forret, P.; Van 
Overmeir, C.; Van Loen, H.; Robert, A.; D’ Alessandro, U. Glucose-6-Phosphate Dehydrogenase 
Deficiency, Chlorproguanil-Dapsone with Artesunate and Post-Treatment Haemolysis in 
African Children Treated for Uncomplicated Malaria. Malar. J. 2012, 11 (1), 139. 
(51)  Triglia, T.; Cowman, A. F. Primary Structure and Expression of the Dihydropteroate 
Synthetase Gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. 1994, 91 (15), 7149–7153. 
(52)  Brooks, D. R.; Wang, P.; Read, M.; Watkins, W. M.; Sims, P. F. G.; Hyde, J. E. Sequence 
Variation of the Hydroxymethyldihydropterin Pyrophosphokinase: Dihydropteroate Synthase 
Gene in Lines of the Human Malaria Parasite, Plasmodium falciparum, with Differing 
Resistance to Sulfadoxine. Eur. J. Biochem. 1994, 224 (2), 397–405. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
50 
 
(53)  Bzik, D. J.; Li, W. B.; Horii, T.; Inselburg, J. Molecular Cloning and Sequence Analysis of 
the Plasmodium falciparum Dihydrofolate Reductase-Thymidylate Synthase Gene. Proc. Natl. 
Acad. Sci. 1987, 84 (23), 8360–8364. 
(54)  Fasan, P. O. Trimethoprim plus Sulphamethoxazole Compared with Chloroquine in the 
Treatment and Suppression of Malaria in African Schoolchildren. Ann. Trop. Med. Parasitol. 
1971, 65 (1), 117–121. 
(55)  Bushby, S. R. M.; Hitchings, G. H. Trimethoprim, a Sulphonamide Potentiator. Br. J. 
Pharmacol. Chemother. 1968, 33 (1), 72–90. 
(56)  White, N. Antimalarial Drug Resistance and Combination Chemotherapy. Philos. Trans. 
R. Soc. B Biol. Sci. 1999, 354 (1384), 739–749. 
(57)  Schlagenhauf, P. Malaria: From Prehistory to Present. Infect. Dis. Clin. North Am. 2004, 
18 (2), 189–205. 
(58)  Aviado, D. M.; Singh, G.; Berkley, R. Pharmacology of New Antimalarial Drugs 
Sulfonamides and Trimethoprim. Chemotherapy 1969, 14 (1), 37–53. 
(59)  Gutman, J.; Mwandama, D.; Wiegand, R. E.; Ali, D.; Mathanga, D. P.; Skarbinski, J. 
Effectiveness of Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine During 
Pregnancy on Maternal and Birth Outcomes in Machinga District, Malawi. J. Infect. Dis. 2013, 
208 (6), 907–916. 
(60)  Rogerson, S. J.; Chaluluka, E.; Kanjala, M.; Mkundika, P.; Mhango, C.; Molyneux, M. E. 
Intermittent Sulfadoxine-Pyrimethamine in Pregnancy: Effectiveness against Malaria 
Morbidity in Blantyre, Malawi, in 1997–1999. Trans. R. Soc. Trop. Med. Hyg. 2000, 94 (5), 549–
553. 
(61)  Burrows, J. N.; Chibale, K.; Wells, T. N. C. The State of the Art in Anti-Malarial Drug 
Discovery and Development. Curr. Top. Med. Chem. 2011, 11, 1226–1254. 
(62)  Hutchinson, D. B.; Chulay, J. D.; Canfield, C. J.; Looareesuwan, S. Malarone 
(Atovaquone and Proguanil Hydrochloride): A Review of Its Clinical Development for 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
51 
 
Treatment of Malaria. Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 1999, 60 
(4), 533–541. 
(63)  Rueangweerayut, R.; Phyo, A. P.; Uthaisin, C.; Poravuth, Y.; Binh, T. Q.; Tinto, H.; Pénali, 
L. K.; Valecha, N.; Tien, N. T.; Abdulla, S.; Borghini-Fuhrer, I.; Duparc, S.; Shin, Chang-Sik.; 
Fleckenstein, L. Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria. N. 
Engl. J. Med. 2012, 366 (14), 1298–1309. 
(64)  Kurth, F.; Bélard, S.; Basra, A.; Ramharter, M. Pyronaridine–artesunate Combination 
Therapy for the Treatment of Malaria. Curr. Opin. Infect. Dis. 2011, 24 (6), 564–569. 
(65)  Ramharter, M.; Kurth, F.; Schreier, A. C.; Nemeth, J.; Glasenapp, I. von; Bélard, S.; 
Schlie, M.; Kammer, J.; Koumba, P. K.; Cisse, B.; Mordmüller, B.; Lell, B.; Issifou, S.; Oeuvray, 
C.; Fleckenstein, L.; Kremsner, P. G. Fixed‐Dose Pyronaridine‐Artesunate Combination for 
Treatment of Uncomplicated Falciparum Malaria in Pediatric Patients in Gabon. J. Infect. Dis. 
2008, 198 (6), 911–919. 
(66)  Gaillard, T.; Madamet, M.; Pradines, B. Tetracyclines in Malaria. Malar. J. 2015, 14 (1), 
445. 
(67)  Gaillard, T.; Madamet, M.; Tsombeng, F. F.; Dormoi, J.; Pradines, B. Antibiotics in 
Malaria Therapy: Which Antibiotics except Tetracyclines and Macrolides May Be Used against 
Malaria? Malar. J. 2016, 15 (1), 556. 
(68)  Vangapandu, S.; Jain, M.; Kaur, K.; Patil, P.; Patel, S. R.; Jain, R. Recent Advances in 
Antimalarial Drug Development. Med. Res. Rev. 2007, 27 (1), 65–107. 
(69)  Price, R. N.; Douglas, N. M. Artemisinin Combination Therapy for Malaria: Beyond 
Good Efficacy. Clin. Infect. Dis. 2009, 49 (11), 1638–1640. 
(70)  Klayman, D. Qinghaosu (Artemisinin): An Antimalarial Drug from China. Science (80-. 
). 1985, 228 (4703), 1049–1055. 
(71)  Majori, G. Combined Antimalarial Therapy Using Artemisinin. Parassitologia 2004, 46 
(1–2), 85–87. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
52 
 
(72)  Aweeka, F. T.; German, P. I. Clinical Pharmacology of Artemisinin-Based Combination 
Therapies. Clin. Pharmacokinet. 2008, 47 (2), 91–102. 
(73)  Fidock, D. A.; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Antimalarial Drug 
Discovery: Efficacy Models for Compound Screening. Nat. Rev. Drug Discov. 2004, 3 (6), 509–
520. 
(74)  Nzila, A.; Ma, Z.; Chibale, K. Drug Repositioning in the Treatment of Malaria and TB. 
Future Med. Chem. 2011, 3 (11), 1413–1426. 
(75)  Cui, L.; Su, X. Discovery, Mechanisms of Action and Combination Therapy of 
Artemisinin. Expert review of anti-infective therapy. October 2009, pp 999–1013. 
(76)  Bakshi, R.; Hermeling-Fritz, I.; Gathmann, I.; Alteri, E. An Integrated Assessment of the 
Clinical Safety of Artemether-Lumefantrine: A New Oral Fixed-Dose Combination Antimalarial 
Drug. Trans. R. Soc. Trop. Med. Hyg. 2000, 94 (4), 419–424. 
(77)  John, G. K.; Douglas, N. M.; von Seidlein, L.; Nosten, F.; Baird, K. J.; White, N. J.; Price, 
R. N. Primaquine Radical Cure of Plasmodium Vivax: A Critical Review of the Literature. Malar. 
J. 2012, 11 (1), 280. 
(78)  Andrews, K. T.; Fisher, G.; Skinner-Adams, T. S. Drug Repurposing and Human Parasitic 
Protozoan Diseases. Int. J. Parasitol. Drugs Drug Resist. 2014, 4 (2), 95–111. 
(79)  Dunne, M. W.; Singh, N.; Shukla, M.; Valecha, N.; Bhattacharyya, P. C.; Dev, V.; Patel, 
K.; Mohapatra, M. K.; Lakhani, J.; Benner, R.; Lele, C.; Patki, K. A Multicenter Study of 
Azithromycin, Alone and in Combination with Chloroquine, for the Treatment of Acute 
Uncomplicated Plasmodium falciparum Malaria in India. J. Infect. Dis. 2005, 191 (10), 1582–
1588. 
(80)  Chico, R. M.; Pittrof, R.; Greenwood, B.; Chandramohan, D. Azithromycin-Chloroquine 
and the Intermittent Preventive Treatment of Malaria in Pregnancy. Malar. J. 2008, 7 (1), 255. 
(81)  Meshnick, S. R. Artemisinin: Mechanisms of Action, Resistance and Toxicity. Int. J. 
Parasitol. 2002, 32 (13), 1655–1660. 
(82)  White, N. J. Antimalarial Drug Resistance. J Clin Invest 2004, 113 (8), 1084–1092. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
53 
 
(83)  Cui, L.; Mharakurwa, S.; Ndiaye, D.; Rathod, P. K.; Rosenthal, P. J. Antimalarial Drug 
Resistance: Literature Review and Activities and Findings of the ICEMR Network. American 
Journal of Tropical Medicine and Hygiene. 2015, pp 57–68. 
(84)  Hewitt, S.; Delacollette, C.; Chavez, I. Malaria Situation in the Greater Mekong 
Subregion. Southeast Asian J. Trop. Med. Public Health 2013, 44 Suppl 1, 46-72-7. 
(85)  Khan, S. Y.; Khan, A.; Arshad, M.; Tahir, H. M.; Mukhtar, M. K.; Ahmad, K. R.; Arshad, 
N. Irrational Use of Antimalarial Drugs in Rural Areas of Eastern Pakistan: A Random Field 
Study. BMC Public Health 2012, 12 (1), 941. 
(86)  Nsimba, S. E. D.; Massele, A. Y.; Eriksen, J.; Gustafsson, L. L.; Tomson, G.; Warsame, M. 
Case Management of Malaria in under-Fives at Primary Health Care Facilities in a Tanzanian 
District. Trop. Med. Int. Heal. 2002, 7 (3), 201–209. 
(87)  Franco-Paredes, C.; Santos-Preciado, J. I. Problem Pathogens: Prevention of Malaria in 
Travellers. Lancet Infect. Dis. 2006, 6 (3), 139–149. 
(88)  Steffen, R.; Behrens, R. H. Travellers’ Malaria. Parasitol. Today 1992, 8 (2), 61–66. 
(89)  Hargreaves, K.; Koekemoer, L. L.; Brooke, B. D.; Hunt, R. H.; Mthembu, J.; Coetzee, M. 
Anopheles Funestus Resistant to Pyrethroid Insecticides in South Africa. Med. Vet. Entomol. 
2000, 14 (2), 181–189. 
(90)  N’Guessan, R.; Corbel, V.; Akogbéto, M.; Rowland, M. Reduced Efficacy of Insecticide-
Treated Nets and Indoor Residual Spraying for Malaria Control in Pyrethroid Resistance Area, 
Benin. Emerg. Infect. Dis. 2007, 13 (2), 199–206. 
(91)  Beutler, E. G6PD Deficiency. Blood 1994, 84 (11), 3613–3636. 
(92)  Olliaro, P.; Nevill, C.; LeBras, J.; Ringwald, P.; Mussano, P.; Garner, P.; Brasseur, P. 
Systematic Review of Amodiaquine Treatment in Uncomplicated Malaria. Lancet 1996, 348 
(9036), 1196–1201. 
(93)  Lind, D. E.; Levi, J. A.; Vincent, P. C. Amodiaquine-Induced Agranulocytosis: Toxic Effect 
of Amodiaquine in Bone Marrow Cultures In vitro. BMJ 1973, 1 (5851), 458–460. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
54 
 
(94)  Hatton, C. Frequency of Severe Neutropenia Associated with Amodiaquine 
Prophylaxis against Malaria. Lancet 1986, 327 (8478), 411–414. 
(95)  Larrey, D. Amodiaquine-Induced Hepatitis. Ann. Intern. Med. 1986, 104 (6), 801. 
(96)  Ferguson, J.; Addo, H. A.; Johnson, B. E.; Frain-Bell, W. Quinine Induced 
Photosensitivity: Clinical and Experimental Studies. Br. J. Dermatol. 1987, 117 (5), 631–640. 
(97)  Ljunggren, B. Systemic Quinine Photosensitivity. Arch. Dermatol. 1986, 122 (8), 909. 
(98)  Kuritsky, J. N.; Lobel, H. O.; Stern, R.; Miller, K. D.; Satriale, R. F.; Campbell, C. C. Severe 
Cutaneous Reactions among American Travelers Using Pyrimethamine-Sulfadoxine 
(Fansidar®) for Malaria Prophylaxis. Am. J. Trop. Med. Hyg. 1986, 35 (3), 451–458. 
(99)  Hellgren, U.; Rombo, L.; Berg, B.; Carlson, J.; Wiholm, B. E. Adverse Reactions to 
Sulphadoxine-Pyrimethamine in Swedish Travellers: Implications for Prophylaxis. BMJ 1987, 
295 (6594), 365–366. 
(100)  Hood, J. E.; Jenkins, J. W.; Milatovic, D.; Rongzhu, L.; Aschner, M. Mefloquine Induces 
Oxidative Stress and Neurodegeneration in Primary Rat Cortical Neurons. Neurotoxicology 
2010, 31 (5), 518–523. 
(101)  Ringqvist, Å.; Bech, P.; Glenthøj, B.; Petersen, E. Acute and Long-Term Psychiatric Side 
Effects of Mefloquine: A Follow-up on Danish Adverse Event Reports. Travel Med. Infect. Dis. 
2015, 13 (1), 80–88. 
(102)  Nevin, R. L. Limbic Encephalopathy and Central Vestibulopathy Caused by Mefloquine: 
A Case Report. Travel Med. Infect. Dis. 2012, 10 (3), 144–151. 
(103)  Abdulla, S.; Sagara, I.; Borrmann, S.; D’Alessandro, U.; González, R.; Hamel, M.; Ogutu, 
B.; Mårtensson, A.; Lyimo, J.; Maiga, H.; Sasi, P.; Nahum, A.; Bassat, Q.; Juma, E.; Otieno, L.; 
Björkman, A.; Beck, H. P.; Andriano, K.; Cousin, M.; Lefèvre, G.; Ubben, D.; Premji, Z. Efficacy 
and Safety of Artemether-Lumefantrine Dispersible Tablets Compared with Crushed 
Commercial Tablets in African Infants and Children with Uncomplicated Malaria: A 
Randomised, Single-Blind, Multicentre Trial. Lancet 2008, 372 (9652), 1819–1827. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
55 
 
(104)  Kurth, F.; Bélard, S.; Adegnika, A. A.; Gaye, O.; Kremsner, P. G.; Ramharter, M. Do 
Paediatric Drug Formulations of Artemisinin Combination Therapies Improve the Treatment 
of Children with Malaria? A Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2010, 10 
(2), 125–132. 
(105)  Tozan, Y.; Klein, E. Y.; Darley, S.; Panicker, R.; Laxminarayan, R.; Breman, J. G. 
Prereferral Rectal Artesunate for Treatment of Severe Childhood Malaria: A Cost-
Effectiveness Analysis. Lancet 2010, 376 (9756), 1910–1915. 
(106)  Barnes, K.; Mwenechanya, J.; Tembo, M.; Mcllleron, H.; Folb, P.; Ribeiro, I.; Little, F.; 
Gomes, M.; Molyneux, M. Efficacy of Rectal Artesunate Compared with Parenteral Quinine in 
Initial Treatment of Moderately Severe Malaria in African Children and Adults: A Randomised 
Study. Lancet 2004, 363 (9421), 1598–1605. 
(107)  Granizo, J. J.; Pía Rodicio, M.; Manso, F. J.; Giménez, M. J. Tinidazole: A Classical 
Anaerobical Drug with Multiple Potential Uses Nowadays]. Rev. Esp. Quimioter. 2009, 22 (2), 
106–114. 
(108)  Yuthavong, Y.; Tarnchompoo, B.; Vilaivan, T.; Chitnumsub, P.; Kamchonwongpaisan, 
S.; Charman, S. A.; McLennan, D. N.; White, K. L.; Vivas, L.; Bongard, E.; Thongphanchang, C.; 
Taweechai, S.; Vanichtanankul, J.; Rattanajak, R.; Arwon, U.; Fantauzzi, P.; Yuvaniyama, J. 
Charman, W. N.; Matthews, D. Malarial Dihydrofolate Reductase as a Paradigm for Drug 
Development against a Resistance-Compromised Target. Proc. Natl. Acad. Sci. 2012, 109 (42), 
16823–16828. 
(109)  Charman, S. A.; Arbe-Barnes, S.; Bathurst, I. C.; Brun, R.; Campbell, M.; Charman, W. 
N.; Chiu, F. C. K.; Chollet, J.; Craft, J. C.; Creek, D. J.;Dong, Y.; Matile, H.; Maurer, M.; Morizzi, 
J.; Nguyen, T.; Papastogiannidis, P.; Scheurer, C.; Shackleford, D. M.; Sriraghavan, K.; Stingelin, 
L.; Tang, Y.; Urwyler, H.; Wang, X.; White, K. L.; Wittlin, S.; Zhou, L.; Vennerstrom, J. L. 
Synthetic Ozonide Drug Candidate OZ439 Offers New Hope for a Single-Dose Cure of 
Uncomplicated Malaria. Proc. Natl. Acad. Sci. 2011, 108 (11), 4400–4405. 
(110)  Paquet, T.; Le Manach, C.; Cabrera, D. G.; Younis, Y.; Henrich, P. P.; Abraham, T. S.; 
Lee, M. C. S.; Basak, R.; Ghidelli-Disse, S.; Lafuente-Monasterio, M. J.; Bantscheff, M.; Ruecker, 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
56 
 
A.; Blagborough, A. M.; Zakutansky, S. E.; Zeeman, A-M.; White, K. L.; Shackleford, D. M.; 
Mannila, J.; Morizzi, J.; Scheurer, C.; Angulo-Barturen, I.; Martínez, M. S.; Ferrer, S.; Sanz, L. 
M.; Gamo, F. J.; Reader, J.; Botha, M.; Dechering, K. J.; Sauerwein, R. W.; Tungtaeng, A.; 
Vanachayangkul, P.; Lim, C. S.; Burrows, J.; Witty, M. J.; Marsh, K. C.; Bodenreider, C.; 
Rochford, R.; Solapure, S. M.; Jiménez-Díaz, M. B.; Wittlin, S.; Charman, S. A.; Donini, C.; 
Campo, B.; Birkholtz, L-M.; Hanson, K. K.; Drewes, G.; Kocken, C. H. M.; Delves, M. J.; 
Leroy, D.; Fidock, D. A.; Waterson, D.; Street, L. J.; Chibale, K. Antimalarial Efficacy of 
MMV390048, an Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase. Sci. Transl. Med. 
2017, 9 (387), eaad9735. 
(111)  Ghidelli-Disse, S.; Lafuente-Monasterio, M. J.; Waterson, D.; Witty, M.; Younis, Y.; 
Paquet, T.; Street, L. J.; Chibale, K.; Gamo-Benito, F. J.; Bantscheff, M.; Drewes, G. 
Identification of Plasmodium PI4 Kinase as Target of MMV390048 by Chemoproteomics. 
Malar. J. 2014, 13 (1), P38. 
(112)  Sulyok, M.; Rückle, T.; Roth, A.; Mürbeth, R. E.; Chalon, S.; Kerr, N.; Samec, S. S.; 
Gobeau, N.; Calle, C. L.; Ibáñez, J.; Sulyok, Z.; Held, J.; Gebru, T.; Granados, P.; Brückner, S.; 
Nguetse, C.; Mengue, J.; Lalremruata, A.; Sim, B. K. L.; Hoffman, S. L.; Möhrle, J. J.; Kremsner, 
P. G.; Mordmüller, B. DSM265 for Plasmodium falciparum Chemoprophylaxis: A Randomised, 
Double Blinded, Phase 1 Trial with Controlled Human Malaria Infection. Lancet Infect. Dis. 
2017, 17 (6), 636–644. 
(113)  Ashley, E. Investment in Antimalarial Drug Development Is Bearing Fruit. Lancet Infect. 
Dis. 2017, 17 (6), 568–570. 
(114)  Rottmann, M.; McNamara, C.; Yeung, B. K. S.; Lee, M. C. S.; Zou, B.; Russell, B.; Seitz, 
P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; Gonzalez-Paez, G. E.; 
Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H.-P.; Brun, R.; 
Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; Fidock, D. A.; Winzeler, E. A.; Diagana, T. T. 
Spiroindolones, a Potent Compound Class for the Treatment of Malaria. Science. 2010, 329 
(5996), 1175–1180. 
(115)  Kuhen, K. L.; Chatterjee, A. K.; Rottmann, M.; Gagaring, K.; Borboa, R.; Buenviaje, J.; 
Chen, Z.; Francek, C.; Wu, T.; Nagle, A.; Barnes, S. W.; Plouffe, D.; Lee, M. C. S.; Fidock, D. A.; 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
57 
 
Graumans, W.; van de Vegte-Bolmer, M.; van Gemert, G. J.; Wirjanata, G.; Sebayang, B.;  
Marfurt, J.; Russell, B.; Suwanarusk, R.; Price, R. N.; Nosten, F.; Tungtaeng, A.; Gettayacamin, 
M.; Sattabongkot, J.; Taylor, J.; Walker, J. R.; Tully, D.; Patra, K. P.;Flannery, E. L.; Vinetz, J. M.; 
Renia, L.; Sauerwein, R. W.; Winzeler, E. A.; Glynne, Richard J.; Diagana, T. T. KAF156 Is an 
Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and 
Prevention of Disease Transmission. Antimicrob. Agents Chemother. 2014, 58 (9), 5060–5067. 
(116)  Siqueira, L. da P.; Fontes, D. A. F.; Aguilera, C. S. B.; Timóteo, T. R. R.; Ângelos, M. A.; 
Silva, L. C. P. B. B.; de Melo, C. G.; Rolim, L. A.; da Silva, R. M. F.; Neto, P. J. R. Schistosomiasis: 
Drugs Used and Treatment Strategies. Acta Trop. 2017, 176, 179–187. 
(117)  Colley, D. G.; Bustinduy, A. L.; Secor, W. E.; King, C. H. Human Schistosomiasis. In The 
Lancet; 2014; Vol. 383, pp 2253–2264. 
(118)  Lamberton, P. H. L.; Faust, C. L.; Webster, J. P. Praziquantel Decreases Fecundity in 
Schistosoma mansoni Adult Worms That Survive Treatment: Evidence from a Laboratory Life-
History Trade-Offs Selection Study. Infect. Dis. Poverty 2017, 6 (1), 110. 
(119)  Utzinger, J.; Shuhua, X.; N’Goran, E. K.; Bergquist, R.; Tanner, M. The Potential of 
Artemether for the Control of Schistosomiasis. International Journal for Parasitology. 2001, 
pp 1549–1562. 
(120)  Bergquist, R.; Utzinger, J.; Keiser, J. Controlling Schistosomiasis with Praziquantel: How 
Much Longer without a Viable Alternative? Infect. Dis. Poverty 2017, 6 (1), 74. 
(121)  King, C. H. Toward the Elimination of Schistosomiasis. N. Engl. J. Med. 2009, 360 (2), 
106–109. 
(122)  King, C. H.; Dickman, K.; Tisch, D. J. Reassessment of the Cost of Chronic Helmintic 
Infection: A Meta-Analysis of Disability-Related Outcomes in Endemic Schistosomiasis. Lancet 
(London, England) 2005, 365 (9470), 1561–1569. 
(123)  Mathers, C. D.; Ezzati, M.; Lopez, A. D. Measuring the Burden of Neglected Tropical 
Diseases: The Global Burden of Disease Framework. PLoS Negl. Trop. Dis. 2007, 1 (2), e114. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
58 
 
(124)  Chitsulo, L.; Engels, D.; Montresor, A.; Savioli, L. The Global Status of Schistosomiasis 
and Its Control. Acta Trop. 2000, 77 (1), 41–51. 
(125)  Keiser, J. Antimalarials in the Treatment of Schistosomiasis. Curr. Pharm. Des. 2012, 
18, 3531–3538. 
(126)  Gray, D. J.; Ross, A. G.; Li, Y.-S.; McManus, D. P. Diagnosis and Management of 
Schistosomiasis. BMJ 2011, 342 (may17 1), d2651–d2651. 
(127)  da Silva, V. B. R.; Campos, B. R. K. L.; de Oliveira, J. F.; Decout, J.-L.; do Carmo Alves de 
Lima, M. Medicinal Chemistry of Antischistosomal Drugs: Praziquantel and Oxamniquine. 
Bioorg. Med. Chem. 2017, 25 (13), 3259–3277. 
(128)  Fenwick, A. Waterborne Infectious Diseases--Could They Be Consigned to History? 
Science (80-. ). 2006, 313 (5790), 1077–1081. 
(129)  Ross, A. G. P.; Bartley, P. B.; Sleigh, A. C.; Olds, G. R.; Li, Y.; Williams, G. M.; McManus, 
D. P. Schistosomiasis. N. Engl. J. Med. 2002, 346 (16), 1212–1220. 
(130)  Gryseels, B.; Polman, K.; Clerinx, J.; Kestens, L. Human Schistosomiasis. Lancet 2006, 
368 (9541), 1106–1118. 
(131)  Gray, D. J.; McManus, D. P.; Li, Y.; Williams, G. M.; Bergquist, R.; Ross, A. G. 
Schistosomiasis Elimination: Lessons from the Past Guide the Future. Lancet Infect. Dis. 2010, 
10 (10), 733–736. 
(132)  Miranda, M. A. C.; Ferraz, Á. A. B.; Domingues, A. L. C.; Chaves, R. C. M.; Jucá, N.; Mota, 
D. L. da. Improvement of Schistosomal Portal Hypertensive Colopathy after Surgical 
Treatment. Arq. Gastroenterol. 2013, 50 (2), 153–156. 
(133)  Leite, L. A. C.; Pimenta Filho, A. A.; Ferreira, R. de C. dos S.; da Fonseca, C. S. M.; dos 
Santos, B. S.; Montenegro, S. M. L.; Lopes, E. P. de A.; Domingues, A. L. C.; Owen, J. S.; Lima, 
V. L. de M. Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic 
Schistosomiasis Mansoni. PLoS One 2015, 10 (8), e0135370. 
(134)  Weerakoon, K. G. A. D.; Gobert, G. N.; Cai, P.; McManus, D. P. Advances in the 
Diagnosis of Human Schistosomiasis. Clin. Microbiol. Rev. 2015, 28 (4), 939–967. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
59 
 
(135)  King, C. H. Parasites and Poverty: The Case of Schistosomiasis. Acta Trop. 2010, 113 
(2), 95–104. 
(136)  Mbabazi, P. S.; Andan, O.; Fitzgerald, D. W.; Chitsulo, L.; Engels, D.; Downs, J. A. 
Examining the Relationship between Urogenital Schistosomiasis and HIV Infection. PLoS Negl. 
Trop. Dis. 2011, 5 (12), e1396. 
(137)  Lardans, V.; Dissous, C. Snail Control Strategies for Reduction of Schistosomiasis 
Transmission. Parasitol. Today 1998, 14 (10), 413–417. 
(138)  Marcial-Rojas, R. A. Neurologic Complications of Schistosomiasis. Ann. Intern. Med. 
1963, 59 (2), 215. 
(139)  Savioli, L.; Fenwick, A.; Rollinson, D.; Albonico, M.; Ame, S. M. An Achievable Goal: 
Control and Elimination of Schistosomiasis. Lancet 2015, 386 (9995), 739. 
(140)  Neves, B. J.; Dantas, R. F.; Senger, M. R.; Melo-Filho, C. C.; Valente, W. C. G.; de 
Almeida, A. C. M.; Rezende-Neto, J. M.; Lima, E. F. C.; Paveley, R.; Furnham, N.; Muratov, E.; 
Kamentsky, L.; Carpenter, A. E.; Braga, R. C.; Silva-Junior, F. P.; Andrade, C. H.  Discovery of 
New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content 
Screening. J. Med. Chem. 2016, 59 (15), 7075–7088. 
(141)  Utzinger, J.; Chollet, J.; Tu, Z.; Shuhua, X.; Tanner, M. Comparative Study of the Effects 
of Artemether and Artesunate on Juvenile and Adult Schistosoma mansoni in Experimentally 
Infected Mice. Trans. R. Soc. Trop. Med. Hyg. 2002, 96, 318–323. 
(142)  Cioli, D.; Valle, C.; Angelucci, F.; Miele, A. E. Will New Antischistosomal Drugs Finally 
Emerge? Trends in Parasitology. 2008, pp 379–382. 
(143)  Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal Drugs: Past, Present … and 
Future? Pharmacol. Ther. 1995, 68, 35–85. 
(144)  Doenhoff, M. J.; Pica-Mattoccia, L. Praziquantel for the Treatment of Schistosomiasis: 
Its Use for Control in Areas with Endemic Disease and Prospects for Drug Resistance. Expert 
Rev. Anti. Infect. Ther. 2006, 4 (2), 199–210. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
60 
 
(145)  Pica-mattoccia, D. C. L.; Archer, S. Antischistosomal Drugs : Pharmacol. Ther. 1995, 68, 
35–85. 
(146)  Colley, D. G. Morbidity Control of Schistosomiasis by Mass Drug Administration: How 
Can We Do It Best and What Will It Take to Move on to Elimination? Trop. Med. Health 2014, 
42 (2 Suppl), 25–32. 
(147)  Utzinger, J.; Chollet, J.; Jiqing, Y.; Jinyan, M.; Tanner, M.; Shuhua, X. Effect of Combined 
Treatment with Praziquantel and Artemether on Schistosoma Japonicum and Schistosoma 
mansoni in Experimentally Infected Animals. Acta Trop. 2001, 80, 9–18. 
(148)  Neves, B. J.; Muratov, E.; Machado, R. B.; Andrade, C. H.; Cravo, P. V. L. Modern 
Approaches to Accelerate Discovery of New Antischistosomal Drugs. Expert Opinion on Drug 
Discovery. 2016, 11 (6), 557–567. 
(149)  Okombo, J.; Singh, K.; Mayoka, G.; Ndubi, F.; Barnard, L.; Njogu, P. M.; Njoroge, M.; 
Gibhard, L.; Brunschwig, C.; Vargas, M.; Keiser, J.; Egan, T. J.; Chibale, K. Antischistosomal 
Activity of Pyrido[1,2- a ]Benzimidazole Derivatives and Correlation with Inhibition of β-
Hematin Formation. ACS Infect. Dis. 2017, 3 (6), 411–420. 
(150)  Neves, B. J.; Braga, R. C.; Bezerra, J. C. B.; Cravo, P. V. L.; Andrade, C. H. In silico 
Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against 
Multiple Life Stages of Schistosoma mansoni. PLoS Negl. Trop. Dis. 2015, 9 (1), e3435. 
(151)  Klug, D. M.; Gelb, M. H.; Pollastri, M. P. Repurposing Strategies for Tropical Disease 
Drug Discovery. Bioorg. Med. Chem. Lett. 2016, 26 (11), 2569–2576. 
(152)  Khan, M. O. F.; Keiser, J.; Amoyaw, P. N. A.; Hossain, M. F.; Vargas, M.; Le, J. G.; 
Simpson, N. C.; Roewe, K. D.; Freeman, T. N. C.; Hasley, T. R.; Maples, R. D.; Archibald, S. J.; 
Hubin, T. Discovery of Antischistosomal Drug Leads Based on Tetraazamacrocyclic Derivatives 
and Their Metal Complexes. Antimicrob. Agents Chemother. 2016, 60 (9), 5331–5336. 
(153)  Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. W. 
Application of Combinatorial Chemistry Science on Modern Drug Discovery. J. Comb. Chem. 
2008, 10(3), 345–354. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
61 
 
(154)  Panic, G.; Duthaler, U.; Speich, B.; Keiser, J. Repurposing Drugs for the Treatment and 
Control of Helminth Infections. Int. J. Parasitol. Drugs Drug Resist. 2014, 4 (3), 185–200. 
(155)  Hughes, J.; Rees, S.; Kalindjian, S.; Philpott, K. Principles of Early Drug Discovery. Br. J. 
Pharmacol. 2011, 162 (6), 1239–1249. 
(156)  Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and 
Development Settings. Adv. Drug Deliv. Rev. 2012, 64, 4–17. 
(157)  Dar, O.; Khan, M. S.; Adagu, I. The Potential Use of Methotrexate in the Treatment of 
Falciparum Malaria: In vitro Assays against Sensitive and Multidrug-Resistant Falciparum 
Strains. Jpn. J. Infect. Dis. 2008, 61 (3), 210–211. 
(158)  Yu, H.; Adedoyin, A. ADME–Tox in Drug Discovery: Integration of Experimental and 
Computational Technologies. Drug Discov. Today 2003, 8 (18), 852–861. 
(159)  Leeson, P. D. Molecular Inflation, Attrition and the Rule of Five. Adv. Drug Deliv. Rev. 
2016, 101, 22–33. 
(160)  Elder, D.; Holm, R. Aqueous Solubility: Simple Predictive Methods (in silico, in vitro and 
Bio-Relevant Approaches). Int. J. Pharm. 2013, 453 (1), 3–11. 
(161)  Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and 
Development. The Article Was Originally Published in Advanced Drug Delivery Reviews 23 
(1997) 3. Adv. Drug Deliv. Rev. 2001, 46 (1–3), 3–26. 
(162)  Krämer, S. D.; Aschmann, H. E.; Hatibovic, M.; Hermann, K. F.; Neuhaus, C. S.; Brunner, 
C.; Belli, S. When Barriers Ignore the “rule-of-Five.” Adv. Drug Deliv. Rev. 2016, 101, 62–74. 
(163)  Ritchie, T. J.; Ertl, P.; Lewis, R. The Graphical Representation of ADME-Related 
Molecule Properties for Medicinal Chemists. Drug Discov. Today 2011, 16 (1–2), 65–72. 
(164)  Kerns, E. H. High Throughput Physicochemical Profiling for Drug Discovery. J. Pharm. 
Sci. 2001, 90 (11), 1838–1858. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
62 
 
(165) Rando, D. G.; Sato, D. N.; Siqueira, L.; Malvezzi, A.; Leite, C. Q. F.; Do_Amaral, A. T.; 
Ferreira, E. I.; Tavares, L. C. Potential Tuberculostatic Agents. Topliss Application on Benzoic 
Acid [(5-Nitro-Thiophen-2-Yl)-Methylene]-Hydrazide Series. Bioorg. Med. Chem. 2002, 10 (3), 
557–560. 
(166)  Jorge, S. D.; Palace-Berl, F.; Masunari, A.; Cechinel, C. A.; Ishii, M.; Pasqualoto, K. F. M.; 
Tavares, L. C. Novel Benzofuroxan Derivatives against Multidrug-Resistant Staphylococcus 
Aureus Strains: Design Using Topliss’ Decision Tree, Synthesis and Biological Assay. Bioorg. 
Med. Chem. 2011, 19 (16), 5031–5038. 
(167)  Jorgensen, W. L. The Many Roles of Computation in Drug Discovery. Science (80-. ). 
2004, 303 (5665), 1813–1818. 
(168)  T’jollyn, H.; Boussery, K.; Mortishire-Smith, R. J.; Coe, K.; De Boeck, B.; Van Bocxlaer, J. 
F.; Mannens, G. Evaluation of Three State-of-the-Art Metabolite Prediction Software Packages 
(Meteor, MetaSite, and StarDrop) through Independent and Synergistic Use. Drug Metab. 
Dispos. 2011, 39 (11), 2066–2075. 
(169)  Rydberg, P.; Olsen, L. Predicting Drug Metabolism by Cytochrome P450 2C9: 
Comparison with the 2D6 and 3A4 Isoforms. ChemMedChem 2012, 7 (7), 1202–1209. 
(170)  Pähler, A.; Brink, A. Software Aided Approaches to Structure-Based Metabolite 
Identification in Drug Discovery and Development. Drug Discov. Today Technol. 2013, 10 (1), 
e207–e217. 
(171)  G. Shin, Y.; Le, H.; Khojasteh, C.; E.C.A. Hop, C. Comparison of Metabolic Soft Spot 
Predictions of CYP3A4, CYP2C9 and CYP2D6 Substrates Using MetaSite and StarDrop. Comb. 
Chem. High Throughput Screen. 2011, 14 (9), 811–823. 
(172)  Basanta K. R. B.; Karunakar,  A. Biopharmaceutics Classification System: A Regulatory 
Approach. Dissolution Technol. 2011, 18 (February), 31–37. 
(173)  Blake, J. Chemoinformatics – Predicting the Physicochemical Properties of “Drug-Like” 
Molecules. Curr. Opin. Biotechnol. 2000, 11 (1), 104–107. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
63 
 
(174)  Shaffer, C. L.; Scialis, R. J.; Rong, H.; Obach, R. S. Using SimCYP® to Project Human Oral 
Pharmacokinetic Variability in Early Drug Research to Mitigate Mechanism-Based Adverse 
Events. Biopharm. Drug Dispos. 2012, 33 (2), 72–84. 
(175)  Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The 
SimCYP® Population-Based ADME Simulator. Expert Opin. Drug Metab. Toxicol. 2009, 5 (2), 
211–223. 
(176)  Rakhit, A.; Pantze, M. P.; Fettner, S.; Jones, H. M.; Charoin, J.-E.; Riek, M.; Lum, B. L.; 
Hamilton, M. The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-
Based Simulation (SimCYP®) Predicts in vivo Metabolic Inhibition. Eur. J. Clin. Pharmacol. 
2008, 64 (1), 31–41. 
(177)  Dumont, C.; Mentré, F.; Gaynor, C.; Brendel, K.; Gesson, C.; Chenel, M. Optimal 
Sampling Times for a Drug and Its Metabolite Using SimCYP® Simulations as Prior Information. 
Clin. Pharmacokinet. 2013, 52 (1), 43–57. 
(178)  Heikkinen, A. T.; Baneyx, G.; Caruso, A.; Parrott, N. Application of PBPK Modeling to 
Predict Human Intestinal Metabolism of CYP3A Substrates – An Evaluation and Case Study 
Using GastroPlusTM. Eur. J. Pharm. Sci. 2012, 47 (2), 375–386. 
(179)  Bolger, M. B.; Lukacova, V.; Woltosz, W. S. Simulations of the Nonlinear Dose 
Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine. AAPS J. 
2009, 11 (2), 353–363. 
(180)  Okumu, A.; DiMaso, M.; Löbenberg, R. Computer Simulations Using GastroPlusTM to 
Justify a Biowaiver for Etoricoxib Solid Oral Drug Products. Eur. J. Pharm. Biopharm. 2009, 72 
(1), 91–98. 
(181)  Lavé, T.; Parrott, N.; Grimm, H. P.; Fleury, A.; Reddy, M. Challenges and Opportunities 
with Modelling and Simulation in Drug Discovery and Drug Development. Xenobiotica 2007, 
37 (10–11), 1295–1310. 
(182)  Chien, J. Y.; Friedrich, S.; Heathman, M. A.; de Alwis, D. P.; Sinha, V. 
Pharmacokinetics/pharmacodynamics and the Stages of Drug Development: Role of Modeling 
and Simulation. AAPS J. 2005, 7 (3), E544--E559. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
64 
 
(183)  Gschwend, D. A.; Good, A. C.; Kuntz, I. D. Molecular Docking towards Drug Discovery. 
J. Mol. Recognit. 1996, 9 (2), 175–186. 
(184)  Yang, S.-Y. Pharmacophore Modeling and Applications in Drug Discovery: Challenges 
and Recent Advances. Drug Discov. Today 2010, 15 (11–12), 444–450. 
(185)  Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. Molecular Docking: A Powerful Approach 
for Structure-Based Drug Discovery. Curr. Comput. Aided-Drug Des. 2011, 7 (2), 146–157. 
(186)  Matsson, P.; Doak, B. C.; Over, B.; Kihlberg, J. Cell Permeability beyond the Rule of 5. 
Adv. Drug Deliv. Rev. 2016, 101, 42–61. 
(187)  Ambre, P. K.; Wavhale, R. D.; Coutinho, E. C. New Horizons in Antimalarial Drug 
Discovery in the Last Decade by Chemoinformatic Approaches. Comb. Chem. High Throughput 
Screen. 2015, 18 (2), 129–150. 
(188)  Frecer, V.; Megnassan, E.; Miertus, S. Design and in silico Screening of Combinatorial 
Library of Antimalarial Analogs of Triclosan Inhibiting Plasmodium falciparum Enoyl-Acyl 
Carrier Protein Reductase. Eur. J. Med. Chem. 2009, 44 (7), 3009–3019. 
(189)  Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and Scoring in Virtual 
Screening for Drug Discovery: Methods and Applications. Nat. Rev. Drug Discov. 2004, 3, 935. 
(190)  Keiser, J.; Utzinger, J. Antimalarials in the Treatment of Schistosomiasis. Curr. Pharm. 
Des. 2012, 18 (24), 3531–3538. 
(191)  Aubé, J. Drug Repurposing and the Medicinal Chemist. ACS Med. Chem. Lett. 2012, 3 
(6), 442–444. 
(192)  Bellera, C. L.; Balcazar, D. E.; Vanrell, M. C.; Casassa, A. F.; Palestro, P. H.; Gavernet, L.; 
Labriola, C. A.; Gálvez, J.; Bruno-Blanch, L. E.; Romano, P. S.; Carrillo, C.; Talevi, A. Computer-
Guided Drug Repurposing: Identification of Trypanocidal Activity of Clofazimine, Benidipine 
and Saquinavir. Eur. J. Med. Chem. 2015, 93, 338–348. 
(193)  De Clercq, D.; Vercruysse, J.; Verlé, P.; Niasse, F.; Kongs, A.; Diop, M. Efficacy of 
Artesunate against Schistosoma mansoni Infections in Richard Toll, Senegal. Trans. R. Soc. 
Trop. Med. Hyg. 2000, 94, 90–91. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
65 
 
(194)  Chong, C. R.; Chen, X.; Shi, L.; Liu, J. O.; Sullivan, D. J. A Clinical Drug Library Screen 
Identifies Astemizole as an Antimalarial Agent. Nat. Chem. Biol. 2006, 2 (8), 415–416. 
(195)  Musonda, C. C.; Whitlock, G. A.; Witty, M. J.; Brun, R.; Kaiser, M. Chloroquine–
astemizole Hybrids with Potent in vitro and in vivo Antiplasmodial Activity. Bioorg. Med. 
Chem. Lett. 2009, 19 (2), 481–484. 
(196)  Yap, Y. G.; Camm, A. J. Potential Cardiac Toxicity of H1-Antihistamines. Clin. Allergy 
Immunol. 2002, 17, 389–419. 
(197)  Rao, K. A.; Adlakha, A.; Verma-Ansil, B.; Meloy, T. D.; Stanton, M. S. Torsades de 
Pointes Ventricular Tachycardia Associated With Overdose of Astemizole. Mayo Clin. Proc. 
1994, 69 (6), 589–593. 
(198)  Smith, S. J. Cardiovascular Toxicity of Antihistamines. Otolaryngol. Neck Surg. 1994, 
111 (3P2), 348–354. 
(199)  Roman, G.; Crandall, I. E.; Szarek, W. A. Synthesis and Anti- Plasmodium Activity of 
Benzimidazole Analogues Structurally Related to Astemizole. ChemMedChem 2013, 8 (11), 
1795–1804. 
(200)  Eissa, M. M.; El-Azzouni, M. Z.; Amer, E. I.; Baddour, N. M. Miltefosine, a Promising 
Novel Agent for Schistosomiasis Mansoni. Int. J. Parasitol. 2011, 41 (2), 235–242. 
(201)  Eissa, M. M.; Mossallam, S. F.; Amer, E. I.; Younis, L. K.; Rashed, H. A. Repositioning of 
Chlorambucil as a Potential Anti-Schistosomal Agent. Acta Trop. 2017, 166, 58–66. 
(202)  Cowan, N.; Keiser, J. Repurposing of Anticancer Drugs: In vitro and in vivo Activities 
against Schistosoma mansoni. Parasit. Vectors 2015, 8 (1), 417. 
(203)  Guidi, A.; Lalli, C.; Perlas, E.; Bolasco, G.; Nibbio, M.; Monteagudo, E.; Bresciani, A.; 
Ruberti, G. Discovery and Characterization of Novel Anti-Schistosomal Properties of the Anti-
Anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female 
Reproductive Systems. PLoS Negl. Trop. Dis. 2016, 10 (8), e0004928. 
(204)  Panic, G.; Vargas, M.; Scandale, I.; Keiser, J. Activity Profile of an FDA-Approved 
Compound Library against Schistosoma mansoni. PLoS Negl. Trop. Dis. 2015, 9 (7), e0003962. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
66 
 
(205)  Lawrence, J. D. The Ingestion of Red Blood Cells by Schistosoma mansoni. J. Parasitol. 
1973, 59 (1), 60–63. 
(206)  Keiser, J.; N’Guessan, N. A.; Adoubryn, K. D.; Silué, K. D.; Vounatsou, P.; Hatz, C.; 
Utzinger, J.; N’Goran, E. K. Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-
Artesunate, and Praziquantel against Schistosoma Haematobium: Randomized, Exploratory 
Open-Label Trial. Clin. Infect. Dis. 2010, 50 (9), 1205–1213. 
(207)  Kumar, S.; Guha, M.; Choubey, V.; Maity, P.; Bandyopadhyay, U. Antimalarial Drugs 
Inhibiting Hemozoin (Beta-Hematin) Formation: A Mechanistic Update. Life Sci. 2007, 80 (9), 
813–828. 
(208)  Sajid, M.; McKerrow, J. H. Cysteine Proteases of Parasitic Organisms. Mol. Biochem. 
Parasitol. 2002, 120 (1), 1–21. 
(209)  Ingram-Sieber, K.; Cowan, N.; Panic, G.; Vargas, M.; Mansour, N. R.; Bickle, Q. D.; Wells, 
T. N. C.; Spangenberg, T.; Keiser, J. Orally Active Antischistosomal Early Leads Identified from 
the Open Access Malaria Box. PLoS Negl. Trop. Dis. 2014, 8 (1), e2610. 
(210)  Van Voorhis, W. C.; Adams, J. H.; Adelfio, R.; Ahyong, V.; Akabas, M. H.; Alano, P.; 
Alday, A.; Alemán Resto, Y.; Alsibaee, A.; Alzualde, A.; Andrews, K. T.; Avery, S. V.; Avery, V. 
M.; Ayong, L.; Baker, M.; Baker, S.; Ben Mamoun, C.; Bhatia, S.; Bickle, Q.; Bounaadja, L.; 
Bowling, T.; Bosch, J.; Boucher, L. E.; Boyom, F. F.; Brea, J.; Brennan, M.; Burton, A.; Caffrey, 
C. R.; Camarda, G.; Carrasquilla, M.; Carter, D.; Belen Cassera, M.; Chih-Chien Cheng, K.; 
Chindaudomsate, W.; Chubb, A.; Colon, B. L.; Colón-López, D. D.; Corbett, Y.; Crowther, G. J.; 
Cowan, N.; D’Alessandro, S.; Le Dang, N.; Delves, M.; De Risi, J. L.; Du, A. Y.; Duffy, S.; Abd El-
Salam El-Sayed, S.; Ferdig, M. T.; Fernández Robledo, J. A.; Fidock, D. A.; Florent, I.; Fokou, P. 
V. T.; Galstian, A.; Gamo, F. J.; Gokool, S.; Gold, B.; Golub, T.; Goldgof, G. M.; Guha, R.; 
Guiguemde, W. A.; Gural, N.; Guy, R. K.; Hansen, Michael A. E.; Hanson, K. K.; Hemphill, A.; 
Hooft van Huijsduijnen, R.; Horii, T.; Horrocks, P.; Hughes, T. B.; Huston, C.; Igarashi, I.; Ingram-
Sieber, K.; Itoe, M. A.; Jadhav, A.; Naranuntarat Jensen, A.; Jensen, L. T.; Jiang, R.H. Y.; Kaiser, 
A.; Keiser, J.; Ketas, T.; Kicka, S.; Kim, S.; Kirk, K.; Kumar, V. P.; Kyle, D. E.; Lafuente, M. J.; 
Landfear, S.; Lee, N.; Lee, S.; Lehane, A. M.; Li, F.; Little, D.; Liu, L.; Llinás, M.; Loza, M. I.; Lubar, 
A.; Lucantoni, L.; Lucet, I.; Maes, L.; Mancama, D.; Mansour, N. R.; March, S.; McGowan, S.; 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
67 
 
Medina Vera, I.; Meister, S.; Mercer, L.; Mestres, J.; Mfopa, A. N.; Misra, R. N.; Moon, S.; 
Moore, J. P.; Morais Rodrigues da Costa, F.; Müller, J.; Muriana, A.; Nakazawa Hewitt, S.; Nare, 
B.; Nathan, C.; Narraidoo, N.; Nawaratna, S.; Ojo, K. K.; Ortiz, D.; Panic, G.; Papadatos, G.; 
Parapini, S.; Patra, K.; Pham, N.; Prats, S.; Plouffe, D. M.; Poulsen, S. -A.; Pradhan, A.; Quevedo, 
C.; Quinn, R. J.; Rice, C. A.; Abdo Rizk, M.; Ruecker, A.; St. Onge, R.; Salgado F.; Rafaela Samra, 
J.; Robinett, N. G.; Schlecht, U.; Schmitt, M.; Silva Villela, F.; Silvestrini, F.; Sinden, R.; Smith, 
D. A.; Soldati, T.; Spitzmüller, A.; Stamm, S. M.; Sullivan, D. J.; Sullivan, W.; Suresh, S.; Suzuki, 
B. M.; Suzuki, Y.; Swamidass, S. J.; Taramelli, D.; Tchokouaha, L. R. Y.; Theron, A.; Thomas, D.; 
Tonissen, K. F.; Townson, S.; Tripathi, A. K.; Trofimov, V.; Udenze, K. O.; Ullah, I.; Vallieres, C.; 
Vigil, E.; Vinetz, J. M.; Voong Vinh, P.; Vu, H.; Watanabe, Nao-aki.; Weatherby, K.; White, P. 
M.; Wilks, A. F.; Winzeler, E. A.; Wojcik, E.; Wree, M.; Wu, W.; Yokoyama, N.; Zollo, P. H. A.; 
Abla, N.; Blasco, B.; Burrows, J.; Laleu, B.; Leroy, D.; Spangenberg, T.; Wells, T. Willis, P. A. 
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected 
Diseases and Beyond. PLOS Pathog. 2016, 12 (7), e1005763. 
(211)  Spangenberg, T.; Burrows, J. N.; Kowalczyk, P.; McDonald, S.; Wells, T. N. C.; Willis, P. 
The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases. PLoS One 
2013, 8 (6), e62906. 
(212)  Ingram-Sieber, K.; Cowan, N.; Panic, G.; Vargas, M.; Mansour, N. R.; Bickle, Q. D.; Wells, 
T. N. C.; Spangenberg, T.; Keiser, J. Orally Active Antischistosomal Early Leads Identified from 
the Open Access Malaria Box. PLoS Negl. Trop. Dis. 2014, 8, 30. 
(213)  Basra, A.; Mombo-Ngoma, G.; Capan Melser, M.; Akerey Diop, D.; Würbel, H.; 
Mackanga, J.-R.; Fürstenau, M.; Manego Zoleko, R.; Adegnika, A. A.; Gonzalez, R.; Menendez, 
C.; Kremsner, P. G.; Ramharter, M. Efficacy of Mefloquine Intermittent Preventive Treatment 
in Pregnancy Against Schistosoma Haematobium Infection in Gabon: A Nested Randomized 
Controlled Assessor-Blinded Clinical Trial. Clin. Infect. Dis. 2013, 56 (6), e68–e75. 
(214)  Lipinski, C. A. Lead- and Drug-like Compounds: The Rule-of-Five Revolution. Drug 
Discov. Today Technol. 2004, 1 (4), 337–341. 
(215)  Di, L.; Fish, P. V.; Mano, T. Bridging Solubility between Drug Discovery and 
Development. Drug Discov. Today 2012, 17 (9–10), 486–495. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
68 
 
(216)  Kawabata, Y.; Wada, K.; Nakatani, M.; Yamada, S.; Onoue, S. Formulation Design for 
Poorly Water-Soluble Drugs Based on Biopharmaceutics Classification System: Basic 
Approaches and Practical Applications. Int. J. Pharm. 2011, 420 (1), 1–10. 
(217)  Alsenz, J.; Kansy, M. High Throughput Solubility Measurement in Drug Discovery and 
Development. Adv. Drug Deliv. Rev. 2007, 59 (7), 546–567. 
(218)  Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral Druggable Space beyond the 
Rule of 5: Insights from Drugs and Clinical Candidates. Chem. Biol. 2014, 21 (9), 1115–1142. 
(219)  Arnott, J. A.; Planey, S. L. The Influence of Lipophilicity in Drug Discovery and Design. 
Expert Opin. Drug Discov. 2012, 7 (10), 863–875. 
(220)  Waring, M. J. Lipophilicity in Drug Discovery. Expert Opin. Drug Discov. 2010, 5 (3), 
235–248. 
(221)  Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F.; Abraham, M. H. ElogP Oct : A 
Tool for Lipophilicity Determination in Drug Discovery. J. Med. Chem. 2000, 43 (15), 2922–
2928. 
(222)  Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD OCt : A Tool for Lipophilicity 
Determination in Drug Discovery. 2. Basic and Neutral Compounds. J. Med. Chem. 2001, 44 
(15), 2490–2497. 
(223)  Abramson, F. P. Methadone Plasma Protein Binding: Alterations in Cancer and 
Displacement from α1-Acid Glycoprotein. Clin. Pharmacol. Ther. 1982, 32 (5), 652–658. 
(224)  Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-
Making in Medicinal Chemistry. Nat. Rev. Drug Discov. 2007, 6 (11), 881–890. 
(225)  Hou, T.; Wang, J.; Zhang, W.; Wang, W.; Xu, X. Recent Advances in Computational 
Prediction of Drug Absorption and Permeability in Drug Discovery. Curr. Med. Chem. 2006, 13 
(22), 2653–2667. 
(226)  Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. 
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 
2002, 45 (12), 2615–2623. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
69 
 
(227)  Benet, L. Z. The Role of BCS (Biopharmaceutics Classification System) and BDDCS 
(Biopharmaceutics Drug Disposition Classification System) in Drug Development. J. Pharm. 
Sci. 2013, 102 (1), 34–42. 
(228)  Lãbenberg, R. Modern Bioavailability, Bioequivalence and Biopharmaceutics 
Classification System. New Scientific Approaches to International Regulatory Standards. Eur. 
J. Pharm. Biopharm. 2000, 50 (1), 3–12. 
(229)  Daousani, C.; Macheras, P. Biopharmaceutic Classification of Drugs Revisited. Eur. J. 
Pharm. Sci. 2016, 95, 82–87. 
(230)  Cook, J.; Addicks, W.; Wu, Y. H. Application of the Biopharmaceutical Classification 
System in Clinical Drug Development—An Industrial View. AAPS J. 2008, 10 (2), 306–310. 
(231)  Daousani, C.; Macheras, P. Scientific Considerations Concerning the EMA Change in 
the Definition of “dose” of the BCS-Based Biowaiver Guideline and Implications for 
Bioequivalence. Int. J. Pharm. 2015, 478 (2), 606–609. 
(232)  Ku, M. S. Use of the Biopharmaceutical Classification System in Early Drug 
Development. AAPS J. 2008, 10 (1), 208–212. 
(233)  Ishikawa, M.; Hashimoto, Y. Improvement in Aqueous Solubility in Small Molecule 
Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. J. Med. Chem. 
2011, 54 (M), 1539–1554. 
(234)  Leuner, C. Improving Drug Solubility for Oral Delivery Using Solid Dispersions. Eur. J. 
Pharm. Biopharm. 2000, 50 (1), 47–60. 
(235)  Huang, Y.; Dai, W.-G. Fundamental Aspects of Solid Dispersion Technology for Poorly 
Soluble Drugs. Acta Pharm. Sin. B 2014, 4 (1), 18–25. 
(236)  Vo, C. L.-N.; Park, C.; Lee, B.-J. Current Trends and Future Perspectives of Solid 
Dispersions Containing Poorly Water-Soluble Drugs. Eur. J. Pharm. Biopharm. 2013, 85 (3), 
799–813. 
(237)  Stella, V. J.; Nti-Addae, K. W. Prodrug Strategies to Overcome Poor Water Solubility. 
Adv. Drug Deliv. Rev. 2007, 59 (7), 677–694. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
70 
 
(238)  Lipinski, C. A. Drug-like Properties and the Causes of Poor Solubility and Poor 
Permeability. J. Pharmacol. Toxicol. Methods 2000, 44 (1), 235–249. 
(239)  Ishikawa, M.; Hashimoto, Y. Improvement in Aqueous Solubility in Small Molecule 
Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. J. Med. Chem. 
2011, 54 (6), 1539–1554. 
(240)  Lin, J. H.; Lu, A. Y. H. Role of Pharmacokinetics and Metabolism in Drug Discovery and 
Development. Pharmacol. Rev. 1997, 49 (4), 403 LP-449. 
(241)  Eddershaw, P. J.; Beresford, A. P.; Bayliss, M. K. ADME/PK as Part of a Rational 
Approach to Drug Discovery. Drug Discov. Today 2000, 5 (9), 409–414. 
(242)  Li, A. P. Screening for Human ADME/Tox Drug Properties in Drug Discovery. Drug 
Discov. Today 2001, 6 (7), 357–366. 
(243)  Ursu, O.; Rayan, A.; Goldblum, A.; Oprea, T. I. Understanding Drug-Likeness. Wiley 
Interdiscip. Rev. Comput. Mol. Sci. 2011, 1 (5), 760–781. 
(244)  Xu, C.; Li, C. Y.-T.; Kong, A.-N. T. Induction of Phase I, II and III Drug 
Metabolism/transport by Xenobiotics. Arch. Pharm. Res. 2005, 28 (3), 249. 
(245)  Vrbanac, J.; Slauter, R. ADME in Drug Discovery. In A Comprehensive Guide to 
Toxicology in Preclinical Drug Development; Elsevier, 2013; pp 3–30. 
(246)  David Josephy, P.; Peter Guengerich, F.; Miners, J. O. “Phase I and Phase II” Drug 
Metabolism: Terminology That We Should Phase Out? Drug Metab. Rev. 2005, 37 (4), 575–
580. 
(247)  Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II Drug Metabolizing Enzymes. 
Biomed. Pap. 2010, 154 (2), 103–116. 
(248)  Frank, A.; Unger, M. Analysis of Frankincense from Various Boswellia Species with 
Inhibitory Activity on Human Drug Metabolising Cytochrome P450 Enzymes Using Liquid 
Chromatography Mass Spectrometry after Automated on-Line Extraction. J. Chromatogr. A 
2006, 1112 (1–2), 255–262. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
71 
 
(249)  Guengerich, F. P. Cytochromes P450, Drugs, and Diseases. Mol. Interv. 2003, 3 (4), 
194–204. 
(250)  Morgan, P.; Van Der Graaf, P. H.; Arrowsmith, J.; Feltner, D. E.; Drummond, K. S.; 
Wegner, C. D.; Street, S. D. A. Can the Flow of Medicines Be Improved? Fundamental 
Pharmacokinetic and Pharmacological Principles toward Improving Phase II Survival. Drug 
Discov. Today 2012, 17 (9–10), 419–424. 
(251)  Wienkers, L. C.; Heath, T. G. Predicting in vivo Drug Interactions from in vitro Drug 
Discovery Data. Nat. Rev. Drug Discov. 2005, 4, 825. 
(252)  Kumar, G. N.; Surapaneni, S. Role of Drug Metabolism in Drug Discovery and 
Development. Med. Res. Rev. 2001, 21 (5), 397–411. 
(253)  Segall, M. D.; Barber, C. Addressing Toxicity Risk When Designing and Selecting 
Compounds in Early Drug Discovery. Drug Discov. Today 2014, 19 (5), 688–693. 
(254)  Kim, S.; Cho, M.; Lee, T.; Lee, S.; Min, H.-Y.; Lee, S. K. Design, Synthesis, and Preliminary 
Biological Evaluation of a Novel Triazole Analogue of Ceramide. Bioorg. Med. Chem. Lett. 
2007, 17 (16), 4584–4587. 
(255)  Biot, C.; Bauer, H.; Schirmer, R. H.; Davioud-Charvet, E. 5-Substituted Tetrazoles as 
Bioisosteres of Carboxylic Acids. Bioisosterism and Mechanistic Studies on Glutathione 
Reductase Inhibitors as Antimalarials. J. Med. Chem. 2004, 47 (24), 5972–5983. 
(256)  Gardiner, S. J. Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. 
Pharmacol. Rev. 2006, 58 (3), 521–590. 
(257)  Cunningham, R. F.; Israili, Z. H.; Dayton, P. G. Clinical Pharmacokinetics of Probenecid. 
Clin. Pharmacokinet. 1981, 6 (2), 135–151. 
(258)  Dacey, R. G.; Sande, M. A. Effect of Probenecid on Cerebrospinal Fluid Concentrations 
of Penicillin and Cephalosporin Derivatives. Antimicrob. Agents Chemother. 1974, 6 (4), 437–
441. 
(259)  Aronov, A. M. Common Pharmacophores for Uncharged Human Ether-a-Go-Go-
Related Gene (hERG) Blockers. J. Med. Chem. 2006, 49 (23), 6917–6921. 
                         Chapter 1                                                                                  Introduction and Literature Review 
 
                       Godfrey Mayoka PhD Thesis 2018                                                         University of Cape Town 
72 
 
(260)  Fermini, B.; Fossa, A. A. The Impact of Drug-Induced QT Interval Prolongation on Drug 
Discovery and Development. Nat. Rev. Drug Discov. 2003, 2 (6), 439–447. 
(261)  Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. hERG-Related Drug Toxicity and 
Models for Predicting hERG Liability and QT Prolongation. Expert Opin. Drug Metab. Toxicol. 
2009, 5 (9), 1005–1021. 
(262)  Aronov, A. Predictive in silico Modeling for hERG Channel Blockers. Drug Discov. Today 
2005, 10 (2), 149–155. 
(263)  Yu, H.; Adedoyin, A. ADME–Tox in Drug Discovery: Integration of Experimental and 











                                                                                 
Pyrido [1,2-a] benzimidazoles 
 
Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 
 Godfrey Mayoka PhD Thesis 2018                                                                University of Cape Town 
 
74 
2.1 Chapter overview 
 
This chapter will provide a brief account of the chemistry and pharmacological spectrum of 
pyridobenzimidazoles and describe their activity with respect to their potential as antimalarial 
and antischistosomal drug development leads. A recap of the unmet medical need and, thus, 
a statement of justification for the current research will be expressed, including the aims, 
objectives and hypothesis underpinning this study. The medicinal chemistry plans leading to 
the synthesis of target compounds and a description of the subsequent work flow will be 
provided. Lastly, using representative compounds, the synthesis and characterization 
undertaken to realise and confirm structures of the target compounds, will be discussed.  
 
2.2 General chemistry and pharmacology 
 
The pyridobenzimidazole (PBI) nucleus consists of benzene, imidazole and pyridine motifs 
fused into a single tricyclic scaffold (b, Figure 2.1).1 On the other hand, the structurally related 
benzimidazole chemotype is a bicyclic structure in which the benzene and imidazole moieties 
have been fused together (a, Figure 2.1). Therefore, the PBI nucleus may be considered as a 
derivative or extension of the benzimidazole core, both of which are pivotal in drug 
discovery.2,3  
 
Figure 2.1: Chemical structures of benzimidazole (a) and pyrido [1, 2-a] 
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Benzimidazole is a privileged structure in medicinal chemistry and has been implicated not 
only in natural biomolecules such as vitamin B12 but also in several drugs with a large spectrum 
of biological and pharmacological activities including as anti-ulcer, antiparasitic, 
antipsychotic, anticancer and antitubercular. Other indications include as antifungal, 
antihypertensive and antiviral (Figure 2.2).4–7  
 
Figure 2.2: Chemical structures of vitamin B12 and drugs incorporating a benzimidazole moiety. 
 
The PBI nucleus has continued to inspire interest in medicinal chemistry towards drug 
discovery. The flourishing of synthesis methods and the amenability of the PBI scaffold to 
chemical modifications has enabled generation of a large range of analogues with diverse 
pharmacological and biological effects.1,8–12 The PBI system is an appealing scaffold in 
medicinal chemistry, lending itself to chemical evolution, allowing for transformation into 
diverse structural derivatives for structure-activity and structure-property relationships 
studies. 
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Figure 2.3: Biological and pharmacological activities of pyridobenzimidazoles. 
 
 
2.3 Pyrido [1,2-a] benzimidazoles as antimalarial agents 
 
As part of the initiative to promote tropical disease research, a commercial compound library 
of 1440 non-propriety compounds with diverse chemical structures was screened in vitro 
against the human malaria parasite Plasmodium falciparum. As a result of this work carried 
out jointly by the WHO-TDR and the Belgian company Tibotec®, hit 1 (Figure 2.4) was 
identified as having moderate activity against P. falciparum GHA and W2 strains (0-17-0.37 
µM).13 A subsequent screening of 535 other compounds that incorporate the PBI core in their 
structures identified compounds 2 and 3 which were more potent and had better selectivity 
indices compared to the hit 1 (Figure 2.4).  
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Unfortunately, neither the hit 1 nor the surrogates 2 and 3 demonstrated any in vivo efficacy 
when tested in a murine model of malaria even to doses up to 4x100mg/kg; a fate attributed 
to poor solubility and metabolic stability. This observation prompted for a SAR campaign 4a 
focussing on introducing diversity around the PBI core with the aim of finding analogues with 
in vivo antimalarial activity. Accordingly, targets with aryl groups at R2 and alkyl amine side 
chains at R were synthesised (Figure 2.4). 
 The most active compound in the series 5 (Figure 2.4), displayed improved in vitro activity 
(IC50=0.047µM) in comparison to both the hit compound 1 and the standard drug used in the 
assay, chloroquine (IC50=0.17 µM), against the K1 drug resistant strain of P. falciparum and 
had negligible cytotoxicity to mammalian (L-6) cell lines as indicated by a high selectivity index 
(SI˃600) towards Plasmodium parasites.  
Distinct SAR trends were unravelled from this initial medicinal chemistry campaign. It was 
observed that the in vitro activity was driven by the lipophilicity of the compounds. Generally, 
the compounds with a secondary or tertiary terminal nitrogen in the side chain (R6, 4b, Figure 
2.4) were more active than those with a primary nitrogen and activity was retained when the 
terminal nitrogen atom was incorporated in cyclic rings (R6, 4b, Figure 2.4). Furthermore, the 
antiplasmodial activity was comparable in compounds with either ethylene (n=0) or 
propylene (n=1) chain linkers between the nitrogen atoms on the alkyl side chain (between 
R5 and R6; 4b, Figure 2.4). Additionally, it was noted that phenyl or aryl substitutions resulted 
in compounds with greater potency than simple alkyl or haloalkyl groups at R7 (4b, Figure 2.4) 
with substitution at the para position being the most ideal.  
Additional SAR findings from our research group have been reported.14 Based on metabolism 
studies carried out on the earlier analogue 5 (Figure 2.4), the des-ethyl analogue 6 was found 
to retain potency and have better DMPK properties compared to the parent compound 5 
(Figure 2.4). Compound 6 was therefore used to guide future optimization campaigns. 
Consequently, the SAR strategy involved modifying the appendages at R and R2, introducing 
small lipophilic groups at R1 with the aim of potentially minimizing crystal packing of the 
molecules, and attempting changes on the benzenoid portion of the motif, R4 (4a, Figure 2.4). 
Regarding changes at R, the alkyl side chain could be replaced with cyclic amines with 
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retention of activity, the best of which was the introduction of 3-hydroxy pyrrolidine, 
compound 10 (Figure 2.4). Introducing fluorine at R1 (as in compound 7), although leading to 
improvement in solubility, was unfortunately detrimental to activity. Groups on the aromatic 
appendage at R7 (4b, Figure 2.4) could be moved around the ring or be replaced with other 
lipophilic groups while maintaining antiplasmodial activity.  
However, polar substituents such as methylester (8a), sulfoxide (8b) and thiomethyl (8c) were 
not tolerated although they had been envisaged to improve solubility. Saturation of the 
aromatic system, consistent with introducing cycloalkyl systems at this site, could be carried 
out but not without the loss of selective antiplasmodial activity as in 9 (Figure 2.4). The 
decreased lipophilicity was also beneficial to increasing solubility but resulted in the decrease 
in microsomal metabolic stability. SAR alterations at R4 (4a, Figure 2.4) aimed at decreasing 
lipophilicity and improving solubility, by incorporating a pyridyl functionality (11), produced 
analogues with good activity but at the expense of selectivity. It was, however, the 
introduction of lipophilic substituents, using halogens, on this portion of the initial lead 
compound that generated analogues, exemplified by compound 12, with not only enhanced 
in vitro activity and metabolic stability but also improved in vivo efficacy.  
Building upon the findings of these earlier works, we devised other SAR approaches to explore 
newer chemical spaces, by introducing other structural variations, with the hope of 
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2.4 Antischistosomal activity of pyrido [1,2-a] benzimidazoles 
 
In the context of drug repositioning, the set of PBI analogues synthesized in the antimalarial 
program described earlier, were screened for activity against schistosome parasites. From this 
work, compounds with modest antischistosomal activity were identified (Figure 2.5).15   
       
             
Figure 2.5: Examples of PBI derivatives with in vitro potency (IC50) against adult S. mansoni. 
 
 
As with the antimalarial program discussed previously, subsequent medicinal chemistry 
studies improved the in vitro activity of second generation analogues but insufficient in vivo 
exposure, perceived to arise from low solubility and metabolic instability, remained a 
challenge.15 These initial results provided a basis for further investigations into new PBIs as 
potential antischistosomal leads.  
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The pyridobenzimidazole scaffold can be utilized to generate small molecule drug leads with 
good in vitro and in vivo antimalarial and antischistosomal activities having favourable 




Malaria and schistosomiasis are the two most prevalent parasitic diseases in the tropical and 
subtropical regions of the world. Mortality and morbidity due to malaria have been on a 
steady decline in the last two decades but the emergence and spread of parasites resistant to 
the front-line regimes comprising the artemisinins present a formidable hurdle in sustaining 
the gains made in malaria control. On the other hand, praziquantel remains, for over three 
decades, the only available pan-active antischistosomal drug against the major species of 
schistosomes associated with human schistosomiasis. Concerns of resistance to praziquantel 
have been on the rise, especially with the use of the drug in mass drug administration for 
preventive chemotherapy in endemic countries.  The search for novel antimalarial and 
antischistosomal drugs is therefore warranted. Safe and effective alternatives should be 
made available, as a necessary precaution, should current therapies become compromised. 
Furthermore, antimalarial treatment with the ability to interrupt other stages of the life cycle 
of the parasite in addition to the asexual blood stage are required to enhance blocking 
transmission and achieving chemoprevention which are additional desirable target product 
profiles within the context of malaria eradication. Similarly, active agents against the larval 
stages of Schistosoma parasites, in addition to the mature forms, are also required since the 
current drug of choice, praziquantel, is only active against the adult worms, making repeated 
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As already alluded to, biological profiling of pyridobenzimidazoles has unravelled vast and 
diverse pharmacological activities including antiplasmodial and antischistosomal effects. The 
initial SAR plan carried out by our group generated compounds with unsatisfactory 
physicochemical attributes such as low solubility. The chemical tractability of the scaffold 
coupled with discernible SAR trends, inspired the prosecution of the current research plan 
with the hope of finding improved antimalarial and antischistosomal leads.  
2.6 Aims and Objectives 
 
2.6.1 Main Objective 
 
The overall objective for this project was to optimise 3-trifluoromethyl pyrido [1, 2-a] 
benzimidazole-based compounds as potential antimalarial and antischistosomal agents. 
 
2.6.2 Specific Aims 
In tandem with the overall objective for this project, we envisaged the following specific aims 
which are expounded in greater detail in subsequent chapters:  
i. Perform the synthesis, antiplasmodial and antischistosomal structure-activity relationship 
(SAR) studies of N-aryl 3-trifluromethyl pyrido [1,2-a] benzimidazole derivatives; 
ii. Profile target compounds for physicochemical properties including melting point, solubility, 
lipophilicity, and discern structure-property trends; 
iii. Undertake metabolic stability, metabolite identification and cytotoxicity studies of 
prioritised compounds; 
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2.7 Design  
 
2.7.1 Medicinal chemistry plan 
 
In the current design, the sites targeted for alteration are as depicted in Figure 2.6 wherein 
we sought to introduce further structural diversity around the PBI core by executing 
modifications at the highlighted positions. 
 
 
Figure 2.6: Medicinal chemistry approach adopted in this study. 
 
At position SAR1, instead of using aliphatic amines as explored earlier (Figure 2.4), aromatic 
side groups in the form of aniline- and benzylamine-type moieties were employed. In the 
aniline-type series, the PBI core is linked directly to the aromatic appendage by means of a 
nitrogen linkage (n=0; Figure 2.6). Conversely, in the analogues with benzylamine-type side 
groups, a methylene linker connects the nitrogen attached to the PBI core with the aromatic 
side portion (n=1; Figure 2.6).  
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In exploring this SAR wherein, a methylene linker is incorporated as opposed to directly 
attaching the side group to the PBI core, we presumed the introduction of some degree of 
flexibility in the analogues with the projected benefit of improving solubility, by potentially 
reducing π-π stacking interactions in the molecules. The substitutions on the aromatic side 
groups in SAR1 were performed in line with medicinal chemistry practices using the Craig plot 
to ensure diversity in the lipophilic and electronic characteristics in target compounds.  
In some analogues, a methyl substitution was introduced on the methylene linker to 
introduce chirality at this position which was envisaged to not only potentially reduce crystal 
packing further but also to explore new chemical space in the series. Such analogues would 
also facilitate the interrogation of the effect of chirality on both biological activity and 
physicochemical properties. Towards improving the solubility attributes of the target 
compounds, analogues in which the methylene linker was replaced with hydrogen bonding 
moieties such as amine (-NH-), sulfone (-SO2-) and amide (-NHCO-) groups were pursued. 
Modification of the linker nitrogen in the side group (R1, Figure 2.6) was proposed for some 
analogues to facilitate the evaluation of steric and electronic factors as well as the influence 
of the presence of a hydrogen-bonding centre around this region of the molecule. 
Furthermore, towards expanding the SAR around position SAR1, and with the aim of 
introducing solubility-enhancing features, heteroaromatic amines were also used (R2, Figure 
2.6). Moreover, other heteroaromatic amines such as the pyridyl group have protonatable 
sites to facilitate salt formation in the context of improving aqueous solubility for oral drug 
administration.  
With the use of aromatic side chains as opposed to the earlier explored aliphatic ones at SAR1, 
significant increases in the molecular weight of the target compounds beyond the Lipinski’s-
recommended 500 Da for good oral absorption were anticipated in case of the 3-
trifluorophenyl (3-Ph-CF3) moiety at position SAR2. For this reason, the smaller 
trifluoromethyl (CF3) group, which from previous studies was tolerated for antiplasmodial 
activity, was used at position SAR2.  
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Since the PBI core is an electron dense system, challenges related to metabolic instability for 
target compounds were anticipated. To forestall this liability, small lipophilic groups that 
could impart metabolic stability by blocking some of the putative metabolic hotspots were 
introduced at SAR4. Halogen substituents were accordingly introduced on this phenyl portion 
of the PBI scaffold (R, Figure 2.6). 
Based on the X-ray crystallographic structure of an analogous PBI (Figure 2.7), the nitrile 
group at SAR3 was depicted to be coplanar to the PBI core, a feature that is likely to encourage 
crystal packing in the compounds, a possible contributor to their low solubility. To thus 
attempt to potentially disrupt this planarity, replacement of this nitrile group with other 
groups hypothesized to result in non-co-planarity with the PBI core was undertaken on some 
analogues (R4, Figure 2.6). Some of the proposed moieties, such as the amide group, were 
expected to help address the solubility shortcoming of this series by facilitating hydrogen-








         
Figure 2.7: Chemical (left) and X-ray (right) structures of a PBI derivative. Coplanarity is exhibited 
between the nitrile group (highlighted in oval) and the PBI core (shown with a rectangle).16 
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2.7.2 Research program 
 
The work flow adopted in this research is depicted in Figure 2.8. Target compounds were 
synthesized and sufficiently characterised as described in section 2.8 of this chapter. All target 
molecules were profiled with respect to their in vitro antiplasmodial and antischistosomal 
activities and structure-activity relationship trends analysed as detailed in Chapters 3 and 4, 
respectively. Initially, antiplasmodial assays were carried out in the chloroquine sensitive 
(NF54) strain of Plasmodium falciparum focussing on the asexual blood stage parasites. 
Selected compounds, based on potency, were then evaluated for activity against the 
gametocyte and liver stages of the parasite as well against the chloroquine resistant (K1) 
strain of Plasmodium falciparum. On the other hand, the antischistosomal tests were 
performed on both the adult worms and the larval stages referred to as newly transformed 
schistosomula (NTS). Concurrently, the physicochemical profile of the analogues (melting 
points, solubility and cLogP) was determined experimentally and by use of in silico tools to 
delineate structure-property relationships as discussed in Chapter 5. The cytotoxicity profile 
of compounds with promising in vitro activity was evaluated by testing their inhibition of the 
growth of Chinese hamster ovarian cells and the selectivity index (SI) determined. Moreover, 
selected analogues were also tested for their ability to interact with the human ether-a-go-
go related gene (hERG) implicated in the functioning of potassium ion channels that controls 
the contractile activity of heart muscles. Inhibition of the hERG channel can cause fatal heart 
arrhythmias called torsade de pointes. 
Analogues that displayed satisfactory cytotoxicity profiles were progressed to in vitro 
metabolic stability evaluation in human and mouse liver microsomes. Those compounds that 
satisfied the in vitro microsomal metabolic stability criteria, possessed a good SI profile with 
acceptable solubility were then investigated for efficacy in appropriate animal models to 
provide in vivo proof-of-concept. Moreover, to understand the predisposition of the series, 
representative compounds were selected for pharmacokinetic studies. Additionally, 
compounds that were active in vitro but portrayed poor metabolic stability in human and 
mouse liver microsomes were proposed for metabolite identification studies.  
 
Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 








































In vitro cytotoxicity 
(CHO) 




≥75% remaining after 30min. 
Pf: Plasmodium falciparum; S.mansoni: Schistosoma mansoni; NTS: Newly transformed schistosomula 
CHO: Chinese Hamster Ovarian cell line; SI: Selectivity Index; HLM/MLM: Human/Mouse liver microsomes 
PK: Pharmacokinetics; F: Bioavailability; t1/2: half-life. 
≤50% remaining after 30min. 
 
 
Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 
 Godfrey Mayoka PhD Thesis 2018                                                                University of Cape Town 
 
88 
2.8 Synthesis and characterization 
 
2.8.1 Synthesis  
 
2.8.1.1 General overview of the synthesis 
 
With the increasing exploitation of the PBI nucleus in medicinal chemistry, the synthesis of 
pyridobenzimidazoles has been reported in the literature. In the present work, reference is 
made mainly to the work reported by researchers from our lab.13–15  Consequently, most of 
the target compounds Va were synthesised using a straightforward three-step approach from 
commercially available benzimidazole acetonitrile IIa. Other targets (Vb and Vc), with 
alterations on the benzenoid portion of the PBI core, required an extra initial step i to 
generate the appropriately substituted benzimidazole acetonitrile intermediates IIb and IIc. 
Regarding changes at SAR3 (Scheme 2.1) wherein the cyano group was replaced with other 
groups, different approaches were employed, including varying the starting material from 
benzimidazole acetonitrile IIa to a benzimidazole methyl ester IId and transformation of the 
nitrile group of the chloro intermediate IVa to the amide VI, to furnish the target compounds 
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Scheme 2.1: SAR modification sites and general scheme for the synthesis of target compounds. Reagents and conditions: (i) 
Ethyl cyanoacetate, DMF, 160˚C, 2 h; (ii) Ethyl 4,4,4-trifluoro-3-oxobutanoate, NH4OAc, 145˚C, 2h; (iii) POCl3, (20eq), 130˚C, 3 h; 
(iv) Relevant amine (RNH2), Et3N,  microwave, 80˚C, 150 W, 20-60 min or the appropriate amine,  Pd2(dba)3, BINAP or Brettphos, 
K2CO3 or Cs2CO3, toluene or 1,4-dioxane or tert-butanol, 100-120˚C, 12-16 h; (v) conc. Sulphuric acid, 2h. 
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2.8.1.2 Synthesis of unsubstituted SAR2 analogues  
 
In the case of analogues with no substitution of the benzene portion of the scaffold, 
benzimidazole acetonitrile IIa was condensed with the beta keto ester ethyl-4,4,4-
trifluoroethylester, in the presence of ammonium acetate, under reflux (ii, Scheme 2.1), to 
afford the tricyclic hydroxyl intermediate IIIa. In this reaction, the ammonium acetate 
abstracts a proton from the methylene carbon, sandwiched between the benzimidazole ring 
and the nitrile group, generating a resonance-stabilized carbanion (i, Scheme 2.2). This 
carbanion then attacks the more electrophilic carbonyl on the beta keto ester (ii, Scheme 2.2). 
Subsequent sequential proton abstraction from ammonium ion and acetic acid forms the 
intermediate v, (Scheme 2.2). The acetate ion picks up the hydrogen on the alpha carbon, 
next to the nitrile, leading to the loss of a water molecule with formation of intermediate vi 
(Scheme 2.2). Next, cyclisation triggered by the more nucleophilic benzimidazole nitrogen, 
which attacks the ester carbonyl group of the beta keto ester, leads to the tricyclic 
intermediate vii (Scheme 2.2). Proton transfer and expulsion of the ethoxy group driven by 
the formation of a keto functionality gives intermediate ix. Finally, the abstraction of the 
acidic proton in ix by the ethoxy anion gives the intermediate product IIIa with ethanol as a 
by-product (Scheme 2.2).  
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Scheme 2.2: Proposed mechanism leading to intermediate IIIa. 
 
In the next reaction (iii, scheme 2.1), the hydroxyl group in intermediate III is converted to 
the chloro group, which is a better leaving group in nucleophilic substitution reactions, 
compared to the hydroxyl. This reaction was readily mediated by phosphoryl oxychloride 
under reflux conditions. The reaction proceeds, as illustrated in i, Scheme 2.3, by the attack 
on the electron-deficient phosphorus by one of the lone pairs of electrons on the hydroxyl 
oxygen. The electron withdrawing nature of the chloro and oxygen atoms attached to the 
phosphorus atom makes the phosphorus readily susceptible to this nucleophilic attack. 
Subsequent steps in this reaction involve reforming the oxygen-phosphorus double bond 
accompanied by the expulsion of a chloride ion.  Next, the ejected chloride ion serves as a 
nucleophile (ii, Scheme 2.3), attacking the carbon on the PBI core which now has enhanced 
electrophilicity due to the positive charge on the oxygen to which it is attached, resulting in 
the breaking of the carbon-oxygen bond and formation of the new carbon-chloro bond. Thus, 
the intermediate IVa is formed with the generation of phosphenic chloride and hydrochloride 
gas as by-products.  
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Scheme 2.3: Proposed chlorination mechanism leading to intermediate IVa. 
 
The chloro penultimate intermediate IVa was then transformed in the final step iv (Scheme 
2.1) that entailed appending the predetermined amine either via nucleophilic aromatic 
substitution or by employing the palladium-catalysed Buchwald-Hartwig reaction conditions 
in the case of unreactive or poorly nucleophilic amines. Where nucleophilic aromatic 
substitution was elected for the synthesis of target compounds, triethylamine was included 
as the base and an appropriate solvent used. This reaction was completed in a microwave 
reactor in a sealed tube.  
This reaction is proposed to proceed as depicted in Scheme 2.4 where the lone pair of 
electrons on the amine nitrogen attack the electron-deficient carbon to which the chlorine 
atom is attached (i).  Due to conjugation in the PBI system and ensuing resonance effects, 
there is a shift in the pyridyl double bonds leading to a negative charge residing on the nitrile 
nitrogen (ii). Consequently, the nitrile triple bond and the double bonds in the pyridyl reform, 
kicking out the chloro group. As a result, the intermediate iii is formed. In the final step, 
triethylamine abstracts a proton from the amino group thus neutralising the positive charge 
and forming the target amine compound Va together with triethylamine hydrochloride salt 
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Scheme 2.4: Proposed mechanism for the nucleophilic substitution reaction leading to final targets Va. 
 
Notably, and expectedly so, this reaction generally resulted in the synthesis of analogues from 
the benzylamine-type series in better yields than those of the aniline-type series (Table 2.1). 
Moreover, the Craig plot substituent on the phenyl ring influenced the reactivity of the amine 
in the nucleophilic substitution reaction: electron withdrawing groups such as cyano and 
amide reduced the nucleophilicity of the amino nitrogen whereas electron-donating or 
releasing groups improved the nucleophilicity of respective amines. These features influenced 
the yields of respective analogues (Table 2.1).  As already alluded to above, targets that could 
not be obtained through the conventional nucleophilic substitutions reactions or whose yields 
were expected to be too low, an alternative synthesis protocol involving the palladium-
catalysed Buchwald-Hartwig amination reaction was utilised.17–20  
In the use of the Buchwald-Hartwig amination reaction, whose general catalytic cycle is 
depicted in Scheme 2.5, various catalyst-ligand combinations were explored. The cycle starts 
with an oxidative addition process in which the palladium inserts between the carbon and 
chloro atom of the chloro intermediate IVa (Scheme2.5) after which the amine coordinates 
with the palladium. Proton abstraction by the base followed by attack on the palladium results 
in expulsion of the chloro leaving group. The target aryl amine product is generated in a 
reductive elimination step accompanied by the regeneration of the catalyst.  
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2.8.1.3 Synthesis of SAR2 analogues 
 
As highlighted earlier, analogues with substitutions on the phenyl portion were derived from 
appropriately substituted diaminobenzenes I (scheme 2.1). In the case of SAR2 analogues, the 
benzimidazole nitrile starting material was synthesized as mechanistically depicted in Scheme 
2.6.  The substituted benzimidazole nitriles II were subsequently used as described in section 
2.8.1.2.to furnish targets Vb and Vc.  
 
Scheme 2.6: Proposed mechanism for the condensation reaction leading to intermediates IIb and IIc. 
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2.8.1.4 Synthesis of SAR3 analogues 
 
To replace the cyano functionality attached to the pyridyl portion of the PBI motif, different 
approaches were explored including varying the benzimidazole starting material. In this case, 
the methyl ester surrogate IId of benzimidazole acetonitrile IIa was used as a starting reagent. 
In exploring this alternative, it was hypothesized that, in line with the proposed mechanism 
for the formation of the hydroxyl intermediate (Scheme 2.2), the ester group would impart 
the necessary electron-withdrawing character as with the cyano group, to render the 
methylene protons acidic enough to be abstracted by the ammonium acetate base. The 
subsequent reaction steps would then proceed as discussed earlier (Scheme 2.2).  
The above mentioned synthetic strategy was successful, albeit it resulted in lower yields of 
intermediate IIId compared to that achieved for IIIa when benzimidazole acetonitrile IIa was 
used as the starting material. An analysis on the other components of the reaction mixture 
revealed the presence of compounds whose identity could be rationalised. Among the major 
peaks observed was that of a protonated molecular ion mass of [M-58] corresponding to the 
decarboxylated product. Given the thermal conditions under which the reaction was carried 
out, it was reasoned that sufficient energy must have been generated to induce the 
decarboxylation reaction.  Improved yields, albeit slightly, were achieved when the reaction 
was carried out at lower temperatures. Intermediate IVd and the final target Vd were 
synthesized subsequently from IIId as per the previously described protocol (Scheme 2.1). 
Serendipitously, the chloro intermediate bearing the ester moiety (IVd, Scheme 2.1) resulted 
in the amination product, which had a mass and spectral profile matching the decarboxylated 
analogue, with a m/z of [M-58]. This observation paralleled that of the decarboxylation 
observed during the formation of the hydroxyl intermediate IIId. The microwave conditions 
applied appear sufficiently forceful to bring about sequential ester hydrolysis and 
decarboxylation (Scheme 2.7). Nonetheless, this unexpected reaction afforded us a useful 
target compound, Ve (Scheme 2.1) that would enable us to interrogate the role of the nitrile 
group in the antimalarial and antischistosomal activities of the PBIs.    
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Scheme 2.7:  Mechanism for the ester hydrolysis and decarboxylation reactions leading to target Ve. 
 
We explored other cyano-replacement strategies including the conversion of the cyano to an 
amide at the hydroxyl stage using concentrated sulphuric acid (Scheme 2.8). The mechanism 
of this functional group interconversion, that entails hydration, is proposed to proceed via an 
initial protonation of the nitrile nitrogen which increases the susceptibility of the nitrile 
carbon to an electrophilic attack carried out by water (b, Scheme 2.8). Subsequent proton 
transfer (c) from the oxygen to nitrogen facilitates formation of the amide carbonyl (d). 
Subsequently, the sulphate anion picks up the proton on the positively charged oxygen (e) to 
regenerate the acid and give the desired amide target. This reaction proceeded readily giving 
quantitative yields.  
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Scheme 2.8: Proposed reaction mechanism for nitrile oxidation using conc. Sulphuric acid. 
 
Chlorination of the now derived hydroxyl intermediate (f, Scheme 2.8) was then carried out 
using POCl3 as described with the other targets (iii, Scheme 2.1). Surprisingly, the expected 
product vi (Scheme 2.9) was not obtained. Instead, on the LCMS, the compound produced a 
peak with a different retention time but the same protonated molecular ion mass [M+H]+ as 
the hydroxyl precursor f, Scheme 2.8. This MS profile was consistent with that of the chloro 
intermediate IVa which has a nitrile group instead of an amide at SAR3, Scheme 2.1. Following 
literature investigations, it was established that POCl3 had converted not only the hydroxyl 
group of ii to the chloro, but also the amide back to the nitrile as illustrated in Scheme 2.9.21 
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Scheme 2.9: (a) Reaction path for the unsuccessful synthesis of vi and (b) the proposed mechanism of 
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Thus, realising that the hydroxyl intermediate was unsuitable for transforming the nitrile to 
the amide under the proposed reaction conditions, this change was attempted at the chloro 
intermediate stage. Gladly, this reaction proceeded unhindered and gave good yields. Using 
the now synthesized chloro intermediate having an amide functionality (VI, Scheme 2.1), the 
final amination step could be carried out as in step iv to furnish analogues Vf (Scheme 2.1).  
Numerous attempts to introduce more diversity at the nitrile site were unsuccessful. For 
example, the well reported cyano to carboxylic acid conversion using base or acid catalysis 
were unfruitful under different conditions of bases, acids, temperatures and solvents. 
Instead, in some cases, molecular ions observed on MS analysis pointed to possible 
fragmentation of the PBI scaffold under some extreme conditions attempted. Similarly, 
attempts to generate the primary amine, carboxylic acid and tetrazole analogues at this 
position failed, despite their wide applications in organic chemistry.22 These syntheses failures 
prompted the hypothesis that the rich electron density and continuous electron flow in the 
PBI scaffold, coupled with conjugation and resonance involving the nitrile group (Scheme 
2.10) are likely features rendering this group inert to the attempted transformations. Changes 
at this SAR site were thus limited by the synthetic challenges experienced. 
 
 
Scheme 2.10: Resonance and conjugation in the PBI system illustrating involvement of the nitrile in 






Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 





2.8.2.1 Overview of characterisation techniques 
 
To establish the identity of intermediates and target compounds, analytical and spectroscopic 
techniques were used, in a complementary manner. Thin layer chromatography (TLC) on silica 
adsorbed on alumina with the corresponding optimised mobile phase enabled monitoring of 
reaction progress. High performance liquid chromatography coupled to a mass spectrometer 
(HPLC-MS) further aided in monitoring progress of reactions through identification of the 
molecular ion of the formed product in the reaction mixture. Following purification and 
isolation of target compounds using an array of methods including trituration, precipitation, 
preparative TLC and column chromatography, purity was determined using HPLC with UV 
detection, given the aromatic nature of the compounds which endows them with UV 
absorption capacity. Nuclear magnetic resonance (NMR) involving both proton (1H) and 
carbon (13C) nuclei further supplemented the compound identification process by generating 
peaks whose chemical shifts (1H and 13C) and coupling patterns (1H) directed the structure 
assignment. In the succeeding section, representative intermediates and target compounds 
from each of the SAR positions are described to illustrate how these techniques were used to 
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2.8.2.2 Hydroxyl Intermediate IIIa with no modification on SAR2 
 
In the case of compounds where there are no changes made at SAR2, and SAR3 is fixed as a 
nitrile, transformation of the benzimidazole acetonitrile IIa to the tricyclic hydroxyl 
intermediate IIIa was detected by a decrease in polarity based on analytical TLC analysis. The 
corresponding mass peak m/z [M+H] of   278.1 on the LC-MS together with the increase in 
retention time, reflective of increased lipophilicity, provided more evidence for the formation 
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Analyses of 1H NMR spectra (Figure 2.10) corroborated with the structure for intermediate 
IIIa wherein peaks that integrated for five protons were observed downfield (6-9 ppm), 
representing the 5 aromatic protons present on the PBI core. Four of these protons are the 
protons in the phenyl region (LHS) of the PBI scaffold displaying chemical shifts between 7.46 
and 8.60 ppm. In addition to the position of the NMR peaks, which reflects the chemical 
environment with respect to shielding and deshielding effects, in which the protons are 
located, the coupling constants directed the assignment of peaks to the respective protons. 
Consequently, proton H1 resonates furthest downfield at 8.60 ppm and appears as a doublet 
of triplet arising from Jortho coupling to H2 (J= 8.16 Hz) and Jmeta coupling to H3 (J=0.91 Hz). 
Signals due to protons H2 and H4 appear in close proximity between 7.70-7.57 ppm with their 
peaks superimposing, resulting in a multiplet which integrates for two protons. The H3 
proton, appearing as a doublet of doublets of doublets at 7.46 ppm, experiences Jortho 
coupling with both H4 (J=8.6 Hz) and H2 (J=6.8 Hz) with an additional Jmeta coupling with H1 
(J=1.8 Hz). The signal at 6.43 ppm, which was diagnostic for this intermediate and integrates 
for one proton, represents the H5 proton present next to the carbon bearing the hydroxyl 
group on the pyridyl portion of the PBI core while the signal due to the hydroxyl proton (H6) 
usually appeared downfield as a broad singlet. 
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Similarly, 13C NMR analysis aided the confirmation of the structure based on the positions of 
the carbon signals which largely paralleled that of the protons. Thirteen (13) carbon signals 
were identifiable with chemical shifts between ca. 100-160ppm due to the aromatic and 




Figure 2.10: 1H NMR of intermediate IIIa in DMSO-d6. 
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2.8.2.3. Chloro Intermediate IVa 
Formation of the chloro intermediate IVa after the reaction between the hydroxyl 
intermediate IIIa and POCl3 was discernible by changes in appearance, molecular mass and 
polarity. In addition to the disappearance of grey colour of IIIa and emergence of a yellow 
one, a molecular ion of m/z [M+H]+ of 296.0/298.0 which gave the classical chlorine splitting 
pattern in the ratio of 3:1, consistent with the ratio of abundance of  35CI to 37Cl, was apparent 
(Figure 2.11).  
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The NMR spectra (Figure 2.12), expectedly, resembled that of the hydroxyl intermediate IIIa, 
with 5 aromatic protons discerned between 6-9 ppm. As such, the peak due to H1 resonates 
downfield at 8.57 ppm and appears as a doublet of triplet resulting from Jortho coupling to H2 
and Jmeta coupling to H3. Signals due to protons H2, H3 and H4 adopted a doublet of doublet 
of doublets splitting pattern occasioned by coupling to immediate neighbouring protons and 
to protons farther away. Effectively, proton H4 couples to H3 (J=8.10 Hz) and H2 (J=1.33 Hz) 
while H2 clearly couples with H1 (J=8.36 Hz) and H3 (J=7.14 Hz) via Jortho coupling and with H4 
(J=1.40 Hz) via Jmeta coupling. The protons H3 and H1 both couple to H2 and to each other 
while H3 has additional coupling to H4. Consistently, the 13C NMR resembled that of 
intermediate IIIa with regards to chemical shift position of the respective carbons. In this case, 
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2.8.2.4 Final compounds Va without SAR2 changes  
 
The final amination targets were, as with the intermediates, confirmed by making 
observations on the colour, mass spectrometry molecular ion and evaluating the respective 
1H and 13C NMR spectra. Since the side groups introduced were mostly aromatic in nature, 
we anticipated additional proton signals, to what was observed for the prior intermediates 
IIIa and IVa, in the aromatic region. Indeed, for the para-substituted aniline-type series 
analogues, signals corresponding to four additional aromatic protons were observed, 
frequently appearing as two separate coupling (doublets) signals, with occasional deviations 
depending on the nature of substituents borne on the aromatic ring. If the side group 
substituent contained aliphatic protons, these emerged, as expected, in the upfield region. 
The corresponding 13C NMR spectra compared with the 1H NMR one with regards to the 
chemical shift positions whereby additional carbon signals in the aromatic regions, arising 
from the carbons on the attached aromatic side group, were evident.  
For equivalent carbons, the signals appeared as taller peaks, consistent with the number of 
equivalent carbons. Where applicable, carbon signal(s) corresponding to the substituent(s) 
on the side group were also identifiable. For example, with 1j/GMP-19, the 1H NMR spectrum 
has four additional protons (H7 and H8; Figure 2.13), to those present in the preceding 
intermediates IIIa and IVa (Figures 2.10 and 2.12), in the aromatic region (6-9 ppm). These 
are the protons present in the trifluoromethoxy aniline appendage and appear as two 
doublets. Protons H8, experiencing shielding effects from the electron-rich trifluoromethoxy 
group, resonate slightly upfield of H7 protons, which are deshielded by the nitrogen linker 
between the PBI nucleus and the aromatic side group. Congruently, the 13C NMR reflects the 
additional carbon signals due to the aromatic and the trifluoromethyl carbons. The proposed 
structure was further supported by the MS profile, which yielded a protonated molecular ion 
of 437.1 in the positive ionisation mode (Figure 2.14).  
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In the case of benzylamine series analogues, in addition to tracing the changes in NMR spectra 
described for the aniline series, there emerged an aliphatic signal upfield integrating for two 
protons, corresponding to the methylene protons linking the aromatic portion of the side 
group to the nitrogen attached to the PBI core. Using 3o/GMP-50 as an example, the proton 
(H6) on the nitrogen linking the aromatic side group and the PBI core is noticeable as a broad 
singlet at 8.64 ppm while the two methylene protons (H7), also appearing as a singlet, 
resonate at 4.86 ppm, rather downfield for aliphatic protons, due to the deshielding effect of 
the nearby phenyl and amine groups. The methyl protons (H10) resonate at 2.29 ppm, 
appearing as a singlet that integrates for three protons, due to shielding effects by the phenyl 
ring to which the carbon bearing them is attached (Figure 2.15). Diagnostic peaks in the 13C 
NMR spectrum comprised of the additional aromatic carbon peaks between 127-130 ppm; 
the methylene carbon peak C14 at 46.57 ppm and the methyl carbon C19 at 21.14 ppm 
(Figure 2.15).  These features were consistent with the proposed structure of the molecule 
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Figure 2.15: 1H and 13C NMR spectra of 3o/GMP-50 in DMSO-d6 with diagnostic signals due to the 
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2.8.2.5 SAR2- modified analogues 
 
The appropriately substituted benzimidazole acetonitrile was synthesised as the first 
intermediate in the case of those analogues having modifications on the LHS of the PBI core 
(SAR2). Subsequent hydroxyl (IIIb and IIIc) and chloro (IVb and IVc) intermediates were 
synthesized using the same protocol as those without SAR2 changes (IIIa and IVa; steps ii and 
iii, Scheme 2.1) and their structures, together with final targets Vb and Vc were ascertained 
as described before, using a combination of colour changes, TLC Rf value, HPLC-MS and NMR 
techniques. As an example, the structures of intermediates IIc, IIIc, IVc and the final target 
4i/GMP-75, bearing 4, 5- dichloro substitutions were rationalised as described hereafter.   
Successful conversion of the substituted di-amino benzene starting material Ib to the 
corresponding intermediate IIc was ascertained by observing a MS peak with m/z of 
226.0/228.0 consistent with the expected pseudomolecular ion [M+H]+ which adopted the 
classical chloro splitting pattern (3:1). Features of the 1H NMR (Figure 2.17) included the 
appearance of proton signals in the aromatic region, integrating for two protons, representing 
the aromatic hydrogens (H1 and H2) on the benzene portion of the benzimidazole core. These 
peaks, due to their comparable electronic environments, appear together at 7.75-7.94 ppm 
and appear as a poorly split doublet which, on manual integration, suggest closely positioned 
singlet peaks, integrating for one proton each at 7.80 (H2) and 7.89 ppm (H1). Moreover, a 
deshielded aliphatic signal integrating for two protons due to the methylene protons (H3) on 
the carbon connected to benzimidazole and the nitrile groups, was evident.  On the other 
hand, the proton H4 on one of the imidazole nitrogen atoms could be discerned at 12.90 ppm, 
consistent with a highly deshielded proton.  Additionally, the position of signals on the 13C 
NMR spectrum reinforced the structure assignment for this intermediate whereby, besides 
the downfield location of benzimidazole and the nitrile carbons, there was an upfield signal 
due to the aliphatic methylene carbon C8 at 18.90 ppm (Figure 2.17).  
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Subsequent hydroxyl (IIIc) and chloro (IVc) intermediates were confirmed by examining their 
LCMS profile whereby m/z profiles matched the expected pseudomolecular ions [M-H]-
=344.0/345.0; 346.0/347.0 (IIIc) and [M+H]+= 364.0/366.0 (IVc) displaying the standard chloro 
pattern. 1H NMR spectra further supported the successful synthesis of these intermediates 
whereby the two methylene protons in the previous benzimidazole derivative IIc disappeared 
and in its stead, a singlet peak integrating for one proton (H3) emerged further downfield at 
5.87 and 6.45ppm in IIIc and IVc, respectively (Figure 2.18). As expected, the 13C NMR of IIIc 
and IVc reflected the increase in the number of carbon atoms to thirteen from nine and the 
disappearance of the methylene carbon, previously observed at 18.90 ppm in IIc (Figure 2.17). 
Like intermediates IIIa and IVa, the chemical shifts of the signals paralleled the electronic 
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 In addition to detecting the anticipated molecular ion using LCMS (Figure 2.19), NMR spectral 
changes for final targets bearing the SAR2 manipulations comprised the presence of additional 
peaks downfield representing the aromatic protons on the appended amine side group as 
exemplified by 4i/GMP-75 in Figure 2.20. Corresponding changes were manifested in the 13C 
NMR spectrum whereby extra carbon peaks due to the benzyl side group appeared in the 
aromatic downfield and aliphatic upfield regions as previously described for 3o/GMP-50.  
.  
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Figure 2.20: 1H NMR spectrum for 4i/GMP-75 in DMSO-d6 with the signals due to the 
benzylamine side group shown in red. 
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2.8.2.6 Cyano-replacement (SAR3) analogues 
 
The replacement of the nitrile at SAR3 with other groups was confirmed as with the other 
intermediates and targets. In the case where the nitrile was replaced by a hydrogen (Ve; 
5a/GMP-120), there was a distinct singlet peak at 7.95 ppm in the proton NMR spectrum, 
integrating for one proton (H5), a feature missing in 1j/GMP-19, the analogous target with a 
nitrile at this position (Figure 2.21). This 1H NMR picture corroborated the MS profile for a 
molecule with the formula C19H11F6N30 that produced a pseudo molecular ion with the 
expected m/z of 412.1 in the positive ionisation mode (Figure 2.21).   
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Figure 2.21:  1H NMR (in DMSO-d6) and LCMS spectra (in positive ionisation 
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The conversion of the nitrile in IVa to the amide analogue VI (step v, Scheme 2.1) was 
detected on the LCMS by observing the molecular ion, in the positive ionisation mode, of 
[M+H]+=314.0. Subsequent amination reactions to give targets in the Vf series were judged 
successful because of both the LCMS and NMR profiles. Using 5b/GMP-128 as an example, 
the 1H NMR spectra was characterised by the presence of two singlet peaks that integrated 
for one proton each at 7.81 and 8.02 ppm, due to the amide hydrogens (H5) (Figure 2.22). 
Resonance in the amide group results in the hydrogens attached to the amide nitrogen being 
magnetically non-equivalent and, therefore, resonate at slightly different frequencies 
resulting in the disparate chemical shifts. In the 13C NMR, the amide carbon signal, being the 
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Figure 2.22:  1H and 13C NMR for 5b/GMP-128 in DMSO-d6. Diagnostic peaks are labelled in red 
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In the synthesis of intermediates leading to the target compound with an ester at SAR3, the 
conspicuous feature on the 1H NMR spectra comprised of an aliphatic singlet signal 
integrating for three protons due to the ester methyl protons H5 (Figure 2.23 and Figure 
2.24). These protons resonated at ca. 3.9 ppm due to the de-shielding effect of the ester 
carbonyl group. The accompanying 13C NMR revealed a diagnostic deshielded methyl carbon 
signal C9 at ca. 52 ppm and a carbonyl signal C8 located downfield at ca. 163 ppm because of 
the ester carbonyl (Figure 2.23 and Figure 2.24). Additional proton and carbon peaks, as 
explained before, were discerned after the reaction between IVd and trifluoromethoxy 
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Figure 2.23: 1H and 13C NMR spectra for IIId (GMP-118) in DMSO-d6 with diagnostic peaks 













Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 






Figure 2.24: 1H and 13C NMR for IVd (GMP-119) in DMSO-d6 with diagnostic peaks 
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2.8.3 Chemical structures and yields of target compounds 
 
Table 2.1: Compound Number/Codes, chemical structures and yields. 
 
Compound Number/Code    X Y Z R R1 aYield (%) 
1. 1a/GMP-06 H H H 
 
CN 38 
2. 1b/GMP-09 H H H 
 
CN 27 
3. 1c/GMP-10 H H H 
 
CN 56 
4. 1d/GMP-11 H H H 
 
CN 23 
5. 1e/GMP-12 H H H 
 
CN 51 
6. 1f/GMP-13 H H H 
 
CN 51 
7. 1g/GMP-15 H H H 
 
CN 13 
8. 1h/GMP-17 H H H 
 
CN 18 
9. 1i/GMP-18 H H H 
 
CN 40 
10. 1j/GMP-19 H H H 
 
CN 19 
11. 1m/GMP-20 H H H 
 
CN 19 
12. 1n/GMP-32 H H H 
 
CN 23 
13. 1p/GMP-46 H H H 
 
CN 25 
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Compound Number/Code    X Y Z R R1 aYield (%) 












19. 2c/GMP-31 H H H 
 
CN 37 
20. 3d/GMP-33 H H H 
 
CN 50 
21. 3o/GMP-50 H H H 
 
CN 35 
22. 3e/GMP-34 H H H 
 
CN 43 
23. 3n/GMP-48 H H H 
 
CN 70 
24. 3f/GMP-35 H H H 
 
CN 49 
25. 3a/GMP-24 H H H 
 
CN 56 
26. 3b/GMP-28 H H H 
 
CN 59 
27. 3g/GMP-36 H H H  CN 56 
28. 3s/GMP-55 H H H 
 
CN 65 
29. 3p/GMP-52 H H H 
 
CN 30 
30. 3q/GMP-53 H H H 
 
CN 67 
31. 3r/GMP-54 H H H  CN 52 
32. 3m/GMP-47 H H H  CN 48 
33. 3h/GMP-38 H H H 
 
CN 38 
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Compound Number/Code    X Y Z R R1 aYield (%) 
35. 3l/GMP-44 H H H 
 
CN 62 
36. 3k/GMP-43 H H H 
 
CN 20 
37. 3c/GMP-29 H H H 
 
CN 63 
38. 3i/GMP-45 H H H 
 
CN 53 
39. 3t/GMP-56 H H H 
 
CN 6 
40. 3v/GMP-87 H H H 
 
CN 32 
41. 3w/GMP-88 H H H 
 
CN 52 
42. 3u/GMP-77 H H H  CN 38 
43. 4k/GMP-81 H CI CI  CN 53 




45. 4b/GMP-66 H Cl Cl 
 
CN 22 
46. 4j/GMP-76 H Cl Cl 
 
CN 37 




48. 4c/GMP-67 H Cl Cl 
 
CN 25 
49. 4e/GMP-69 H Cl Cl 
 
CN 50 
50. 4a/GMP-62 Cl H Cl 
 
CN 86 
51. 4d/GMP-68 H Cl Cl 
 
CN 39 
52. 4g/GMP-71 H Cl Cl 
 
CN 56 
53. 4h/GMP-72 H Cl Cl 
 
CN 28 
54. 4l/GMP-96 H Cl Cl  CN 58 
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Compound Number/Code    X Y Z R R1 aYield (%) 
55. 4m/GMP-97 H Cl Cl 
 
CN 6 




















61. 1k/GMP-121 H H H 
 
CN 10 




63. 5b/GMP-128 H H H 
 
CONH2 35 
64. 5c/GMP-129 H H H 
 
CONH2 20 
65. 5d/GMP-130 H H H 
 
CONH2 76 





                         Chapter 2                                                                                               Pyrido [1,2-a] benzimidazoles 
 
                          Godfrey Mayoka PhD Thesis 2018                                                                University of Cape Town 
 
 
2.9 Chapter Summary 
 
In this chapter, an account of previously reported antimalarial and antischistosomal activities 
of PBIs have been described. Initial SAR work on these title compounds and identified 
liabilities which contribute to the hypothesis, justification and aims of the study, have also 
been detailed. A rational approach to the medicinal chemistry design, the research program 
detailing the work flow, have been provided. Using representative intermediates and target 
compounds, the synthesis and characterisation of the compound library generated have been 
articulated as were the approaches to circumvent challenges encountered in the synthesis of 
some of the compounds. Detailed compound-specific synthesis and characterisation have 
been provided in the experimental information section, Chapter 7. The target compounds 
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3.1 Chapter overview 
 
This chapter will address one of the specific aims of the thesis, which was to evaluate the 
biological activity of the target compounds with respect to their antimalarial effects.  In 
addition to assessing the potency against the asexual blood stage parasites that are 
responsible for clinical symptoms, activities against the dormant liver and the transmissible 
gametocyte stage parasites, will also be presented. Furthermore, the potential for the target 
compounds to display cross-resistance with standard antimalarials will be evaluated by 
comparing their potency against both the drug-sensitive (PfNF54) and multidrug-resistant 
(PfK1) strains of Plasmodium falciparum. Towards investigating probable mechanisms of 
antimalarial action, the ability of the compounds to interfere with the haemoglobin 
degradation pathway will be discussed. Thereafter, the chapter will also detail the observed 
in vitro ADME profiles of the compounds especially in view of their microsomal metabolic 
stability and cytotoxicity, including the potential to interact with the myocardial potassium 
ion channel, hERG. Finally, results from the in vivo proof-of-concept antimalarial efficacy, in 
addition to in vivo pharmacokinetics following experimentation in mouse models will be 
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3.2 In vitro asexual blood stage activity against the drug-sensitive PfNF54 strain 
 
Consistent with our outlined workflow, target compounds were first tested for their in vitro 
antiplasmodial activity against the asexual erythrocytic stage parasites responsible for the 
clinical manifestations of malaria.  Initially, the experiments were carried out on the drug 
sensitive PfNF54 strain either at the Division of Clinical Pharmacology, Department of 
Medicine, University of Cape Town (UCT) or at the Swiss Tropical and Public Health Institute 
(STPH), University of Basel, Switzerland, following established procedures. 
In summary, at UCT, parasites were incubated with compounds reconstituted to varying 
concentrations in dimethyl sulfoxide (DMSO) and activity measured by monitoring the activity 
of the parasites’ lactate dehydrogenase (pLDH). LDH is a redox enzyme involved in the last 
step of anaerobic respiration during glycolysis in which lactate is converted to pyruvate and 
NAD+ reduced to NADH.1,2 When parasite growth is inhibited, the accompanying decrease in 
metabolic activities, including glycolysis, is reflected in diminished LDH function. 
Experimentally, the NADH produced in this redox reaction can react with a probe substrate, 
producing a colour that is detected and quantified spectrophotometrically.3–5 The readouts 
are then converted to logarithmic values and plotted against compound concentrations to 
generate dose-response curves from which compound concentrations resulting in half the 
maximum inhibition (IC50) are determined.  
In the case of in vitro antiplasmodial studies carried out at Swiss TPH, the modified [3H]-
Hypoxanthine incorporation assay was employed as a measure of parasite viability.6–8 This 
assay exploits the fact that Plasmodium parasites do not have the capacity for de novo DNA 
synthesis. Therefore, they obtain bases from external sources in what is referred to as the 
salvage pathway of DNA synthesis.9–11 For proliferating parasites, when such purine base 
precursors such as hypoxanthine are added to the parasite culture, viable cells will utilise 
them for DNA synthesis. In the hypoxanthine incorporation assay, radiolabelled hypoxanthine 
is used as the purine source. Consequently, proliferating parasites take up the hypoxanthine, 
and hence the radioactivity, which is detected and quantified by means of a scintillation 
counter. This assay is regarded as the gold-standard for measuring the proliferation and 
inhibition of Plasmodium parasites in vitro.5 
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As previously described in Chapter 2, the medicinal chemistry plan focussed on introducing 
diversity around the appendages to the PBI core as re-depicted in Figure 3.1 below. The 
antiplasmodial data emanating from this work are presented in the subsequent Tables 3.1-
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3.2.1 SAR1 Targets 
 
Structural modifications at this site produced compounds that may be classified broadly into 
either N-linked (n=0; aniline-type) or N-methylene-linked (n=1; benzylamine-type) series 
(Figure 3.1).  In the first series, the side group moiety comprises a phenyl ring directly linked 
to the PBI central core by a nitrogen. The electronic and lipophilic features of substitutions 
around the aromatic ring influenced the observed antiplasmodial activity. Unlike hydrophilic 
substituents, lipophilic groups on the aromatic side chains favoured antiplasmodial activity. 
Active analogues in the low [1c/GMP-10 (IC50=1.16 µM), 1d/GMP-11 (IC50=1.01 µM), 1j/GMP-
19 (IC50=0.17 µM) and 1m/GMP-20 (IC50=1.59 µM)] to moderate [1a/GMP-06 (IC50=2.14 µM) 
and 1e/GMP-12 (IC50=2.26 µM)] micromolar range were identified (Table 3.1). The most 
active derivative in the series is 1j/GMP-19 (IC50=0.17 µM) which has a trifluoromethoxy 
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Table 3.1: Antiplasmodial (PfNF54) and β-hematin inhibition potency of SAR1 Targets. 
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 3u/GMP-77  10.03 >100 
aValues are a mean of n≥3 determinations. b Chloroquine and artesunate were used as 
controls whose established standard IC50 values from n≥10 determinations in our lab 
are 0.016 µM and 0.004 µM, respectively. 
 
When a methylene linker (n=1; Figure 3.1) was introduced into the side group to extend the 
SAR from aniline-type to benzylamine-type series, some potent analogues were produced, 
achieving antiplasmodial activity in the low micromolar range: 3b/GMP-28 (IC50=1.28 µM), 
3f/GMP-35 (IC50=0.917 µM) and 3o/GMP-50 (IC50=1.49 µM) [Table 3.1]. As observed with the 
aniline-type series, the nature of the substituent on the aromatic ring was crucial with respect 
to antiplasmodial activity whereby, equally, lipophilic electron-withdrawing groups were 
favoured.  
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Isosteric replacement of the phenyl ring with various heteroaromatic groups produced 
diverse compounds including pyridyl (2b/GMP-30, 3j/GMP-25, 3k/GMP-43, 3l/GMP-44), 
pyrimidyl (2a/GMP-23, 2d/GMP-57, 3t/GMP-56), pyrazinyl (3i/GMP-45 and 2e/GMP-58), 
and thiazolyl (2c/GMP-31) [Table 3.1]. Among them, only the pyridyl ring in the benzylamine 
series produced an active compound 3j/GMP-25 (IC50=1.16 µM). Interestingly, there seems 
to be a stringent requirement with regards to the positioning of the nitrogen on the pyridyl 
moiety with only the 2 (ortho)-position (3j/GMP-25; IC50=1.16 µM) entertained for potent 
activity while the 3 (meta)-  and 4 (para)- positions produced compounds with lower activities 
as expressed with compounds 3l/GMP-44 and 3k/GMP-43, respectively (Table 3.1).  
The retention of activity upon isosteric replacement of the aromatic side chain provided new 
chemical space and enhanced the structural diversity in expanding the SAR profile of the 
series. This manipulation was also beneficial to the exploration of structure-property trends 
arising from analysis of physicochemical profiles of the generated analogues as discussed later 
in Chapter 5. Replacement of the bulky aromatic side groups with the more polar, heterocyclic 
groups like piperazine was detrimental to activity as seen with 3u/GMP-77 (IC50= 10.03 µM). 
When a methyl substituent was introduced on the nitrogen bridging the PBI core and the 
aromatic appendage (R1, Figure 3.1), activity diminished as evident with 3c/GMP-29 (IC50 
>2.72 µM) that bears a tertiary nitrogen compared to the analogue 3j/GMP-25 (IC50 =1.16 
µM) in which this nitrogen is secondary. This observation may indicate unfavourable steric 
orientation in the case of a tertiary nitrogen or that the presence of a hydrogen-bonding 
centre, in the case of a secondary nitrogen, as in 3j/GMP-25, are important for suitable 
interactions with the target leading to the observed biological activity.   
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3.2.2 SAR2: Left Hand-side modified targets  
 
Targets arising from structural changes on this portion of the PBI core are as exemplified in 
Table 3.2. Rewardingly, following this modification, there was a general trend towards 
retention or improvement in potency. For instance, 4d/GMP-68 (IC50= 1.42 µM) is about 
equipotent to 3j/GMP-25 (IC50= 1.16 µM) while 4c/GMP-67 (IC50= 0.44 µM) and 4e/GMP-69 
(IC50= 0.40 µM) are about 2-4-fold as potent as their corresponding analogues, 3f/GMP-35 
(IC50= 0.84 µM) and 3o/GMP-50 (IC50= 1.49 µM), respectively, which lack the dichloro 
modification (Table 3.2). Similarly, close to a 5-fold improvement in potency was observed 
with 4b/GMP-66 (IC50= 0.26 µM), the dichloro substituted analogue of 3b/GMP-28 (IC50= 1.28 
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X Y Z R 
aIn vitro activity 
IC50 (µM) 
PfNF54b BHI 
        
 4a/GMP-62 Cl H Cl 
 
0.31 >100 
 4b/GMP-66 H Cl Cl 
 
0.44 >100 
 4c/GMP-67 H Cl Cl 
 
0.44 >100 
 4d/GMP-68 H Cl Cl 
 
1.42 59 
 4e/GMP-69 H Cl Cl 
 
0.40 >100 
 4f/GMP-70 H Cl Cl 
 
>1.97 32 
 4g/GMP-71 H Cl Cl 
 
0.44 >100 
 4h/GMP-72 H Cl Cl 
 
0.31 >100 
 4i/GMP-75 H Cl Cl 
 
0.17 139 
 4j/GMP-76 H Cl Cl 
 
0.19 >100 
 4k/GMP-81 H Cl Cl  8.11 >100 
 4l/GMP-96 H Cl Cl 
 
5.34 >100 
 4m/GMP-97 H Cl Cl 
 
4.97 32 
 4n/GMP-98 H Cl Cl 
 
5.64 >100 
 4o/GMP-99 H Cl Cl 
 
6.73 78 
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X Y Z R 
aIn vitro activity 
IC50 (µM) 
PfNF54b BHI 
 4p/GMP-100 H Cl Cl 
 
>6 >100 
aValues are a mean of n≥3 determinations. b Chloroquine and artesunate were used as 
controls whose established standard PfNF54 IC50 values from n≥10 determinations in our lab 
are 0.016 µM and 0.004 µM, respectively. 
 
Further SAR iterations within this series revealed that the phenyl ring at SAR1 (Figure 3.1) 
could be replaced with smaller heteroaromatic systems such as furanyl 4g/GMP-71 (IC50= 
0.44 µM) and thiofuranyl 4h/GMP-72 (IC50= 0.31 µM) with retention of activity when 
accompanied by changes on the LHS. However, replacement of the bulky aromatic side groups 
with the more polar, heterocyclic groups like piperazine, resulted in diminished activity as 
seen with 4k/GMP-81 (IC50= 8.11 µM). Among analogues in which the methylene linker (n=1, 
SAR1, Figure 3.1) is substituted by the more polar sulfonyl group (-SO2-), poor antiplasmodial 
activity was observed as with 4o/GMP-99 (IC50= 6.73 µM) vs 3f/GMP-35 (IC50= 0.92 µM), 
respectively (Table 3.2).  
When comparing the position of the chloro groups on the LHS of the scaffold, the 3,5- dichloro 
analogue 4a/GMP-62 (IC50= 0.21 µM) and the 4,5-dichloro compound 4b/GMP-66 (IC50= 0.26 
µM) were equipotent indicating the negligible impact of regio-isomerism on this portion of 
the scaffold. On the contrary, regio-isomerism appears to be more crucial in the side groups 
at SAR1. For example, moving the position of the substituents on the aromatic side group 
between ortho, meta and para positions resulted in 4j/GMP-76 (meta, IC50= 0.19 µM) and 
4i/GMP-75 (ortho, IC50= 0.17 µM) being equipotent and about twice as potent as analogue 
4b/GMP-66 (para, IC50= 0.44 µM) [Table 3.2].  
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3.2.3 SAR3 Targets 
 
To explore effects on antiplasmodial activity by initiating structural changes around SAR3 
(Figure 3.1), analogues of previously active targets were prepared in which the nitrile at this 
position was replaced with other small groups. Effectively, this modification resulted in 
compounds 5a/GMP-120 (H; IC50= 4.24 µM), 5b/GMP-128, (CONH2; IC50 > 6 µM), 5c/GMP-129 
(CONH2, IC50= 5.16 µM), 5d/GMP-130 (CONH2, IC50 >10 µM) and 5e/GMP-120E (COOMe, IC50= 
5.52 µM) [Table 3.3]. Realising a drastic drop in antiplasmodial potency, it was conjectured 
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 5a/GMP-120 H 
 
4.24 
 5b/GMP-128   
>6 
 5c/GMP-129   
5.16 
 5d/GMP-130   
>10 
 5e/GMP-120E  
 
5.52 
aValues are a mean of n≥3 determinations. b Chloroquine and artesunate were 
used as controls whose established standard PfNF54 IC50 values from n≥10 
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3.3 In vitro asexual blood stage activity against the multidrug-resistant PfK1 strain 
 
Antimalarial drug discovery projects aim to identify compounds with not only good potency 
against the sensitive strains of Plasmodium but also possessing activity against drug-resistant 
parasite strains. The preference is towards advancing a new antimalarial lead possessing 
chemical novelty and which is differentiated in its mechanism of action and that is not cross-
resistant with current drugs.  
Consequently, compounds with potent activity in the chloroquine sensitive (CQS) PfNF54 
strain (IC50 ≤ 1µM), were also tested against the multi-drug resistant (CQR) PfK1 strain. An 
assessment for the potential to manifest cross-resistance with chloroquine was performed by 
determining the fold change in the IC50 between drug-sensitive and drug-resistant strains, 
expressed as the resistance index (RI), calculated as the ratio of IC50PfK1 to IC50PfNF54. This 
assay was carried out at the Swiss TPH, using the modified [3H]-Hypoxanthine incorporation 
assay described earlier.  
Generally, activity trends were maintained across the strains whereby potent compounds 
retained their potency while inactive compounds in the CQS PfNF54 strain also showed 
inactivity in the CQR PfK1 strain (Table 3.4). These results, therefore, suggest that these 
compounds are unlikely to demonstrate cross-resistance with chloroquine as indicated by a 
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Table 3.4: In vitro activities of frontrunner compounds against drug sensitive (PfNF54) and resistant 
(PfK1) asexual blood stage parasites. 
Compound number/code Chemical structure 
aAsexual blood stage IC50 (µM) Resistance Index 
PfK1IC50: PfNF54IC50 PfNF54 PfK1 
1j/GMP-19 
 
0.17 0.15 0.88 
1k/GMP-121 
 
0.40 0.23 0.58 
1l/GMP-122 
 
0.87 0.62 0.71 
3b/GMP-28 
 
1.28 1.70 1.33 
3f/GMP-35 
 
0.92 0.84 0.91 
3j/GMP-25 
 
1.16 1.64 1.41 
4a/GMP-62 
 
0.31 0.21 0.68 
4b/GMP-66 
 
0.44 0.28 0.64 
4c/GMP-67 
 
0.44 - - 
4d/GMP-68 
 
1.42 - - 
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Compound number/code Chemical structure 
aAsexual blood stage IC50 (µM) Resistance Index 
PfK1IC50: PfNF54IC50 PfNF54 PfK1 
4e/GMP-69 
 
0.4 - - 
4g/GMP-71 
 
0.44 0.23 0.52 
4h/GMP-72 
 
0.31 0.19 0.61 
4i/GMP-75 
 
0.17 0.14 0.82 
4j/GMP-76 
 
0.19 0.15 0.79 
4l/GMP-96 
 
5.34 5.61 1.05 
4o/GMP-99 
 
6.73 5.85 0.87 
5a/GMP-120 
 
4.24 3.36 0.79 
5c/GMP-129 
 
5.16 7.59 1.47 
5d/GMP-130 
 
>10 >10 - 
 Chloroquine 0.016 0.194 12 
 Artesunate 0.004 0.003 0.75 
aActivity determined using the [3H]-Hypoxanthine incorporation assay and values are a mean of n≥3 
determinations.  
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The resistance to chloroquine arises due to a mutation in the parasite membrane protein 
referred to as Plasmodium falciparum chloroquine resistance transporter, PfCRT, responsible 
for the influx of chloroquine into the food vacuole of the parasite.12–14 Subsequently, this 
mutation results in decreased intracellular accumulation of the drug hence reducing access 
to the site of action. From the observed activity against PfK1 strain, PBIs obtained in this study 
may therefore not be substrates for the PfCRT protein. Effectively, the demonstrated 
antiplasmodial activity may be presumed to arise through the ability of the compounds to 
gain access to the parasite and inflicting parasiticidal effects via different and, possibly, novel 
mechanisms.  
 
3.4 Probing the mechanism of action 
 
The library of compounds generated, being endowed with features present in standard 
antimalarial drugs like the quinolines which target the haemoglobin degradation process, 
were evaluated for their ability to inhibit beta hematin (BH) formation, an in vitro mimic of 
the in vivo hemozoin formation process.15–17 The conversion of free soluble toxic heme in vivo 
to the insoluble inert hemozoin is promoted by several factors, including neutral lipids. Heme 
can be chemically synthesised and the formation of hemozoin mimicked in vitro.18–21 The 
potential for small molecules to inhibit hemozoin formation can therefore be examined            
in vitro by measuring the inhibition of the formation of beta-hematin (the surrogate of 
hemozoin) from hematin (the in vitro analogue of heme), under optimised experimental 
conditions that mirror physiological conditions.  
Besides possessing a planar architecture imparted by the PBI central core, the studied 
compounds have a rich electron density and protonatable centres. Planarity is a key feature 
facilitating interactions between heme molecules and the inhibitors of the hemozoin 
formation process. Moreover, the high electron density further augments binding of 
inhibitors to heme via by π-π  hydrophobic interactions.22 On the other hand, the existence 
of protonatable sites makes it feasible for compounds to accumulate in the acidic digestive 
food vacuole of the parasite due to a pH gradient.23  
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The protonated compound within the acidic food vacuole of the parasite has reduced 
permeability compared to the neutral, uncharged compound in the physiological pH outside 
the digestive vacuole and hence will not readily diffuse out of the parasite lysosome. 
Additional coordinate interactions between inhibitor molecules and heme are feasible via 
oppositely charged centres.24,25   
The BH inhibition evaluation for target compounds was, therefore, conducted using 
established procedures in our lab.15 Briefly, compounds were reconstituted in DMSO to yield 
a 20mM stock concentration from which serial dilutions were prepared. Next, the NP40 
detergent was used to mediate BH formation in a preparation mix containing predetermined 
compound concentrations, hematin solution, buffer and pyridine solution. The inhibition of 
the formation of the beta-hematin was evaluated spectrophotometrically by observing the 
optical density of the complex formed between hematin and pyridine which observes the 
beer-lambert’s law.26,27 Hematin converted to BH is optically inactive. Consequently, a higher 
absorbance reading reflects greater inhibition of the BH formation process and hence greater 
compound potency. Control experiments using chloroquine, an established inhibitor of this 
pathway and the non-inhibitor drug pyrimethamine, were performed in addition to a blank in 
which no test compound was included. Concentrations resulting in 50% inhibitory effects 
were subsequently determined from constructed concentration-response curves. Resulting 
from this assay, compounds with an IC50 above 100 µM were classified as poor BH formation 
inhibitors.   
Most of the compounds had weak BHI activity (IC50 > 100 µM) Tables 3.1 and 3.2. Only six 
compounds: 1p/GMP-46 (IC50=50 µM); 4d/GMP-68 (IC50=59 µM); 4f/GMP-70 (IC50=32 µM); 
4i/GMP-75 (IC50=139 µM); 4m/GMP-97 (IC50=32 µM) and 4o/GMP-99 (IC50=78 µM) 
demonstrated BHI activity in the desired range (IC50 < 100 µM), with 4f/GMP-70 and 
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The dichloro substitution on the LHS improved the BHI potency 4m/GMP-97 (IC50=32 µM) of 
the previously inactive 3h/GMP-38 (IC50>100 µM) analogue, a pattern observed with 
4d/GMP-68 (IC50=59 µM) vs 3j/GMP-25 (IC50>100 µM). A sulfonyl linker (X= -SO2-, Figure 3.1, 
SAR1) between the nitrogen attached to the PBI core and the aromatic portion of the side 
chain in the stead of a methylene group was detrimental to the potential to disrupt BH 
formation as in the case of 4p/GMP-100 (IC50>100 µM) vs 4d/GMP-68 (IC50=59 µM). 
Interestingly, the chiral compound 4m/GMP-97 (IC50=32 µM) was more potent than its achiral 
analogue 4l/GMP-96 (IC50>100 µM). Noteworthy, there is no obvious correlation between 




Figure 3.2: Relationship between BHI and antiplasmodial potency; both are 




























BHI activity vs antiplasmodial potency (PfNF54)
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Several compounds weakly active in the BHI assay showed potent antiplasmodial activity (for 
example, 1j/GMP-19: PfNF54IC50=0.17µM; BHIAIC50 >100 µM, Table 3.1) whereas some with 
good BHI activity also displayed good antiplasmodial potency (as with 4d/GMP-68: 
PfNF54IC50=1.42 µM; BHIAIC50=59 µM, Table 3.2). Whereas the planar architecture of these 
compounds would be expected to impart BHI capabilities as observed with analogous 
targets15,28, it appears that the structural diversity pursued in this study introduced features 
that distorted the ability for appropriate binding to heme, hence the low BHI activities for 
most of the compounds. Nonetheless, owing to the presence of protonatable centres on 
these molecules, it is imaginable that intracellular uptake might occur to sufficient 
concentrations that may achieve meaningful inhibition of the haemoglobin degradation 
process which occurs largely in the digestive food vacuole of the parasite. This possibility is 
not recapitulated in the in vitro conditions of the assay.  
Overall, with reference to the foregoing observations, it is conceivable that these compounds 
elicit antiplasmodial potency via a hemozoin independent mechanism of action or that other 
mechanisms, in addition to hemozoin formation inhibition, may be involved. To confidently 
establish the role of BHI as a contributing mechanism, the BH fractionation assay will be 
necessary.28 In this evaluation, a decrease in the amount of BH accompanied by an increase 
in the fraction of hematin with increased compound concentrations is diagnostic for a true 
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In pursuing the specific aim of evaluating the stage-specificity and multi-stage antiplasmodial 
activity of derived compounds, selected compounds having good asexual blood stage activity 
(IC50 ≤ 1µM) were tested against gametocytes and liver forms of Plasmodium parasites. The 
liver stage assays were performed at the Instituto de Medicina Molecular, Faculdade de 
Medicina, Universidade de Lisboa, in Lisboa, Portugal. On the other hand, the gametocyte 
assays were performed jointly at the Wits Research Institute for Malaria, University of the 
Witswatersrand (Wits) and the Department of Biochemistry, Institute of Sustainable Malaria 
Control, University of Pretoria (UP), South Africa. Two independent assay methods were 
applied for these gametocyte assays with the ATP-based and Luciferase line reporter-based 
platforms performed at Wits and UP, respectively. 
Regarding the liver stage assay, a luciferase-expressing Plasmodium berghei line, PbGFP-
Luccon, was used to infect a human hepatoma cell line (HuH 7) and parasite viability, after 
incubation with test compounds, determined by luminescence readings using a luciferase 
assay kit.29 Accordingly, lower luminescence reflect fewer number of viable parasites and 
hence greater potency of the test compound.  
Concerning the assessment of the gametocytocidal activity of the selected compounds, the 
gametocytes were produced using the approach adopted from Carter30 whereby nutritional 
restrictions and reduction of haematocrit were used to induce gametocytogenesis of the 
asexual PfNF54 parasites. As mentioned earlier, and to facilitate accurate, sensitive and 
quantitative measurements of the gametocytocidal effects of test compounds, both the 
luciferase reporter and ATP-based assays were employed. Using these dual platforms, which 
target different metabolic processes, increases the chances of identifying active compounds 
in a chemically diverse data set.2 
 
 
                        Chapter 3                                                 Antimalarial Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                      Godfrey Mayoka PhD Thesis 2018                                                               University of Cape Town 
160 
 
Briefly, the luciferase assay depends on the observations and recording of luminescence when 
a luciferin substrate is added to a parasite containing or expressing the luciferase enzyme. In 
this case, the PfNF54 engineered to express the enzyme GFP-Luciferase according to the work 
by Lucantoni and co-workers was used.31  
For specific early gametocyte stage detection, NF54-PfS16-GFP-Luc was used whereas NF54-
Mal8p1.16-GFP-Luc was utilised for the late gametocyte stage.  
In the ATP-based assay, the ability of the compounds to inhibit gametocyte growth was 
detected by monitoring changes in energy production by measuring ATP levels in a 
bioluminescent-based detection assay.32 Since gametocytes display differential 
susceptibilities to drugs in the early vs. late stages of development,33,34 the compounds were 
evaluated against these two stages. Stage specific action was determined by testing 
compounds against the parasite load established to be predominantly (>90%) early or late 
stage. Stage specificity towards either early or late gametocytes was determined by 
comparing the fold-change in the IC50 between the two stages whereby a ratio higher than 2 
was interpreted to imply differential susceptibility. 
All the compounds tested were active in both the liver and gametocyte stages of the 
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 1  5  1  5  1  5 
1j/GMP-19 0.11         3.32  
3b/GMP-28 0.89           
3f/GMP-35 0.48 7 18  1 0  0 0   
4a/GMP-62 1-10c 11 55 5.51 28 76 1.87 44 89 0.74 3.0/0.3 
4b/GMP-66  15 46  81 91 5.73  44 89 0.69  
4c/GMP-67 0.19 15 64 11.91 13 22  88 89 0.21  
4d/GMP-68  3 17  22 64 6.80 5 61 2.48  
4e/GMP-69  23 54 1.06 12 54 6.32 61 89 0.60 0.2/6.0 
4g/GMP-71 0.06 1 44  15 9  19 79 2   
4h/GMP-72 0.14 26 49  0 0  21 80 1.67  
4i/GMP-75 0.05 0 20  0 65 2.21 71 89 0.37  
4j/GMP-76 0.07 0 51 2.49 0 80 1.21 80 89 0.27 1.2/0.5 
Primaquine 6.25           
Methylene 
blue 
   0.195   *0.143    #0.9  
DHA    0.043   *0.011   14  
MMV390048    0.214   0.14     
aValues are the average of n≥3 determinations. bEG: Early stage gametocyte; LG: Late stage gametocytes. cEstimated IC50 
range based on primary activity screening. Value based on *luciferase and #ATP assay. 
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3.5.2 Liver stage activity 
 
The complete set of compounds tested (Table 3.5) demonstrated in vitro sub-micromolar liver 
stage activity with potency greater than that observed for primaquine (IC50=6.25 µM), the 
control drug used in this assay. With tafenoquine having received US FDA approval only 
recently, primaquine is presently the only clinical compound widely used for radical cure of 
Plasmodium vivax and ovale-induced malaria.19 Despite the low in vitro activity observed with 
primaquine, the drug displays potent in vivo activity alluded to its biotransformation to the 
active metabolite.37 An accurate extrapolation of the in vivo potency of these compounds is 
therefore not possible based on direct comparisons with primaquine but will, rather, require 
animal experimentation in a model recapitulating the liver stage infection.  The bioactivation 
of primaquine has been demonstrated to be dependent on the CYP 2D6 enzyme which is 
polymorphic with up to half of the population being intermediate to poor metabolisers, a 
scenario that attracts caution in the use of primaquine in mass drug administration during 
malaria elimination campaigns.37,38  
 
3.5.3 Gametocyte activity 
 
Using the luciferase reporter assay at an initial compound screening concentration of 5 µM 
against early stage gametocytes, four compounds (4a/GMP-62, 4c/GMP-67, 4e/GMP-69 and 
4j/GMP-76) achieved parasite mortality greater than 50%. At the lower concentration of 1 
µM, only two compounds (4e/GMP-69 and 4h/GMP-72) resulted in ≥ 20% parasite death 
(Table 3.5).  On examining the potency against the late stage gametocyte based on the 
luciferase reporter assay, six compounds induced a mortality of ≥50% at 5 µM while three 
compounds showed ≥20% mortality at 1 µM. In contrast, the ATP-based assay generally 
showed higher compound activity against the late stage gametocytes in comparison to the 
luciferase-based platform, with the exceptions of 4b/GMP-66 and 4d/GMP-68 at 1 µM for 
which the luciferase platform gave higher potency (Table 3.5). 
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The two assays employed to test for gametocytocidal activities of target molecules allow for 
the interrogation of different biochemical and metabolic pathways in the parasite and is a 
likely contributing reason for the discordant results observed between the assays. Notably, 
considering effects on late stage gametocytes, compound 4b/GMP-66 showed good activity 
only on the luciferase platform whereas 4c/GMP-67, 4e/GMP-69, 4i/GMP-75 and 4j/GMP-
76 demonstrated good activity only on the ATP-based platform. Regardless of the platform, 
4a/GMP-62, 4d/GMP-68, 4g/GMP-71 and 4h/GMP-72 produced moderate activity.  
For compounds predicted, based on the initial screening at 1 and 5 µM to have IC50 values 
below 1 µM, full IC50 determinations were performed using three biological replicates, each 
carried out as technical triplicates. Conversely, those compounds estimated to be moderately 
potent (IC50 between 1-5 µM), were progressed for a single IC50 determination performed as 
a single biological assay in technical triplicates.  
From these studies, two compounds, 4b/GMP-66 and 4j/GMP-76 achieved higher activity in 
the late gametocyte stage compared to the early forms of gametocytes. On the contrary, 
4e/GMP-69 displayed greater potency towards the early gametocytes compared to the late 
gametocyte stage. The early and late gametocyte stages are distinct from morphological and 
biochemical perspectives. It is therefore possible for certain cellular and molecular pathways 
to be targeted by drugs in one stage and yet be either absent or incompletely developed in 
the other stage leading to the observed differential susceptibility. 
With regards to transmission-blocking antimalarial properties, primaquine and the 
artemisinin-derived drugs artemether and artesunate, are the only clinically useful 
antimalarial drugs with demonstrable gametocytocidal activity and the WHO recommends 
use of Primaquine at a dose of 0.25mg/kg for targeting gametocytes.39–41   Unfortunately, 
resistance towards artemisinins and the deficiency of the enzyme Glucose-6-phosphate 
dehydrogenase (G6PDH) important in primaquine metabolism, whose deficiency predisposes 
to potentially fatal haemolysis, raise concerns in the use of these agents and agitate for the 
discovery of novel, safe and efficacious antimalarial agents capable of targeting these sexual 
forms of Plasmodium.2  
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Taken together, in view of the sub-micromolar potency of these compounds across the life 
cycle stages, these PBI derivatives are promising leads towards the identification of pan-active 
agents capable of preventing transmission and enabling chemoprevention. From the current 
antimalarial arsenal, over 90% of the drugs do not show potent activity towards late stage 
gametocytes and only primaquine and atovaquone have liver stage activities.42   
 
3.6 Profiling for in vitro cytotoxicity and microsomal metabolic stability  
 
3.6.1 Cytotoxicity against CHO cell line  
 
To guide selection of compounds for in vivo assays, compounds with the most potent in vitro 
antiplasmodial activity were prioritised to be evaluated for their cytotoxicity profile in the 
Chinese Hamster Ovarian cell line. Based on these studies, structure-cytotoxicity trends were 
delineated (Table 3.6). Cytotoxicity assessment allows for the determination of the risk for 
cellular toxicity by comparing the concentration required to elicit the desired biological 
activity to that which induces toxic effects to the normal, healthy cells.  
The cytotoxicity assay was performed at UCT using the colorimetric 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay.43 Briefly, the MTT assay works based on the 
conversion of the water-soluble tetrazolium dye (MTT) to the insoluble coloured product 
(formazan) by redox enzymes present in living, respiring cells. The resulting formazan is then 
solubilised, and its amount detected spectrophotometrically. Accordingly, viable cells are 
capable of respiration, thus have more redox activity, producing more formazan which is 
reflected in greater colour intensity and higher optical density readings. 
 As with the antiplasmodial assay, the IC50 values were calculated from which selectivity 
indices were derived. The selectivity index represents the ratio of the IC50 of the compound 
in Plasmodium parasites to that in the CHO cells. A higher ratio, which is a desirable profile, 
denotes that the compound is more selective for the parasite being targeted, in this case 
Plasmodium, than the healthy cells. To progress compounds according to the predetermined 
screening cascade, a SI of 10 was selected as the cut-off.  
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Generally, in both the aniline-type and benzylamine-type series without manipulations on the 
LHS, good selectivity indices (SI) were obtained. In this series, all the compounds had a SI 
above 30 except for 3o/GMP-50, having a methyl substituent, that showed lower selectivity 
(SI=17). Compounds 1j/GMP-19, 3j/GMP-25 and 3f/GMP-35 displayed the best safety 
profiles (SI>100). Interestingly, it appears that introducing a methylene bridge in the aromatic 
side chain of 1j/GMP-19 (SI=103) to give 3f/GMP-35 (SI>241) is beneficial to selectivity as the 
safety profile increases more than two-fold. Within the benzylamine series, better selectivity 
was achieved with 3f/GMP-35 (SI>241) that has the more lipophilic trifluoromethoxy 
substituent compared to 3b/GMP-28 (SI=35) bearing a fluoro substituent. On the other hand, 
the methyl substituted analogue 3o/GMP-50 had the least attractive safety profile (SI=17) 
[Table 3.6].  
Notably, the LHS modification whereby dichloro substitutions were performed, although this 
improved the potency of many of the compounds, it also increased the potential for inducing 
cytotoxicity. Consequently, 3b/GMP-28 (SI=35) without this modification has a better safety 
profile than both 4a/GMP-62 (SI=5) and 4b/GMP-66 (SI=30) which have diminished selectivity 
whereas 3o/GMP-50 (SI=17) and 4e/GMP-69 (SI=15) have about the same selectivity profiles. 
Similarly, 3j/GMP-25 with an excellent safety profile (SI>234) completely lost selectivity when 
dichloro groups were introduced on the LHS to give 4d/GMP-68 (SI=0.5). Regio-isomerism of 
the LHS seems to impact on the selectivity profiles of these compounds since 4a/GMP-62 
(SI=5) with a 3,5 dichloro substitution pattern is less selective compared to its 4, 5 dichloro 
substituted analogue 4b/GMP-66 (SI=30). In contrast, regio-isomerism with regards to the 
position of substituents on the aromatic side group appears inconsequential to selectivity as 
4b/GMP-66 (para-F, SI=30), 4i/GMP-75 (ortho-F, SI=25) and 4j/GMP-76 (meta-F, SI-37) have 
comparable selectivity indices.  
Overall, this series shows that the cytotoxicity profile of the compounds is amenable to 
modulation with subtle changes resulting in significant changes in SI. Ultimately, two out of 
the 14 compounds, 4a/GMP-62 and 4d/GMP-68, failed to meet our defined criteria for 
compounds with good selectivity (SI>10). 
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% rem. after 30min (t1/2min) in vitro IC50 (µM) 
Selectivity Index 
MLM HLM CHO NF54 
1j/GMP-19 
 
110 (>150) 105 (>150) 17.58 0.17 103 
2e/GMP-58 
 
38 (22) 56 (36) 181.34 4.42 41 
3b/GMP-28 
 
- - 45 1.28 35 
3f/GMP-35 
 
- - >222 0.92 >241 
3j/GMP-25 
 
- - >272 1.16 >234 
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% rem. after 30min (t1/2min) in vitro IC50 (µM) 
Selectivity Index 
MLM HLM CHO NF54 
3o/GMP-50 
 
- - 25 1.49 17 
4a/GMP-62 
 
76 (75) 82 (105) 1.66 0.31 5 
4b/GMP-66 
 
72 (63) 102 (>150) 13 0.44 30 
4c/GMP-67 
 
82 (105) 109 (>150) 5.02 0.44 11 
4d/GMP-68 
 
31 (18) 72 (63) 0.75 1.42 0.5 
4e/GMP-69 
 
69 (56) 91 (>150) 6.06 0.4 15 
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% rem. after 30min (t1/2min) in vitro IC50 (µM) 
Selectivity Index 
MLM HLM CHO NF54 
4g/GMP-71 
 
66 (50) 100 (>150) 4.84 0.44 10 
4h/GMP-72 
 
- - 8.48 0.31 27 
4i/GMP-75 
 
84 (119) 97 (>150) 4.30 0.17 25 
4j/GMP-76 
 
84 (119) 100 (>150) 7.03 0.19 37 
MLM: Mouse Liver Microsomes; HLM: Human Liver Microsomes; CHO: Chinese Hamster Ovarian Cell lines; %rem: Percent compound remaining after 30 minutes 
incubation using the one-point assay; t1/2min: Projected half-life in minutes; SI: selectivity index is the ratio of CHO IC50: PfNF54IC50 All data represents the mean of n≥3 
determinations. 
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3.6.2 In vitro hepatic microsomal metabolic stability 
In vitro metabolic stability data enables the rational prediction of drug exposure in 
subsequent in vivo studies. For equally in vitro active compounds, highly metabolically labile 
analogues are expected to achieve low systemic levels which might compromise 
pharmacological outcomes in comparison to metabolically stable analogues. Accordingly, 
unlike the metabolically unstable molecules, their stable counterparts would ordinarily be 
considered for further in vivo investigations. 
For this study, the single-point metabolic stability assay was employed44 whereby prioritised 
compounds were incubated with mouse and human liver microsomes, (MLM) and (HLM), 
respectively, for 30 minutes and the incubation mixture investigated for changes consistent 
with metabolic transformations. Microsomes are hepatic sub-cellular fractions containing 
drug metabolising enzymes, chiefly CYP450, which are involved in Phase I drug metabolism of 
many clinically marketed drugs.45,46  
Accordingly, compounds were incubated in microsomes with the requisite co-factors 
including NADPH and optimised conditions of temperature. After half-an hour, the amount of 
compound remaining unchanged was determined using LC-MS. The percentage of compound 
remaining was calculated and metabolic stability assigned according to the criteria in Table 
3.7.  
Table 3.7: Metabolic stability criteria applied in this study 
% Compound remaining Metabolic stability status 
>75% Highly Stable 







                        Chapter 3                                                 Antimalarial Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                      Godfrey Mayoka PhD Thesis 2018                                                               University of Cape Town 
170 
 
Based on the preceding analysis, the   compounds, generally, showed moderate to high 
metabolic stability as tested in the mouse and human liver microsomes.  Compounds 
incorporating heteroaromatic moieties tended to be more labile as exemplified by 2e/GMP-
58 and 4d/GMP-68 (Table 3.6) which had less than 75% of compound remaining after 30 
minutes incubation period in both HLM and MLM. Moreover, the compounds seem to be 
more efficiently metabolised in mouse than human microsomes except for 1j/GMP-19 which 
proved equally stable in both species. Overall, molecules with the greatest microsomal 
stability in both species, with over 75% remaining after an incubation period of 30 minutes 
were 1j/GMP-19, 4i/GMP-75 and 4j/GMP-76 (Table 3.6).   
Evaluation of species variation in drug metabolism is crucial in guiding follow-up experimental 
models. For instance, a compound that displays good microsomal metabolic stability in HLM 
but poor stability in MLM would require judicious choice of animal species for the in vivo 
proof-of-concept studies. Working with an in vivo mouse model for a compound showing low 
metabolic stability in MLM would likely result in poor exposure and potentially low efficacy 
leading to the termination of a series which would otherwise be promising and worthy of 
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3.6.3 hERG interaction risk assessment 
 
To understand the potential risk arising from interactions with the hERG potassium ion 
channel whose inhibition can cause fatal cardiac arrhythmias, representative compounds 
1b/GMP-09, 2a/GMP-23, 4g/GMP-71, 4h/GMP-72, 4i/GMP-75 and 4j/GMP-76 were 
profiled. This experiment was carried out by Metrion Biosciences, Cambridge, United 
Kingdom. In summary, compounds were prepared as 10mM stock solutions in DMSO from 
which four- point concentrations (0.3, 1, 3 and 10 µM) were subsequently prepared by serial 
dilution in such a way that the final DMSO content was 0.1%. The CHO cell lines were used to 
express the hERG ion channel cells, which were accordingly validated biophysically and 
pharmacologically, using in-house procedures.  
To test for the inhibition of the electrical performance of this ion channel, the 
electrophysiology pattern was observed in the presence of the test compounds at the pre-
determined concentrations. In parallel, a blank, compound-free set-up containing the vehicle 
as well as a positive control containing verapamil hydrochloride were prepared. Each test 
concentration was performed in triplicate using three separate cells and electrophysiological 
readings used to examine the effects of the compounds on the hERG tail current amplitude 
in comparison to the positive control and the blank.   
Concentration-response curves were then constructed based on the percent inhibition from 
each cell and 50% inhibitory concentrations determined. If the highest tested concentration 
(10 µM) failed to induce ≥ 40% inhibition, an arbitrary IC50 value of 30 µM (0.5 log units above 
10 µM) was assigned and the compound considered to be inactive. Data for the tested 
compounds is summarised in Table 3.8. 
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% inhibition (SD) at 0.3 µM aIC50, µM 
1b/GMP-09 
 
8.36 (2.82) 30 
1j/GMP-19 
 
7.51 (2.85) 30 
2a/GMP-23 
 
8.45 (6.40) 30 
4g/GMP-71 
 
6.82 (2.81) 30 
4h/GMP-72 
 
6.13 (5.14) 30 
4i/GMP-75 
 
5.49 (3.90) 30 
4j/GMP-76 
 
6.53 (4.15) 30 
aCompounds showed less than 40% inhibition at the highest tested concentration of 10 µM 
and hence an arbitrary IC50 value 0.5 log units above 10 µM was assigned as the IC50 for these 
compounds. All values represent the mean of 3 results obtained from experiments 
performed as biological and technical triplicates.  
                        Chapter 3                                                 Antimalarial Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                      Godfrey Mayoka PhD Thesis 2018                                                               University of Cape Town 
173 
 
This series showed no potential to cause cardiotoxicity arising from interactions with the 
hERG ion channel as depicted by the high IC50 values (>30 µM) [Table 3.8]. The positive control 
drug used in the experiment, verapamil hydrochloride, inhibited the target potently with IC50 
between 0.2-0.8 µM which was consistent with the acceptable established value for this 
assay.  Even though the assigned IC50 values for the compounds are imprecise, it nonetheless 
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3.7 In vivo antiplasmodium efficacy 
 
Animal studies to provide proof-of-concept on the antimalarial potential of these series were 
conducted at the Swiss TPH on the most promising leads that fulfilled the progression criteria 
of in vitro potency and ADME, with acceptable cytotoxicity profiles. Based on these filters, 
compounds 1j/GMP-19 and 4i/GMP-75, representing leads from the aniline and benzylamine 
series were selected. Accordingly, mice infected with the rodent species P. berghei were 
treated with 1j/GMP-19 and 4i/GMP-75 on four consecutive days at an oral dose of 50mg/kg 
(4X50mg/kg). The in vivo antimalarial efficacy was determined by comparing the parasitaemia 
in the infected untreated control and the treated animals. Animals were pronounced to have 
been cured if no parasitaemia was detected 30 days after treatment.  
 
Table 3.9: In vivo efficacy of lead targets and chloroquine. 




Dose (mg/kg) 4X50 4X50 4X30 
    
Reduction in 
parasitaemia (%) 
98 99.9 99.9 
    
Mean survival days 12 14 21 
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Following in vivo experimentation in a murine model of malaria, it was gratifying to record an 
impressive 98% and 99.9% reduction in parasitaemia in mice treated with 1j/GMP-19 and 
4i/GMP-75, respectively (Table 3.9). This observation provided the vital proof-of-concept 
that, indeed, the test compounds achieved systemic exposure following oral administration 
and elicited antimalarial activity in the experimental animal model. Furthermore, the treated 
animals survived much longer compared to the control (MSD, 6 days), untreated group, with 
mean survival times of 12 and 14 days for 1j/GMP-19 and 4i/GMP-75, respectively. In 
comparison, the reference drug used in the experiment, chloroquine, at a daily oral dose of 
30mg/kg for four consecutive days (4X30mg/kg) achieved 99.9% reduction in parasitaemia 
and resulted in a mean survival time of 21 days.   
The two compounds having achieved high in vivo activity, it was expected that this would 
translate into a longer survival span. However, this is not totally surprising as has been 
reported previously for related series of compounds28,47 with solubility-limited absorption 
postulated to result in decreased bioavailability. For poorly soluble compounds, the 
absorption is largely driven by lipophilicity. Consequently, the absorption at a low dose may 
be about the same as that of a moderate dose since, at higher doses, the compound could 
precipitate in the gastro intestinal tract of the animal and is therefore not available for 
absorption. The presumed low exposure in the systemic circulation could result in sub-
optimal levels of the compound in vivo. Several factors relating to drug disposition including 
binding to proteins or tissues and clearance could modify in vivo outcomes. To investigate 
some of these possible scenarios, we performed pharmacokinetic (PK) analysis on the two 
lead compounds-1j/GMP-19 and 4i/GMP-75- to understand the in vivo disposition of the 
series.   
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3.8 In vivo pharmacokinetic profile 
 
The oral disposition of representative compounds 1j/GMP-19 and 4i/GMP-75 was studied in 
mice to enable investigation of the PK profile of this series. The PK studies were conducted at 
the Division of Clinical Pharmacology, Department of Medicine, University of Cape Town. In 
this regard, C57B1/6 mice (n=3) were dosed orally at 20mg/kg for each of the compounds 
while in another set, the animals (n=2 mice) were dosed intra-venously at 2mg/kg. Blood was 
sampled between 0-24 hours at the intervals shown in Figure 3.3. Corresponding PK 
parameters were calculated using non-compartmental analysis and are presented in Table 
3.10.  
 
         
 
Figure 3.3: Pharmacokinetics profile for a) 1j/GMP-19, iv; b) 1j/GMP-19, oral; c) 4i/GMP-75, iv and 
d) 4i/GMP-75, oral. Each data point represents the mean from 2 (iv) and 3 (oral) mice with error 
bars indicating the standard deviation. 
 
 




































































































































a. 1j/GMP-19 iv b. 1j/GMP-19 oral 
c. 4i/GMP-75 iv d. 4i/GMP-75 oral 
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Compound 1j/GMP-19 displayed a delayed absorption profile as can be inferred from the 
time taken to reach the maximum concentration (Tmax=5h) post oral administration. At the 
oral dose of 20mg/kg, the maximum concentration reached (Cmax=1.1 µM) is six-fold above 
the in vitro IC50 value (0.17 µM) for this compound which, in conjunction with its good 
metabolic stability, corroborates the observed oral efficacy. Furthermore, 1j/GMP-19 
maintains plasma levels above in vitro IC50 for over 20 hours in both the oral and iv routes of 
administration (Figure 3.3) and displays a low volume of distribution (Vd=0.9L/kg) and a very 
low plasma clearance (CL=0.97ml/min/kg) [Table 3.10].  
 
Table 3.10: Pharmacokinetics parameters for 1j/GMP-19 and 4i/GMP-75 in mice. 
 
                          
      
          
                    1j/GMP-19                    4i/GMP-75 
Parameter i.v. (2mg/kg) a p.o. (20mg/kg) b i.v. (2mg/kg) a p.o. (20mg/kg) b 
Cmax (µM) - 1.1 - 0.3 
Tmax (h) - 5 - 3 
t1/2 (h) 11.4 7.86 2.6 0.3 
Vd (L/kg) 0.90 - 0.18 - 








- 2 - <1% 
aFor intravenous dosing (n=2 mice), compounds were formulated in a solution of dimethylacetamide,        
polyethylene glycol and propylene glycol/ethanol mixture 4:1 at a ratio 1:3:6.b For oral dosing (n=3 mice), 
compounds were formulated as suspension in 100% HPMC. 
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In contrast to 1j/GMP-19, 4i/GMP-75 attained peak plasma concentrations slightly earlier 
(Tmax= 3h). The Cmax (0.3 µM), however, was much lower than that reached by 1j/GMP-19 
and was less than 2-fold the in vitro IC50 (0.17 µM) for the compound. Similarly, 4i/GMP-75 
had a shorter half-life (t1/2=0.3h) than 1j/GMP-19, a profile consistent with the previously 
observed in vitro microsomal metabolic stability whereby 4i/GMP-75 had 84% compound 
remaining after 30 minutes while 1j/GMP-19 remained unchanged after the same period, 
when evaluated in mouse liver microsomes. Just like 1j/GMP-19, 4i/GMP-75 showed slow 
clearance (CL=0.81 mL/min/kg) but had a much lower volume of distribution (Vd=0.18 L/kg). 
Notably, both compounds had very low bioavailability: 1j/GMP-19 (F=2%) and 4i/GMP-75 (F 
< 1%).  
Taken together, the pharmacokinetics analysis of these compounds reveal that they have 
delayed absorption, low volume of distribution and low in vivo clearance. The meagre 
bioavailability and variability in absorption, a frequent profile amongst compounds with poor 
solubility, indicates the need for optimising this parameter towards improved PK and, 
potentially, oral efficacy. Further investigations are required into understanding the tissue 
localisation and distribution of these compounds. Based on the high in vitro metabolic 
stability, low in vivo clearance and time above in vitro IC50 concentrations, these compounds 
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3.9 Chapter summary 
 
In this chapter, the antimalarial activities of the PBI derivatives synthesised in this project 
have been described. Based on the medicinal chemistry iterations undertaken, tractable 
structure-activity relationship trends have been delineated. Arising from testing in both 
chloroquine sensitive and multidrug-resistant strains of Plasmodium falciparum, the series 
was found to have low cross-resistance potential relative to the quinoline antimalarial drugs. 
Besides possessing blood-stage activity, these analogues display potent activity towards the 
liver and gametocyte stages. Moreover, in probing the mechanism of antimalarial action, the 
molecules were evaluated for their potential to interfere with the formation of BH, an in vitro 
analogue of hemozoin. Only few compounds displayed good inhibitory activity which was 
nonetheless not always correlated to antiplasmodial activity. Additionally, the chapter has 
discussed metabolic stability and cytotoxicity in mammalian cells, along with the assessment 
of hERG interaction potential from which structure-property relationship trends were 
delineated. Finally, both the in vivo pharmacokinetics and efficacy of the frontrunner leads 
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4.1 Chapter overview 
 
In this chapter, the activity of target compounds towards adult and immature Schistosomes 
will be presented. Emanating from observed antischistosomal activities, structure-activity 
relationship trends will be extracted. As with the preceding chapter, the in vitro drug 
metabolism, pharmacokinetics and cytotoxicity profiles of selected compounds will be 
discussed. Based on in vitro microsomal metabolic stability profiles, metabolite identification 
studies will be discussed for selected compounds. Finally, using the frontrunner compounds, 
results of in vivo efficacy and pharmacokinetics will also be discussed. 
4.2 In vitro antischistosomal activities 
 
The chemical architecture and antiplasmodial potency of the synthesised PBI derivatives 
prompted their antischistosomal evaluation, following a drug repositioning approach. In so 
doing, the presence of common druggable biological pathways between Plasmodium 
parasites and schistosomes, such as the heme detoxification process, was presumed.1  In line 
with current antischistosomal drug discovery programs2,3 and with the intention of identifying 
leads that are active across multiple stages of the parasite, in vitro antischistosomal activities 
of target compounds was performed against adult worms and immature larva referred to as 
newly transformed schistosomula (NTS). As discussed before, the standard of care therapy in 
schistosomiasis, praziquantel, weakly targets immature forms of schistosomes which proceed 
to mature into adult worms and perpetuate the infection. Finding a multi-stage active 
antischistosomal lead that can eradicate both adult worms and the larval forms is therefore 
a key priority and target candidate profile for antischistosomal drug discovery and 
development.4–6 
The antischistosomal assays were conducted at the Swiss TPH under the supervision of Prof. 
Jennifer Keiser.  Briefly, infected snails were mechanically stimulated to shed S. mansoni 
cercariae which were transformed into schistosomula by removal of cercarial tail.7  For assays 
against mature Schistosomes, the adult worms were harvested after 7-8 weeks from the 
hepatic portal and mesenteric veins of mice previously infected with cercariae.7,8  
                       Chapter 4                                            Antischistosomal Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                             Godfrey Mayoka PhD Thesis 2018                                                           University of Cape Town 
188 
 
With the aim of prioritising compounds capable of targeting NTS, test compounds were first 
screened for activity at an initial concentration of 10 µM against juvenile S.  mansoni worms. 
Thereafter, compounds that displayed significant inhibition (≥70%) of the NTS were 
subsequently exposed to adult schistosomes at a similar concentration. Compounds with 
significant activity in the adult worms at 10 µM were progressed for further dose-response 
experiments from which IC50 values were determined. Ensuing SAR trends were analysed 
based on the observed activities as presented in the following Tables 4.1- 4.3, stratified 
according to the SAR manipulations carried out in this project. 
 
4.2.1 SAR1 Targets 
 
In the first series, where the side chain has the phenyl ring directly linked to the PBI core by a 
nitrogen (compounds 1a/GMP-06 - 2e/GMP-58), 10 compounds were identified having 
activity in the low micromolar range (<10 µM). Out of these, 1b/GMP-09 (IC50=0.21 µM), 
1i/GMP-18 (IC50=0.97 µM) and 1j/GMP-19 (IC50=0.21 µM) all displayed sub-micromolar 
potency, while the unsubstituted analogue 1n/GMP-32 (IC50=2.81 µM) had lower potency, 
suggesting that activity was favoured in compounds incorporating substituents with electron-
withdrawing effects. On the contrary, hydrophilic groups on the aromatic side group (R, Table 
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% S. mansoni 
mortality at 10 µM 




73.9 33.3 - 
1b/GMP-09 
 
100 100 0.21 
1c/GMP-10 
 
100 50 - 
1e/GMP-12 
 
95.7 63.3 6.40 
1f/GMP-13 
 
43.5 - - 
1g/GMP-15 
 
30.4 - - 
1h/GMP-17 
 
30.4 - - 
1i/GMP-18 
 
100 91.7 0.97 
1j/GMP-19 
 
100 100 0.21 
1k/GMP-121 
 
- 100 1.05 
1l/GMP-122 
 
- 100 1.65 
1n/GMP-32 
 
100 79.2 2.81 
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% S. mansoni 
mortality at 10 µM 




26.1 - - 
1p/GMP-46 
 
100 83.3 3.14 
2a/GMP-23 
 
100 100 1.38 
2b/GMP-30 
 
100 97.9 0.75 
2c/GMP-31 
 
100 100 0.4 
2d/GMP-57 
 
30.4 - - 
2e/GMP-58 
 
91.3 91.7 2.01 
3a/GMP-24 
 
17.4 - - 
3b/GMP-28 
 
4.4 - - 
3c/GMP-29 
 
8.7 11.1 - 
3d/GMP-33 
 
0 0 - 
3e/GMP-34 
 
4.4 - - 
3f/GMP-35 
 
8.7 - - 
3g/GMP-36 
 
13 - - 
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% S. mansoni 
mortality at 10 µM 




47.8 - - 
3i/GMP-45 
 
30.4 - - 
3j/GMP-25 
 
21.7 - - 
3k/GMP-43 
 
30.4 - - 
3l/GMP-44 
 
4.4 - - 
3m/GMP-47  
8.7 - - 
3n/GMP-48 
 
4.4 - - 
3o/GMP-50 
 
0 0 - 
3p/GMP-52 
 
17.4 - - 
3q/GMP-53 
 
26.1 - - 
3r/GMP-54 
 
21.7 - - 
3s/GMP-55 
 
26.1 - - 
3t/GMP-56 
 
26.1 - - 
3u/GMP-77  9 - - 
3v/GMP-87 
 
89 29 - 
                       Chapter 4                                            Antischistosomal Profiling of Pyrido [1,2-a] benzimidazoles 
 
 









% S. mansoni 
mortality at 10 µM 




9 - - 
Praziquantel    0.1 
aValues are a mean of n≥3 determinations. 
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Additional compounds with good antischistosomal activity were identified among 
compounds incorporating heteroaromatic side groups exemplified by pyrimidyl, pyridyl, 
thiazolyl and pyrazinyl groups as in 2a/GMP-23 (IC50=1.38 µM), 2b/GMP-30 (IC50=0.75 µM), 
2c/GMP-31 (IC50=0.4 µM) and 2e/GMP-58 (IC50=2.01 µM), respectively. The retention of 
activity of these heteroaromatic analogues not only allowed for the exploration of new 
chemical spaces, but also had the attendant advantage of incorporating solubility-enhancing 
features. 
The morpholino-containing analogue 1p/GMP-46 also displayed modest antischistosomal 
activity in both young and adult worms with a mortality of 100% and 83%, respectively, at 10 
µM and an IC50 value of 3.14 µM against the adult worms. The positioning of the nitrogen 
atoms in the phenyl side chain seem crucial for antischistosomal activity since 2d/GMP-57, in 
which the nitrogen atoms have a 2,6 relationship, showed poor activity compared to its regio-
isomer 2e/GMP-58 (IC50=2.01 µM) where the nitrogen atoms occur in a 2,5 relationship.  
The next SAR analysis concerns a series of analogues comprising the aromatic side group 
attached to the PBI core via a methylamine bridge (3a/GMP-24- 3t/GMP-56; Table 4.1). In 
the absence of modifications elsewhere in the scaffold, these compounds displayed poor 
antischistosomal activity. Most of these compounds were weakly active against NTS at the 
screening concentration of 10 µM rendering them ineligible for additional screening in adult 
worms according to the workflow adopted in the assay. For example, in comparing 1j/GMP-
19 (IC50 = 0.21 µM) vs 3f/GMP-35 (IC50 >10 µM); 1i/GMP-18 (IC50 = 0.97 µM) vs 3g/GMP-36 
(IC50 >10 µM), the analogues with a methylene linker in each case, are all inactive. A similar 
pattern of inactivity was maintained with the heteroaromatic analogues of previously active 
aniline-type series compounds as in 2e/GMP-58 (IC50 = 2.01 µM) vs 3i/GMP-45 (IC50 >10 µM).  
The capacity for the nitrogen connecting the PBI core and the aromatic appendage to act as 
a hydrogen-bond donor appears important for antischistosomal activity. In comparing   
1e/GMP-12 vs 1o/GMP-37 and 3j/GMP-25 vs 3c/GMP-29, there was a decrease in the 
mortality induced at 10 µM in both NTS and adult worms for 1o/GMP-37 and 3c/GMP-29 
which contain a methyl substitution on this nitrogen.  
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Furthermore, when the methylene linker in 3d/GMP-33 (0% NTS and adult; 10 µM) was 
substituted by an amino group to produce 3v/GMP-87, better activity in both the immature 
and adult worms was observed. Other side groups such as the more polar piperazine and 
hydrazide found in 3u/GMP-77 and 3w/GMP-88, respectively, were detrimental to activity 
(9% NTS, 10 µM). 
 
4.2.2. SAR2 Targets 
 
This SAR involved introducing changes on the LHS of the PBI core through installation of 
chloro- substitutions. Interestingly, for target compounds in the benzylamine series which 
were previously inactive, this modification seemed to restore their activity. For example, 
3b/GMP-28 has poor activity (Table 4.1; IC50 >10 µM), with less than 10% reduction in juvenile 
worms and no effect against adult worms at 10 µM. In contrast, the analogues 4a/GMP-62 
and 4b/GMP-66 (Table 4.2) with dichloro substitution on the phenyl portion of the PBI 
scaffold have potent activity at 10 µM against both juvenile and adult worms (98-100% 
mortality). Consistent observations are seen with 3o/GMP-50 vs 4e/GMP-69; 3f/GMP-35 vs 
4c/GMP-67 and 3j/GMP-25 vs 4d/GMP-68 in which enhanced mortality is observed with the 
di-chlorinated analogues, in both NTS and adult worms at 10 µM.    
Regio-isomerism in the aromatic side group appears inconsequential to antischistosomal 
activity: shifting the position of the fluoro substituent from the para position in 4b/GMP-66 
(100% NTS, 98% adult; 10 µM) to the ortho- [4i/GMP-75 (IC50 = 0.38 µM)] and meta- [4j/GMP-
76 (IC50 = 0.40 µM)] analogues maintained good antischistosomal activity.  
The relevance of chirality with regards to antischistosomal activity was evaluated by 
comparing the achiral compound 4l/GMP-96 (23% NTS), which has poor activity, to that of 
analogous racemic 4m/GMP-97 (100%, NTS and adult), which portrays good potency against 
both the immature and adult worms at 10µM. This observation may indicate the possible 
existence of a chiral target with which the compounds interact to elicit antischistosomal 
activity.  This hypothesis will need to be tested through the synthesis and evaluation of the 
respective enantiomers.  
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Table 4.2: In vitro antischistosomal activity of SAR2 Targets in NTS and adult worms.a 
 
Compound 
 Number/ Code 
R 
% S. mansoni mortality 
at 10 µM 




100 100 0.77 
4b/GMP-66 
 
100 98 *- 
4c/GMP-67 
 
100 100 *- 
4d/GMP-68 
 
100 99 *- 
4e/GMP-69 
 
100 100 *- 
4f/GMP-70 
 
100 100 *- 
4g/GMP-71 
 
100 100 0.47 
4h/GMP-72 
 
100 100 0.43 
4i/GMP-75 
 
100 100 0.38 
4j/GMP-76 
 
100 100 0.40 
4l/GMP-96 
 
23 - - 
4m/GMP-97 
 
100 100 *- 
4n/GMP-98 
 
44 84 *- 
4o/GMP-99 
 
93 87 *- 
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 Number/ Code 
R 
% S. mansoni mortality 
at 10 µM 




9 - - 
Praziquantel    0.1 
aValues are a mean of n≥3 determinations. *Not determined as compound failed 
potency criteria at 1µM.  
 
When the methylene linker in the side group R was replaced with a sulfonyl group, there were 
mixed observations: activity was lost with 4p/GMP-100 (9% NTS, 10 µM), an analogue of 
4d/GMP-68 (100% NTS, 99% adult; 10 µM) whereas similar changes only diminished slightly 
the activity of 4o/GMP-99 (93% NTS, 87% adult; 10 µM), the analogue of 4c/GMP-67 (100% 
NTS and adult; 10 µM).   
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4.2.3 SAR3 Targets 
 
Towards interrogating the relevance of the nitrile substitution on the pyridyl portion of the 
PBI scaffold, some compounds were synthesised wherein this group was replaced by other 
small groups. It was discovered that this modification led to a decrease in antischistosomal 
activity as seen in Table 4.3. Taken together, these results suggest that the nitrile at this 
position is important or optimal for antischistosomal activity.  
 





% S. mansoni 
mortality at 10 µM 
Adult 
IC50 
(µM) NTS Adult 
5a/GMP-120 H 
 
- 77 3.37 
5b/GMP-128   
4 34 - 
5c/GMP-129   
21 53 - 
5d/GMP-130   
8 15 - 
5e/GMP-120E   
67 57 - 
Praziquantel     0.1 
aValues are a mean of n≥3 determinations. 
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4.3 Correlation between antischistosomal and BHI activity 
 
Target compounds were evaluated against the BHI process as a putative mechanism of 
antischistosomal activity. As discussed previously in Chapter 1, this process is observed to 
occur in Schistosoma as in Plasmodium parasites. The potencies of the compounds in this 
assay is as recorded in Chapter 3 alongside their antiplasmodial potency. In this section, an 
analysis for correlation between BHI activity and antischistosomal action of these compounds, 
is examined.  
As observed with the antimalarial actions of these series, there was a lack of correlation 
between the ability to interfere with the formation of hemozoin and the observed 
antischistosomal potency (Figure 4.1). This inference is drawn from recorded good in vitro 
antischistosomal activities of compounds such as 1b/GMP-09, 1j/GMP-19 and 4i/GMP-75 
which displayed poor BHI action (IC50 >100 µM) while 1p/GMP-46, 4f/GMP-70 and 4m/GMP-
97 despite having potent BHI activity, were only weakly active against adult schistosomes at 
1 µM.  
 
 
Figure 4.1: Correlation plot between BHI and in vitro antischistosomal activity of 


























BHI potency vs antischistosomal activity
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These results point to the likelihood of divergent or additional mechanisms of action besides 
inhibition of BH formation, through which these compounds may act to achieve the observed 
antischistosomal activities.  
 
4.4 ADME and cytotoxicity profiling of frontrunner compounds 
 
To gain insight into the anticipated pharmacokinetic behaviour, selective toxicity and to 
prioritise compounds for in vivo efficacy studies, in vitro metabolic stability and cytotoxicity 
experiments were conducted as explained in Chapter 3. Metabolic stability was carried out 
using mouse and human liver microsomes whereas cytotoxicity was evaluated using the 
Chinese Hamster Ovarian cell lines. The percentage of compound remaining after 30 minutes 
incubation was determined and the projected half-life calculated as previously described.9 
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% rem. after 30min (t1/2min) In vitro IC50 (µM) 
Selectivity 
Index 





97 (>150) 92 (>150) 7.27 0.21 35 
1i/GMP-18 
 
105 (>150) 77 (80) 148 0.97 153 
1j/GMP-19 
 
110 (>150) 105 (>150) 17.58 0.21 84 
2a/GMP-23 
 
28 (17) 69 (57) 23.99 1.38 17 
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% rem. after 30min (t1/2min) In vitro IC50 (µM) 
Selectivity 
Index 





56 (36) 29 (17) 111.15 0.75 148 
2c/GMP-31 
 
73 (66) 64 (47) 33.37 0.4O 83 
2e/GMP-58 
 
38 (22) 56 (36) 181.34 2.01 90 
4a/GMP-62 
 
76 (75) 82 (105) 1.66 0.77 2 
4b/GMP-66 
 
72 (63) 102 (>150) 13 1-10  
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% rem. after 30min (t1/2min) In vitro IC50 (µM) 
Selectivity 
Index 





82 (105) 109 (>150) 5.02 1-10  
4d/GMP-68 
 
31 (18) 72 (63) 0.75 1-10  
4e/GMP-69 
 
69 (56) 91 (>150) 6.06 1-10  
4g/GMP-71 
 
66 (50) 100 (>150) 4.84 0.47 10 
4h/GMP-72 
 
  8.48 0.43 20 
4i/GMP-75 
 
84 (119) 97 (>150) 4.30 0.38 11 
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% rem. after 30min (t1/2min) In vitro IC50 (µM) 
Selectivity 
Index 





84 (119) 100 (>150) 7.03 0.40 18 
4n/GMP-98 
 
9 (9) 16 (11) >50 1-10  
4o/GMP-99 
 
38 (21) 83 (112) >50 1-10  
aValues are the mean of n≥3 determinations. MLM-mouse liver microsomes; HLM-human liver microsomes; CHO-
Chinese Hamster ovarian cell line. %rem. Is the percent compound remaining; t1/2: estimated half-life in minutes. 
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Overall, the most stable compounds were 1b/GMP-09, 1j/GMP-19, 4c/GMP-67, 4i/GMP-75 
and 4j/GMP-76 in which over 80% of the compound was remaining after incubating for 30 
minutes with an estimated half-life of over 100 minutes in both MLM and HLM. The lipophilic 
electron-withdrawing property of groups attached to the aromatic side chain (as in 1j/GMP-
19 and 4c/GMP-67) imparted better metabolic stability as opposed to hydrophilic, electron-
rich substituents (as found in 1a/GMP-06, 1i/GMP-18 and 4e/GMP-69). 
 Introducing heteroatoms in the side chain decreased metabolic stability as evident with, 
2a/GMP-23, 2b/GMP-30, 2c/GMP-31, 2e/GMP-58, and 4d/GMP-68 which had less than 75% 
of compound remaining in both MLM and HLM species. Similarly, when a sulfonyl group was 
used in the stead of a methylene linker, metabolic stability was greatly diminished with 
4n/GMP-98 being the least metabolically stable compound in the sub-series with this 
modification.  
Species variation in the metabolic stability of this series was evident. Metabolism was more 
efficient in mouse liver microsomes for ten of the tested compounds: 2a/GMP-23, 2e/GMP-
58, 4b/GMP-66, 4c/GMP-67, 4d/GMP-68, 4e/GMP-69, 4g/GMP-71, 4i/GMP-75, 4j/GMP-76, 
4n/GMP-98 and 4o/GMP-99. Only three compounds (1i/GMP-18, 2b/GMP-30 and 2c/GMP-
31) showed enhanced susceptibility to HLM compared to MLM whereas two compounds 
(1b/GMP-09 and 1j/GMP-19) were equally stable in both species.  
Most of the compounds had a good cytotoxicity profile (SI>10) with only 4a/GMP-62, with a 
selectivity index of 2, showing high potential for causing cytotoxicity. Evidently, as seen with 
the antimalarial evaluation of these compounds, although the introduction of chloro 
substitutions on the LHS of the molecules improved their antischistosomal potency, this also 
increased their risk for inducing cytotoxicity as reflected in their reduced selectivity indices 
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4.5 Metabolite identification studies for 2a/GMP-23 and 2e/GMP-58 
 
For selected compounds (2a/GMP-23 and 2e/GMP-58) that portrayed good in vitro 
antischistosomal activity but were beset by enhanced susceptibility to drug metabolising 
enzymes, metabolite identification studies were conducted with the three-fold purposes of: 
i) Identifying the metabolic hotspot in the compounds, ii) understanding the nature of 
biotransformation and iii) establishing the putative metabolites. These studies were 
performed at the Division of Clinical pharmacology, Department of Medicine, UCT.  
In summary, compounds were incubated separately in MLM and HLM in the presence of 
requisite co-factors and conditions such as NADPH, magnesium chloride and potassium 
phosphate buffer at pH 7.4 to mimic the physiological milieu. After shaking for 60 minutes at 
37 ֯C, chilled acetonitrile was added to the incubation mix which was then centrifuged and 
filtered prior to LC-MS analysis. Control experiments in which NADPH, microsomes or test 
compounds were individually excluded were prepared as described for the test compounds. 
The set up in which NADPH was excluded served to facilitate the evaluation of any non-
CYP450-dependent metabolism. Moreover, the experiments where microsomes and test 
compounds were not included helped to assess any background instability, potentially due to 
chemical degradation of the compound in the experimental medium and instrumental 
instability, respectively. The LC-MS peaks resulting from the respective incubations were used 
to assign putative metabolic biotransformation and metabolites while referring to the parent 
structure and considering the mass difference pattern.  
Regarding 2a/GMP-23, incubation in HLM in the presence of NADPH showed two additional 
LC-MS peaks with [M+H] = 401, a mass difference of 14Da relative to the parent compound 
(Figure 4.2b). This pattern, consistent with the loss of a methyl group, was not discernible 
neither at the start of the incubation nor in the incubation lacking NADPH; a clear indication 
that it is most likely a metabolic transformation that required CYPP450 catalysis. Background 
and instrumental instability were ruled out based on the absence of similar profiles in the 
incubations in which microsomes and test compounds were excluded.  
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LC-MS analysis of the incubation of 2a/GMP-23 in MLM, interestingly, displayed only one 
additional peak and not two as seen with the HLM incubation. This peak maintained the          
14Da mass difference pattern, suggesting, again, a mono-dealkylation process (Figure 4.2c). 
Examining the retention times of the peaks, both HLM and MLM produce the same metabolite 
that shows a peak at 2.5 minutes. This is most probably one of the de-alkylation metabolites 
arising from the removal of one of the methyl groups in the pyrimidyl side group. The other 
metabolite, which elutes at 3.2 minutes and is observed only in HLM, is likely the other de-
alkylation product caused by removal of the other methyl group (Figure 4.2). It appears that 
MLM are not capable of performing this transformation at the tested conditions. These 
observations further support the disparity in metabolism between species as reflected in the 
overall metabolic stability between HLM and MLM as discussed earlier. 
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Figure 4.2: Extracted ion chromatogram for a) 2a/GMP-23 
[M+H]=415 at T0 before incubation with HLM and b) 2a/GMP-23 
[M+H]=415 and its two mono-dealkylation metabolites, each with 
[M+H]=401, at T60 and c) 2a/GMP-23 and its one  mono-delakylation 
metabolite after  incubation with MLM for 60 minutes. 
  
XIC of +EMS: Exp 1, 401 to 402 Da from Sample 23 (GMP-23 HLM T0_1) of Gemini C6Ph-717184-1.wiff (Turbo Spray) Max. 5.6e6 cps.




























XIC of +EMS: Exp 1, 401 to 402 Da from Sample 25 (GMP-23 HLM T60_1) of Gemini C6Ph-717184-1.wiff (Turbo Spray), Smoothed Max. 3.5e7 cps.
























XIC of +EMS: Exp 1, 401 to 402 Da from Sample 35 (GMP-23 MLM T60_1) of Gemini C6Ph-717184-1.wiff (Turbo Spray), Smoothed Max. 3.0e7 cps.
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On the other hand, metabolite identification studies of 2e/GMP-58 revealed the major 
metabolite peak, in HLM, with a positive mass difference pattern of 17Da relative to the 
parent compound; indicative of a hydroxylation transformation (Figure 4.3b). Other minor 
peaks which were more polar compared to the parent compound, based on the retention 
times, could not be rationalised as their concentrations were insufficient for detection. The 
peaks could possibly be due to additional hydroxylation metabolites arising from changes to 
the PBI core or the pyrazinyl side group (Figure 4.3b).  
In contrast to HLM, the peak corresponding to an additional mass of 17Da was the only visible 
signal with no additional minor peaks in MLM (Figure 4.3c). The observed metabolite peaks, 
including the minor ones in MLM, were not present in the incubations that lacked NADPH, 
test compound or microsomes, further attesting to the fact that they must be CYP450-
mediated. Differences in observed profile of metabolites for 2e/GMP-58 between HLM and 
MLM, again, points to the probability of species differences in the metabolism of these 
compounds.  
To better understand their potential antiparasitic potency, the putative metabolites of 
2a/GMP-23 and 2e/GMP-58 described herein would need to be synthesized and tested in 
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Figure 4.3: Extracted ion chromatogram for a) 2e/GMP-58 [M+H]=355 before 
incubation, T0; b) 2e/GMP-58 [M+H]=355 and its hydroxylation metabolites, 
including [M+H]=371 at T60 and c) 2e/GMP-58 [M+H]=371 with its 




XIC of +EMS: Exp 1, 371 to 372 Da from Sample 58 (GMP-58 HLM T0_2) of Gemini C6Ph-717184-1.wiff (Turbo Spray) Max. 4.6e6 cps.





















XIC of +EMS: Exp 1, 371 to 372 Da from Sample 59 (GMP-58 HLM T60_1) of Gemini C6Ph-717184-1.wiff (Turbo Spray), Smoothed, Smoothed Max. 1.4e7 cps.



















XIC of +EMS: Exp 1, 371 to 372 Da from Sample 70 (GMP-58 MLM T60_2) of Gemini C6Ph-717184-1.wiff (Turbo Spray), Smoothed, Smoothed Max. 5.5e6 cps.
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4.6 In vivo efficacy and pharmacokinetics of lead compounds 
 
Compounds were selected for in vivo proof-of-concept studies in a mouse model of 
schistosomiasis based on their in vitro potency and acceptable cytotoxicity profile. These 
experiments were carried out at the Swiss TPH under Prof. Jennifer Keiser. In vivo potency 
was measured based on the degree of worm reduction achieved in infected and treated mice 
relative to the initial cercarial infection load and comparing with infected but untreated mice, 
serving as controls. Accordingly, mice were dosed orally 49 days post-infection, with 
compounds dissolved or suspended in 7% tween 80 and 3% ethanol in water (v/v/v) at 
400mg/kg.  The dosing schedule coincided with the period at which the juvenile worms used 
in the infection phase would have matured into adults.10 Twenty-one days after dosing, mice 
were sacrificed, dissected and adult worms retrieved from the mesenteric and hepatic portal 
blood vessels.  The harvested worms were sexed, examined for lethal effects and the percent 
worm reduction for tested compounds determined. The results are as presented in Table 4.5. 
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nd: not determined 
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Of the eleven compounds tested, 2a/GMP-23 failed to induce any in vivo effect, 1i/GMP-18, 
2b/GMP-30, 2c/GMP-31, 2e/GMP-58, 4g/GMP-71 and 4h/GMP-72 all produced slight (30-
42%) reduction in worm burden while significant (>50%) reduction in worms was realised with 
1b/GMP-09, 1j/GMP-19, 4i/GMP-75 and 4j/GMP-76. Overall, the best efficacy was obtained 
with 1j/GMP-19, 4i/GMP-75 and 4j/GMP-76 that resulted in total worm reduction between 
60-70%. It is notable that compounds bearing heteroaromatic side chains (2a/GMP-23, 
2b/GMP-30, 2c/GMP-31, 2e/GMP-58, 4g/GMP-71, and 4h/GMP-72) generally produced low 
in vivo efficacy.  
Expectedly, there was a trend towards poor activity for compounds that had shown low 
metabolic stability and higher activity for those with better metabolic stability. Although 
praziquantel has a short half-life, the drug displays potent activity due to active metabolites.11 
It is likely the metabolically unstable compounds encountered in this study are transformed 
to metabolites with decreased or no antischistosomal activity.  
Furthermore, it is also probable that physicochemical hurdles are responsible, at least in part, 
for the low or lack of in vivo activity of some compounds such as 2a/GMP-23. Compound 
2a/GMP-23 is likely poorly absorbed, a hypothesis supported by a negative human intestinal 
absorption (HIA) index score predicted by Stardrop™ software; all other compounds were 
predicted to have a positive HIA score. Moreover, suboptimal bioavailability may be the 
reason for the lower efficacy of otherwise in vitro potent compounds with outstanding 
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Pharmacokinetics experiments carried out on two representative compounds, 1j/GMP-19 
and 4i/GMP-75, as described previously in Chapter 3, confirmed that there was limited 
systemic exposure of these compounds following oral administration. Despite the low 
bioavailability of 1-2% at the oral dose of 20mg/kg used in the PK studies, the systemic 
exposure attained concentrations (0.3-1.1 µM) that match the in vitro IC50 values of the two 
compounds (0.21-0.38 µM).  At the higher dosing schedule of 400mg/kg adopted for the 
efficacy studies, it is conceivable that systemic exposure did not increase proportionately with 
the dose. 
Solubility-limited absorption, as further suggested by the delayed peaking of plasma 
compound concentrations, is a potential phenomenon contributing to the suboptimal efficacy 
of these compounds. Based on the low in vivo clearance and length of time above in vitro IC50 
concentration for these compounds, improved bioavailability through modulation of 
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In conclusion, this chapter has described the antischistosomal properties of the target 
compounds generated in this study. Based on in vitro potency against the newly transformed 
schistosomula and adult worms, analysis of SAR trends has identified features compatible 
with good activity. Generally, electron-withdrawing groups as substituents on the aromatic 
appendage were favourable for potent activity. The aniline series generally provided more 
active compounds in the absence of changes on the LHS, compared to the benzylamine series. 
It was notable that changes on the LHS of the PBI scaffold restored the activity of previously 
inactive benzylamine series analogues.  
As observed for the antimalarial properties of these compounds, there was no correlation 
between the ability of these compounds to interfere with the BHI process and their 
antischistosomal potency, and that introducing changes on the LHS diminished the selectivity 
of these compounds. Similarly, attempts to change the nitrile on the pyridyl portion of the PBI 
core was detrimental to antischistosomal activity. In vitro ADME evaluation indicated that 
heteroatoms in the structures of target compounds rendered them more susceptible to 
metabolism.  
Arising from in vivo efficacy studies on selected compounds, good antischistosomal activities 
were displayed by 1j/GMP-19, 4i/GMP-75 and 4j/GMP-76 which produced 60-70% worm 
burden reduction. Pharmacokinetics hurdles, especially solubility-limited absorption was 
identified as a likely contributing factor for the sub-optimal potency achieved by the lead 
compounds as was microsomal metabolic instability. 
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5.1 Chapter overview 
 
This chapter will describe the physicochemical profile of the target compounds produced in 
this thesis. Consequently, structure-property correlations will be investigated towards 
establishing effects of structural changes on various physicochemical attributes. At the onset, 
the chapter will present solubility of the compounds based on an array of experimental and 
in silico methods. Subsequently, other physicochemical properties including lipophilicity and 
melting point will be described and interrelationships between the various physical and 
chemical characteristics for the project compounds investigated. Moreover, the profiled 
attributes will be compared to recommended classical medicinal chemistry references for 
leads projected to possess good drug metabolism and pharmacokinetics properties.  
The chapter will also discuss the relationships between the physicochemical parameters of 
these compounds and their corresponding biological activities previously described in 
Chapters 3 and 4. At the end, the chapter will compare the physicochemical profile of the 
study compounds with that of marketed drugs and leads in antimalarial and antischistosomal 
drug discovery and development to identify any overlapping or diverging chemical spaces.    
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As alluded to previously, solubility is a key physicochemical property with pivotal significance 
in drug discovery and as such, its determination and optimisation of leads for this property 
early in the drug discovery continuum is paramount.1,2  There are various methods used to 
measure solubility whose choice depends on factors such as turn-around time, throughput, 
cost and the stage reached in drug discovery and development. Generally, the two categories 
are thermodynamic and kinetic solubility.1,3 
Thermodynamic solubility refers to the solubility of a compound in an aqueous media and is 
devoid of co-solvent effects. As such, the compound is directly dissolved in the aqueous 
solution and an equilibrium established between the dissolved and undissolved compound. 
Expectedly, this method provides more accurate evaluation of the solubility of a compound 
considering that an aqueous medium, simulating in vivo physiological conditions, is used. A 
downside of this method, however, is that it is time- consuming and is not amenable to high 
throughput.3  
Conversely, in kinetic solubility, the compound is first pre-dissolved in an organic solvent, 
commonly DMSO, in which the compound is completely soluble. Subsequent dilutions are 
then prepared from the stock using an aqueous buffer. 
In the initial phases of drug discovery projects, kinetic solubility is usually applied due to its 
higher throughput and lower costs compared to thermodynamic solubility assay. With a faster 
turn-around time, kinetic solubility generates data that can be used to interrogate biological 
data from in vitro bio-assays and allow for structure-solubility trends to be extracted.4,5 
Thermodynamic solubility, however, is considered superior and more meaningful further 
down the drug discovery pipeline when the crystalline nature of the compound is expected 
to have been characterised and its impact on solubility and other PK parameters established.  
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The thermodynamic solubility of a lead is critical in guiding in vivo experiments and 
formulation strategies including filing of regulatory applications for late discovery and early 
stage drug development.6 
Based on molecular characteristics of compounds such as melting point and lipophilicity, 
equations and algorithms have also been developed to enable calculation or in silico 
prediction of solubility.7–9 Application of these computational tools can be time saving and 
enable quicker ranking and selection of compounds deemed to possess favourable 
physicochemical properties. 
 In this research, solubility of the target compounds was evaluated using multiple methods 
comprising kinetic solubility based on the turbidimetric and HPLC-based methods as well as 
through in silico prediction tools and by employing general solubility equations initially 
proposed by Yalkowsky.1  
 
5.2.2 Turbidimetric-based kinetic solubility determination 
 
The turbidimetric assay is a kinetic solubility-based approach in which spectrophotometry is 
employed to determine solubility due to the turbidity that arises when the solubility limit of 
a compound is exceeded.10 Accordingly, compounds were first dissolved in an organic solvent, 
DMSO, and diluted using potassium phosphate buffer, adjusted to pH 7.4, to yield a range of 
concentrations (0-200 µM). After equilibrating for two hours at ambient temperature, the 
optical density readings were recorded from which concentration-absorbance graphs were 
constructed using Microsoft® excel. From the plotted graphs, the concentration at which the 
curve deflected above the baseline was considered as the upper limit of solubility for the 
compound. 
As part of a quality control check for the assay, two compounds representing a highly soluble 
drug (hydrocortisone) and a poorly soluble drug (reserpine) were used as controls (Figure 
5.1). The hydrocortisone graph shows the lines remaining at baseline throughout the 
concentration range, implying the high solubility of the compound.  
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On the contrary, in the case of reserpine, whereas the line corresponding to the DMSO 
incubation remains at baseline, the corresponding aqueous buffer incubation line deflects 




Figure 5.1: Solubility graphs for (a) hydrocortisone and (b) reserpine in DMSO 
(blue line) and aqueous buffer pH 7.4 (purple line) using the turbidimetric-based 
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The solubility of test compounds was therefore determined as described above and the point 
of deviation from the baseline in the aqueous buffer incubation taken to represent the limit 
of solubility (Table 5.1).  
 
5.2.3 HPLC-based kinetic solubility determination  
 
Even though turbidimetric-based assays are relatively fast and less laborious to perform, with 
generally higher throughput, the presence of DMSO in the test samples modify their 
solubility.11 To mitigate these solvent effects, a modified version of the turbidimetric 
solubility, incorporating a HPLC-based approach to determining the amount of compound 
dissolved, was pursued.  
In this approach, first, a standard curve is constructed using low, medium and high 
concentrations of each test compound. Subsequently, assay samples are prepared as in the 
turbidimetric assay; however, a key difference is in drying off the DMSO followed by 
reconstitution of the ensuing solid sample material in aqueous buffer, a step which eliminates 
the enhancement of solubility due to DMSO. Re-dissolved samples were thereafter incubated 
at 37 ֯C with shaking for 30 minutes, after which the supernatant was filtered off and the 
concentration of dissolved sample determined by HPLC, with UV detection, against the 
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5.2.5 Solubility using General Solubility Equations (GSE) 
 
The melting point and lipophilicity of a compound can be used to calculate the solubility of 
the compound according to general solubility equations, the first of which was proposed by 
Yalkowsky.8  
 
The melting point reflects the strength of intermolecular forces, hence a measure of 
crystallinity within the compound, that would need to be broken prior to the solvation and 
dissolving of a compound by solvent molecules. Consequently, higher melting point 
compounds are generally predicted to have lower solubility. On the other hand, the 
lipophilicity of a compound is indicative of the likelihood for the compound to associate with 
an organic phase as opposed to an aqueous phase. Appropriately, compounds with higher 
lipophilicity (high clogP values) are generally less soluble.  
The Yalkowsky equation (Equation 1, Figure 5.2) and some subsequent variations to it, such 
as those proposed by Wang and colleagues (Equation 2, Figure 5.2) were sampled to calculate 
the solubility of compounds generated in this project and the data obtained recorded in Table 
5.1. In another modified solubility equation advanced by Delaney (Equation 3, Figure 5.2), 
molecular weight, clogP, number of rotatable bonds and aromatic proportion, have been 
explored to estimate the solubility of small molecules. This approach is particularly appealing 
to drug discovery scientists as it allows for quick solubility prediction without recourse to 
measuring any of the molecule descriptors employed in the equation as these can be readily 
Log S = 0.5 - logP - 0.01 (Tm - 25) …………………….…………1 
Log S = 3.513 - 0.010Tm- 1.112logP……………………….…...2 
           Log S = 0.16 - 0.63clogP - 0.0062Mwt + 0.066nRB - 0.74AP…….3 
 
Figure 5.2: Solubility equations as proposed by (1) Yalkowsky8, (2) Wang et al.,1 and (3) Delaney.9 
LogP is the lipophilicity; Tm is the melting point in ֯C; Mwt. Is molecular weight; nRB is the number 
of rotatable bonds and AP is the aromatic proportion defined as the number of aromatic atoms ÷ 
total number of atoms in a molecule, excluding hydrogen atoms. 
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generated by various accessible software. Using this method, the solubility of compounds in 
this project were also calculated (Table 5.1).  
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Table 5.1: Solubility of project compounds using assorted solubility methods.a 
Compound structure and Number/Code 
Experimental In silico Calculated 
T. sol HPLC Sol. ChemDraw® StarDrop® ChemAxon® Yalkowsky  Delaney Wang  
 
 
1a/GMP-06 <5 <5 1.07 4.61 0.17 0.03 2.84 4.67 
 
1b/GMP-09 5 <5 1.88 2.83 0.30 0.02 6.61 5.05 
 
1c/GMP-10 10 <5 0.52 3.49 0.13 0.12 1.99 17.63 
 
1d/GMP-11 5 <5 0.19 1.63 0.02 0.03 0.84 3.70 
 
1e/GMP-12 20 <5 2.14 10.14 0.56 0.15 7.26 28.49 
 
1f/GMP-13 5 <5 1.00 11.07 0.89 0.11 4.24 18.82 
 
1g/GMP-15 <5 <5 1.86 7.09 0.45 0.54 16.30 126 
 
1h/GMP-17 10 <5 1.86 20.94 0.46 1.15 9.90 254 
 
1i/GMP-18 5 <5 0.71 2.99 1.17 1.66 16.85 413 
 
1j/GMP-19 20 <5 0.11 2.52 0.03 0.004 0.44 0.52 
 
1k/GMP-121 20 5 0.11 2.52 0.03 7.76 0.44 992 
 
1l/GMP-122 20 <5 2.22 2.52 0.03 7.76 0.44 992 
 
1m/GMP-20 10 - 1.18 3.42 0.36 - 4.86 - 
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Compound structure and Number/Code 
Experimental In silico Calculated 
T. sol HPLC Sol. ChemDraw® StarDrop® ChemAxon® Yalkowsky  Delaney Wang  
 
2a/GMP-23 80 6.4 13.15 9.59 0.62 8.13 21.04 1970 
 
 
3a/GMP-24 20 <5 0.94 9.62 1.26 1.91 6.03 365 
 3j/GMP-25 20 <5 13.96 9.12 6.31 13.18 50.62 3479 
 
3b/GMP-28 20 <5 1.24 1.99 0.40 0.87 6.47 165 
 
3c/GMP-29 20 <5 4.99 6.96 7.08 12.30 18.11 2781 
 
2b/GMP-30 20 <5 7.94 1.80 0.85 - 14.88 - 
 
2c/GMP-31 20 17 7.96 15.74 1.00 0.74 11.85 157 
 
1n/GMP-32 20 <5 2.43 8.35 0.51 0.17 6.95 31 
 3d/GMP-33 20 <5 2.37 9.15 0.71 1.23 9.97 242 
 
3e/GMP-34 20 <5 2.02 8.18 0.79 2.09 10.20 428 
 
3f/GMP-35 20 <5 0.11 2.23 0.04 0.03 0.61 3.34 
 
3g/GMP-36 10 <5 0.71 2.82 1.70 12.02 23.56 3189 
 
1o/GMP-37 20 <5 0.76 7.61 0.47 2.29 4.50 417 
 
3h/GMP-38 10 <5 0.28 1.72 0.85 4.57 10.99 1090 
 
3k/GMP-43 20 <5 15.74 9.12 10.47 18.20 56.84 4901 
 
3l/GMP-44 20 <5 15.74 9.12 10.47 7.59 56.84 2043 
 3i/GMP-45 20 <5 4.65 10.72 93.32 125.89 292.93 45503 
 
1p/GMP-46 20 <5 2.15 11.48 1.58 2.09 4.47 415 
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Compound structure and Number/Code 
Experimental In silico Calculated 
T. sol HPLC Sol. ChemDraw® StarDrop® ChemAxon® Yalkowsky  Delaney Wang  
 
 3m/GMP-47 20 <5 2.12 14.09 2.34 2.75 5.66 582 
 3n/GMP-48 20 <5 3.43 11.67 1.95 0.26 12.79 56.03 
 3o/GMP-50 10 <5 1.03 5.00 0.23 0.30 4.00 51 
 
3p/GMP-52 20 <5 1.83 8.61 0.63 6.17 22.78 1541 
 
3q/GMP-53 20 <5 1.83 23.23 0.66 1.29 14.00 304 
 
3r/GMP-54 20 <5 1.82 25.76 1.41 13.49 32.90 3806 
 
3s/GMP-55 10 <5 0.18 1.78 0.03 0.06 1.17 8.61 
 
3t/GMP-56 20 - 76.38 10.72 18.20 - 57.70 - 
 
2d/GMP-57 20 21 29.79 8.17 2.00 3.63 41.42 926 
 
2e/GMP-58 20 <5 1.95 10.26 31.62 5.75 97.48 1709 
 3u/GMP-77 160 27 63.39 345.14 26.92 56.23 142.35 16837 
 
3v/GMP-87 5 - 0.50 - 0.54 93.33 - 15763 
 
3w/GMP-88 10 - 0.12 - 0.06 162.18 - 29142 
 
 4a/GMP-62 5 <5 0.05 0.28 0.02 0.008 0.45 1.13 
 
 
4b/GMP-66 5 <5 0.05 0.26 0.02 0.04 0.45 4.81 
 
4c/GMP-67 <5 <5 0.004 0.49 0.002 0.85 0.04 84.95 
 4d/GMP-68 5 <5 0.55 1.07 0.30 309 3.55 59687 
 4e/GMP-69 5 <5 0.04 0.60 0.01 6.92 0.28 873 
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Compound structure and Number/Code 
Experimental In silico Calculated 
T. sol HPLC Sol. ChemDraw® StarDrop® ChemAxon® Yalkowsky  Delaney Wang  
 
4f/GMP-70 <5 - 0.004 0.54 0.001 0.48 0.03 44.79 
 
4g/GMP-71 5 <5 0.98 1.47 0.12 0.22 3.23 41.17 
 
4h/GMP-72 5 <5 0.33 1.17 0.03 0.03 0.74 4.45 
 
4i/GMP-75 10 <5 0.05 0.26 0.02 0.03 0.45 3.82 
 
4j/GMP-76 5 5 0.05 0.26 0.02 0.03 0.45 4.10 
 4k/GMP-81 40 - 2.51 49.20 1.23 - 9.83 - 
 
4l/GMP-96 80 <5 0.03 0.58 0.10 2.46 1.65 477 
 
4m/GMP-97 40 <5 0.01 0.36 0.05 0.34 0.75 59.18 
 
4n/GMP-98 20 <5 0.03 1.09 0.02 0.16 0.81 29.14 
 
4o/GMP-99 10 <5 0.002 1.47 0.002 0.02 0.05 2.23 
 
4p/GMP-100 20 <5 0.25 2.74 0.13 - 2.15 - 
  
5a/GMP-120 5 <5 0.07 1.00 0.04 5.62 0.47 693 
  
5e/GMP-120E 5 <5 0.11 1.87 0.03 5.50 0.32 675 
 
 
5b/GMP-128 40 <5 0.19 11.25 0.54 9.33 26.24 2297 
 
5c/GMP-129 40 <5 24.95 9.47 0.05 1.17 2.44 207 
 5d/GMP-130 80 5 1.07 23.78 8.32 
338 205.82 116016 
aAll solubility values are in µM. T.sol: Turbidimetric solubility; HPLC Sol: solubility as determined by the HPLC-based DMSO “dry-down” method as 
described in the text. 
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5.2.4 In silico prediction of solubility 
 
Structural features of a compound have a bearing on the overall solubility profile of the 
molecule. Based on this, solubility can be predicted by establishing the contribution of 
different portions of the molecule to solubility.12 Utilising this information and by applying 
various algorithms, in silico solubility prediction can be performed. Several software have 
been developed in drug discovery for predicting physicochemical properties including 
solubility.13 In this thesis, ChemDraw®14, StarDrop™15 and ChemAxon®16 were utilised to 
predict solubility of the library set. All solubility values were converted into µM to allow for 
direct comparisons among the different solubility-determination approaches applied in this 
project (Table 5.1). 
5.2.6 Comparisons of solubility from the different approaches 
 
5.2.6.1 Experimental methods 
 
As can be seen in Table 5.1, there were evident disparities in the solubility values of the 
compounds across the range of solubility methods employed. Within the experimentally 
determined solubility category, solubility readings from the turbidimetric method were 
generally either comparable to or higher than those obtained from the HPLC-based DMSO 
“dry-down” approach. This trend is not surprising given the expected solubility-enhancement 
effects in the turbidimetric assay due to the co-solvent effects of DMSO in which the test 
compounds were initially dissolved.12 Nonetheless, turbidimetric solubility remained useful 
in providing estimated solubility and general overview of the ranking of compounds with 
respect to their solubility to facilitate analysis of structure-solubility relationships trends. 
Based on this method, most of the compounds displayed low solubility (≤20 µM).  
The removal of DMSO in the HPLC-based method, hence annulling the possible solubility- 
enhancement effects of the organic solvent, allows for a more accurate recapitulation of the 
inherent solubility of compounds in aqueous media. Most of the compounds displayed low 
solubility (< 5 µM) with only 2a/GMP-23 (6 µM), 2c/GMP-31 (17 µM), 2d/GMP-57 (21 µM) 
and 3u/GMP-77 (27 µM) displaying solubility above 5 µM. 
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5.2.6.2 Computational methods 
 
Computational models for predicting solubility depend of algorithms and compound training 
sets used to develop and validate them.17,18 Consequently, variations are expected in the 
solubility values as predicted from different platforms consistent with the diversity in the 
chemical spaces occupied by compounds utilised in developing the respective models. 
Comparing the three computational platforms evaluated in this project, higher solubility 
values were generally obtained with StarDrop® whereas ChemAxon® returned the lowest 
predicted solubility for most of the compounds (Figure 5.3). Notably, the general solubility 
trend held across the three software wherein the compounds predicted to have high and low 
solubility values were largely the same with few exceptions.  
 



























Solubility comparison across computational tools 
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5.2.6.3 General solubility equations 
 
As with computational tools, the solubility equations are based on algorithms such as linear 
regression models developed using variable compound data sets. Based on established 
relationships between various physicochemical properties and their influence on solubility, 
different parameters are accorded varying levels of significance in the algorithm. Thus, 
suitability of a solubility equation depends on the set of compounds used to develop, train 
and validate the model. Furthermore, the accuracy of the solubility values used in generating 
the models will also influence the performance of the solubility algorithms in predicting the 
solubility of a new data set of small molecules.9 
In comparing the three solubility equations explored in calculating solubility of target 
compounds, the model by Wang and co-workers consistently predicted higher solubility. The 
Yalkowsky equation generally produced the least predicted solubility, often comparing more 
closely with the values from Delaney than those from Wang and colleagues (Figure 5.4). 
In contrast to the other general solubility equations, the model proposed by Delaney obviates 
the need for experimental determination of physicochemical parameters. The descriptors 
included in the equation (Molecular weight, clogP, number of rotatable bonds and aromatic 
proportion) may be visualised as incorporating components that influence both the 
lipophilicity and melting point of a compound as contained in the other two solubility 
equations.  
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Figure 5.4: Calculated solubility from different general solubility equations. 
 
In applying solubility equations to assess solubility, the ionizability of a compound is generally 
ignored to simplify the calculation. This, in effect, may lead to the under prediction of the true 
solubility of ionisable compounds. Overall, however, despite discrepancies in absolute 
solubility values, there was a general trend towards a uniform solubility pattern that would 
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As described previously, lipophilicity and melting point are primary characteristics useful in 
estimating other secondary characteristics such as solubility. Besides experimental 
determination of logP, computational tools are frequently applied to establish lipophilicity of 
compounds.19–21 Furthermore, experimental parameters such as the retardation factor based 
on analytical Thin Layer Chromatography and the retention times on HPLC can be used as 
surrogates of hydrophobicity and polarity of compounds. For instance, using gradient HPLC, 
the lipophilicity of several compound sets has been determined.5,22,23 
For this assessment, the clogP was computed using ChemAxon®. Additionally, HPLC-based 
retention times and the retardation factor profile based on analytical TLC on silica adsorbed 
on alumina and using a uniform mobile phase were used to compare the hydrophobicity of 
the compound series (Table 5.2).  
The series demonstrated a wide range in their lipophilicity property (clogP=1.83 to 7.07) with 
most compounds having a clogP ≤ 5. Unsurprisingly, compounds incorporating heteroatoms 
in the side appendage (e.g., 3i/GMP-45) had lowered clogP. Similarly, incorporating sulfonyl 
linkages (such as in 4o/GMP-99) was observed to reduce lipophilicity over analogues that 
comprised methylene linkers (e.g. 4c/GMP-67). Moreover, SAR3 targets (5b/GMP-128, 
5c/GMP-129 and 5d/GMP-130) that incorporated an amide moiety instead of a nitrile, had 
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5.3.2 Melting point 
 
Other physicochemical properties were profiled for the compound series such as melting 
point. The melting point of molecules is dependent on the strength of intramolecular and 
intermolecular interactions with stronger forces requiring more energy to break up the solid 
lattice and thus higher melting points.24 The compound data set displayed generally high 
melting points with most compounds melting above 200 °C. 
Arising from the planar architecture imparted by the pyridobenzimidazole (PBI) core, these 
molecules can be envisaged as having potential for strong π-π interactions that would require 
more energy to break the crystal arrangement. Structural changes around the PBI appendages 
can be explored to disrupt this crystal packing and lower the melting point. For instance, 
introducing a methyl substitution on the nitrogen attached to the PBI core in 3j/GMP-25 (258 
֯C) and 3e/GMP-34 (240 ֯C) resulted in analogues 3c/GMP-29 (201 ֯C) and 1o/GMP-37 (190 ֯C), 
respectively, which have decreased melting points. The methyl substituents can potentially 
limit the stacking in the molecules by reducing the ability of these compounds to assume flat 
conformations (Figure 5.5).   
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Benzylamine analogues that differed from their aniline-type series counterparts only in 
having a methylene linker generally showed lower melting points. For example, in comparing 
the following pairs: 1a/GMP-06 (335 ֯ C) vs 3o/GMP-50 (258 ֯C) ; 1e/GMP-12 (331 ֯C) vs 
3e/GMP-34 (240 ֯C) ; 1f/GMP-13 (319 ֯C) vs 3a/GMP-24 (218 ֯C); 1g/GMP-15 (352 ֯C) vs 
3p/GMP-52 (270 ֯C) and 1n/GMP-32 (310 ֯C) vs 3d/GMP-33 (248 ֯C), all the benzylamine series 
displayed reduced melting points over their aniline series analogues. The benzylamine series 
are expected to display greater molecular flexibility compared to the aniline series 
compounds as depicted by the three-dimensional structures of 1a/GMP-06 and 3o/GMP-50 
in Figure 5.5. The methylene linker in benzylamine analogues, therefore, might contribute to 
disruption of planarity resulting in the observed decrease in melting point. 
Hydrophilic substituents on the aromatic side group produced compounds with high melting 
points (for example 3n/GMP-48, 345 ֯C) most likely due to the potential for intermolecular 
hydrogen bonding, requiring more energy to break apart. Regio-isomerism on the side group 
appendage appeared to influence the melting points as seen with 1j/GMP-19 (328 °C), 
1k/GMP-121 (287 °C) and 1l/GMP-122 (271°C). It may be hence conjectured that different 
regio-isomers assume varied crystal arrangements requiring different levels of energy to 
disrupt. Finally, 5a/GMP-120 and 5e/GMP-120E, the cyano-replacement analogues of 
1j/GMP-19 had much lower melting points possibly attributed to weaker intermolecular 
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5.4 Evaluation of target compounds for compliance with Lipinski’s guideline 
 
Physical and chemical characteristics of drugs can be used to estimate expected 
pharmacokinetic behaviour during in vivo studies. Primary physicochemical descriptors such 
as the size, topological polar surface area (tPSA), number of hydrogen-bond donors and 
acceptors and lipophilicity influence the overall physicochemistry and pharmacokinetics of a 
compound. Good oral absorption and bioavailability is expected for a compound that 
complies with Lipinski’s guidelines, based on predefined descriptors, as previously 
discussed.23,25,26  
Physicochemical attributes of compounds generated in this study were computed using 
ChemAxon® and output parameters compared with reference values advanced by Lipinski 
(Table 5.2). To follow is an assessment of compliance of the compound data set with the 
widely accepted medicinal chemistry criteria for good oral absorption.  
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Mw. logP HBD HBA HBA+HBD TPSA RB 
Lipinski 
Compliance 








1a/GMP-06 366.35 4.94 1 3 4 53.12 3 Yes 335 3.223 0.53 
 
1b/GMP-09 377.33 4.28 1 4 5 76.91 3 Yes >405 3.154 0.42 
 
1c/GMP-10 410.40 5.15 1 4 5 62.35 6 No 254 3.297 0.47 
 
1d/GMP-11 394.40 5.67 1 3 4 53.12 4 No 264 3.338 0.58 
 
1e/GMP-12 382.35 4.27 1 4 5 62.35 4 Yes 331 3.112 0.42 
 
1f/GMP-13 395.39 4.54 1 4 5 56.36 4 Yes 319 3.086 0.42 
 
1g/GMP-15 409.37 3.50 2 4 6 82.22 4 Yes 352 3.045 0.08 
 
1h/GMP-17 423.40 3.73 1 4 5 73.43 4 Yes 296 2.950 0.08 
 
1i/GMP-18 430.41 3.27 1 5 6 87.26 4 Yes 326 3.025 0.13 
 
1j/GMP-19 436.32 5.86 1 4 5 62.35 5 No 328 3.461 0.42 
 
1k/GMP-121 436.32 5.86 1 4 5 62.35 5 No 287 3.540 0.33 
 
1l/GMP-122 436.32 5.86 1 4 5 62.35 5 No 271 3.463 0.40 
 
1m/GMP-20 410.36 4.43 1 4 5 79.42 5 Yes - 3.267 0.34 
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Mw. logP HBD HBA HBA+HBD TPSA RB 
Lipinski 
Compliance 








2a/GMP-23 414.35 3.38 1 7 8 97.36 5 Yes 246 3.011 0.256 
 
3a/GMP-24 409.42 4.29 1 4 5 56.36 5 Yes 218 3.202 0.42 
 
3j/GMP-25 367.34 3.05 1 4 5 66.01 4 Yes 258 3.062 0.42 
 
3b/GMP-28 384.34 4.33 1 3 4 53.12 4 Yes 248 3.040 0.36 
 
3c/GMP-29 381.36 3.65 0 4 4 57.22 4 Yes 201 2.879 0.31 
 
2b/GMP-30 371.30 3.75 1 4 5 66.01 3 Yes ND 3.154 0.28 
 
2c/GMP-31 373.36 3.90 1 4 5 66.01 3 Yes 298 3.114 0.11 
 
1n/GMP-32 352.32 4.43 1 3 4 53.12 3 Yes 310 3.249 0.28 
 
3d/GMP-33 366.35 4.18 1 3 4 53.12 4 Yes 248 3.070 0.28 
 
3e/GMP-34 396.37 4.03 1 4 5 62.35 5 Yes 240 3.052 0.50 
 
3f/GMP-35 450.34 5.62 1 4 5 62.35 6 No 274 3.241 0.44 
 
3g/GMP-36 444.43 3.03 1 5 6 87.26 5 Yes 264 2.751 0.14 
 
1o/GMP-37 396.37 4.49 0 4 4 53.56 4 Yes 190 3.032 0.64 
 
3h/GMP-38 458.46 3.44 1 5 6 87.26 5 Yes 265 2.795 0.19 
 
 
3k/GMP-43 367.34 2.97 1 4 5 66.01 4 Yes 252 2.774 0.03 
 
3l/GMP-44 367.34 2.97 1 4 5 66.01 4 Yes 290 2.898 0.06 
 
3i/GMP-45 368.32 1.83 1 5 6 78.90 4 Yes 282 2.871 0.22 
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Mw. logP HBD HBA HBA+HBD TPSA RB 
Lipinski 
Compliance 







1p/GMP-46 451.45 4.15 1 5 6 65.59 5 Yes 228 2.927 0.06 
 3m/GMP-47 465.48 3.91 1 5 6 65.59 6 Yes 240 2.867 0.06 
 
3n/GMP-48 382.35 3.88 2 4 6 73.35 4 Yes 345 2.996  
 
3o/GMP-50 380.37 4.70 1 3 4 53.12 4 Yes 258 3.266 0.42 
 
3p/GMP-52 423.40 3.26 2 4 6 82.22 5 Yes 270 2.684 0.06 
 
3q/GMP-53 437.43 3.48 1 4 5 73.43 5 Yes 316 2.989 0.08 
 
3r/GMP-54 445.42 2.79 2 5 7 113.28 5 Yes 283 2.621 0.06 
 
3s/GMP-55 408.43 5.43 1 3 4 53.12 5 No 254 3.396 0.44 
 
3t/GMP-56 368.32 2.95 1 5 6 78.90 4 Yes - 3.089 0.32 
 
2d/GMP-57 354.30 3.18 1 5 6 78.90 3 Yes 301 3.050 0.22 
 
 
2e/GMP-58 354.30 2.59 1 5 6 78.90 3 Yes 340 3.187 0.22 
 3u/GMP-77 345.33 2.56 1 4 5 56.36 2 Yes 244 2.576 0.07 
 
3v/GMP-87 367.34 4.78 2 4 6 65.15 4 Yes 264 3.379 0.79 
 
3w/GMP-88 429.79 4.54 2 4 6 82.22 4 Yes 273 3.141 0.20 
  
4a/GMP-62 453.22 5.54 1 3 4 53.12 4 No 330 3.107 0.66 
 
 
4b/GMP-66 453.22 5.54 1 3 4 53.12 4 No 267 3.389 0.59 
 
4c/GMP-67 519.23 6.82 1 4 5 62.35 6 No 270 3.569 0.52 
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Mw. logP HBD HBA HBA+HBD TPSA RB 
Lipinski 
Compliance 







4d/GMP-68 436.22 4.26 1 4 5 66.01 4 Yes - 2.940 0.55 
 
4e/GMP-69 449.26 5.91 1 3 4 53.12 4 No - 3.153 0.55 
 
4f/GMP-70 505.20 7.07 1 4 5 62.35 5 No - 3.730 0.54 
 
4g/GMP-71 425.19 4.45 1 3 4 66.26 4 Yes 295 2.954 0.52 
 
4h/GMP-72 441.25 5.31 1 3 4 53.12 4 No 296 3.597 0.52 
 
4i/GMP-75 453.22 5.54 1 3 4 53.12 4 No 277 3.168 0.52 
 
4j/GMP-76 453.22 5.54 1 3 4 53.12 4 No 275 3.095 0.52 
 
 4k/GMP-81 414.21 3.77 1 4 5 56.36 2 Yes - 2.925 0.79 
 
4l/GMP-96 513.32 4.23 1 5 6 87.26 5 No 213 3.036 0.27 
 
4m/GMP-97 527.34 4.65 1 5 6 87.26 5 No 257 3.046 0.40 
 
4n/GMP-98 510.27 4.54 1 5 6 111.05 3 No >300 3.180 0.42 
 
4o/GMP-99 569.26 6.11 1 5 6 96.49 5 No 237 3.347 0.47 
 
4p/GMP-100 486.25 4.06 1 5 6 100.15 3 Yes - 3.098 0.38 
  
5a/GMP-120 411.31 6.00 1 3 4 38.56 5 No 266 3.254 0.33 
 
 
5e/GMP-120E 469.34 6.01 1 4 5 64.86 7 No 231 3.686 0.87 
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Mw. logP HBD HBA HBA+HBD TPSA RB 
Lipinski 
Compliance 








5b/GMP-128 402.35 3.32 2 3 5 72.42 5 Yes 246 2.942 0.24 
 
5c/GMP-129 468.36 4.61 2 4 6 81.65 7 Yes 225 3.013 0.26 
 
5d/GMP-130 385.35 2.04 2 4 6 85.31 5 Yes 218 2.640 0.21 
Reference values ≤500 ≤5 ≤5 ≤10 ≤12 ≤140 ≤10  
Mw. Molecular weight (g/mol); HBD: Hydrogen bond donor (NH/OH) count; HBA: Hydrogen bond acceptor (N/O) count; LogP: log of the partition co-efficient between n-
octanol and water; tPSA: topological polar surface area: all parameters were generated using ChemAxon® software. MP-melting point; HPLC retention times obtained 
according to the HPLC conditions described in the experimental section, Chapter 7; TLC retardation factor (Rf) as determined using 2%MeoH:DCM mobile phase. 
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Most compounds (68%) had all the considered physicochemical parameters agreeing with 
suggested guidelines for sufficient oral absorption and systemic exposure. Of the compounds 
with violations, 28% failed in only one parameter whereas 3% had two violations with no 
compound failing beyond two counts. Furthermore, the most violations were regarding 
lipophilicity (81%) and the remaining non-compliance attributed to molecular weight. 
Notably, there were more compounds that violated the Lipinski’s guidelines arising from SAR2 
modifications in which changes were performed on the LHS of the PBI scaffold by 
incorporating two halogen substitutions. This modification had the accompanying effect of 
increasing the overall molecular weight and lipophilicity of target compounds. 
Number of rotatable bonds, which is a measure of the flexibility of a compound and hence 
impacts solubility and membrane permeation, was generally ≤5 for this series.  With 7 
rotatable bonds apiece, 5e/GMP-120E and 5c/GMP-129, both SAR3 targets incorporating an 
ester and amide groups, respectively had the highest number for this descriptor. It is generally 
agreed that compounds with less than 10 rotatable are likely to be well absorbed.27  
The mean topological surface area, a measure of the total surfaces of polar atoms in a 
molecule, was 68.96±15.43Å2 with 3r/GMP-54 (113.28Å2), 4n/GMP-98 (111.05Å2) and 
4p/GMP-100 (100.15Å2) possessing the highest tPSA (≥100Å2) while 5a/GMP-120 (38.56Å2) 
had the lowest value for this property. Higher tPSA correlates with increased tendency for 
hydrophilic interactions due to the higher count of heavy atoms (N/O) capable of hydrogen 
bonding. Very low tPSA is consistent with highly lipophilic molecules for which hydrophobic 
interactions are predominant. All the studied compounds were compliant with the 
recommended tPSA range of between 75-140 Å2.28,29  
When considering the number of hydrogen bond donors and hydrogen bond acceptors, all 
target compounds were compliant with the considered criteria. Moreover, the sum of the 
two properties, preferred not to exceed 12, was also met by all the compounds with no 
exception. Having the right balance of HBD and HBA atoms in a molecule ensures the correct 
degree of polarity to facilitate interaction with aqueous media while at the same time 
imparting appropriate hydrophobicity to membrane permeation towards systemic 
exposure.30,31 
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 Interestingly, the two frontrunner compounds – 1j/GMP-19 and 4i/GMP-75 - which were 
characterised to possess potent in vitro antiplasmodial and antischistosomal activities as well 
as acceptable in vitro drug metabolism and pharmacokinetics profiles, failed to meet the 
lipophilicity criteria proposed by Lipinski. It is likely that had stringent adherence to the 
guideline been enforced, these target molecules, which also delivered the most promising in 
vivo efficacy outcomes, would have been filtered off and excluded from downstream assays. 
This observation affirms the caution with which the physicochemical characteristics should 
be treated in deciding compound progression in the discovery and development process since 
indiscriminate enforcement can cause de-prioritisation of otherwise promising target 
compounds.  
Moreover, other pharmacokinetic factors such as in vivo biotransformation to active 
analogues or transporter-mediated absorption need to be considered in view of their impact 
on bioavailability.32  There is a consensus that compounds beyond the rule of 5 are worth 
considering in drug development if they fulfil other critical criteria given the shift in protein 
targets against which small molecules are being developed. In the advent of the rule of 5, 
most pharmaceutical industry players focused on aminergic G-protein coupled receptors as 
drug targets for which the rule of 5 is largely applicable. Protein targets explored after the 
proposition of the rule of 5 have expanded and may necessitate revisiting the evaluation of 
physicochemical characteristics that are optimal, some of which may accommodate small 
molecules beyond the rule of 5.27,33,34  
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5.5 Correlation of physicochemical properties with biological activity 
 
At a molecular level, biological activity is a consequence of the interaction between the ligand 
(chemical matter) and the protein target such as a receptor. The protein-ligand binding can 
be mediated by hydrophobic and polar forces, which are influenced by the physicochemical 
properties of the ligand. Additionally, access to the biological target by the ligand following 
oral administration (or during in vitro whole cell screening), requires the compound to cross 
biological membranes, a process that demands optimum physicochemical characteristics.  
To evaluate the influence of the physicochemical properties of the target compounds on the 
observed biological activities, various correlations and comparisons were examined and 
ensuing trends noted as described in the following sections.  
 
5.5.1 Lipophilicity vs antiplasmodial activity 
 
Antiplasmodial activity was generally favoured when lipophilic electron-withdrawing groups 
were introduced into the appendages to the PBI core. Both lipophilic attributes at SAR1 and 
SAR2 correlated positively with improved antiplasmodial activity. It is plausible that lipophilic 
characteristics around these portions of the molecules offer beneficial interactions with 
putative targets in the parasite resulting in the observed antiparasitic activities. As can be 
seen in Figure 5.6, an increase in lipophilicity generally concurred with improved 
antiplasmodial potency. 
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Figure 5.6: Correlation plot of lipophilicity (clogP) vs PfNF54 potency expressed 
as -log IC50, µM (pIC50). 
 
5.5.2 Lipophilicity vs antischistosomal activity 
 
In contrast to the trends observed with antiplasmodial potency of these compounds, there 
were mixed effects of lipophilicity on the antischistosomal activities of these analogues. On 
one hand, like compounds with potent antiplasmodial activity, 1j/GMP-19 and 4i/GMP-75 
which have high lipophilicity, elicited potent antischistosomal activity. On the other hand, less 
lipophilic compounds such as 1b/GMP-09 and 1i/GMP-18 as well as those incorporating 
heteroaromatic groups such as 2a/GMP-23, 2b/GMP-30, 2c/GMP-31 and 2e/GMP-58 also 
maintained potent activity. Based on this observation, it may be presumed that there might 
be additional targets in Schistosomes with which the compounds may be interacting and for 
which a wider range of lipophilicity may be tolerated. As noted earlier in Chapter 4, an 
interesting observation is the restoration of activity among previously inactive analogues 
when lipophilic groups were introduced on the LHS of the PBI core. Figure 5.7 is a correlation 
plot for lipophilicity vs antischistosomal activity for the analysed set of compounds which, 
















Lipophilicity vs antiplasmodial potency (PfNF54)
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Figure 5.7: Plot of lipophilicity (clogP) vs adult S. mansoni potency expressed as    -
logIC50, µM (pIC50). 
 
5.5.3 Lipophilicity vs BHI activity 
 
The planar conformation and rigid tricyclic system present in the studied compounds offer 
favourable attributes for interaction with heme in the inhibition of the hemozoin formation 
process. Lipophilic π-π interactions between heme and recognized inhibitors of this 
biochemical pathway prompted the hypothesis that lipophilicity may be an important 
contributor to the observed BHI potency among some of the compounds. 
Overall, there was a mixed profile regarding lipophilicity and BHI activity for these compounds 
(Figure 5.8). Whereas lipophilicity would have been expected to impart better BHI profile, 
other compound-specific factors, including the overall geometry, may have compromised 
potential compound-haematin binding interactions thus rendering them poor inhibitors. 
Additionally, other interactions comprising hydrogen-bonding and electrostatic forces are 
















pIC50 adult S. mansoni
Lipophilicity vs antischistosomal activity (adult S. mansoni)
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5.5.4 Lipophilicity vs cytotoxicity 
 
Introducing modifications on the LHS of the PBI scaffold, leading to the generation of SAR2 
analogues, generally attenuated the selectivity of this series. This chemical change has an 
accompanying increase in lipophilicity due to the additional chlorine atoms in the molecule. 
High lipophilicity is generally associated with the propensity for indiscriminate binding to 
tissue proteins and other unintended targets, contributing to off-target toxicity.35–37 
Considering the analysed compounds, a weak correlation is portrayed between lipophilicity 
















Lipophilicity vs BHI potency
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It remains to be investigated whether this toxicity profile is restricted to the nature of 
substituents (halogens in this case) or is generally driven by lipophilicity. To address this 
uncertainty, less lipophilic substitutes for the halogens should be evaluated at this position or 
hydrophilic electron-rich groups explored to reduce the lipophilicity. Resulting target 
compounds should then be assessed for their cytotoxicity profiles for comparison with the 




Figure 5.9: Correlation plot of lipophilicity (clogP) vs mammalian cell toxicity (Log IC50, 
















Lipophilicity vs mammalian cell toxicity
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5.5.5 Lipophilicity vs metabolic stability and human intestinal absorption 
 
5.5.5.1 Lipophilicity vs metabolic stability 
 
In analysing the compounds data set, the more lipophilic drugs such as 1j/GMP-19 and 
4i/GMP-75 displayed particularly high metabolic stability whereas the more hydrophilic 
molecules with lower lipophilicity (2a/GMP-23, 2b/GMP-30, 2c/GMP-31, 2e/GMP-58, 
4l/GMP-96 and 4m/GMP-97) showed increased susceptibility to metabolism. This trend may 
be explained by the fact that the latter subset of compounds which showed decreased 
metabolic stability generally incorporate heteroatoms in their structures which increase the 
overall electron density in the molecules, a factor that has been implicated in enhanced 
metabolism by the CYP450 drug metabolising enzymes. Taken together, the data set 
displayed a positive correlation between lipophilicity and microsomal metabolic stability in 
HLM as depicted in Figure 5.9. Notably, this correlation is much weaker when considering 
MLM, probably highlighting species differences in metabolism of these compounds as 
mentioned previously. 
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Figure 5.10: Correlation plots of lipophilicity (clogP) vs metabolic stability 
expressed as percent compound after 30 minutes in: a) HLM, considering all 
compounds; b) HLM, with the exclusion of 2b/GMP-30 and 4n/GMP-98 and c) 
















% compound remaining (30 min, HLM)












%compound remaining (30 min, HLM)










%compound remaining (30 min, MLM)
c. clogP vs metabolic stability (MLM)
4n/GMP-98 
                        Chapter 5                                           Physicochemical Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                            Godfrey Mayoka PhD Thesis 2018                                                                          University of Cape Town 
251 
 
5.5.5.2 Human intestinal absorption 
 
Drug absorption is dependent on solubility and lipophilicity. Good solubility facilitates 
solubilisation of a drug prior to intestinal absorption, which is influenced by lipophilicity and 
size of the molecule. A poorly lipophilic drug will be unable to cross the lipid bilayer 
membrane whereas a highly lipophilic one may fail to efficiently traverse the hydrophilic 
interface. An optimal lipophilicity (clogP) of between 3 and 5 is generally deemed requisite 
for good oral absorption.  
This series displayed lipophilicity largely compliant with recommended range with positively 
predicted human intestinal absorption (Stardrop®) for all compounds except 2a/GMP-23. The 
pyrimidyl component of the side chain appendage, which contains two methoxy substituents 
likely contribute to this predicted poor intestinal absorption. Notably, 2a/GMP-23 failed to 
induce any in vivo efficacy when tested in the mouse model of schistosomiasis, despite having 
shown good in vitro potency; a fate likely attributable to poor absorption and systemic 
exposure following oral administration. A confirmatory investigation to this hypothesis would 
require performing pharmacokinetics studies on 2a/GMP-23 to establish its PK profile.    
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5.5.6 Ligand lipophilic efficiency of compound series 
 
The impact of lipophilicity on biological activity may be further investigated by determining 
the ligand lipophilicity efficiency (LLE). This matrix evaluates the effect of increasing 
lipophilicity on the observed potency and is calculated according to Equation 4 (Figure 5.11). 
The higher the LLE value, the better the compound interacts with the target protein over 
partitioning into an organic phase. A negative LLE is undesirable and generally implies the 
need for further potency and physicochemical optimisation to improve the profile of the 
compound.  For leads intended for oral drug administration, a LLE of 5 to 7 is considered 
suitable.38–40 
 
LLE=pIC50 - clogP………….4 
Figure 5.11: Ligand lipophilicity equation. LLE: ligand lipophilic efficiency; pIC50: -log IC50 
(Molar) (PfNF54 or adult S. Mansoni); clogP: calculated lipophilicity. 
 
This series generally produced compounds with low LLE, the best being 3j/GMP-25 with an 
LLE of only 2.03 in the antimalarial SAR and 2b/GMP-30 (LLE=2.12) in the antischistosomal 
SAR. For better pharmacokinetics outcomes, subsequent physicochemical optimisations 
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5.6 Interrelationships between physicochemical parameters 
 
Physicochemical parameters are often interdependent such that modulating one parameter 
can effectively lead to changes in the other property. Assessing this interdependence can 
enable determination of the parameter that exerts greater influence towards modifying 
another property.  
Based on the cassette of experimental and predicted physicochemical data of the studied 
compounds, correlations were analysed towards investigating which properties show 
interdependence and the nature of the correlation. Some of these relationships are presented 
in the following sections. 
 
5.6.1 Melting point vs lipophilicity and solubility 
 
Melting point values provide an indication of the strength of interactions within and between 
molecules of a compound. Molecules that experience strong hydrophobic forces, through for 
instance π-π stacking, are generally lipophilic. On the contrary, compounds capable of making 
hydrogen-bonding interactions, although may display high melting points, will have lower 
lipophilicity due to enhanced polarity.  
Since melting points may be suggestive of the crystallinity of a molecule on which solubility 
depends, some relationship may be expected between melting point and solubility. Highly 
crystalline compounds require higher solvation energies resulting in lower solubility. 
However, if the high melting points is due to strong polar forces, the compounds will display 
high solubility.    
In the library of compounds generated, there was neither a correlation between the melting 
point and lipophilicity nor between melting point and solubility (Figure 5.12). High melting 
points may arise from either an increase in the hydrophobic surface area or increased polarity 
in molecules, which facilitates hydrogen-bond interactions. This observation, therefore, 
implies that improvements in solubility or lipophilicity profile of molecules in this series 
cannot be realised by solely focussing on monitoring melting point patterns.  
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Figure 5.12: Correlation plots of melting point presented as Log melting point (֯C) 
vs (a) lipophilicity (clogP) and (b) solubility as predicted by ChemAxon® and 
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5.6.2 Lipophilicity vs solubility 
 
Whereas lipophilicity estimates the likelihood of a molecule to associate with an organic 
phase, solubility measures the amount of dissolved substance in aqueous media. In a given 
molecule, features that increase lipophilicity usually confer an opposing effect on solubility. 
Expectedly therefore, analysis of this compound set revealed an inverse correlation between 
the lipophilicity and solubility of the compounds (Figure 5.13). Thus, to achieve improved 
solubility among these compounds, medicinal chemistry strategies involving incorporation of 
water-solubilising features are vital. This approach is bound to decrease the lipophilicity of 
some of the compounds that flouted the Lipinski’s guidelines on this property and can 
potentially improve oral absorption during in vivo studies. 
 
 
Figure 5.13: Correlation plot between lipophilicity (clogP) and solubility as 
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5.6.3 Molecular weight vs solubility and lipophilicity 
 
Molecular weight is a measure of molecular size and volume. In general, an increase in 
molecular weight corresponds to additional surfaces for interaction with solvent. Most lead-
optimisation campaigns result in derivatives with higher molecular weight and accompanying 
increase in lipophilicity that decreases solubility of initial lead compounds.41  
This general trend is reflected in the current data set whereby solubility was inversely 
correlated with molecular weight whereas lipophilicity increased with increasing molecular 
weight (Figure 5.14). Moreover, the inverse relationship between molecular weight and 
solubility (R2=0.49) was stronger than the positive correlation between molecular weight and 
lipophilicity (R2=0.28).  Considering these findings, solubility improvements can be pursued 
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Figure 5.14: Correlation plots between molecular weight presented as Log 
Molecular weight (gmol-1) vs (a) solubility as predicted by ChemAxon® and 




































b. Molecular weight vs lipophilicity
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5.6.4. HPLC retention time and TLC retardation factor vs solubility and lipophilicity 
 
Experimental data from analytical measurements such as retention time on HPLC and 
retardation factor from TLC analysis can give insights into the relative polarity or 
hydrophobicity of a series of compounds. In the absence of more elaborate solubility or 
lipophilicity measurements, these primary parameters can be used to rank compounds when 
compared to a known standard as explored in chromatographic hydrophobicity index 
measurements.42–46  
The stationary phase employed in analytical TLC contains polar silanol groups which interact 
more strongly with polar compounds thus reducing the distance moved by such compounds 
when using a less polar mobile phase. The result is a lower retardation factor compared to 
that of a hydrophobic compound, which will partition better into the mobile phase than it 
does interact with the stationary phase. 
In contrast, reversed phase HPLC, as used in this project, engages a non-polar stationary phase 
and a polar mobile phase. Accordingly, non-polar compounds associate more strongly with 
the stationary phase and remain retained in the column for longer leading to longer retention 
times.  
There was an evident, albeit modest, direct relationship between TLC retardation factors and 
the HPLC retention times of the compounds as reflected in Figure 5.15. Furthermore, longer 
retention times were generally associated with lower solubility and higher lipophilicity while 
lower retardation factors were indicative of higher polarity within the compounds (Figure 
5.15).  
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Figure 5.15: Correlation plots between (a) TLC retardation factor vs HPLC 
retention time; (b) HPLC retention time vs solubility as predicted by 
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c. HPLC retention time vs lipophilicity
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5.7 Comparisons of physicochemical properties of project compounds with marketed 
drugs and drug discovery leads  
 
An analysis was performed with the aim of establishing similarities and differences in 
physicochemical profiles between the project compounds and clinically marketed drugs and 
leads in various stages of the drug discovery and development continuum. In this regard, the 
molecular descriptors: Molecular weight, clogP, HBD, HBA, tPSA and number of rotatable 
bonds were compared between the PBI project compounds and the approved drugs and 
discovery leads. For this assessment, a range of chemically diverse leads with reported sub-
micromolar in vitro antiplasmodial potency or in vivo efficacy based on antimalarial animal 
studies, were considered. For the selected antischistosomal leads, a lower adult S. mansoni 
in vitro potency criterion of ≤10 µM, which is a generally accepted cut-off for antischistosomal 
drug discovery, was chosen.  
When the PBIs (1) are compared against all the antischistosomal (2) and antimalarial agents 
(3) surveyed for this analysis, it was evident that the project compounds had a higher 
molecular weight and lipophilicity (Table 5.3). Besides, there were greater differences in the 
tPSA between the project compounds (1) and antischistosomal agents (2) than between 
project compounds (1) and antimalarial agents (3). Furthermore, the absolute mean values 
for hydrogen bond donors, hydrogen bond acceptors and number of rotatable bonds were 
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In addition to the overall comparison of physicochemical properties between PBIs (1) and the 
antimalarial (2) and antischistosomal (3) agents grouped together, further analysis was 
performed wherein the antimalarial agents were sub-classified according their chemical class 
or mechanism of action (categories 4 to 8) [Table 5.3]. This additional stratification of the 
compounds was intended to enable the determination of similarities or differences between 
the PBIs and those specific chemical classes. Based on the stratified comparison, PBIs (1) 
showed greater similarities in molecular weight with hemozoin inhibitors (4) and PI4K 
targeting agents (8). When considering lipophilicity, only the hemozoin inhibitors (4) 
approximated the average value observed for the PBIs (1) with much lower clogP values 
displayed by the other sub-classes [Table 5.3]. 
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Table 5.3: Physicochemical properties comparison between project compounds and drugs and leads in 




clogP HBD HBA tPSA nRB 







































Antimalarial leads and drugs stratified according to chemical class and mechanism of action 
(4) 










































































aParameters were determined using StarDrop® and values represent the mean (standard deviation) 
for each entry.  n is the number of compounds in each category. Abbreviations: clogP-calculated 
partition co-efficient between n-octanol and water; HBD-hydrogen bond donor count; HBA-hydrogen 
bond acceptor count; tPSA-topological polar surface area and nRB-number of rotatable bonds. ATP-
Adenosine triphosphate; PI4K-Phosphatidyl inositol-4-kinase. 
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To determine if the observed differences across the studied parameters were statistically 
significant, a Student’s t-Test was performed using Microsoft® excel.  The data for each set of 
pair being compared was treated as having unequal variance and the one-tailed distribution 
option applied.   
As can be seen in Table 5.4, there were statistically significant differences in various 
physicochemical properties between PBIs and the categories of antimalarial and 
antischistosomal agents. Regarding molecular weight, PBIs did not show a significant 
difference only with hemozoin and PI4K targeting agents. Notably also, the discrepancy in 
lipophilicity was statistically significant across all the categories, when compared to the PBIs. 
Other attributes such as tPSA and number of rotatable bonds also showed significant 
differences to varying degrees across the categories. Arising from these analyses, it can be 
conjectured that the PBIs potentially occupy a different chemical space from that of most 
standard antimalarial and antischistosomal drugs and leads in discovery and development. 
Table 5.4: Statistical significance comparisons of physicochemical properties of project compounds, 
antischistosomal and antimalarial leads and drug. 
  
 
Category/Property Mw clogP HBD HBA tPSA nRB 
A. PBIs vs antischistosomal 
drugs and leads 
0.029* 0.003** 0.007** 0.002** 0.005** 0.379 





0.401 0.239 0.393 
C. PBIs vs Hemozoin 
formation 
inhibitors 
0.137 0.027* 0.005** 0.090 0.042* 0.004** 
D. PBIs vs Artemisinin 
analogues 
0.033* 0.000*** 0.086 0.071 0.369 0.009** 
E. PBIs vs Antifolates 0.000*** 0.000*** 0.002** 0.209 0.021* 0.007** 
F. PBIs vs ATP targeting 
leads 
0.047* 0.015* 0.019* 0.238 0.236 0.078 
G. PBIs vs PI4K targeting 
leads 
0.386 0.000*** 0.116 0.047* 0.004** 0.290 
aDifference is significant at *p<0.05; **p<0.01 and ***p<0.001. Abbreviations: Mw-molecular weight; 
clogP-calculated partition co-efficient between n-octanol and water; HBD-hydrogen bond donor count; 
HBA-hydrogen bond acceptor count; tPSA-topological polar surface area and nRB-number of rotatable 
bonds. ATP-Adenosine triphosphate; PI4K-Phosphatidyl inositol-4-kinase. 
                        Chapter 5                                           Physicochemical Profiling of Pyrido [1,2-a] benzimidazoles 
 
 
                            Godfrey Mayoka PhD Thesis 2018                                                                          University of Cape Town 
264 
 
5.8 Chapter summary 
 
This chapter has described the physical and chemical profile of compounds generated in this 
thesis. Solubility values as determined by experimental and in silico methods although 
disparate, were consistent in their ability to guide structure-solubility relationship studies. 
Other structure-property relationships have been delineated as have the influence of 
physicochemical properties on biological activity. 
Lipophilicity emerges as a key factor driving compound potency as well as increases in cellular 
toxicity risk. Optimisation of lipophilicity together with solubility have been highlighted as 
being vital in improving oral drug-likeness of lead compounds.  
In comparison to widely recognised medicinal chemistry criteria predictive of good oral 
bioavailability, most of the compounds were found to be compliant. A further evaluation of 
physicochemical properties of project compounds in contrast to drugs and discovery leads or 
those under development reveal that there are potential divergent chemical spaces occupied 
by the PBIs. This observation makes the current series appealing as a new chemotype towards 
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Previous phenotypic whole cell screening against the human malaria parasite            
Plasmodium falciparum identified active hits embodying a pyridobenzimidazole (PBI) core, 
thereby inspiring the exploration of this chemotype as a potential antimalarial drug discovery 
scaffold. Ensuing structure-activity relationship studies produced active compounds mainly 
incorporating alkyl amine side chains and for which physicochemical liabilities were 
implicated in downstream in vivo assays. Further medicinal chemistry iterations, the focus of 
this thesis work, were launched via introduction of various substituents around the PBI core, 
as depicted in Figure 6.1, to extend the chemical diversity in this scaffold in search of suitable 
antimalarial leads.  
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Arising from this work, analogues with sub-micromolar potency against the asexual blood 
stage parasites of PfNF54 were identified and structure-activity relationship trends observed 
as summarised in Figure 6.2. Generally, as opposed to hydrophilic electron-donating moieties, 
lipophilic electron- withdrawing Craig plot substituents on appended aromatic side group 
resulted in potent antiplasmodial activity. Manipulations on the left hand-side, by 
incorporating halogen groups, improved activity.  
Additional assays revealed that these compounds retained activity against the multidrug-
resistant PfK1 strain, suggesting the unlikelihood of the compounds to show cross-resistance 
with drugs like chloroquine. Further evaluation against the liver and gametocyte stages of 
Plasmodium parasites revealed the multi-stage activity of these compounds and that most of 
the compounds displayed differential susceptibility to the late stage over early stage 
gametocytes.  
Subsequent profiling of in vitro potent analogues for in vitro drug metabolism and 
pharmacokinetics allowed for the delineation of structure-property trends wherein the left 
hand-side modification was found to reduce the selectivity profile as examined in Chinese 
Hamster Ovarian cell lines (Figure 6.2). Notably, these compounds have low cardiotoxicity risk 
potential as evaluated in the hERG potassium ion channel inhibition assay whereby all the 
tested compounds were projected to interact weakly with this protein target.  
Towards probing the mechanism of antiplasmodial action, prompted by the planar 
morphology, rich electron density and presence of protonatable sites, compounds were 
tested for their ability to inhibit the formation of beta haematin. Majority of the compounds 
were inactive in this assay with only few showing significant inhibition potency. Furthermore, 
there was no correlation between the beta haematin inhibition activity and the 
antiplasmodial activity of these compounds, suggesting different or additional antiparasitic 
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Figure 6.2: SAR summary of the asexual blood stage PfNF54 activities (IC50, µM) of target compounds. 
 
When subjected to in vivo antimalarial efficacy studies in a murine model of malaria, 1j/GMP-
19 and 4i/GMP-75, representing the two classes of compounds generated from the SAR 
iterations produced impressive 98% and 99.9% reduction in parasitaemia with mean survival 
times of 12 days and 14 days, respectively, compared to 6 days for the control, untreated 
animals. Pharmacokinetic studies revealed that systemic exposure was limited by the low 
solubility profiles of these compounds. 
In the context of drug repositioning, the pyridobenzimidazole scaffold was evaluated for its 
potential application in antischistosomal drug discovery. The targets produced in the 
antimalarial program were therefore tested in adult and larva stages of S. mansoni. Several 
compounds with potent sub-micromolar activity against adult worms were identified                
(Figure 6.3). Additionally, these compounds also displayed good activity against the immature 
worms, a profile which is critical to the disruption of the Schistosome life cycle by preventing 
formation of more adult worms, a feature lacking with praziquantel, the current sole 
treatment for human schistosomiasis. 
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Figure 6.3: SAR summary of the antischistosomal activities (IC50, µM) of target compounds. 
 
Concerning in vivo antischistosomal efficacy of these series, the best activities were observed 
with 1j/GMP-19, 4i/GMP-75 and 4j/GMP-76 which produced between 60% and 70% total 
worm reductions. Other targets produced lesser in vivo efficacy probably due to the 
metabolically labile heteroaromatic side groups. Metabolite identification studies pointed to 
dealkylation and hydroxylation as the major metabolic pathways for 2a/GMP-23 and 
2e/GMP-58, the targets incorporating a substituted pyrimidyl and pyrazinyl side groups, 
respectively. It may thus be inferred that the metabolites of 2a/GMP-23 and 2e/GMP-58 are 
inactive, unlike those of praziquantel, the current standard antischistosomal drug which 
although having poor metabolic stability, maintains in vivo potency.  
The observed overlap in the antimalarial and antischistosomal potency of these compounds 
as exemplified by 1j/GMP-19 and 4i/GMP-75 (Table 6.1) is interesting and lends support to 
the current practise of screening the database of antimalarial drugs or leads for 
antischistosomal activity. Besides the hemozoin formation pathway, there might be other 
unexplored molecular and biochemical pathways existent in the two parasites making drug 
repositioning a particularly appealing approach to expedite drug discovery for neglected 
tropical diseases such as schistosomiasis.  The possibility of targeting two diseases with one 
single small molecule has the potential to reduce treatment costs and simplify treatment 
regimens.  
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Examination of physicochemical properties for the series showed compliance of most 
compounds with the widely accepted medicinal chemistry criteria for leads with predicted 
good oral absorption and bioavailability. Moreover, the series could be differentiated in a 
range of physicochemical parameters when compared to marketed drugs or leads in 
discovery and development for malaria and schistosomiasis. This observation shows the 
potential for novelty regarding the chemical space occupied by PBIs. Solubility, however, 
emerged as a critical property requiring further optimisation towards improving in vivo 




Table 6.1: In vitro and in vivo antimalarial and antischistosomal profile of frontrunner compounds. 
 
  





P. falciparum K1: IC50, µM 
 
0.15 0.14 
Adult S. Mansoni: IC50, µM 0.21 0.38 
CHO, IC50, µM (SI) 17.58 (103) 4.31 (25) 
% Plasmodium parasitaemia 
reduction at 4x50mg/kg oral 
dose 
 
98.0 99.9  
Mean Survival Days 12 14 
Schistosome worm burden 
reduction (%) at a single oral 
dose of 400mg/kg  
62 69 
CHO: Chinese Hamster ovarian cell line.  
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Arising from analysis of structure-activity and structure-property trends, it is evident that the 
series displays an evolvable type of SAR with regards to both antimalarial and 
antischistosomal activities. Subtle changes to the compounds led to the generation of a library 
of compounds with a wide spectrum of differences in biological activity and a range in 
physicochemical attributes, an appealing characteristic for a drug discovery chemotype. For 
this scaffold, it is possible to modulate toxicity and other physicochemical attributes while 




In conclusion, the work pursued in this thesis has contributed to the further understanding of 
the structural features compatible with antimalarial activities of 3-trifluoromethyl N-aryl-
substituted pyrido [1,2-a] benzimidazoles. Moreover, in demonstrating the utility of drug 
repositioning as a drug discovery strategy, the antischistosomal potency of this series of 
compounds has been unravelled and accompanying SAR trends elucidated. The two lead 
compounds 1j/GMP-19 and 4i/GMP-75 identified from this research are worth of further 
investigations as promising antimalarial and antischistosomal leads possessing multi-stage 
antiparasitic activity. Given the spectrum of their activities, the two compounds, if adequately 
optimised, bear the potential to contribute to malaria chemoprevention and blocking 
transmission. Furthermore, the susceptibility of the larval stages of schistosomes further 
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6.3 Directions for future work 
 
Arising from the structure-activity and structure-property relationship trends uncovered in 
this thesis, some directions for future work emerge. Based on diminished selectivity upon 
introduction of chloro atoms on the left-hand side of the PBI core, further medicinal chemistry 
iterations using chloro isosteric groups, such as the less lipophilic fluoro, should be explored. 
Towards improving solubility, incorporating substituents with hydrogen-bonding capacity or 
those with reduced lipophilicity compared to those used in the frontrunner compounds 
should be investigated as represented in (Figure 6.4). Other solubility-enhancing approaches 
including formulation strategies and supramolecular derivation are also worth pursuing as 
they have the potential to improve the pharmacokinetic profile and oral efficacy of these 
compounds. 
To ascertain the gametocytocidal potency of the compounds found active in this assay, the 
membrane feeding assay, considered to be the gold-standard of this investigation, should be 
explored. Moreover, a wider panel of Plasmodium parasite strains need to be tested to 
establish the spectrum of antiplasmodial activity of this series of compounds across various 
strains. Additional tests regarding resistance potential towards these compounds through, for 
example, mutant generation, will provide information on any similarities or differences in the 
mechanisms compared to that found with standard antimalarial drugs. Chemogenomic and 
proteomic analysis are also recommended to establish the potential targets and 
mechanism(s) of action for these compounds. 
That the frontrunner compounds elicited impressive antimalarial efficacy in a mouse model 
despite low bioavailability inspire interest in studying their tissue distribution profile. Finally, 
given the potential novelty of the chemical space occupied by these compounds, drug hybrid 
strategies through chemically linking the PBIs with other antimalarial drugs comprising 
different scaffolds such as the quinolines, should be investigated. In combining with other 
recognised antimalarial chemotypes, synergy in antimalarial action and delayed emergence 
of resistance are potential benefits of this approach.  
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7.1 Chapter overview 
 
This chapter will provide additional information regarding the materials, methods and 
experimental procedures followed in this thesis. Firstly, the chemistry information will be 
described regarding general instrumentation and equipment used. This will then be followed 
by the synthesis and characterization of intermediate and target compounds. Thereafter, 
materials and methods used in the biological assays will be described together with in vitro 
ADME procedures and those for in vivo efficacy and pharmacokinetics studies. Finally, the 




7.2.1 General information 
 
Chemical reagents and analytical grade solvents used for reactions were purchased from 
either Sigma- Aldrich (South Africa) or Combi Blocks Limited (USA). Other solvents, such as 
methanol, dichloromethane, hexane and ethylacetate, were sourced from Kimix Chemicals 
(South Africa). Compounds were purified by either recrystallisation, trituration or by applying 
column chromatography. Column chromatography was performed on silica gel 60 (Fluka), 
particle size = 0.063−0.2 mm (70−230 mesh) as the stationary phase with appropriately 
optimised mobile phase. Identity and characterization of intermediates and target 
compounds was done by NMR and LC-MS, supplemented by TLC analysis using appropriate 
combinations of solvents as the mobile phase and silica adsorbed on alumina (Merck or 
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NMR spectra were recorded on either a Varian Mercury-300 (1H 300.1 MHz, 13C 75.5 MHz) or 
a Bruker-400 (1H 400.2 MHz, 13C 100.6 MHz) instrument using DMSO-d6 or methanol-d4 as 
solvent. The multiplicity of 1H NMR peaks is reported as either: s, singlet; bs, broad singlet; d, 
doublet; t, triplets; dd, doublet of doublets; dt, doublet of triplets; td, triplet of doublets; ddd, 
doublet of doublet of doublets or m, multiplets with the chemical shifts (in parts per million, 
ppm) and coupling constants (J in Hertz, Hz) recorded to three and two significant figures, 
respectively. Protons represented by the reported chemical shifts are indicated by a 
superscript integer corresponding to the numbering of protons in the chemical structure. 
Signals from 13C NMR were obtained in the decoupled mode and chemical shifts are listed 
without assigning them to carbons in the structure as is conventional with most international 
medicinal chemistry journals. 
The liquid chromatograph coupled to a mass spectrometer (LC-MS) system comprised an 
Agilent 1260 Infinity binary pump, an Agilent 1260 Infinity diode array detector, an Agilent 
1290 Infinity column compartment, an Agilent 1260 Infinity standard autosampler and an 
Agilent 6120 quadrupole (single) mass spectrometer. The MS component was equipped with 
two ionisation techniques functioning via atmospheric pressure chemical ionisation (APCI) 
and electron-spray ionisation (ESI) of test compounds either in the positive or negative 
modes. In the positive ionisation mode, a pseudo-molecular ion corresponding to the (M+1) 
of the exact mass of the compound was obtained whereas a mass-to-charge (m/z) ratio peak 
corresponding to (M-1) was generated in the negative ionisation mode.   
Sample purities were established by considering the peak area on LC corresponding to sample 
peak (as informed by the m/z ion on MS) relative to the total of all peak areas and expressed 
as a percentage. The column used for sample elution was a Kinetex Core C18 2.6 μm column 
(30 mm × 2.1 mm) with a gradient mobile phase consisting of two solvent systems employed 
(Table 7.1). Mobile phase A consisted of 0.4% acetic acid in 10 mM ammonium acetate in 
HPLC grade (type 1) water while mobile phase B contained 0.4% acetic acid, 10 mM 
ammonium acetate in a 9:1 ratio of HPLC grade methanol, and type 1 water. A flow rate of 
0.7 mL/min and injection volume of 2 µL were applied and samples detected by means of a 
diode array detector using UV-absorbance over a 210-640 nm wavelength range. 
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Table 7.1: HPLC gradient conditions for analysis of compounds. 
Time (min) % A % B 
0.00 85 15 
0.30 85 15 
1.20 0.0 100 
4.50 0.0 100 
A: 10 mM NH4OAc in buffer (0.4% acetic acid); 
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7.2.2 Synthesis and characterisation 
 
7.2.2.1 SAR1 intermediates  
 
a) 1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile: IIIa 
2-(1H-benzo[d]imidazol-2-yl) acetonitrile IIa (1.0 equiv.), ethyl 4,4,4-trifluoro-3-oxobutanoate (1.2 
equiv.) and ammonium acetate (2 equiv.) were stirred at 145°C for 2 hours. Reaction was 
monitored using TLC and LC-MS. Reaction mixture was cooled to 70°C, acetonitrile added while 
stirring for a further 10 minutes. After cooling to room temperature, the mixture was filtered, 
residue washed with acetonitrile and the product left to dry and used in subsequent step without 
further purification. 
 
Obtained as a light yellow powder (66%); Rf (EtOAc:Hexane, 7:3) 0.8; 1H 
NMR (400 MHz, DMSO) δ 14.10 (bs, 1H, H6), 8.60 (d, J = 8.2 Hz, 1H, H1), 
7.71 – 7.56 (m, 2H, H3, 4), 7.46 (ddd, J = 8.6, 6.8, 1.8 Hz, 1H, H2), 6.43 (s, 
1H, H5); 13C NMR (101 MHz, DMSO) δ 158.05, 148.14, 138.59, 132.21, 
127.46, 123.92, 123.48, 121.36, 116.71, 114.62, 112.24, 103.27, 64.56. 
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b) 1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile: IVa  
Phosphoryl oxychloride (POCl3; 20 equiv.) was added to 1-hydroxy-3-(trifluoromethyl) 
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile IIIa (1 equiv.) and stirred at 130°C for 3 hours. 
Excess POCl3 was removed under reduced pressure. On cooling to room temperature, ice cold 
water was added with consistent stirring for 15 minutes. The mixture was neutralized using 
sodium carbonate, the crude product filtered off, washed with water, dried at ambient 
conditions and used subsequently without further purification. 
 
Obtained as tan brown (91%); Rf (EtoAc:Hexane, 3:7) 0.5; 1H NMR (300 
MHz, DMSO) δ 8.74 (d, J = 8.6 Hz, 1H, H1), 8.08 (d, J = 8.3 Hz, 1H, H4), 7.81 
– 7.71 (m, 2H, H3,5), 7.65 – 7.56 (m, 1H, H2); 13C NMR (101 MHz, DMSO) 
δ 158.10, 147.99, 138.63, 132.31, 127.83, 123.93, 123.57, 121.09, 
116.77, 114.60, 112.19, 103.32, 64.50. MS (EI+) m/z calcd for 
C13H5CIF3N3:295.01; found, 296.00 (M + 1). 
 
7.2.2.2 SAR2 intermediates  
 
  a) General procedure for the synthesis of IIb and IIc 
 
DMF (4 ml) was added to a mixture of the appropriately substituted diaminobenzene (1 equiv.) 
and ethyl cyanoacetate (3 equiv.). The reaction mixture was stirred and heated at 160  ̊C for 2 
hours, cooled to room temperature and extracted using ethyl acetate. The organic layer was 
washed with 5% LiCl (5 x), distilled water (4 x), brine (5 x) and dried over MgSO4. Organic solvent 
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2-(5, 7-dichloro-1H-benzo[d]imidazol-2-yl) acetonitrile: IIb  
 
Obtained from 3,5-dichlorobenzene-1,2-diamine Ia and ethylcyano 
acetate as a brown solid (61%); Rf (EtOAc:Hexane, 1:1) 0.3;  1H NMR 
(300 MHz, DMSO-d6) δ 7.63 (d, J = 1.8 Hz, 1H, H2), 7.39 (d, J = 1.8 
Hz, 1H, H1), 4.43 (s, 2H, H3). 13C NMR (101 MHz, DMSO) δ 147.89 
(2C), 127.27, 122.11 (2C), 116.53, 113.57, 55.30, 18.84. MS (EI+) 





Obtained from 4,5-dichlorobenzene-1,2-diamine Ib and 
ethylcyano acetate as a brown solid (76%); Rf (EtOAc:Hexane, 1:1) 
0.33; 1H NMR (300 MHz, DMSO-d6) δ 12.90 (s, 1H, H4), 7.83 (s, 2H, 
H1, 2), 4.41 (s, 2H, H3). 13C NMR (101 MHz, DMSO) δ 162.19, 148.31 
(2C), 143.29, 127.18, 116.57 (2C), 116.13, 26.63. MS (EI+) m/z 
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b) General procedure for the synthesis of hydroxyl intermediates 
 
The appropriately substituted benzimidazole acetonitrile (1 equiv.), ethyl 4,4,4-trifluoro-3-
oxobutanoate (1.2 equiv.) and ammonium acetate (2 equiv.) were stirred at 145°C for 2 
hours. Reaction was monitored using TLC and LCMS. Reaction mixture was cooled to 70°C, 
acetonitrile added while stirring for a further 10 minutes. After cooling to room temperature, 
the mixture was filtered, residue washed with acetonitrile and the product left to dry and 






Obtained from IIb as a grey solid (28%); Rf (EtOAc:Hexane, 7:3) 
0.18;  1H NMR (300 MHz, DMSO-d6) δ 8.48 (d, J = 2.0 Hz, 1H, H2), 
7.57 (d, J = 2.0 Hz, 1H, H1), 5.93 (s, 1H, H3). 13C NMR (101 MHz, 
DMSO) δ 159.70, 153.00, 139.36, 131.27, 129.32, 127.54, 
124.70, 123.47, 120.66, 117.43, 116.91, 114.45, 95.59. MS (EI-) 




Obtained from IIc as a grey powder (49%); Rf (EtOAc:Hexane, 
3:2) 0.31; 1H NMR (300 MHz, DMSO-d6) δ 8.64 (s, 1H, H2), 7.83 
(s, 1H, H1), 5.85 (s, 1H, H3). 13C NMR (101 MHz, DMSO) δ 
172.53, 169.51, 159.85, 154.00, 144.91, 129.71, 127.43, 
124.22, 120.92, 117.79, 117.22, 116.56, 94.50. MS (EI-) m/z 
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c) General procedure for the synthesis of chloro intermediates  
 
Phosphoryl oxychloride (POCl3; 20 equiv.) was added to the appropriately substituted 
hydroxyl intermediate (1 equiv.) and stirred at 130°C for 3 hours. Excess POCl3 was removed 
under reduced pressure. On cooling to room temperature, ice cold water was added with 
consistent stirring for 15 minutes. The mixture was neutralized using sodium carbonate, the 
crude product filtered off, washed with water and dried at ambient conditions and used 




Obtained from IIIb as a red-brown solid (63%); Rf 
(EtOAc:Hexane, 7:3) 0.56;     1H NMR (300 MHz, DMSO-d6) δ 
8.77 (d, J = 1.7 Hz, 1H, H2), 8.05 (d, J = 1.6 Hz, 1H, H1), 7.94 (s, 
1H, H3); 13C NMR (101 MHz, DMSO) δ 174.79, 158.66, 150.55, 
144.16, 139.79, 133.58, 130.44, 126.23 (2C), 121.26, 115.13 
(2C), 100.59.  MS (EI+) m/z calcd for C13H3Cl3F3N3:362.93; 





Obtained from IIIc as a red solid (94%); Rf: (EtOAc:Hexane, 9:1) 
0.53; 1H NMR (300 MHz, DMSO-d6) δ 8.86 (s, 1H, H2), 8.36 (s, 
1H, H1), 7.86 (s, 1H,H3); 13C NMR (101 MHz, DMSO) δ 158.25, 
150.17, 139.16, 132.68, 129.49, 127.76, 124.34, 120.29, 117.42 
(2C), 114.55, 112.77, 101.70. MS (EI-) m/z calcd for 
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7.2.2.3 SAR3 intermediates  
 
a) Methyl 1-hydroxy-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate:IIId  
 
Synthesised using methyl 2-(1H-benzo[d]imidazol-2-yl)acetate IId according to the method 
described in 7.2.2.1a and used subsequently without further purification. 
 
Obtained as a light yellow powder (27%); Rf (EtOAc:Hexane, 2:3) 0.38; 
1H NMR (300 MHz, DMSO-d6) δ 8.64 (d, J = 8.0 Hz, 1H, H1), 7.77 (d, J = 
8.1 Hz, 1H, H4), 7.58 (td, J = 8.4, 7.9, 1.2 Hz, 1H, H3), 7.41 (td, J = 7.9, 
1.2 Hz, 1H, H2), 6.40 (s, 1H, H6), 3.90 (s, 3H, H5). 13C NMR (101 MHz, 
DMSO) δ 163.86, 158.49, 146.50, 137.93, 132.47, 127.51, 123.15, 
121.81, 117.09, 116.75, 112.78, 111.53, 104.09, 52.35. MS (EI-) m/z 
calcd for C14H9F3N2O3:310.06; found, 309.00(M-1).  
 
 
b) Methyl 1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate:IVd 
 
 
Synthesised from IIId according to procedure described in 7.2.2.1b and 
obtained as light yellow powder (90%); Rf (EtoAc:Hexane, 3:7) 0.63; 1H NMR 
(400 MHz, DMSO-d6) δ 8.65 (dt, J = 8.2, 1.0 Hz, 1H, H1), 7.77 (dt, J = 8.1, 1.0 
Hz, 1H, H4), 7.62 – 7.55 (m, 1H, H3), 7.42 (ddd, J = 8.4, 7.4, 1.1 Hz, 1H, H2), 
6.40 (s, 1H, H6), 3.90 (s, 3H, H5). 13C NMR (101 MHz, DMSO) δ 164.01, 
145.13, 133.01, 129.64, 127.55, 126.14, 125.80, 123.98, 123.60, 120.61, 
116.45, 106.87, 106.83, 54.09.  MS (EI+) m/z calcd for C14H8ClF3N2O2:328.02; 
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c) 1-chloro-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carboxamide: VI 
Synthesised by reacting IVa with conc. Sulfuric acid (60 equiv.) at 85 °C with stirring for 2 hours. The 
reaction mixture was cooled and slowly added to ice-cold water while stirring. The precipitate that 
formed was filtered and dried at 50 °C in the oven and used without further purifications.  
 
Obtained as light grey powder (89%); Rf (2% MeoH/DCM) 0.14 
1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 8.6 Hz, 1H, H1), 8.14 (s, 1H, H5), 
8.03 (d, J = 8.2 Hz, 1H, H4), 8.00 (s, 1H, H5), 7.70 (ddd, J = 8.2, 7.1, 1.0 Hz, 1H, 
H3), 7.56 (ddd, J = 8.4, 7.2, 1.1 Hz, 1H, H2), 7.51 (s, 1H, H6). 13C NMR (101 
MHz, DMSO) δ 164.27, 146.13, 145.05, 130.80, 129.50, 127.33, 126.10, 
124.93, 124.30, 123.40, 120.62, 116.28, 107.19. MS (EI+) m/z calcd for 
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7.2.2.4 General procedures for the synthesis of target compounds  
 
Target compounds were accessed via either of the two methods described hereafter. In the 
first instance, a nucleophilic substitution reaction, under microwave irradiation, was carried 
out using the elected amine and the appropriate chloro intermediate.  In the second method, 
catalyst-mediated Buchwald-Hartwig reaction conditions were employed. 
 
a) Nucleophilic substitution under microwave irradiation 
 
The appropriate amine was added to a stirred mixture of the chloro intermediate 
(1.015mmol, 1 equiv.), triethylamine (2.03mmol, 2 equiv.) and tetrahydrofuran (THF) (4mL) 
and subjected to microwave irradiation at 150W, 80°C for 20-40 minutes. The cooled reaction 
mixture was transferred to a round bottom flask and concentrated. Minimum amount of 
either acetone or ethanol was added to precipitate the final product which was filtered off 
and dried. If further purification was needed, recrystallization in ethanol or column 
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1-(p-tolylamino)-3-(trifluoromethyl) benzo [4,5] imidazo [1,2-a]pyridine-4-carbonitrile: 
1a/GMP-06. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using p-
toluidine (0.218g, 2.03mmol, 2 equiv.) as a yellow fluffy 
powder (38%). 1H NMR (400 MHz, DMSO) δ 8.77 (d, J = 8.3 Hz, 
1H, H1), 7.74 (d, J = 7.9 Hz, 1H, H4), 7.60 (t, J = 7.7 Hz, 1H, H3), 
7.49 – 7.34 (m, 1H, H2), 7.26 (d, J = 8.0 Hz, 2H, H7), 7.09 (d, J = 
6.2 Hz, 2H, H8), 6.25 (s, 1H, H5), 2.35 (s, 3H, H9). 13C NMR (151 
MHz, DMSO) δ 148.42, 147.89, 135.37, 134,52, 131.42, 
128.71, 127.33, 125.04 (2C), 124.03, 123.13, 121.97 (2C), 
121.30, 119.62, 117.83, 114.91, 112.47, 96.91, 20.94. MS (EI+) 
m/z calcd for C20H13F3N4:366.11; found, 367.10 (M + 1). HPLC 
purity: 99%. 
 




Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
propoxyaniline (0.46g, 3.045mmol, 3 equiv.) as a light green 
powder (56%). 1H NMR (400 MHz, DMSO) δ 8.77 (d, J = 8.3 
Hz, 1H, H1), 7.78 (d, J = 7.2 Hz, 1H, H4), 7.61 (t, J = 7.7 Hz, 1H, 
H3), 7.43 (t, J = 7.8 Hz, 1H, H2), 7.18 (s, 2H, H7), 7.04 (d, J = 8.7 
Hz, 2H, H8), 6.21 (s, 1H, H5), 3.99 (t, J = 6.5 Hz, 2H, H9), 1.85 
– 1.70 (m, 2H, H10), 1.02 (t, J = 7.4 Hz, 3H, H11). 13C NMR (151 
MHz, DMSO) δ 148.38, 144.85, 142.84, 138.92, 132.78, 
128.71, 126.86, 123.64, 122.56, 121.82 (2C), 119.92, 117.18, 
116.21 (2C), 114.92, 112.36, 110.64, 94.78, 69.98, 22.57, 
10.75. MS (EI+) m/z calcd for C22H17F3N4O:410.14; found, 
411.10 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-
isopropylaniline (0.412g, 3.045mmol, 3 equiv.), 
triethylamine (0.205g (0.28ml); 2.03mmol, 2Eq) as a yellow 
powder (23%); m.p. 262-266 °C; Rf (MeOH: DCM, 0.5:9.5) 
0.53; 1H NMR (400 MHz, DMSO) δ 8.78 (d, J = 7.9 Hz, 1H, H1), 
7.75 (d, J = 11.3 Hz, 1H, H4), 7.60 (t, J = 7.6 Hz, 1H, H3), 7.42 
(t, J = 7.8 Hz, 1H, H2), 7.33 (d, J = 8.1 Hz, 2H, H7), 7.13 (s, 2H, 
H8), 6.28 (s, 1H, H5), 3.01 – 2.89 (m, 1H, H9), 1.27 (d, J = 6.9 
Hz, 6H, H10); 13C NMR (151 MHz, DMSO) δ 148.60, 145.17, 
137.56, 135.40, 134.84, 133.92, 131.78. 129.34, 128.77, 
127.87, 127.13, 125.40, 123.65, 122.58 (2C), 121.78, 117.16 
(2C), 114.98, 33.58, 24.41 (2C). MS (EI+) m/z calcd for 
C22H17F3N4:394.14; found, 395.10 (M + 1). HPLC purity: 99%.  
  




Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
isopropylaniline (0.375g, 3.045mmol, 3 equiv.) as a light green 
powder (51%).  1H NMR (400 MHz, DMSO) δ 8.78 (d, J = 7.3 Hz, 1H, 
H1), 8.35 (d, J = 8.4 Hz, 1H, H4), 7.61 (t, J = 7.6 Hz, 1H, H3), 7.44 (t, J 
= 7.9 Hz, 1H, H2), 7.19 (d, J = 8.6 Hz, 2H, H7), 7.05 (d, J = 8.4 Hz, 2H, 
H8), 6.18 (s, 1H, H5), 3.80 (s, 3H, H9). 13C NMR (101 MHz, DMSO) δ 
157.43, 149.23, 148.60, 134.78, 128.72, 127.09, 126.83, 124.89 
(2C), 124.10, 122.41, 121.38, 118.71, 117.17, 115.60 (2C), 114.89, 
112.82, 88.74, 55.92. MS (EI+) m/z calcd for C20H13F3N4O:382.10; 
found, 383.10 (M + 1). HPLC purity: 96%. 
                           Chapter 7                                                                                                  Experimental Information  
 
 




4- carbonitrile 1f/GMP-13.   
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using N1,N1- 
dimethylbenzene-1,4-diamine (0.415g, 3.045mmol, 3 equiv.) 
as a dark green powder (51%). 1H NMR (300 MHz, DMSO) δ 
8.75 (d, J = 8.4 Hz, 1H, H1), 7.82 (d, J = 7.4 Hz, 1H, H4), 7.61 (t, 
J = 7.6 Hz, 1H, H3), 7.43 (t, J = 7.9 Hz, 1H, H2), 7.18 (d, J = 7.3 
Hz, 2H, H7), 6.84 (d, J = 8.6 Hz, 2H, H8), 6.15 (s, 1H, H5), 2.95 
(s, 6H, H9). 13C NMR (101 MHz, DMSO) δ 150.01, 149.05, 
148.88, 141.89, 135.92, 132.68, 128.73, 126.99 (2C), 125.91, 
121.92, 121.35 (2C), 118.86, 117.94, 116.82, 115.32, 113.65, 
96.72, 46.58 (2C). MS (EI+) m/z calcd for C21H16F3N5:395.14; 
found, 396.10 (M + 1). HPLC purity: 96%. 
 
4-((4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)amino)-N-
methylbenzamide  1g/GMP-15. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-amino- 
N-methylbenzamide (0.458g, 3.045mmol, 3 equiv.), 
triethylamine (0.205g (0.28ml); 2.03mmol, 2 equiv.) as a light 
yellow fluffy powder (13%). 1H NMR (400 MHz, DMSO) δ 8.81 
(d, J = 8.2 Hz, 1H, H1), 8.16 (d, J = 4.2 Hz, 1H, H9), 7.90 (d, J = 
8.6 Hz, 2H, H7), 7.70 (d, J = 8.1 Hz, 1H, H4), 7.63 – 7.57 (m, 1H, 
H3), 7.46 – 7.40 (m, 1H, H2), 7.15 (d, J = 8.0 Hz, 2H, H8), 6.28 (s, 
1H, H5), 2.83 (d, J = 4.5 Hz, 3H, H10). 13C NMR (151 MHz, DMSO) 
δ 166.84, 148.54, 148.08, 138.26, 134.98, 130.36, 129.19 (2C), 
128.77, 127.24, 125.44, 123.63, 122.97, 121.68 (2C), 117.61 
(2C), 115.05, 113.39, 95.97, 26.35. MS (EI+) m/z calcd for 
C21H14F3N5O:409.12; found, 410.10 (M + 1). HPLC purity: 98%. 
 
                           Chapter 7                                                                                                  Experimental Information  
 
 




a]pyridine-4- carbonitrile 1j/GMP-19. 
 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(trifluoromethoxy)aniline (0.36g, 2.03mmol, 2 equiv.) as a 
light green fluffy powder (16%). 1H NMR (400 MHz, DMSO) δ 
8.82 (d, J = 8.1 Hz, 1H, H1), 7.69 (d, J = 8.0 Hz, 1H, H4), 7.64 – 
7.54 (m, 1H, H3), 7.46 – 7.42 (m, 1H, H2), 7.39 (d, J = 8.3 Hz, 
2H, H7), 7.20 (d, J = 8.4 Hz, 2H, H8), 6.24 (s, 1H, H5). 13C NMR 
(151 MHz, DMSO) δ 148.53, 144.88, 135.23, 128.91, 127.21, 
125.36, 123.71, 122.92, 122.71 (2C), 121.81, 121.58, 120.05, 
119.68, 117.77 (2C), 115.20, 113.38, 95.93, 46.29. MS (EI+) 
m/z calcd for C20H10F6N4O:436.08; found, 437.10   (M + 1). 





Obtained from IVa (0.3g, 1.015mmol, 1equiv.) using  methyl 4-
aminobenzoate (0.184g, 1.218mmol, 1.2 equiv.) as a light 
green fluffy powder (19%); Rf (MeOH: DCM, 0.5:9.5) 0.42; 1H 
NMR (400 MHz, DMSO) δ 8.80 (d, J = 8.2 Hz, 1H, H1), 8.00 (d, J 
= 8.4 Hz, 2H, H8), 7.68 (d, J = 8.0 Hz, 1H, H4), 7.60 (t, J = 7.6 Hz, 
1H, H3), 7.42 (t, J = 7.8 Hz, 1H, H2), 7.18 (d, J = 8.2 Hz, 2H, H7), 
6.27 (s, 1H, H5), 3.87 (s, 3H, H9); 13C NMR (101 MHz, DMSO) δ 
166.47, 148.42, 147.89, 135.37, 131.42 (2C), 128.71, 127.33, 
125.04 (2C), 124.03, 123.13, 121.97 (2C), 121.30, 117.83, 
114.91, 114.03, 112.47, 96.91, 52.19. MS (EI+) m/z calcd for 
C21H13F3N4O2:410.10; found, 411.10   (M + 1). HPLC purity: 95%.  
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(aminomethyl)-N,N-dimethylaniline (0.183g, 1.218mmol, 1.2 
equiv.) as a yellow powder (56%).  1H NMR (300 MHz, DMSO) δ 
8.69 (d, J = 8.4 Hz, 1H, H1), 8.58 (bs, 1H, H6), 7.92 (d, J = 7.8 Hz, 
1H, H4), 7.72 – 7.59 (m, 1H, H3), 7.53 – 7.43 (m, 1H, H2), 7.33 (d, J 
= 8.7 Hz, 2H, H8), 6.72 (d, J = 8.8 Hz, 2H, H9), 6.36 (s, 1H, H5), 4.77 
(s, 2H, H7), 2.87 (s, 6H, H10). 13C NMR (101 MHz, DMSO) δ 150.34, 
149.83, 148.46, 145.44, 137.25, 136.94, 128.60 (2C), 128.28, 
127.07, 124.50, 124.11, 121.73, 121.38, 119.35, 115.54, 114.88, 
112.88 (2C), 86.70, 46.58 (2C). MS (EI-) m/z calcd for 







Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using pyridin-2- 
ylmethanamine (0.132g, 1.218mmol, 1.2 equiv.) as a light green fine 
powder (63%). 1H NMR (300 MHz, DMSO) δ 8.76 – 8.59 (m, 3H, 
H1,6,11), 7.93 (d, J = 8.1 Hz, 1H, H4), 7.85 (td, J = 7.7, 1.8 Hz, 1H, H9), 7.65 
(t, J = 7.7 Hz, 1H, H10), 7.57 (d, J = 7.9 Hz, 1H, H8), 7.54 – 7.47 (m, 1H, 
H3), 7.42 – 7.33 (m, 1H, H2), 6.40 (s, 1H, H5), 4.99 (s, 2H, H7). 13C NMR 
(101 MHz, DMSO) δ 156.06, 149.87, 149.43, 148.30, 145.57, 137.68, 
137.24, 128.33, 127.10, 124.14, 123.30, 122.38, 122.02, 121.32, 
119.55, 115.22, 114.55, 86.72, 48.56. MS (EI+) m/z calcd for 
C19H12F3N5:367.10; found, 368.1 (M + 1). HPLC purity: 97%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
fluorophenyl)methanamine (0.152g, 1.218mmol, 1.2 equiv.) as a 
light green powder (59%).  1H NMR (300 MHz, DMSO) δ 8.71 (d, J = 
8.3 Hz, 1H, H1), 8.63 (bs, 1H, H6), 7.92 (d, J = 8.2 Hz, 1H, H4), 7.71 – 
7.61 (m, 1H, H3), 7.61 – 7.53 (m, 2H, H8), 7.53 – 7.45 (m, 1H, H2), 7.25 
– 7.16 (m, 2H, H9), 6.30 (s, 1H, H5), 4.90 (s, 2H, H7). 13C NMR (101 
MHz, DMSO) δ 163.26, 160.84, 149.97, 148.43, 137.33, 134.34, 
133.80, 129.70 (2C), 129.62, 128.48, 127.05, 121.80, 119.35, 115.92 
(2C), 115.71, 114.59, 86.63, 46.56. MS (EI+) m/z calcd for 
C20H12F4N4:384.10; found, 385.1 (M + 1). HPLC purity: 96%. 
 
1-(methyl(pyridin-2-ylmethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 3c/GMP-29. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using N-
methyl-1- (pyridin-2-yl)methanamine (0.148g, 1.218mmol, 
1.2 equiv.) as a dark green solid (63%). 1H NMR (300 MHz, 
DMSO) δ 8.52 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H, H11), 8.42 (d, J = 
8.4 Hz, 1H, H1), 8.01 (d, J = 8.1 Hz, 1H, H4), 7.80 (td, J = 7.7, 1.8 
Hz, 1H, H9), 7.69 (ddd, J = 8.3, 7.3, 1.0 Hz, 1H, H3), 7.53 (ddd, 
J = 8.4, 7.2, 1.2 Hz, 1H, H2), 7.42 (d, J = 7.8 Hz, 1H, H8), 7.32 
(ddd, J = 7.5, 4.9, 1.1 Hz, 1H, H10), 6.85 (s, 1H, H5), 4.76 (s, 2H, 
H7), 2.98 (s, 3H, H6). 13C NMR (101 MHz, DMSO) δ 155.73, 
154.08, 149.70, 148.00, 145.57, 137.36, 136.33, 136.00, 
129.15, 127.40, 123.91, 123.34, 122.74, 119.93, 117.18, 
113.64, 96.69, 96.65, 90.06, 58.79. MS (EI+) m/z calcd for 
C20H14F3N5:381.12; found, 382.10 (M + 1). HPLC purity: 96%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 
phenylmethanamine (0.131g, 1.218mmol, 1.2 equiv.) as a 
dark yellow solid (50%). 1H NMR (300 MHz, DMSO) δ 8.73 
(d, J = 8.4 Hz, 1H, H1), 7.91 (d, J = 7.6 Hz, 1H, H4), 7.70 – 7.59 
(m, 1H, H3), 7.53 – 7.43 (m, 3H, H2, 8), 7.41 – 7.33 (m, 2H, H9), 
7.34 – 7.24 (m, 1H, H10), 6.29 (s, 1H, H5), 4.91 (s, 2H, H7).  
13C NMR (101 MHz, DMSO) δ 150.07, 148.58, 145.42, 
137.83, 137.22, 129.07 (2C), 128.55, 127.81 (2C), 127.55 
(2C), 126.92, 124.17, 121.67, 119.19, 115.70, 114.83, 86.79, 
47.41. MS (EI+) m/z calcd for C20H13F3N4:366.11; found, 






Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using aniline 
(0.113g, 1.218mmol, 1.2 equiv.), triethylamine (0.205g 
(0.28ml); 2.03mmol, 2 equiv) as a yellow powder (23%). 1H NMR 
(300 MHz, DMSO) δ 8.80 (d, J = 8.2 Hz, 1H, H1), 7.70 (d, J = 7.0 
Hz, 1H, H4), 7.59 (t, J = 7.3 Hz, 1H, H3), 7.50 – 7.37 (m, 3H, H2, 7), 
7.27 – 7.00 (m, 3H, H8, 9), 6.22 (s, 1H, H5). 13C NMR (101 MHz, 
DMSO) δ 148.59, 148.45, 148.29, 136.94, 134.74, 132.38, 
130.10, 128.77, 127.17 (2C), 124.55, 124.09, 122.75 (2C), 
122.59, 119.85, 117.54, 115.05, 114.40. MS (EI+) m/z calcd for 
C19H11F3N4:352.09; found, 353.10 (M + 1). HPLC purity: 99%. 
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carbonitrile  3e/GMP-34. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
methoxyphenyl)methanamine (0.167g, 1.218mmol, 1.2 
equiv.) as a light green solid (43%). 1H NMR (300 MHz, DMSO) 
δ 8.71 (d, J = 8.4 Hz, 1H, H1), 7.91 (d, J = 8.1 Hz, 1H, H4), 7.64 (t, 
J = 7.6 Hz, 1H, H3), 7.52 – 7.41 (m, 3H, H2, 8), 6.98 – 6.89 (m, 2H, 
H9), 6.31 (s, 1H, H5), 4.82 (s, 2H, H7), 3.74 (s, 3H, H10). 13C NMR 
(101 MHz, DMSO) δ 159.24, 149.98, 148.55, 145.43, 137.09, 
129.58, 128.95 (2C), 128.49, 126.94, 124.02, 121.66, 121.44, 
119.22, 115.66, 114.80, 114.65 (2C), 86.76, 55.64, 46.82. MS 
(EI+) m/z calcd for C21H15F3N4O:396.12; found, 397.10 (M + 1). 
HPLC purity: 99%. 
 
1-((4-(trifluoromethoxy)benzyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-
4- carbonitrile 3f/GMP-35. 
 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
(trifluoromethoxy)phenyl)methanamine (0.233g, 
1.218mmol, 1.2 equiv.) as a yellow shiny solid (49%). 1H 
NMR (300 MHz, DMSO) δ 8.71 (d, J = 8.4 Hz, 1H, H1), 7.92 
(d, J = 7.7 Hz, 1H, H4), 7.72 – 7.60 (m, 3H, H3, 8), 7.49 (ddd, 
J = 8.4, 7.2, 1.2 Hz, 1H, H2), 7.37 (dd, J = 8.8, 0.9 Hz, 2H, 
H9), 6.31 (s, 1H, H5), 4.95 (s, 2H, H7). 13C NMR (101 MHz, 
DMSO) δ 150.00, 148.48, 148.17, 137.28, 135.81, 
133.84, 130.28, 129.51, 128.51, 127.00, 126.78, 124.13, 
122.84, 121.48 (2C), 119.22, 115.75 (2C), 114.49, 86.73, 
46.50. MS (EI+) m/z calcd for C21H12F6N4O:450.09; found, 
451.10 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
(methylsulfonyl)phenyl)methanamine (0.226g, 
1.218mmol, 1.2 equiv.) as a tan solid (56%). 1H NMR (300 
MHz, DMSO) δ 8.74 (d, J = 8.3 Hz, 1H, H1), 7.98-7.88 (m, 
3H, H4,9), 7.79 (d, J = 8.3 Hz, 2H, H8), 7.65 (t, J = 7.6 Hz, 1H, 
H3), 7.54 – 7.45 (m, 1H, H2), 6.31 (s, 1H, H5), 5.04 (s, 2H, 
H7), 3.21 (s, 3H, H10). 13C NMR (101 MHz, DMSO) δ 
150.04, 148.22, 144.13, 140.23, 136.98, 128.56, 128.23 
(2C), 127.50 (2C), 126.99, 122.24, 121.78, 121.17, 119.38, 
119.14, 115.83, 114.75, 86.83, 47.01, 44.10. MS (EI+) m/z 
calcd for C21H15F3N4O2S:444.09; found, 445.10 (M + 1). 
HPLC purity: 99%. 
 
1-((4-methoxyphenyl)(methyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 1o/GMP-37. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-
methoxy-N-methylaniline (0.167g, 1.218mmol, 1.2 equiv.) 
as a dark red solid (15%). 1H NMR (400 MHz, DMSO) δ 7.95 
(d, J = 8.2 Hz, 1H, H1), 7.88 (dt, J = 8.5, 0.9 Hz, 1H, H4), 7.57 
(ddd, J = 8.3, 7.1, 1.1 Hz, 1H, H3), 7.27 (ddd, J = 8.4, 7.1, 1.2 
Hz, 1H, H2), 7.10 – 7.03 (m, 3H, H5,7), 6.87 – 6.80 (m, 2H, 
H8), 3.69 (s, 3H, H9), 3.59 (s, 3H, H6). 13C NMR (101 MHz, 
DMSO) δ 156.34, 150.85, 148.00, 145.37, 139.07, 136.28, 
135.87, 128.40, 127.25, 122.52, 121.58 (2C), 119.70, 
117.06, 115.33 (2C), 113.78, 100.06, 91.88, 55.75, 41.83. 
MS (EI+) m/z calcd for C21H15F3N4O:396.12; found, 397.10 
(M + 1). HPLC purity: 98%. 
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a]pyridine- 4-carbonitrile 3h/GMP-38. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 1-(4- 
(methylsulfonyl)phenyl)ethan-1-amine (0.248g, 
1.218mmol, 1.2 equiv.) as a yellow fluffy powder (38%).  1H 
NMR (400 MHz, DMSO) δ 8.65 (d, J = 7.74 Hz, 1H, H1), 7.97 
– 7.92 (m, 2H, H10), 7.92 – 7.85 (m, 3H, H4, 9), 7.65 (t, J = 7.7 
Hz, 1H, H3), 7.49 (t, J = 7.6 Hz, 1H, H2), 6.23 (s, 1H, H5), 5.30 
(q, J = 6.8 Hz, 1H, H7), 3.17 (s, 3H, H11), 1.80 (d, J = 6.7 Hz, 
3H, H8). 13C NMR (101 MHz, DMSO) δ 149.54, 139.86, 
134.27, 127.70 (2C), 126.85, 126.45, 125.70, 125.37, 
124.58, 124.22, 121.93, 121.81 (2C), 121.40, 116.78, 
116.56, 116.35, 95.84, 54.25, 43.73, 23.00. MS (EI+) m/z 
calcd for C22H17F3N4O2S:458.10; found, 459.10 (M + 1). 





Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using pyridin-3- 
ylmethanamine (0.132g, 1.218mmol, 1.2 equiv.) as a yellow 
powder (62%). 1H NMR (400 MHz, DMSO) δ 8.75 (d, J = 1.6 Hz, 
1H, H11), 8.70 (d, J = 8.4 Hz, 1H, H1), 8.51 (dd, J = 4.8, 1.6 Hz, 1H, 
H10), 7.98 – 7.86 (m, 2H, H4, 8), 7.70 – 7.59 (m, 1H, H3), 7.53 – 
7.43 (m, 1H, H2), 7.40 (ddd, J = 7.9, 4.8, 0.8 Hz, 1H, H9), 6.34 (s, 
1H, H5), 4.96 (s, 2H, H7). 13C NMR (101 MHz, DMSO) δ 150.38 
(2C), 148.16, 144.89, 143.36, 137.34, 136.34, 134.41, 133.80, 
129.07, 124.63, 122.37, 119.81, 115.05 (2C), 106.72, 95.92, 
85.77, 45.34. MS (EI+) m/z calcd for C19H12F3N5:367.10; found, 
368.10 (M + 1). HPLC purity: 98%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using pyrazin-
2- ylmethanamine (0.133g, 1.218mmol, 1.2 equiv.) as a yellow 
powder (53%). 1H NMR (400 MHz, DMSO) δ 8.88 (d, J = 1.4 Hz, 
1H, H8), 8.71 – 8.65 (m, 2H, H1,9), 8.61 (d, J = 2.6 Hz, 1H, H10), 
7.91 (d, J = 8.1 Hz, 1H, H4), 7.64 (t, J = 7.7 Hz, 1H, H3), 7.53 – 
7.42 (m, 1H, H2), 6.47 (s, 1H, H5), 5.09 (s, 2H, H7). 13C NMR (101 
MHz, DMSO) δ 148.16 (3C), 144.89, 143.36, 137.34, 136.34, 
134.41, 133.80, 129.07, 124.63, 122.37, 119.81, 115.05 (2C), 
106.72, 85.77, 45.34. MS (EI+) m/z calcd for 
C18H11F3N6:368.10; found, 369.10 (M + 1). HPLC purity: 99%. 
 
1-((4-(morpholinomethyl)phenyl)amino)-3-(trifluoromethyl) benzo[4,5] imidazo[1,2-
a]pyridine-4- carbonitrile 1p/GMP-46. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(morpholinomethyl)aniline (0.234g, 1.218mmol, 1.2 equiv.) 
and purified by column chromatography (1%MeOH:DCM) 
as an orange powder (25%). 1H NMR (300 MHz, DMSO) δ 
8.79 (d, J = 8.1 Hz, 1H, H1), 7.61 (d, J = 8.1 Hz, 1H, H4), 7.47 –
7.38 (m, 3H, H3,7), 7.22 (t, J = 7.4 Hz, 1H, H2), 7.07 (d, J = 8.2 
Hz, 2H, H8), 5.95 (s, 1H, H5), 3.99 (s, 2H, H9), 3.81-3.61 (m, 
4H, H11), 3.02-2.79 (m, 4H, H10). 13C NMR (101 MHz, DMSO) 
δ 149.61, 134.71, 132.13 (2C), 130.01, 127.23, 126.46, 
125.70, 125.51 (2C), 124.88, 122.47, 121.41, 121.24, 120.48, 
117.17 (2C), 115.34, 113.14, 64.99 (2C), 61.03, 52.24 (2C). 
MS (EI+) m/z calcd for C24H20F3N5O:451.16; found, 452.10 
(M + 1). HPLC purity: 97%. 
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a]pyridine-4- carbonitrile: 3m/GMP-47. 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
(morpholinomethyl)phenyl)methanamine (0.251g, 
1.218mmol, 1.2 equiv.) as a yellow powder (48%). 1H 
NMR (300 MHz, DMSO) δ 8.74 (d, J = 8.4 Hz, 1H, H1), 8.63 
(bs, 1H, H6), 7.92 (d, J = 7.8 Hz, 1H, H4), 7.65 (t, J = 7.6 Hz, 
1H, H3), 7.54 – 7.42 (m, 3H, H2,8), 7.32 (d, J = 8.0 Hz, 2H, 
H9), 6.29 (s, 1H, H5), 4.90 (s, 2H, H7), 3.65 – 3.52 (m, 4H, 
H12), 3.49 (s, 2H, H10), 2.46-2.26 (m, 4H, H11). 13C NMR 
(101 MHz, DMSO) δ 149.56, 148.26, 145.35, 136.70, 
129.88(2C), 128.39, 127.44 (2C), 127.05, 125.92, 123.98, 
122.62, 121.65, 119.26, 115.90, 115.55, 114.73, 86.76, 
66.45(2C), 62.24, 53.45 (2C), 46.86. MS (EI+) m/z calcd 





Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(aminomethyl)phenol (0.250g, 2.03mmol, 2 equiv) as a 
yellow fine powder (70%). 1H NMR (400 MHz, DMSO) δ 8.70 
(d, J = 8.4 Hz, 1H, H1), 8.57 (bs, 1H,6), 7.91 (d, J = 8.1 Hz, 1H, 
H4), 7.65 (t, J = 7.6 Hz, 1H, H3), 7.48 (t, J = 7.7 Hz, 1H, H2), 
7.32 (d, J = 8.3 Hz, 2H, H8), 6.76 (d, J = 8.4 Hz, 2H, H9), 6.31 
(s, 1H, H5), 4.78 (s, 2H, H7). 13C NMR (101 MHz, DMSO) δ 
157.17, 149.90, 148.57, 146.13, 145.25, 136.71, 128.91(2C), 
128.40, 127.71, 126.97, 121.54, 121.42, 119.21, 115.88(2C), 
115.65, 115.02, 86.89, 46.74. MS (EI+) m/z calcd for 
C20H13F3N4:382.10; found, 383.10 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using p-
tolylmethanamine (0.246g, 2.03mmol, 2 equiv.) as a yellow 
fluffy powder (35%). 1H NMR (300 MHz, DMSO) δ 8.71 (d, J 
= 8.4 Hz, 1H, H1), 8.64 (bs, 1H, H6), 7.93 (d, J = 8.1 Hz, 1H, 
H4), 7.66 (t, J = 7.3 Hz, 1H, H3), 7.56 – 7.43 (m, 1H, H2), 7.40 
(d, J = 8.0 Hz, 2H, H8), 7.18 (d, J = 7.8 Hz, 2H, H9), 6.30 (s, 1H, 
H5), 4.86 (s, 2H, H7), 2.29 (s, 3H, H10). 13C NMR (101 MHz, 
DMSO) δ 149.81, 148.37, 145.37, 137.06, 135.43, 134.46, 
131.64, 129.69, 128.23, 127.50, 127.03, 121.69 (2C), 119.39 
(2C), 115.61, 114.83, 112,74, 86.41, 46.57, 21.14. MS (EI+) 
m/z calcd for C21H15F3N4:380.12; found, 381.10 (M + 1). 




Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(aminomethyl)-N-methylbenzamide (0.333g, 2.03mmol, 2 
equiv.) as a brown powder (30%). 1H NMR (300 MHz, DMSO) 
δ 8.74 (d, J = 8.3 Hz, 1H, H1), 8.39 (d, J = 4.8 Hz, 1H, H10), 7.90 
(d, J = 8.0 Hz, 1H, H4), 7.83 (d, J = 8.1 Hz, 2H, H9), 7.67-7.54 
(m, 3H, H3,8), 7.47 (t, J = 7.9 Hz, 1H, H2), 6.24 (s, 1H, H5), 4.95 
(s, 2H, H7), 2.78 (d, J = 4.5 Hz, 3H, H11). 13C NMR (101 MHz, 
DMSO) δ 166.81, 150.10, 148.65, 145.30, 141.15, 134.04, 
132.94, 130.76, 128.63, 127.83, 127.32 (2C), 126.85, 121.56 
(2C), 119.07, 118.54, 117.48, 115.81, 86.83, 47.17, 26.66. 
MS (EI+) m/z calcd for C22H16F3N5O:423.13; found, 424.10 
 (M + 1). HPLC purity: 99%. 
 
                           Chapter 7                                                                                                  Experimental Information  
 
 





 Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(aminomethyl)-N,N-dimethylbenzamide (0.362g, 
2.03mmol, 2 equiv.) as a yellow shiny solid (67%). 1H 
NMR (300 MHz, DMSO) δ 8.77 (d, J = 8.4 Hz, 1H, H1), 7.90 
(d, J = 7.8 Hz, 1H, H4), 7.64 (t, J = 7.5 Hz, 1H, H3), 7.57 (d, 
J = 8.2 Hz, 2H, H9), 7.51 – 7.43 (m, 1H, H2), 7.40 (d, J = 8.3 
Hz, 2H, H8), 6.28 (s, 1H, H5), 4.95 (s, 2H, H7), 2.93 (s, 6H, 
H10). 13C NMR (101 MHz, DMSO) δ 170.37, 150.01, 
148.66, 145.36, 142.98, 139.28, 135.96,  128.56, 127.74, 
127.36 (2C), 126.90, 121.63, 119.10, 118.32, 116.94, 
115.82, 115.11(2C), 86.87, 47.05, 46.06 (2C). MS (EI+) 
m/z calcd for C23H18F3N5O:437.15; found, 438.10  
(M + 1). HPLC purity: 99%. 
4-(((4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)amino)methyl)- 
benzenesulfonamide 3r/GMP-54. 
 Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(aminomethyl)benzenesulfonamide (0.378g, 
2.03mmol, 2 equiv.) as light brown shiny crystals (52%). 
1H NMR (300 MHz, DMSO) δ 8.73 (d, J = 8.4 Hz, 1H, H1), 
8.65 (bs, 1H, H6), 7.93 (d, J = 7.7 Hz, 1H, H4), 7.83 (d, J = 
8.5 Hz, 2H, H9), 7.70 (d, J = 8.5 Hz, 2H, H8), 7.67 – 7.61 
(m, 1H, H3), 7.54 – 7.44 (m, 1H, H2), 7.34 (bs, 2H, H10), 
6.28 (s, 1H, H5), 5.00 (s, 2H, H7). 13C NMR (101 MHz, 
DMSO) δ 149.97, 148.52, 143.58, 141.90, 137.22, 
128.48, 127.90 (2C), 127.03, 126.34 (2C), 124.11, 
121.76, 121.32, 119.28, 115.78 (2C), 114.93, 86.42, 
46.82. MS (EI+) m/z calcd for C20H14F3N5O2S:445.08; 
found, 446.00 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using (4- 
isopropylphenyl)methanamine (0.182g, 1.218mmol, 1.2 
equiv.) as a yellow powder (65%). 1H NMR (300 MHz, 
DMSO) δ 8.73 (d, J = 8.3 Hz, 1H, H1), 7.88 (d, J = 7.9 Hz, 
1H, H4), 7.62 (t, J = 7.5 Hz, 1H, H3), 7.44 (m, 3H, H2,8), 7.24 
(d, J = 8.1 Hz, 2H, H9), 6.31 (s, 1H, H5), 4.84 (s, 2H, H7), 
2.87 (m, 1H, H10), 1.18 (d, J = 6.9 Hz, 6H, H11). 13C NMR 
(101 MHz, DMSO) δ 150.10, 148.82, 147.93, 145.37, 
136.68, 135.53, 132.84, 128.64, 127.64, 126.95, 126.75, 
124.71, 121.46 (2C), 118.99, 115.75 (2C), 115.30, 86.78, 
47.29, 33.55, 24.31 (2C). MS (EI+) m/z calcd for 
C23H19F3N4:408.16; found, 409.10 (M + 1). HPLC purity: 
99%. 
1-(piperazin-1-yl)-3-(trifluoromethyl) benzo [4,5] imidazo[1,2-a]pyridine-4-carbonitrile 
3u/GMP-77. 
 
Obtained from IVa (0.1g, 0.338mmol, 1 equiv.) and 
piperazine (0.146g, 1.69mmol, 5 equiv.) as a yellow solid 
(38%). 1H NMR (300 MHz, Methanol-d4) δ 8.44 (d, J = 8.9 Hz, 
1H, H4), 7.96 (d, J = 8.4 Hz, 1H, H1), 7.69 (t, J = 7.7 Hz, 1H, H3), 
7.57 (t, J = 7.7 Hz, 1H, H2), 6.87 (s, 1H, H5), 3.60 (d, J = 11.7 
Hz, 2H, H7e,8e), 3.30 – 2.96 (m, 6H, H6,9,7a,8a). 13C NMR (101 
MHz, DMSO) δ 154.52, 147.89, 145.30, 136.31, 128.95, 
127.37 (2C), 122.82, 119.98, 116.67 (2C), 113.72, 95.05, 
51.46 (2C), 44.86 (2C). MS (EI+) m/z calcd for 
C17H14F3N5:345.12; found, 346.10 (M + 1). HPLC purity: 99%.  
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Obtained from IVa (0.1g, 0.338 mmol, 1 equiv.) using 3-
(trifluoromethoxy) aniline (0.072g, 0.406 mmol, 1.2 equiv.) 
as a yellow solid (10%), m.p. 285-289 °C; Rf  (EtoAc: Hex, 
1:5) 0.26; 1H NMR (300 MHz, DMSO-d6) δ 8.81 (d, J = 8.3 Hz, 
1H, H1), 7.58 (m, 3H, H2,4,9), 7.42 (t, J = 7.8 Hz, 1H, H3), 7.19 
– 6.96 (m, 3H, H7,8,10), 6.23 (s, 1H, H5). 13C NMR (101 MHz, 
DMSO) δ 149.82, 148.61, 148.38, 135.72, 133.54, 131.74, 
128.58, 127.31, 124.01, 123.11, 121.86, 121.27 (2C), 
119.32, 117.88, 115.96, 115.17, 114.61, 112.64, 96.61. MS 
(EI+) m/z calcd for C20H10F6N4O:436.08; found, 437.10 (M + 








Obtained from IVa (0.1g, 0.338 mmol, 1 equiv.) using 2-
(trifluoromethoxy) aniline (0.072g, 0.406 mmol, 1.2 equiv.) as 
a yellow solid (29%), m.p. 270-272°C; Rf (1% MeoH/DCM) 0.47; 
1H NMR (300 MHz, DMSO-d6) δ 8.87 (d, J = 8.3 Hz, 1H, H1), 7.75 
– 7.52 (m, 2H,H4,3), 7.52 – 7.34 (m, 3H,H2,7,8), 7.22 (m, 2H,H9,10), 
6.10 (s, 1H,H5). 13C NMR (101 MHz, DMSO) δ 148.65, 141.74, 
140.85, 135.03, 134.72, 133.29, 129.07, 128.59, 127.43, 
124.84, 123.90, 123.24, 122.01, 121.27, 119.47, 117.73, 
115.18, 112.16, 100.00, 97.15. MS (EI+) m/z calcd for 
C20H10F6N4O:436.08; found, 437.10 (M + 1). HPLC purity: >99%. 
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Obtained, serendipitously, from IVd (0.1g, 0.304mmol, 1 equiv.) 
using 4-(trifluoromethoxy)aniline (0.108g, 0.608 mmol, 2 
equiv.). Yellow solid (19%), m.p. 266-268 °C; Rf (EtoAC: Hex, 1:4) 
0.17; 1H NMR (400 MHz, DMSO-d6) δ 8.52 (d, J = 8.6 Hz, 1H, H1), 
7.99 (d, J = 8.3 Hz, 1H, H4), 7.95 (s, 1H, H5), 7.77 (t, J = 7.8 Hz, 1H, 
H3), 7.55 (td, J = 7.9, 7.3, 1.0 Hz, 1H, H2), 7.47 – 7.35 (m, 4H, H8,9), 
7.00 (s, 1H, H6). 13C NMR (101 MHz, DMSO) δ 145.99, 144.54, 
140.66, 137.63, 135.40, 128.68, 127.43, 124.44, 123.35, 123.08 
(2C), 121.72, 121.87 (2C), 119.36, 117.99, 116.00, 103.65, 97.79. 
MS (EI+) m/z calcd for C19H11F6N3O:411.08; found, 412.00 (M + 




Obtained from VI (0.1g, 0.32mmol, 1 equiv.) using 4-
fluorobenzylamine (0.048g, 0.385 mmol, 1.2 equiv.) as a light 
yellow powder (35%), m.p. 244-246 °C; Rf  (2% MeoH/DCM) 
0.21; 1H NMR (600 MHz, DMSO-d6) δ 8.66 (d, J = 8.4 Hz, 1H, H1), 
8.02 (s, 1H, H5), 7.90 (d, J = 8.2 Hz, 1H, H4), 7.81 (s, 1H, H5), 7.65 
(bs, 1H, H7), 7.61 (t, J = 7.6 Hz, 1H, H3), 7.57 (dd, J = 8.5, 5.6 Hz, 
2H, H10), 7.48 – 7.42 (m, 1H, H2), 7.20 (t, J = 8.9 Hz, 2H, H9), 6.03 
(s, 1H, H6), 4.74 (s, 2H, H8). 13C NMR (151 MHz, DMSO) δ 165.14, 
162.09, 160.48, 146.64, 146.09, 144.77, 134.00, 129.11 (2C), 
127.62, 125.77, 124.11 (2C), 122.29, 120.67, 118.81, 115.16, 
113.47, 84.12, 45.53. MS (EI+) m/z calcd for 
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Obtained from VI (0.1g, 0.32mmol, 1 equiv.) using 4-
trifluorobenzylamine (0.075g, 0.385 mmol, 1.2 equiv.)  as a 
light grey solid (20%), m.p. 206-208 °C; Rf (EtoAc: Hex 7:3) 
0.21;  1H NMR (300 MHz, DMSO-d6) δ 8.67 (d, J = 8.2 Hz, 1H, 
H1), 8.03 (s, 2H, H5), 7.90 (d, J = 8.1 Hz, 1H, H4), 7.62 – 7.52 
(m, 1H, H3), 7.45 – 7.38 (m, 1H, H2), 7.48 (bs, 1H,H7), 7.44 
(d, J = 7.1 Hz, 2H, H10), 7.37 (d, J = 7.7 Hz, 2H,H9), 6.02 (s, 
1H, H6), 4.79 (s, 2H, H8). 13C NMR (151 MHz, DMSO) δ 
165.14, 162.09, 160.48, 146.64, 146.09, 144.77, 134.00, 
129.11 (2C), 127.62, 127.30, 125.77, 124.11, 122.29, 
120.67, 118.81, 115.16 (2C), 113.47, 84.12, 45.53. MS (EI+) 
m/z calcd for C21H14F6N4O2:468.10; found, 469.10 (M + 1). 




Obtained from VI (0.15g, 0.48 mmol, 1 equiv.) using 2-
picolylamine (63g/0.08mL, 0.58 mmol, 1.2 equiv.) as a 
light grey solid (66%), m.p.215-218°C; Rf(2% 
MeoH/DCM) 0.15; 1H NMR (300 MHz, DMSO-d6) δ 8.69 
(d, J = 8.2 Hz, 1H, H1), 8.63 (d, J = 4.2 Hz, 1H, H12), 8.05 (s, 
2H, H5), 7.91 (d, J = 8.3 Hz, 1H, H4), 7.82 (td, J = 7.7, 1.6 
Hz, 1H, H3), 7.66 (d, J = 4.2 Hz, 1H, H11), 7.62 (s, 1H, H6), 
7.61 – 7.52 (m, 1H, H9), 7.47 (t, J = 7.8 Hz, 1H, H2), 7.40 – 
7.29 (m, 1H, H10), 6.10 (bs, 1H, H7), 4.85 (s, 2H, H8).  13C 
NMR (101 MHz, DMSO) δ 165.65, 157.24, 149.41, 
147.19, 146.70, 145.36, 137.55, 128.09, 126.32, 125.12, 
123.10, 122.39, 122.14, 121.35, 119.44, 115.51, 113.73, 
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84.42, 48.57. MS (EI+) m/z calcd for C19H14F3N5O:385.12; 
found, 386.10 (M + 1). HPLC purity: >99%.  
 
7,9-dichloro-1-((4-fluorobenzyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 4a/GMP-62. 
 
 
Obtained from IVb (0.1g, 0.274mmol, 1 equiv.) and (4- 
fluorophenyl)methanamine (0.041g, 0.329mmol, 1.2 equiv.) as a 
yellow solid (86%). 1H NMR (300 MHz, DMSO-d6) δ 8.82 (d, J = 4.1 
Hz, 1H, H2), 8.70 (s, 1H, H4), 7.81 (d, J = 6.8 Hz, 1H, H1), 7.56 (dd, J = 
8.5, 5.5 Hz, 2H, H6), 7.20 (t, J = 8.9 Hz, 2H, H7), 6.32 (s, 1H, H3), 4.89 
(s, 2H, H5). 13C NMR (101 MHz, DMSO) δ 163.13, 160.71, 150.15 (2C), 
141.56, 137.93, 133.95, 129.83, 129.50 (2C), 126.22, 125.36, 123.06, 
121.27, 115.87 (2C), 114.78, 112.78, 88.01, 46.85. MS (EI+) m/z calcd 
for C20H10Cl2F4N4:452.02; found, 453.00 (M + 1). HPLC purity: 99%. 
 
7,8-dichloro-1-((4-fluorobenzyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 4b/GMP-66. 
 
 
Obtained from IVc (0.163g, 0.448mmol, 1 equiv.) and (4- 
fluorophenyl)methanamine (0.0618g, 0.493mmol, 1.2 equiv.) as a 
yellow solid (22%). 1H NMR (300 MHz, DMSO-d6) δ 9.03 (s, 1H, H2), 
7.69 (s, 1H, H1), 7.52 (dd, J = 8.6, 5.6 Hz, 2H, H6), 7.43 (dd, J = 8.4, 5.6 
Hz, 2H, H7), 6.00 (s, 1H, H3), 4.59 (s, 2H, H5). 13C NMR (101 MHz, 
DMSO) δ 162.97, 160.18, 154.24, 150.99, 145.67, 139.02, 135.82, 
134.57, 130.64, 129.58, 125.88, 119.90, 117.50, 116.55, 115.63, 
115.57, 115.18, 100.00, 88.62, 43.67. MS (EI+) m/z calcd for 
C20H10Cl2F4N4:452.02; found, 453.00 (M + 1). HPLC purity: 97%. 
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(trifluoromethyl)benzo[4,5]imidazo[1,2- a]pyridine-4-carbonitrile 4c/GMP-67. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and (4- 
(trifluoromethoxy)phenyl)methanamine (0.094g, 0.493mmol, 
1.2 equiv.) as a brown solid (25%). 1H NMR (300 MHz, DMSO-
d6) δ 9.04 (s, 1H, H2), 7.70 (s, 1H, H1), 7.59 (dd, J = 14.0, 8.6 Hz, 
2H, H7), 7.38 (t, J = 8.8 Hz, 2H, H6), 6.01 (s, 1H, H3), 4.64 (s, 2H, 
H5). 13C NMR (101 MHz, DMSO) δ 151.42, 148.67, 148.48, 
137.28, 134.58, 132.48, 130.43, 129.51, 128.51, 127.00 (2C), 
124.13, 121.48 (2C), 119.22, 116.56, 115.75, 114.49, 112.94, 
86.73, 51.67. MS (EI+) m/z calcd for C21H10Cl2F6N4O:518.01; 
found, 519.00 (M + 1). HPLC purity: 99%. 
 
7,8-dichloro-1-((pyridin-2-ylmethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 4d/GMP-68. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and (pyridin-2- 
ylmethanamine (0.0534g, 0.493mmol, 1.2 equiv.) as a brown 
solid (39%). 1H NMR (300 MHz, DMSO-d6) δ 9.01 (s, 1H, H2), 8.66 
– 8.52 (m, 1H, H9), 8.10 (s, 1H, H1), 7.83 (td, J = 7.6, 1.8 Hz, 1H, 
H7), 7.58 (d, J = 7.9 Hz, 1H, H6), 7.42 – 7.26 (m, 1H, H8), 6.39 (s, 
1H, H3), 4.94 (s, 2H, H5). 13C NMR (101 MHz, DMSO) δ 150.22, 
149.36 (2C), 145.21, 137.52 (2C), 129.15, 128.31, 127.64, 
123.18, 122.26 (2C), 119.39, 118.56, 117.09, 116.96, 115.08, 
88.03, 49.95. MS (EI+) m/z calcd for C19H10Cl2F3N5:435.03; 
found, 436.00 (M + 1). HPLC purity: 97%. 
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a]pyridine-4- carbonitrile 4e/GMP-69. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and p-
tolylmethanamine (0.058g, 0.494mmol, 1.2 equiv.) as a 
brown powder (50%). 1H NMR (300 MHz, DMSO-d6) δ 
9.06 (s, 1H, H2), 7.74 (s, 1H, H1), 7.35 (d, J = 8.1 Hz, 2H, 
H6), 7.20 (d, J = 7.9 Hz, 2H, H7), 6.03 (s, 1H, H3), 4.59 (s, 
2H, H5), 2.31 (s, 3H, H8). 13C NMR (101 MHz, DMSO) δ 
160.73, 159.00, 155.06, 146.31, 135.62, 134.93, 
129.58, 129.21 (2C), 127.62 (2C), 126.38, 121.69, 
119.39, 117.52, 116.80, 115.61, 114.83, 88.39, 42.88, 
21.08. MS (EI+) m/z calcd for C21H13Cl2F3N4:448.05; 
found, 449.00 (M + 1). HPLC purity: 99%. 
 
7,8-dichloro-1-((4-(trifluoromethoxy)phenyl)amino)-3-
(trifluoromethyl)benzo[4,5]imidazo[1,2- a]pyridine-4-carbonitrile 4f/GMP-70. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and 4- 
(trifluoromethoxy)aniline (0.088g, 0.494mmol, 1.2 equiv.) as 
dark (red-brown) crystals (9%). 1H NMR (300 MHz, DMSO-d6) 
δ 8.93 (s, 1H, H2), 7.79 (s, 1H, H1), 7.36 – 7.30 (m, 2H, H5), 7.12 
– 7.04 (m, 2H, H6), 5.76 (s, 1H, H3). 13C NMR (101 MHz, DMSO) 
δ 163.05, 156.19, 148.53, 142.12, 137.62, 128.91, 127.21, 
125.36, 123.75 (2C), 122.46 (2C), 120.35, 117.64 (2C), 115.20, 
113.50, 102.34, 95.93, 46.29. MS (EI+) m/z calcd for 
C20H8Cl2F6N4:504.00; found, 505.00 (M + 1). HPLC purity: 98%. 
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a]pyridine-4- carbonitrile 4g/GMP-71. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and furan-2- 
ylmethanamine (0.048g, 0.494mmol, 1.2 equiv.) as a brown 
solid (56%). 1H NMR (300 MHz, DMSO-d6) δ 9.00 (s, 1H, H2), 
7.90 (s, 1H, H1), 7.63 (dd, J = 1.8, 0.9 Hz, 1H, H6), 6.43 (m, 2H, 
H7,8), 6.27 (s, 1H, H3), 4.72 (s, 2H, H5). 13C NMR (101 MHz, 
DMSO) δ 155.27, 153.52, 150.99, 145.30, 142.96, 142.30, 
134.97, 130.77, 128.78, 123.76, 117.67, 117.45, 114.20, 
110.89, 107.15, 94.33, 93.02, 43.95. MS (EI+) m/z calcd for 
C18H9Cl2F3N4:424.01; found, 425.00 (M + 1). HPLC purity: 99%. 
 
7,8-dichloro-1-((thiophen-2-ylmethyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine- 4-carbonitrile 4h/GMP-72. 
 
 
Obtained from IVc (0.15g, 0.411mmol, 1 equiv.) and 
thiophen-2- ylmethanamine (0.056g, 0.494mmol, 1.2 
equiv.) as a brown solid (28%). 1H NMR (300 MHz, DMSO-
d6) δ 9.16 (s, 1H, H2), 7.77 (s, 1H, H1), 7.42 (dd, J = 5.0, 1.3 
Hz, 1H, H6), 7.11 – 7.05 (m, 1H, H8), 7.02 (dd, J = 5.0, 3.4 
Hz, 1H, H7), 6.05 (s, 1H, H3), 4.80 (s, 2H,H5). 13C NMR (101 
MHz, DMSO) δ 150.91, 145.53, 138.51, 130.23, 129.21, 
128.19, 127.02 (2C), 124.34 (2C), 123.52, 123.23, 117.75 
(2C), 116.95 (2C), 88.34, 47.38. MS (EI+) m/z calcd for 
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a]pyridine-4- carbonitrile 4i/GMP-75. 
 
 
Obtained from IVc (0.1g, 0.274mmol, 1 equiv.) and (2- 
fluorophenyl)methanamine (0.069g, 0.548mmol, 2 equiv.) 
as an orange solid (58%). 1H NMR (300 MHz, DMSO-d6) δ 
9.00 (s, 1H, H2), 7.94 (s, 1H, H1), 7.59 (t, J = 7.5 Hz, 1H, H8), 
7.40 – 7.12 (m, 3H, H6, 7, 9), 6.22 (s, 1H, H3), 4.79 (s, 2H, H5). 
13C NMR (101 MHz, DMSO) δ 161.91, 159.49, 152.40, 
150.75, 145.34, 136.58, 132.84, 131.42, 129.92, 129.22, 
126.94, 127.87, 124.84, 121.78, 118.14, 117.37 (2C), 116.51, 
115.46, 87.88. MS (EI+) m/z calcd for C20H10Cl2F4N4:452.02; 
found, 453.00 (M + 1). HPLC purity: 98%. 
 
7,8-dichloro-1-((3-fluorobenzyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-
a]pyridine-4- carbonitrile 4j/GMP-76. 
 
 
Obtained from IVc (0.1g, 0.274mmol, 1 equiv.) and (3- 
fluorophenyl)methanamine (0.069g, 0.548mmol, 2 equiv.) as a 
yellow solid (37%). 1H NMR (300 MHz, DMSO-d6) δ 9.05 (s, 1H, H2), 
8.69 (bs, 1H, H4), 8.20 (s, 1H, H1), 7.51 – 7.29 (m, 3H, H7, 8, 9), 7.18 – 
7.06 (m, 1H, H6), 6.32 (s, 1H, H3), 4.96 (s, 2H, H5). 13C NMR (101 
MHz, DMSO) δ 161.91, 159.49, 152.40, 150.75, 145.34, 136.58, 
131.42, 129.96, 129.22, 127.87, 125.10, 124.70, 121.78, 118.14, 
117.37(2C), 116.51, 115.65, 115.46, 87.83. MS (EI+) m/z calcd for 
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Obtained from IVc (0.1g, 0.274mmol, 1 equiv.) and 
piperazine (0.118g, 1.372mmol, 5 equiv.) as a yellow solid 
(53%); Rf (5% MeoH: DCM); 0.33 1H NMR (300 MHz, 
Methanol-d4) δ 8.56 (s, 1H, H2), 8.08 (s, 1H, H1), 6.96 (s, 1H, 
H3), 3.61 (d, J = 11.9 Hz, 2H, H5e,6e), 3.33 – 3.27 (m, 4H, H5a,6a, 
4e,7e), 3.18 (dd, J = 12.7, 6.3 Hz, 2H, H4a,7a). 13C NMR (101 
MHz, DMSO) δ 154.20 (2C), 149.71, 144.71, 130.07, 128.22, 
124.71, 120.92 (2C), 117.68 (2C), 113.34, 96.37, 51.04 (2C), 
44.64 (2C). MS (EI+) m/z calcd for C17H12Cl2F3N5:413.04; 





Obtained from IVc (0.2g, 0.55mmol, 1 equiv.) and (4- 
(methylsulfonyl) phenyl)methanamine (0.138g, 
1.357mmol, 0.746 equiv.) as a brown solid (58%). 1H NMR 
(300 MHz, DMSO-d6) δ 9.11 (bs, 1H, H4), 8.17 (s, 1H, H1), 
8.05 (s, 1H, H2), 7.91 (d, J = 8.5 Hz, 2H, H7), 7.75 (d, J = 8.5 
Hz, 2H, H6), 6.24 (s, 1H, H3), 5.00 (s, 2H, H5), 3.21 (s, 3H, H8). 
13C NMR (101 MHz, DMSO) δ 160.38, 150.68, 150.25, 
149.66, 146.47, 144.95, 138.07, 135.72, 133.78, 130.50, 
128.25, 127.96 (2C), 127.63 (2C), 121.12, 119.42, 117.22, 
108.24, 46.22, 44.21. MS (EI-) m/z calcd for 
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imidazo [1,2-a]pyridine-4-carbonitrile 4m/GMP-97. 
 
 
Obtained from IVc (0.2g, 0.55mmol, 1 equiv.) and 1-(4- 
(methylsulfonyl)phenyl)ethan-1-amine (0.189g, 0.95mmol, 1.73 
equiv.) as a yellow solid (6%). 1H NMR (300 MHz, DMSO-d6) δ 
8.83 (s, 1H, H1), 8.24 (s, 1H, H2), 7.95 (d, J = 8.6 Hz, 2H, H8), 7.88 
(d, J = 8.4 Hz, 2H, H7), 6.27 (s, 1H, H3), 5.47 – 5.30 (m, 1H, H5), 
3.21 (s, 3H, H9), 1.80 (d, J = 7.7 Hz, 3H, H6). 13C NMR (101 MHz, 
DMSO) δ 162.33, 162.10, 153.77, 148.58, 133.77, 133.21, 
130.84, 128.76, 127.70 (2C), 126.87, 126.35, 124.58, 121.81 
(2C), 117.96, 116.73, 114.52, 96.89, 63.59, 44.08, 22.97.              
MS (EI-) m/z calcd for C22H15Cl2F3N402S:526.02; found, 525.00 













                           Chapter 7                                                                                                  Experimental Information  
 
 
                            Godfrey Mayoka PhD Thesis 2018                                                                          University of Cape Town 
316 
 
b) Amination using Buchwald-Hartwig conditions 
A mixture of the chloro intermediate, the appropriate amine (1.2 equiv.), 
Tris(dibenzylideneacetone)  dipalladium(0), Pd2(dba)3 (0.1 equiv.), 2,2'-
Bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (0.06 equiv.) or BrettPhos (0.04 equiv.) or 
RuPhos (0.1 equiv.), Potassium carbonate, K2CO3 or Caesium Carbonate, Cs2CO3 (3 equiv.) and 
toluene:tert-butanol (1:1; 5ml) or 1,4-dioxane (5mL) were stirred in a sealed tube at 100-
120˚C for 4-17 hours. Reactions were monitored by TLC and LC-MS. The cooled reaction 
mixture was stirred in ethylacetate (50ml) and water (100ml) for 10-20 minutes. The 
separated organic layer was washed with water (2X50ml), followed by saturated NaCl 
(2X50ml), dried over magnesium sulphate and filtered over celite. The organic fraction was 
concentrated under reduced pressure and ethanol used to precipitate the crude product 
which was filtered to furnish the final product. In some cases, compounds were purified by 
recrystallization from ethanol or by column chromatography.  
 
1-((4-cyanophenyl)amino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile 1b/GMP-09.  
 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-
aminobenzonitrile (0.24g, 1.218mmol, 1.2 equiv.) as a pale-
yellow powder (27%). 1H NMR (300 MHz, DMSO) δ 8.80 (d, J = 7.9 
Hz, 1H, H1), 7.84 (d, J = 8.7 Hz, 2H, H8), 7.66 (d, J = 7.3 Hz, 1H, H4), 
7.63 – 7.56 (m, 1H, H3), 7.49 – 7.36 (m, 1H, H2), 7.21 (d, J = 8.5 Hz, 
2H, H7), 6.22 (s, 1H, H5). 13C NMR (101 MHz, DMSO) δ 148.37, 
148.11, 135.32, 135.00, 134.41, 132.48, 130.84, 128.61, 127.40, 
123.17, 122.96 (2C), 119.80, 118.34, 117.93 (2C), 116.74, 115.21, 
105.52, 96.60. MS (EI+) m/z calcd for C20H10F3N5:377.09; found, 
378.10 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-amino- 
N,N-dimethylbenzamide (0.2g, 1.218mmol, 1.2 equiv.) as a 
yellow powder (18%). ; 1H NMR (300 MHz, DMSO) δ 8.81 (d, J 
= 8.3 Hz, 1H, H1), 7.67 (d, J = 8.3 Hz, 1H, H4), 7.59 (t, J = 7.4 Hz, 
1H, H3), 7.48 (d, J = 8.3 Hz, 2H, H7), 7.42 (t, J = 8.2 Hz, 1H, H2), 
7.12 (d, J = 6.8 Hz, 2H, H8), 6.27 (s, 1H, H5), 3.00 (s, 6H, H9).  13C 
NMR (151 MHz, DMSO) δ 170.55, 148.55, 148.21, 135.01, 
132.14, 129.21, 128.77, 127.22 (2C), 126.74, 125.37, 123.63, 
122.92, 121.79, 120.00, 118.82, 117.72 (2C), 115.04, 96.35, 
46.06 (2C). MS (EI+) m/z calcd for C22H16F3N5O:423.13; found, 
424.10 (M + 1). HPLC purity: 98%. 
 
1-((4-(methylsulfonyl) phenyl) amino)-3- (trifluoromethyl) benzo[4,5]imidazo [1,2-
a]pyridine-4- carbonitrile 1i/GMP-18. 
 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4- 
(methylsulfonyl)aniline (0.209g, 1.218mmol, 1.2 equiv.) as a 
yellow powder (40%). 1H NMR (300 MHz, DMSO) δ 8.79 (d, J = 
8.0 Hz, 1H, H1), 7.88 (d, J = 8.6 Hz, 2H, H8), 7.62 (d, J = 7.9 Hz, 
1H, H4), 7.51 – 7.41 (m, 1H, H3), 7.29 – 7.20 (m, 3H, H2,7), 6.00 
(s, 1H, H5), 3.21 (s, 3H, H9). 13C NMR (101 MHz, DMSO) δ 155.13, 
149.37, 133.81, 132.83, 130.01, 129.64, 129.07, 127.68, 125.52, 
122.74 (2C), 121.41, 120.45, 117.20 (2C), 115.04, 106.70, 91.45, 
86.09, 44.03. MS (EI+) m/z calcd for C20H13F3N4O2S:430.07; 
found, 431.00 (M + 1). HPLC purity: 99%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 2-
fluoropyridin-4- amine (0.137g, 1.218mmol, 1.2 equiv.) as a 
yellow powder (6%). 1H NMR (400 MHz, DMSO) δ 8.78 (d, J = 
8.3 Hz, 1H, H1), 8.13 (d, J = 5.4 Hz, 1H, H9), 7.68 (d, J = 8.1 Hz, 
1H, H4), 7.57 (t, J = 7.6 Hz, 1H, H3), 7.38 (t, J = 7.9 Hz, 1H, H2), 
6.98 (dt, J = 5.4, 1.7 Hz, 1H, H8), 6.72 (s, 1H, H7), 6.23 (s, 1H, 
H5). 13C NMR (101 MHz, DMSO) δ 166.34, 164.04, 161.07, 
148.68 (2C), 135.88, 128.78, 127.21, 124.13, 122.77, 121.40, 
117.91, 116.13, 115.31, 113.38, 101.75, 101.36, 95.71. MS 
(EI+) m/z calcd for C18H9F4N5:371.08; found, 372.10 (M + 1). 





a]pyridine-4- carbonitrile 2a/GMP-23. 
 
 
Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 5,6- 
dimethoxypyrimidin-4-amine (0.189g, 1.218mmol, 1.2 equiv.) 
as a yellow fluffy powder (17%). 1H NMR (300 MHz, DMSO) δ 
9.08 (d, J = 10.1 Hz, 1H, H1), 8.36 (s, 1H, H9), 7.69 (d, J = 8.7 Hz, 
1H, H4), 7.67 – 7.59 (m, 1H, H3), 7.52 – 7.43 (m, 1H, H2), 7.40 (s, 
1H, H5), 4.00 (s, 3H, H8), 3.80 (s, 3H, H7).  13C NMR (101 MHz, 
DMSO) δ 163.29, 162.70, 151.38, 147.54, 141.49, 135.42, 
135.09, 128.73, 127.71(2C), 124.15, 123.12 (2C), 121.42, 
118.52, 114.91, 100.05, 60.64, 54.00. MS (EI+) m/z calcd for 
C19H13F3N6O2:414.11; found, 415.10 (M + 1). HPLC purity: 98%. 
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Obtained from IVa (0.3g, 1.015mmol, 1 equiv.) using 4-
methylthiazol- 2-amine (0.139g, 1.218mmol, 1.2 equiv.) as a 
brown powder (37%). 1H NMR (400 MHz, DMSO) δ 9.04 (d, J 
= 8.0 Hz, 1H, H1), 7.83 (d, J = 8.1 Hz, 1H, H4), 7.59 (ddd, J = 
8.3, 7.2, 1.2 Hz, 1H, H3), 7.41 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H, 
H2), 6.97 (s, 1H, H5), 6.84 (d, J = 1.2 Hz, 1H, H7), 2.33 (d, J = 
1.2 Hz, 3H, H8). 13C NMR (101 MHz, DMSO) δ 150.97, 148.06, 
140.91, 137.55, 136.71, 136.39, 131.52, 129.88, 126.78, 
121.87, 118.93, 118.18, 117.84, 114.97, 104.81, 100.04, 
14.62. MS (EI+) m/z calcd for C17H10F3N5S:373.06; found, 





Obtained from IVa (0.15g, 0.51mmol, 1 equiv.) using pyridin-
4- ylmethanamine (0.066g, 0.062ml; 0.609mmol, 1.2 equiv.) 
as a brown powder (20%). 1H NMR (300 MHz, DMSO) δ 8.72 
(d, J = 8.4 Hz, 1H, H1), 8.62 (bs, 1H, H6), 8.55 (d, J = 6.0 Hz, 2H, 
H9), 7.94 (d, J = 8.2 Hz, 1H, H4), 7.67 (t, J = 7.5 Hz, 1H, H3), 
7.58 – 7.39 (m, 3H, H2,8), 6.26 (s, 1H, H5), 4.98 (s, 2H, H7). 13C 
NMR (101 MHz, DMSO) δ 158.18, 150.26 (2C), 148.21, 
147.06, 142.92, 133.29, 133.09, 131.24, 128.64, 128.33, 
127.12, 122.49 (2C), 121.86, 119.30, 115.78, 114.84, 46.27. 
MS (EI+) m/z calcd for C19H12F3N5:367.10; found, 368.10       
(M + 1). HPLC purity: 98%. 
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Obtained from IVa (0.15g, 0.51mmol, 1 equiv.) using 
pyrimidin-2- ylmethanamine (0.066g, 0.61mmol, 1.2 equiv.) 
as a red powder (6%). 1H NMR (600 MHz, DMSO) δ 8.88 (d, J 
= 4.9 Hz, 2H, H8,10), 8.70 (d, J = 8.4 Hz, 1H, H1), 8.61 (bs, 1H, 
H6), 7.95 (d, J = 8.1 Hz, 1H, H4), 7.67 (t, J = 7.6 Hz, 1H, H3), 
7.55 – 7.47 (m, 2H, H2,9), 6.48 (s, 1H, H5), 5.13 (s, 2H, H7). 13C 
NMR (151 MHz, DMSO) δ 165.36, 158.23 (2C), 150.27, 
148.36, 145.51, 137.33, 131.62, 128.19, 126.91, 123.75, 
121.52, 120.30, 119.02, 115.22, 114.57, 86.83, 65.14. MS 
(EI+) m/z calcd for C18H11F3N6:368.10; found, 369.10 (M + 1). 
HPLC purity: 98%. 
 
1-(pyrimidin-2-ylamino)-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile 2d/GMP-57.  
 
 
Obtained from IVa (0.15g, 0.51mmol, 1 equiv.) using pyrimidin-
2-amine (0.058g, 0.61mmol, 1.2 equiv.) as an orange powder 
(25%). 1H NMR (300 MHz, DMSO) δ 8.99 (d, J = 8.4 Hz, 1H, H1), 
8.77 (d, J = 5.1 Hz, 2H, H7,9), 7.83 (d, J = 8.0 Hz, 1H, H4), 7.71 (s, 
1H, H5), 7.66 – 7.46 (m, 1H,H3), 7.46 – 7.29 (m, 1H, H2), 7.11 (t, J 
= 5.1 Hz, 1H, H8).  13C NMR (151 MHz, DMSO) δ 158.43, 150.56, 
148.30, 143.29, 135.63, 129.69, 126.91, 125.67, 123.86, 122.12, 
121.73, 120.42, 118.97, 117.44, 115.05, 112.64, 96.36. MS (EI+) 
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Obtained from IVa (0.15g, 0.51mmol, 1 equiv.) using pyrazin-2-
amine (0.058g, 0.61mmol, 1.2 equiv.) as an orange powder (23%). 
1H NMR (400 MHz, DMSO) δ 9.08 (d, J = 8.4 Hz, 1H, H1), 8.54 (d, J 
= 1.4 Hz, 1H, H7), 8.41 (dd, J = 2.7, 1.4 Hz, 1H, H8), 8.25 (d, J = 2.7 
Hz, 1H, H9), 7.69 (ddd, J = 8.1, 1.2, 0.7 Hz, 1H, H4), 7.63 (ddd, J = 
8.2, 7.3, 1.1 Hz, 1H, H3), 7.57 (s, 1H, H5), 7.47 (ddd, J = 8.5, 7.3, 1.3 
Hz, 1H, H2). 13C NMR (101 MHz, DMSO) δ 161.20, 156.43, 149.86, 
147.99, 147.30, 142.50 (2C), 138.59, 135.58, 128.83, 127.54, 
123.16, 118.91, 118.58, 114.80, 112.86, 99.37. MS (EI+) m/z calcd 
for C17H9F3N6:354.08; found, 355.10 (M + 1). HPLC purity: 98%. 
4-cyano-N-(7,8-dichloro-4-cyano-3-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl) 
benzene sulphonamide 4n/GMP-98. 
 
 
Obtained from IVc (0.1g, 0.274mmol, 1 equiv.) and 4-
cyanobenzenesulfonamide (0.06g, 0.329mmol, 1.2 equiv.) as a 
yellow solid (26%). 1H NMR (300 MHz, DMSO-d6) δ 8.91 (s, 1H, 
H1), 8.14 – 7.88 (m, 5H, H2,5,6), 6.77 (s, 1H, H3). 13C NMR (101 MHz, 
DMSO) δ 160.90, 158.91, 153.29, 152.32, 150.28, 148.25, 145.11, 
141.56, 136.66, 133.55 (2C), 127.19 (2C), 125.74, 122.09, 119.72, 
115.15, 114.63, 108.93, 97.85. MS (EI-) m/z calcd for 
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Obtained from the reaction between IVc (0.1g, 0.274mmol, 1 
equiv.) and 4-(trifluoromethoxy)benzenesulfonamide (0.079g, 
0.329mmol, 1.2 equiv.) as a brown powder (21%). 1H NMR (300 
MHz, DMSO-d6) δ 8.90 (s, 1H, H1), 8.04 (m, 3H, H2,5), 7.54 (d, J = 
8.0, 2H, H6), 6.75 (s, 1H, H3). 13C NMR (101 MHz, DMSO) δ 152.29, 
150.91, 150.78, 147.36, 145.13, 143.23, 140.19, 129.29 (2C), 
128.88, 128.81, 122.36, 121.70, 121.57 (2C), 119.14, 118.91, 
115.11, 107.89, 91.57. MS (EI-) m/z calcd for 






Obtained from IVc (0.1g, 0.274mmol, 1 equiv.) and pyridine-2-
sulfonamide (0.052g, 0.329mmol, 1.2 equiv.) as a dark brown 
powder (10%). 1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H, H1), 
8.69 – 8.63 (m, 1H, H8), 8.08 – 7.99 (m, 2H, H5,6), 7.97 (s, 1H, H2), 
7.58 (ddd, J = 6.8, 4.7, 2.1 Hz, 1H, H7), 7.04 (s, 1H, H3). 13C NMR 
(101 MHz, DMSO) δ 178.80, 164.26, 163.54, 160.73, 152.10, 
150.98, 150.27, 148.67, 146.38, 142.05, 131.51, 126.66 (2C), 
120.03 (2C), 106.09, 92.81, 89.35. MS (EI-) m/z calcd for 
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Obtained from IVd (0.2g, 0.608mmol, 1 equiv.) using 4-
(trifluoromethoxy)aniline (0.22g, 1.22 mmol, 2 equiv.) as a yellow 
solid (48%), m.p. 230-233 °C; Rf (1% MeoH/DCM) 0.38; 1H NMR 
(400 MHz, DMSO-d6) δ 8.88 (d, J = 8.4 Hz, 1H, H1), 7.81 (d, J = 8.1 
Hz, 1H, H4), 7.62 – 7.52 (m, 1H, H3), 7.45 – 7.38 (m, 1H, H2), 7.36 
(d, J = 8.6 Hz, 2H, H9), 7.13 (d, J = 8.7 Hz, 2H, H8), 6.35 (s, 1H, H6), 
3.89 (s, 3H, H5). 13C NMR (101 MHz, DMSO) δ 164.08, 148.31, 
147.91, 147.17, 144.47, 135.94, 128.01, 126.92, 124.71, 123.25 
(2C), 122.85, 122.63 (2C), 121.98, 117.85, 113.40, 113.21, 112.99, 
98.53, 52.03. MS (EI+) m/z calcd for C21H13Cl2F6N303:469.09; 
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7.3 Biological assays 
 
7.3.1 In vitro antiplasmodial assays 
 
7.3.1.1 Asexual blood stage activity using the LDH assay at UCT  
 
The chloroquine-sensitive NF54 strain of Plasmodium falciparum was used in testing the 
antiplasmodial asexual blood stage activity of test compounds. The parasites were cultured 
and maintained according to the approach by Trager and Jensen with slight variations.1 The 
antiplasmodial activity was monitored by determining the activity of the parasite lactate 
dehydrogenase enzyme.  
Stock solutions of samples were prepared at 20 mg/ml in 100% DMSO and kept at -20 ֯C prior 
to analysis. On the assay day, subsequent dilutions of the stock solutions were prepared in 
medium to give the highest starting concentration of 100 µg/ml. From these, serial dilutions 
in complete medium were performed to achieve ten concentrations with the concentration 
range being between 0.2-100 µg/ml. Using these concentrations, a dose response analysis 
was performed to establish the concentration resulting in inhibition of parasite growth by 
50%. Chloroquine and artesunate were employed as controls for all the assays for which their 
initial testing concentrations was 1000 ng/ml. The dilution approach adopted for the samples 
and controls was similar. In each case, the final concentration of DMSO had no effects on 
parasite growth. Non-linear dose-response curves generated in GraphPad Prism v.4.0 
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7.3.1.2. Asexual blood stage activity using the modified [3H]-hypoxanthine incorporation 
assay at Swiss TPH 
 
The modified [3H]-hypoxanthine incorporation assay was used to test compounds against 
drug-sensitive (NF54) and resistant (K1) strains of Plasmodium falciparum. The parasites were 
cultivated in human erythrocytes as previously described1,2 but with some variations to the 
medium which comprised RPMI 1640 supplemented with 0.5% ALBUMAX® II, 25 mM Hepes, 
25 mM NaHCO3 (pH 7.3), 0.36 mM hypoxanthine, and 100 µg/ml neomycin. Parasite cultures 
were maintained in an environment of 37 °C, 3% O2, 4% CO2, and 93% N2 in humidified 
modular chambers. 
Test compounds were dissolved in 100% DMSO, by sonication, to give 10 mg/ml stock 
solutions and diluted in culture medium devoid of hypoxanthine. Infected erythrocytes (100 
microliter per well with 2.5% hematocrit and 0.3% parasitemia) were added to each 
compound titrated in 100 microliter duplicates over a 64-fold range and incubated for 48 h. 
After this period, 0.5 microCi of [3H] hypoxanthine in 50 microliter media was added and the 
culture plates allowed to incubate for a further 24 h. From the parasites harvested on glass-
fiber filters at the end of the total incubation period, radioactivity was determined using a 
Betaplate liquid scintillation counter (Wallac, Zurich). The radioactivity was recorded as 
counts per minute per well at each concentration of test compound and presented as 
percentage relative to the untreated controls. The concentrations resulting in 50% inhibition 
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7.3.1.3 In vitro activity against P. berghei liver stages.  
 
Liver stage infection was initiated using P. berghei parasites with human hepatoma cell line, 
Huh-7 cells, as host cells. These were cultured in 1640 RPMI medium supplemented with 10% 
v/v fetal calf serum (FCS), 1% v/v non-essential amino acids, 1% v/v penicillin/streptomycin, 
1% v/v glutamine and 10 mM HEPES. Additionally, an environment of pH 7, 37 ֯C and 5% CO2 
was maintained. Luminescence of Huh-7 cell lysates 48 hours after infection with a firefly 
luciferase-expressing P. berghei line, PbGFP-Luccon, was used to determine the degree of 
inhibition of the P. berghei liver stage infection as described previously.4,5 
Briefly, cells (10 × 103/well) were seeded in 96-well plates the day before drug treatment and 
infection. Predetermined amounts of test compounds were weighed and dissolved in 100% 
DMSO to give 10 mM stock solutions. Dilutions of the stock solution with medium were then 
performed to provide the desired concentrations. One hour prior to infection with parasite, 
medium was replaced with fresh medium containing the appropriate concentration of each 
compound.  After a further one hour, sporozoites (10,000 spz/well), freshly obtained through 
disruption of salivary glands of infected female Anopheles stephensi mosquitoes, were added 
to the wells and plates centrifuged at 1700 g for 5 minutes. 
The Biotium’s Firefly Luciferase Assay Kit was employed to establish the parasite load, 48 
hours after infection whereas the AlamarBlue assay (Invitrogen, UK) was used to determine 
the effects of the compounds on the viability of Huh-7 cells. Results from dose-response 
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7.3.1.4 In vitro activity against gametocyte stage. 
 
Two different platforms, ATP- and luciferase reporter line-based assays, were used to 
determine the gametocytocidal effects of test compounds. In the luciferase assays, two 
transgenic parasite lines, NF54-PfS16-GFP-Luc (early stage) and NF54-Mal8p1.16-GFP-Luc 
(late stage), which enable stage-specific assessment of gametocytocidal activity, were 
utilised. The bioluminescent ATP assay provided an additional independent evaluation of late 
stage gametocyte activity of test compounds. 
Gametocytes were produced as per Reader and co-workers.6 Experiments were performed 
on day 5 and 10 (representing >90% of either early stage I/II/III or mature stage IV/V 
gametocytes, respectively). In each case, assays were set up using a 2 to 3% gametocytaemia, 
1.5% haematocrit culture and 48 h drug pressure in a gas chamber (90% N2, 5% O2, and 5% 
CO2) and temperature maintained at 37 °C. Luciferase activity was determined in 20 μl 
parasite lysates by adding 50 μl luciferin substrate (Promega Luciferase Assay System) at room 
temperature and detection of resultant bioluminescence at an integration constant of 10 s 
with the GloMax®-Multi+ Detection System with Instinct® Software. For the ATP assay, 
gametocytes representing >90% of late stage IV/V gametocytes (predominantly stage V) were 
enriched using density gradient centrifugation and magnetic separation. Drug dilutions were 
placed in triplicate in 96-well plates. Approximately 50 000 gametocytes in glucose-rich 
complete medium were added to each well in a final volume of 100 μl and the plates 
incubated for 24 h in a humidified gas chamber (90% N2, 5% O2, and 5% CO2) at 37 °C. ATP 
levels were determined using the BacTiter-Glo™ assay (Promega) in accordance with 
manufacturer’s instructions, at room temperature in the dark with assay substrate incubated 
for 10 minutes. Bioluminescence was detected at an integration constant of 0.5 s with the 
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7.3.2 In vitro antischistosomal assays 
 
7.3.2.1 Screening against Newly Transformed Schistosomula  
 
Newly transformed schistosomula (NTS) were obtained from Schistsosoma mansoni cercaria 
according to previously described methods.7,8 Briefly, light stimulation of snails was applied 
to produce cercaria whose tails were subsequently removed by washing the cercarial 
suspension three times with cold Hank’s Basal Salt Solution (HBSS). The resultant NTS were 
incubated overnight in culture medium for use the following day. The culture Medium 
consisted of Medium 199 (Invitrogen, Carlsbad, CA) supplemented with 5% fetal calf serum 
(Lucerne, Switzerland) and 1% penicillin/ streptomycin mixture (Lucerne, Switzerland).  
Test compounds and controls were prepared by dissolving in 100% DMSO (Fluka, Buchs, 
Switzerland) to make 10 mM stock concentrations. NTS (100) were transferred in each well 
of a 96-well plate containing culture medium and 10 µM test compound for a final well 
volume of 250 µL. The test set up was performed in triplicates while NTS incubated in <1% 
DMSO acted as control. The plate was incubated at 37 °C and 5% CO2 for up to 72 hours after 
which NTS were microscopically examined for any lethality using the scale of 3 (normal 
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7.3.2.2 Adult S. mansoni Worms.  
 
Adult S. mansoni worms were obtained from mice previously infected subcutaneously with 
ca. 80-100 cercariae. After 7-8 weeks, the mice were euthanized using CO2 and the worms 
harvested from the hepatic portal and mesenteric veins. Male and female worms were paired, 
and two pairs incubated in each well in a 24-well plate with 2mL culture medium and the test 
compound (10 µM). The culture medium consisted of RPMI 1640 (Invitrogen, Carlsbad, CA) 
supplemented with 5% fetal calf serum (Lucerne, Switzerland) and 1% penicillin/streptomycin 
mixture (Lucerne, Switzerland). Incubations containing less than 1% DMSO were used as 
controls. 
The plates were incubated at 37 °C and 5% CO2 for up to 72 hours, after which the worms 
were examined microscopically, and effects scored using a scale from 3 (normal activity and 
no morphological alterations) to 0 (dead). Compound concentration causing 50% lethality 
(IC50) in the adult worms was determined for compounds with >60% activity. All viability 
scores were averaged across replicates and normalized to the average viability scores of the 
control wells. Subsequently, IC50 values were calculated using CompuSyn2 (ComboSyn Inc., 
Paramus, NJ). 
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7.3.3 Beta haematin inhibition  
 
Controls and test compounds were reconstituted to 20 mM in 100% DMSO (Fluka, Buchs, 
Switzerland). In a 96-well plate, columns 1-11 were filled with a solution constituting 
water/305.5 μM NP40/DMSO at a v/v ratio of 70%/20%/10%, respectively, while to column 
12, 140 μLof water and 40 μL of 305.5 μM NP40 were introduced to mediate the formation 
of β-hematin. To column 12, 20 µL of 20 mM compound stock solution was added and 100 μL 
of this solution serially diluted to column 2. Column 1 was left as a blank with no compound 
present (0 µM). Some 100 µL of haematin suspension, prepared by suspending an aliquot 
(178.8 μL) of haematin stock solution in 20 mL of a 1 M acetate buffer, pH 4.9, was added into 
each well and the plates left to incubate for 5 hours at 37 °C. Thereafter, pyridine solution (32 
µl) comprising 20% water, 20% acetone, 10% 2 M HEPES buffer (pH 7.4) and 50% pyridine was 
added followed by the addition of 60 μL of acetone to all wells. Optical readings of the plates 
were taken at 405 nm to give concentration-response values. The concentrations resulting in 
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7.4 Pharmacokinetics and efficacy studies 
 
7.4.1 In vitro metabolic stability 
Metabolic stability was conducted using the one-time point assay.9 Experiments were 
performed in triplicate in a 96-well microtiter plate using test compounds at a concentration 
of 0.1 µM, incubated individually in a solution containing 0.35 mg/mL mouse (male mouse 
BALB/c, Xenotech) or human (mixed gender, Xenotech) liver microsomes.  NADPH (1 mM) in 
phosphate buffer (100 mM) and at pH 7.4 were added to the wells to initiate metabolic 
reactions and the plates incubated for 30 minutes. After this period, 300 μL of ice-cold 
acetonitrile containing internal standard (carbamazepine, 0.0236 μg/mL) was added to each 
well to quench the reactions. The supernatant was centrifuged and filtered after which LC-
MS/MS (Agilent Rapid Resolution HPLC, AB SCIEX 4000 QTRAP MS) analysis was performed to 
determine concentration of test compounds. Differences in the amounts of compounds 
before and after incubation were therefore determined by LC-MS/MS and results recorded 
as per cent compound remaining after 30 minutes incubation. Search for products of 












                           Chapter 7                                                                                                  Experimental Information  
 
 





In vitro cytotoxicity was conducted on the Chinese Hamster ovarian cell lines using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.10 Test compounds were 
dissolved in 100% DMSO to yield a 20 mg/mL stock solution while the reference standard, 
emetine, was dissolved in distilled water to prepare a 2 mg/mL solution. From an initial test 
compound and control concentration of 100 µg/mL, serial 10-fold dilutions, in complete 
medium, were performed to achieve six concentrations with 0.001 µg/mL being the lowest 
concentration. The highest concentration of DMSO exposed to cells had no effects on cell 
viability. Plates were incubated for 48 h with 100 μL of drug and 100 μL of cell suspension in 
each well after which they were developed by the addition of 25 μL of sterile MTT (Thermo 
Fisher Scientific) to each well and a further incubation in the dark for 4 hours. Thereafter, the 
plates were centrifuged, the medium aspirated off and DMSO (100 µL) added to dissolve 
crystals and absorbance readings taken at 540 nM.  Nonlinear dose-response curve fitting 
analysis conducted using GraphPad Prism v.4.0 software (La Jolla, USA), was applied to 
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7.4.3 hERG interaction  
 
Inhibition potency for test compounds towards the hERG potassium ion channel was carried 
out using a four-point concentration-response format applying the QPatch hERG assay, 
Metrion biosciences, Cambridge, United Kingdom.11,12 Test compounds were dissolved in 
100% DMSO to give a 10mM stock solution and thereafter diluted further in DMSO using 0.5-
log unit dilutions to achieve the screening concentrations of 0.3, 1, 3 and 10 µM. 
Chinese hamster ovarian cell lines stably expressing hERG were used. Electrophysiological 
recordings of hERG currents were obtained according to in-house procedures and effects on 
hERG tail current measured. Concentration-response curves were constructed by cumulative 
double sample additions of each concentration to the same cell. Experiments were carried 
out in three separate cells and as technical replicates. Inhibition activity was calculated as the 
reduction in the mean peak current in the test compound relative to the peak current prior 
to exposure of the cells to the compounds.  Percent inhibition values from each cell were used 
to construct concentration-response curves using the 4-parameter logistic fit with 0% and 
100% inhibition levels fixed at very low and very high concentration, respectively and 
concentrations resulting in a 50% inhibition determined. Verapamil was used as a positive 
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7.4.4 Metabolite identification studies 
 
Metabolite identification studies were performed in male mouse (BALB/c, Xenotech) and 
human (mixed gender, Xenotech) liver microsomes. Microsomes (1 mg/mL) were suspended 
in a solution containing MgCl2 (0.67 mg/mL) and phosphate buffer (100mM, pH 7.4). The test 
compound was spiked in a portion of this microsome mix, in a separate Eppendorf tube, to 
achieve a compound concentration of 10 µM. A buffer mixture was also prepared, containing 
only phosphate buffer and MgCl2 (0.67 mg/mL) but not microsomes.    
Two separate 96-well microtiter plates were used; one for T0 (0 minutes) and the other for 
T60 (60 minutes) incubations set up. Each plate was laid out to accommodate four sets of 
incubations in duplicates. In the first case, 90 µL of the microsomal mix containing the test 
compound (10 µM) was introduced into two separate sets of wells. In another set of wells, 90 
µL from the pre-mix lacking microsomes (buffer mixture) was placed. To yet another set of 
wells, a control was prepared by placing an aliquot of 90 µL from the microsomal mix which 
did not have the test compound. Thereafter, NADPH (10µL, 1mM) was added to one of the 
two sets of wells containing microsomal mix that had been spiked with test compound. To 
the other sets of wells, 10 µL of buffer was added such that all the wells held a total volume 
of 100 µL of samples. The above procedures were performed for both T0 and T60 plates.                   
To one of the plates (T0 plate), 300 µL of acetonitrile was added to all the wells and the plate 
immediately stored at -20 °C, pending analysis. The other plate (T60 plate) was incubated for 
60 minutes at 37 °C with gentle shaking, prior to adding acetonitrile (300 µL) in all wells.  Both 
T0 and T60 plates were centrifuged and the supernatant transferred to a clean microtiter 
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7.4.5 In vivo antimalarial efficacy  
 
This work was carried out at the Swiss Tropical and Public Health Institute in accordance with 
Swiss national and cantonal regulations on animal welfare. In vivo antimalarial efficacy studies 
were conducted in mice harbouring Plasmodium berghei infection. A GFP-transfected P. 
berghei ANKA strain (donated by A. P. Waters and C. J. Janse, Glasgow and Leiden Universities 
respectively), was used to infect three mice and the level of parasitemia determined by flow 
cytometry, having a detection limit of 0.1% (that is, 1 parasite per 1,000 erythrocytes).  A 
solution or suspension of test compounds in 90/10 Tween80/ethanol (v/v), diluted 10 times 
with water, was administered orally as four consecutive doses at 4, 24, 48 and 72 h post-
infection. The control group of mice received only the vehicle which has no antimalarial 
activity. Activity was then determined by calculating the difference between the mean per 
cent parasitemia for the control and treated groups, presented as a per cent relative to the 
control group. Mice were cured if parasitemia was undetectable on day 30 after the infection, 
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7.4.6 In vivo antischistosomal efficacy 
 
The in vivo antischistosomal efficacy of frontrunner compounds was carried out in compliance 
with the Swiss national and cantonal regulations on animal welfare at the Swiss Tropical and 
Public Health Institute, Switzerland. Groups of four NMRI mice, previously infected with 
Schistosoma mansoni cercariae and presently containing chronic S. mansoni infection were 
treated orally, at a dose of 400 mg/kg, with test compounds dissolved in 7% Tween 80 and 
3% ethanol in water (v/v/v). Untreated control mice received only the vehicle, 7% Tween 80 
and 3% ethanol in water, which lacks antischistosomal properties. Animals were euthanized 
on day 21 after treatment using the CO2 method and dissected. Surviving worms were 
retrieved from the mesenteric veins and the liver, counted and sexed as previously 
described.13 Activity of test compounds was determined by comparing the worm reduction in 
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7.4.7 In vivo pharmacokinetics 
The pharmacokinetic studies were conducted with prior approval of the Animal Ethics 
Committee of the University of Cape Town (approval number 017/026) in accordance with 
the South African National Standard (SANS 10386:008) for the Care and Use of Animals for 
Scientific Purposes,14 and guidelines from the Department of Health.15 The studies were 
performed in male (C57B1/6) mice housed in temperature-controlled rooms and fed a 
standard diet with free access to water. Test compounds were weighed and prepared freshly 
before dosing. For intravenous dosing, compounds were prepared in dimethylacetamide, 
poly- ethylene glycol, and propylene glycol/ethanol mixture 4:1 at a ratio of 1:3:6. An 
intravenous dose of 2 mg/kg contained in a volume of 50 μL was administered to two mice 
via the tail vein after anesthetizing the animals. 
For oral administration, compounds were suspended in 2mL of 100% hydroxypropyl 
methylcellulose and given to three mice by gavage at a dose of 20 mg/kg. Blood samples were 
drawn from the tail of each animal at specified time intervals and collected into 
microcentrifuge tubes equipped with the anticoagulant lithium heparin S12. Samples were 
kept on ice and transferred to storage at −80 °C within 1 hour of collection, pending analysis. 
Samples were subsequently analysed by high-performance liquid chromatography and mass 
spectrometry (LC-MS/MS) following in-house procedures.  
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7.5 Physicochemical property profiling 
 
7.5.1 Turbidimetric-based kinetic solubility 
 
Target compounds and controls were dissolved in DMSO to make 10 mM stock solutions. 
From this, a predilution plate was prepared in Nunc™ 96-well fluorescence plates in triplicate 
by serial dilution in DMSO such that a concentration range of between 0.125 and 8 mM was 
achieved. Each predilution solution was then used to make secondary dilutions in DMSO and 
PBS (0.01 M; pH 7.4) in a second plate in triplicates such that each well contained 200µl of 
solvent and covering a concentration range of between 0 (solvent only, no compound) to 200 
µM. After incubation at room temperature for 2 hours, absorbance was measured at 620nm 
using a SpectraMax 340PC microplate reader (Molecular Devices, Sunnydale, CA). 
Concentration-absorbance curves were then plotted in Microsoft Excel® and the point of 
deflection from baseline in the PBS incubation was considered the limit of solubility of a 
compound. Hydrocortisone and reserpine were treated similarly and used as controls for a 
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7.5.2 Solubility using HPLC-based DMSO “dry-down” method  
 
This method of determining kinetic solubility of test compounds was employed to minimise 
the solvent-enhancement of solubility experienced in the turbidimetric method. Test 
compounds were   dissolved in 100% DMSO to yield 10 mM stock solutions. HPLC analysis 
with UV-detection was used to construct calibration curves for each compound using low (11 
µM), medium (100 µM) and high (220 µM) concentrations. The high and medium 
concentrations were prepared by placing 4.4 µL and 2 µL aliquots of the 10 mM stock solution 
into wells A and B of a 96-well microtiter plate and diluted by adding 195.6 µl and 198 µl of 
DMSO, respectively. On the other hand, the low concentration was prepared into well C by 
diluting 10 µL, obtained from well A, with 190 µL of DMSO to yield a 20-fold dilution of the 
220 µM concentration.  
Thereafter, each test sample (4 µL of 10mM stock), in triplicates, was placed in wells D, E and 
F and DMSO removed by freeze-drying under Genevac®. This step reduces solubility-
enhancement due to DMSO. Phosphate buffer (200 µL) at pH 7.4 was added to the wells now 
containing the dry solid material of test samples. The plates were covered and placed on a 
shaker at 37 °C for 24 hours. After this period, the plates were centrifuged for 15 minutes at 
3,500 rpm using a digitor 21R® centrifuge set at 23 °C and supernatant carefully transferred 
to an analytical 96-well microtiter plate for HPLC analysis fitted with UV-detection. 
Concentration of dissolved samples was determined by comparing the average peak areas 
produced by the samples (wells D, E, F) against the previously constructed standard curve 
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